Journal name,Article/Patent Title,DOI/Pantent number,Article/Patent,Cell line name,Assay name,Standard Type,SMILES,Standard Relation,Standard Value,Standard Units
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist,10.1021/ml300133f,Article,CHO,Unknown,EC50,O=C(CC(C#CC)C1=CC=C(OCC2=CC=C(C=C2)C3=CC=CC=C3)C=C1)O[H],=,7.7,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA2 Full Agonist,10.1021/ml300133f,Article,CHO,Unknown,EC50,O=C(CC(C#CC)C1=CC=C(OCC2=CC=C(C=C2)C3=CC(OC)=CC=C3)C=C1)O[H],=,2.3,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA3 Full Agonist,10.1021/ml300133f,Article,CHO,Unknown,EC50,O=C(C[C@H](C#CC)C1=CC=C(OCC2=CC=C(C=C2)C3=CC(OC)=CC=C3)C=C1)O[H],=,0.65,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA4 Full Agonist,10.1021/ml300133f,Article,CHO,Unknown,EC50,O=C(C[C@@H](C#CC)C1=CC=C(OCC2=CC=C(C=C2)C3=CC(OC)=CC=C3)C=C1)O[H],=,4,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA5 Full Agonist,10.1021/ml300133f,Article,CHO,Unknown,EC50,O=C(C[C@@H](C#CC)C1=CC=C(OCC2=CC=C(C=C2)C3=CC(OC)=CC=C3F)C=C1)O[H],=,2.3,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA6 Full Agonist,10.1021/ml300133f,Article,CHO,Unknown,EC50,O=C(CCC1=CC=C(OCC2=CC=C(C=C2)C3=CC(OC)=CC=C3F)C=C1)O[H],=,1.9,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA7 Full Agonist,10.1021/ml300133f,Article,CHO,Unknown,EC50,FC1=CC=C(OC)C=C1C2=CC=C(COC3=CC=CC(CCC(O[H])=O)=C3)C=C2,=,1.2,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA8 Full Agonist,10.1021/ml300133f,Article,CHO,Unknown,EC50,O=C(CCC1=CC(OCC2=CC=C(C3=C(F)C=CC(OC)=C3)C(C(C)(C)C)=C2)=CC=C1)O[H],=,0.9,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA9 Full Agonist,10.1021/ml300133f,Article,CHO,Unknown,EC50,O=C(C[C@@H](C)C1=CC(OCC2=CC=C(C3=C(F)C=CC(OC)=C3)C(C(C)(C)C)=C2)=CC=C1)O[H],=,0.77,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA10 Full Agonist,10.1021/ml300133f,Article,CHO,Unknown,EC50,O=C(C[C@@H](CC)C1=CC(OCC2=CC=C(C3=C(F)C=CC(OC)=C3)C(C(C)(C)C)=C2)=CC=C1)O[H],=,0.68,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA11 Full Agonist,10.1021/ml300133f,Article,CHO,Unknown,EC50,O=C(C[C@@H](CCC)C1=CC(OCC2=CC=C(C3=C(F)C=CC(OC)=C3)C(C(C)(C)C)=C2)=CC=C1)O[H],=,0.69,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA12 Full Agonist,10.1021/ml300133f,Article,CHO,Unknown,EC50,O=C(C[C@@H](C(C)C)C1=CC(OCC2=CC=C(C3=C(F)C=CC(OC)=C3)C(C(C)(C)C)=C2)=CC=C1)O[H],=,2.2,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA13 Full Agonist,10.1021/ml300133f,Article,CHO,Unknown,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=CC=C(C4=C(F)C=CC(OC)=C4)C(C(C)(C)C)=C3)=CC=C2)O[H],=,0.37,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA14 Full Agonist,10.1021/ml300133f,Article,CHO,Unknown,EC50,O=C(C[C@@H](C1CCC1)C2=CC(OCC3=CC=C(C4=C(F)C=CC(OC)=C4)C(C(C)(C)C)=C3)=CC=C2)O[H],=,0.42,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA15 Full Agonist,10.1021/ml300133f,Article,CHO,Unknown,EC50,O=C(C[C@@H](C1CCCC1)C2=CC(OCC3=CC=C(C4=C(F)C=CC(OC)=C4)C(C(C)(C)C)=C3)=CC=C2)O[H],=,1.3,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA16 Full Agonist,10.1021/ml300133f,Article,CHO,Unknown,EC50,O=C(C[C@@H](C1CCCCC1)C2=CC(OCC3=CC=C(C4=C(F)C=CC(OC)=C4)C(C(C)(C)C)=C3)=CC=C2)O[H],=,2.1,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA17 Full Agonist,10.1021/ml300133f,Article,CHO,Unknown,EC50,O=C(C[C@@H](C1=CC=CC=C1)C2=CC(OCC3=CC=C(C4=C(F)C=CC(OC)=C4)C(C(C)(C)C)=C3)=CC=C2)O[H],=,1.2,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA18 Full Agonist,10.1021/ml300133f,Article,CHO,Unknown,EC50,O=C(C[C@@H](C(F)(F)F)C1=CC(OCC2=CC=C(C3=C(F)C=CC(OC)=C3)C(C(C)(C)C)=C2)=CC=C1)O[H],=,2.1,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Improving the Pharmacokinetics of GPR40/FFA1 Full Agonists,10.1021/ml4005123,Article,CHO,Aequorin Ca2+ flux assay,EC50,O=C(O[H])C[C@@H](CCC)C1=CC(OCC(C=C2C(C)(C)C)=CC=C2C3=CC=CC(OC)=C3)=CC=C1,=,0.37,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Improving the Pharmacokinetics of GPR40/FFA2 Full Agonists,10.1021/ml4005123,Article,CHO,Aequorin Ca2+ flux assay,EC50,O=C(O[H])C[C@@H](CCC)C1=CC(OCC(C=C2C(C)(C)C)=CC=C2C3=CC=CC(OC)=N3)=CC=C1,=,3.7,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Improving the Pharmacokinetics of GPR40/FFA3 Full Agonists,10.1021/ml4005123,Article,CHO,Aequorin Ca2+ flux assay,EC50,O=C(O[H])C[C@@H](CCC)C1=CC(OCC(C=C2C(C)(C)C)=CC=C2C3=CN=CC(OC)=C3)=CC=C1,=,30,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Improving the Pharmacokinetics of GPR40/FFA4 Full Agonists,10.1021/ml4005123,Article,CHO,Aequorin Ca2+ flux assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(OCC(C=C3C4=CCCC4(C)C)=CC=C3C5=C(F)C=NC(OC)=C5)=CC=C2,=,0.12,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Improving the Pharmacokinetics of GPR40/FFA5 Full Agonists,10.1021/ml4005123,Article,CHO,Aequorin Ca2+ flux assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(OCC(C=C3C4=CCCC4(C)C)=CC=C3C5=C(F)C=CC(OC)=C5)=CC=C2,=,0.161,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Improving the Pharmacokinetics of GPR40/FFA6 Full Agonists,10.1021/ml4005123,Article,CHO,Aequorin Ca2+ flux assay,EC50,FC1=C(C=C(C=C1)OC)C(C([C@H]2C(C)(C)CCC2)=C3)=CC=C3COC4=CC=CC([C@H](C5CC5)CC(O[H])=O)=C4,=,0.076,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Improving the Pharmacokinetics of GPR40/FFA7 Full Agonists,10.1021/ml4005123,Article,CHO,Aequorin Ca2+ flux assay,EC50,FC1=C(C=C(N=C1)OC)C(C([C@H]2C(C)(C)CCC2)=C3)=CC=C3COC4=CC=CC([C@H](C5CC5)CC(O[H])=O)=C4,=,0.068,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Improving the Pharmacokinetics of GPR40/FFA8 Full Agonists,10.1021/ml4005123,Article,CHO,Aequorin Ca2+ flux assay,EC50,FC1=C(C=C(N=C1)OC)C(C([C@H]2C(C)(C)CCC2)=C3)=CC=C3COC4=CC=CC([C@H](C5CC5)CC(O[H])=O)=C4F,=,0.093,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Improving the Pharmacokinetics of GPR40/FFA9 Full Agonists,10.1021/ml4005123,Article,CHO,Aequorin Ca2+ flux assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(OCC3=CC=C(C4=C(F)C=CC(OC)=C4)C([C@@H]5CCCC5(C)C)=C3)=CC=C2,=,0.076,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Improving the Pharmacokinetics of GPR40/FFA10 Full Agonists,10.1021/ml4005123,Article,CHO,Aequorin Ca2+ flux assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(OCC3=CC=C(C4=C(F)C=CC(OC)=C4)C(CC(C)(C)C)=C3)=CC=C2,=,0.088,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Improving the Pharmacokinetics of GPR40/FFA11 Full Agonists,10.1021/ml4005123,Article,CHO,Aequorin Ca2+ flux assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(OCC3=CC=C(C4=C(F)C=CC(OC)=C4)C([C@H](F)C(C)(C)C)=C3)=CC=C2,=,0.105,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Improving the Pharmacokinetics of GPR40/FFA12 Full Agonists,10.1021/ml4005123,Article,CHO,Aequorin Ca2+ flux assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(OCC3=CC=C(C4=C(F)C=CC(OC)=C4)C([C@H](OC)C(C)(C)C)=C3)=CC=C2,=,0.147,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Improving the Pharmacokinetics of GPR40/FFA13 Full Agonists,10.1021/ml4005123,Article,CHO,Aequorin Ca2+ flux assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(OCC3=CC=C(C4=C(F)C=CC(OC)=C4)C([C@H](OCC)C(C)(C)C)=C3)=CC=C2,=,0.114,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Improving the Pharmacokinetics of GPR40/FFA14 Full Agonists,10.1021/ml4005123,Article,CHO,Aequorin Ca2+ flux assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(OCC3=CC=C(C4=C(F)C=CC(OC)=C4)C([C@H]5C(C)(C)CCCO5)=C3)=CC=C2,=,0.227,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Improving the Pharmacokinetics of GPR40/FFA15 Full Agonists,10.1021/ml4005123,Article,CHO,Aequorin Ca2+ flux assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(OCC3=CC=C(C4=C(F)C=CC(OC)=C4)C([C@@H](OC)C(C)(C)C)=C3)=CC=C2,=,1.41,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Improving the Pharmacokinetics of GPR40/FFA16 Full Agonists,10.1021/ml4005123,Article,CHO,Aequorin Ca2+ flux assay,EC50,FC1=C(C(C([C@@H]2CCCC2(C)C)=C3)=CC=C3COC4=NC=CC([C@@H](CC(O[H])=O)C5CC5)=C4)C=C(N=C1)OC,=,0.108,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Improving the Pharmacokinetics of GPR40/FFA17 Full Agonists,10.1021/ml4005123,Article,CHO,Aequorin Ca2+ flux assay,EC50,FC1=C(C(C([C@@H]2CCCC2(C)C)=C3)=CC=C3COC4=NC=CC([C@@H](CC(O[H])=O)CC)=C4)C=C(N=C1)OC,=,0.15,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Improving the Pharmacokinetics of GPR40/FFA18 Full Agonists,10.1021/ml4005123,Article,CHO,Aequorin Ca2+ flux assay,EC50,FC1=C(C(C([C@@H]2CCCC2(C)C)=C3)=CC=C3COC4=NC=CC([C@@H](CC(O[H])=O)C)=C4)C=C(N=C1)OC,=,0.281,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Improving the Pharmacokinetics of GPR40/FFA19 Full Agonists,10.1021/ml4005123,Article,CHO,Aequorin Ca2+ flux assay,EC50,FC1=C(C(C([C@@H]2CCCC2(C)C)=C3)=CC=C3COC4=NC=C5C([C@@](CC(O[H])=O)(CC5)C)=C4)C=C(N=C1)OC,=,0.128,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Improving the Pharmacokinetics of GPR40/FFA20 Full Agonists,10.1021/ml4005123,Article,CHO,Aequorin Ca2+ flux assay,EC50,FC1=C(C(C([C@@H]2CCCC2(C)C)=C3)=CC=C3COC4=NC=C5C([C@@]([C@]6([H])C(O[H])=O)(C6)CC5)=C4)C=C(N=C1)OC,=,0.249,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Improving the Pharmacokinetics of GPR40/FFA21 Full Agonists,10.1021/ml4005123,Article,CHO,Aequorin Ca2+ flux assay,EC50,FC1=C(C(C([C@@H](C(C)(C)C)OC)=C2)=CC=C2COC3=NC=C4C([C@@]([C@]5([H])C(O[H])=O)(C5)CC4)=C3)C=C(N=C1)OC,=,0.25,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Improving the Pharmacokinetics of GPR40/FFA22 Full Agonists,10.1021/ml4005123,Article,CHO,Aequorin Ca2+ flux assay,EC50,FC1=C(C(C([C@@H](C(C)(C)C)OC)=C2)=CC=C2COC3=NC=CC([C@H](C4CC4)CC(O[H])=O)=C3)C=C(N=C1)OC,=,0.162,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Improving the Pharmacokinetics of GPR40/FFA23 Full Agonists,10.1021/ml4005123,Article,CHO,Aequorin Ca2+ flux assay,EC50,FC1=C(C(C([C@@H](C(C)(C)C)OC)=C2)=CC=C2COC3=NC=C4C([C@@](C)(CC(O[H])=O)CC4)=C3)C=C(N=C1)OC,=,0.235,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist,10.1021/ml500391n,Article,CHO,Calcium flux assay,EC50,O=C(O[H])CC(OCC)C1=CC=C(C=C1)OCC2=CC=CC=C2C,=,0.02,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of DS-1558: A Potent and Orally Bioavailable GPR41 Agonist,10.1021/ml500391n,Article,CHO,Calcium flux assay,EC50,O=C(O[H])CC(OCC)C1=CC=C(C=C1)OCC2=CC=C(Cl)C(Cl)=C2,=,0.0062,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of DS-1558: A Potent and Orally Bioavailable GPR42 Agonist,10.1021/ml500391n,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](OCC)C1=CC=C(C=C1)OCC2=CC=C(Cl)C(Cl)=C2,=,0.0039,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of DS-1558: A Potent and Orally Bioavailable GPR43 Agonist,10.1021/ml500391n,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@@H](OCC)C1=CC=C(C=C1)OCC2=CC=C(Cl)C(Cl)=C2,=,0.36,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of DS-1558: A Potent and Orally Bioavailable GPR44 Agonist,10.1021/ml500391n,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](OCC)C1=CC=C(C=C1)OCC2=CC=C(C(F)(F)F)C=C2,=,0.0053,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of DS-1558: A Potent and Orally Bioavailable GPR45 Agonist,10.1021/ml500391n,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](OCC)C1=CC=C(O[C@@H]2CCC3=C2C=CC=C3)C=C1,=,0.031,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of DS-1558: A Potent and Orally Bioavailable GPR46 Agonist,10.1021/ml500391n,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](OCC)C1=CC=C(O[C@H]2CCC3=C2C=CC=C3)C=C1,=,0.069,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of DS-1558: A Potent and Orally Bioavailable GPR47 Agonist,10.1021/ml500391n,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](OCC)C1=CC=C(OC2CC(C=CC=C3)=C3C2)C=C1,=,0.083,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of DS-1558: A Potent and Orally Bioavailable GPR48 Agonist,10.1021/ml500391n,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](OCC)C1=CC=C(O[C@@H]2CCC3=C2C=CC=C3C)C=C1,=,0.029,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of DS-1558: A Potent and Orally Bioavailable GPR49 Agonist,10.1021/ml500391n,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](OCC)C1=CC=C(O[C@@H]2CCC3=C2C=CC=C3OCC)C=C1,=,0.063,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of DS-1558: A Potent and Orally Bioavailable GPR50 Agonist,10.1021/ml500391n,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](OCC)C1=CC=C(O[C@@H]2CCC3=C2C=CC=C3Cl)C=C1,=,0.005,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of DS-1558: A Potent and Orally Bioavailable GPR51 Agonist,10.1021/ml500391n,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](OCC)C1=CC=C(O[C@@H]2CCC3=C2C=CC=C3C(F)(F)F)C=C1,=,0.0037,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of DS-1558: A Potent and Orally Bioavailable GPR52 Agonist,10.1021/ml500391n,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](OCC)C1=CC=C(O[C@H]2CCC3=C2C=CC=C3C(F)(F)F)C=C1,=,0.019,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of DS-1558: A Potent and Orally Bioavailable GPR53 Agonist,10.1021/ml500391n,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@@H](OCC)C1=CC=C(O[C@H]2CCC3=C2C=CC=C3C(F)(F)F)C=C1,=,2.6,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of DS-1558: A Potent and Orally Bioavailable GPR54 Agonist,10.1021/ml500391n,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@@H](OCC)C1=CC=C(O[C@@H]2CCC3=C2C=CC=C3C(F)(F)F)C=C1,=,0.33,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of DS-1558: A Potent and Orally Bioavailable GPR55 Agonist,10.1021/ml500391n,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](OCC)C1=CC=C(O[C@H]2C3=C(C=CC=C3)CCC2)C=C1,=,0.062,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"AMG 837: A potent, orally bioavailable GPR40 agonist",10.1016/j.bmcl.2011.10.118,Article,CHO,Calcium flux assay,EC50,[H]C(CC(O[H])=O)C(C=C1)=CC=C1OCC(C=C2)=CC=C2OC,=,1.1,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"AMG 837: A potent, orally bioavailable GPR41 agonist",10.1016/j.bmcl.2011.10.118,Article,CHO,Calcium flux assay,EC50,O=C(CC(CC)C(C=C1)=CC=C1OCC(C=C2)=CC=C2OC)O[H],=,3.2,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"AMG 837: A potent, orally bioavailable GPR42 agonist",10.1016/j.bmcl.2011.10.118,Article,CHO,Calcium flux assay,EC50,O=C(CC(C=C)C(C=C1)=CC=C1OCC(C=C2)=CC=C2OC)O[H],=,0.9,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"AMG 837: A potent, orally bioavailable GPR43 agonist",10.1016/j.bmcl.2011.10.118,Article,CHO,Calcium flux assay,EC50,O=C(CC(/C=C(C)/C)C(C=C1)=CC=C1OCC(C=C2)=CC=C2OC)O[H],=,0.12,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"AMG 837: A potent, orally bioavailable GPR44 agonist",10.1016/j.bmcl.2011.10.118,Article,CHO,Calcium flux assay,EC50,O=C(CC(C(C)=C)C(C=C1)=CC=C1OCC(C=C2)=CC=C2OC)O[H],=,1.2,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"AMG 837: A potent, orally bioavailable GPR45 agonist",10.1016/j.bmcl.2011.10.118,Article,CHO,Calcium flux assay,EC50,O=C(CC(C#CC)C(C=C1)=CC=C1OCC(C=C2)=CC=C2OC)O[H],=,0.26,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"AMG 837: A potent, orally bioavailable GPR46 agonist",10.1016/j.bmcl.2011.10.118,Article,CHO,Calcium flux assay,EC50,O=C(C[C@@H](C#CC)C(C=C1)=CC=C1OCC(C=C2)=CC=C2OC)O[H],=,6.7,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"AMG 837: A potent, orally bioavailable GPR47 agonist",10.1016/j.bmcl.2011.10.118,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=C2)=CC=C2OC)O[H],=,0.064,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"AMG 837: A potent, orally bioavailable GPR48 agonist",10.1016/j.bmcl.2011.10.118,Article,CHO,Calcium flux assay,EC50,O=C(CC(C1=CC=C(F)C=C1)C(C=C2)=CC=C2OCC(C=C3)=CC=C3OC)O[H],=,0.58,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"AMG 837: A potent, orally bioavailable GPR49 agonist",10.1016/j.bmcl.2011.10.118,Article,CHO,Calcium flux assay,EC50,O=C(O[H])CC(C#CC)C(C=C1)=CC=C1OCC2=CC=CC=C2,=,0.62,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"AMG 837: A potent, orally bioavailable GPR50 agonist",10.1016/j.bmcl.2011.10.118,Article,CHO,Calcium flux assay,EC50,O=C(O[H])CC(C#CC)C(C=C1)=CC=C1OCC2=CC=C(C)C=C2,=,0.18,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"AMG 837: A potent, orally bioavailable GPR51 agonist",10.1016/j.bmcl.2011.10.118,Article,CHO,Calcium flux assay,EC50,O=C(O[H])CC(C#CC)C(C=C1)=CC=C1OCC2=CC=C(C(F)(F)F)C=C2,=,27,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"AMG 837: A potent, orally bioavailable GPR52 agonist",10.1016/j.bmcl.2011.10.118,Article,CHO,Calcium flux assay,EC50,O=C(O[H])CC(C#CC)C(C=C1)=CC=C1OCC2=CC=CC(OC)=C2,=,0.11,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"AMG 837: A potent, orally bioavailable GPR53 agonist",10.1016/j.bmcl.2011.10.118,Article,CHO,Calcium flux assay,EC50,O=C(O[H])CC(C#CC)C(C=C1)=CC=C1OCC2=CC=C(C3=CC=CC=C3)C=C2,=,1.2,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"AMG 837: A potent, orally bioavailable GPR54 agonist",10.1016/j.bmcl.2011.10.118,Article,CHO,Calcium flux assay,EC50,O=C(O[H])CC(C#CC)C(C=C1)=CC=C1OCC2=CC=CC=C2C3=CC=CC=C3,=,0.24,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"AMG 837: A potent, orally bioavailable GPR55 agonist",10.1016/j.bmcl.2011.10.118,Article,CHO,Calcium flux assay,EC50,O=C(O[H])CC(C#CC)C(C=C1)=CC=C1OCC2=CC(C3=CC=CC=C3)=CC=C2,=,0.058,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"AMG 837: A potent, orally bioavailable GPR56 agonist",10.1016/j.bmcl.2011.10.118,Article,CHO,Calcium flux assay,EC50,O=C(O[H])CC(C#CC)C(C=C1)=CC=C1OC2=CC(C3=CC=CC=C3)=CC=C2,=,0.36,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"AMG 837: A potent, orally bioavailable GPR57 agonist",10.1016/j.bmcl.2011.10.118,Article,CHO,Calcium flux assay,EC50,O=C(O[H])CC(C#CC)C1=CC=C(OCC2=CC(C3=CC=C(C(F)(F)F)C=C3)=CC=C2)C=C1,=,0.025,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"AMG 837: A potent, orally bioavailable GPR58 agonist",10.1016/j.bmcl.2011.10.118,Article,CHO,Calcium flux assay,EC50,O=C(O[H])CC(C#CC)C1=CC=C(OCCC2=CC=CC=C2)C=C1,=,6.2,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-6226: A Potent and Orally Bioavailable GPR40 Full Agonist that Displays Efficacy in Non-Human Primates.,10.1021/acsmedchemlett.8b00213,Article,CHO,Unknown,EC50,COC1=CC(C(C([C@H]2C(C)(C)CCC2)=C3)=CC=C3COC4=CC=CC(C(CC(O[H])=O)[H])=C4)=C(F)C=C1,=,0.45,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-6226: A Potent and Orally Bioavailable GPR41 Full Agonist that Displays Efficacy in Non-Human Primates.,10.1021/acsmedchemlett.8b00213,Article,CHO,Unknown,EC50,COC1=CC(C(C([C@H]2C(C)(C)CCC2)=C3)=CC=C3COC4=CC=CC([C@H](C)CC(O[H])=O)=C4)=C(F)C=C1,=,0.17,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-6226: A Potent and Orally Bioavailable GPR42 Full Agonist that Displays Efficacy in Non-Human Primates.,10.1021/acsmedchemlett.8b00213,Article,CHO,Unknown,EC50,COC1=CC(C(C([C@H]2C(C)(C)CCC2)=C3)=CC=C3COC4=CC=CC([C@H](CC)CC(O[H])=O)=C4)=C(F)C=C1,=,0.08,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-6226: A Potent and Orally Bioavailable GPR43 Full Agonist that Displays Efficacy in Non-Human Primates.,10.1021/acsmedchemlett.8b00213,Article,CHO,Unknown,EC50,COC1=CC(C(C([C@H]2C(C)(C)CCC2)=C3)=CC=C3COC4=CC=CC([C@H](CCC)CC(O[H])=O)=C4)=C(F)C=C1,=,0.11,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-6226: A Potent and Orally Bioavailable GPR44 Full Agonist that Displays Efficacy in Non-Human Primates.,10.1021/acsmedchemlett.8b00213,Article,CHO,Unknown,EC50,COC1=CC(C(C([C@H]2C(C)(C)CCC2)=C3)=CC=C3COC4=CC=CC([C@H](C5CC5)CC(O[H])=O)=C4)=C(F)C=C1,=,0.08,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-6226: A Potent and Orally Bioavailable GPR45 Full Agonist that Displays Efficacy in Non-Human Primates.,10.1021/acsmedchemlett.8b00213,Article,CHO,Unknown,EC50,COC1=CC(C(C([C@H]2C(C)(C)CCC2)=C3)=CC=C3COC4=CC=CC([C@H](C5CCC5)CC(O[H])=O)=C4)=C(F)C=C1,=,0.09,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-6226: A Potent and Orally Bioavailable GPR46 Full Agonist that Displays Efficacy in Non-Human Primates.,10.1021/acsmedchemlett.8b00213,Article,CHO,Unknown,EC50,COC1=CC(C(C([C@H]2C(C)(C)CCC2)=C3)=CC=C3COC4=CC=CC([C@H](CC5CC5)CC(O[H])=O)=C4)=C(F)C=C1,=,0.1,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-6226: A Potent and Orally Bioavailable GPR47 Full Agonist that Displays Efficacy in Non-Human Primates.,10.1021/acsmedchemlett.8b00213,Article,CHO,Unknown,EC50,COC1=CC(C(C([C@H]2C(C)(C)CCC2)=C3)=CC=C3COC4=CC=CC([C@@H](CC)CC(O[H])=O)=C4)=C(F)C=C1,=,1.96,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-6226: A Potent and Orally Bioavailable GPR48 Full Agonist that Displays Efficacy in Non-Human Primates.,10.1021/acsmedchemlett.8b00213,Article,CHO,Unknown,EC50,COC1=CC(C(C([C@H]2C(C)(C)CCC2)=C3)=CC=C3COC4=CC=CC([C@@H](C5CC5)CC(O[H])=O)=C4)=C(F)C=C1,=,1.83,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-6226: A Potent and Orally Bioavailable GPR49 Full Agonist that Displays Efficacy in Non-Human Primates.,10.1021/acsmedchemlett.8b00213,Article,CHO,Unknown,EC50,COC1=CC(C(C([C@H]2C(C)(C)CCC2)=C3)=CC=C3COC4=CC=CC([C@H](CC)CC(O[H])=O)=C4F)=C(F)C=C1,=,0.12,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-6226: A Potent and Orally Bioavailable GPR50 Full Agonist that Displays Efficacy in Non-Human Primates.,10.1021/acsmedchemlett.8b00213,Article,CHO,Unknown,EC50,COC1=CC(C(C([C@H]2C(C)(C)CCC2)=C3)=CC=C3COC4=CC=C(F)C([C@H](CC)CC(O[H])=O)=C4)=C(F)C=C1,=,0.21,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-6226: A Potent and Orally Bioavailable GPR51 Full Agonist that Displays Efficacy in Non-Human Primates.,10.1021/acsmedchemlett.8b00213,Article,CHO,Unknown,EC50,COC1=CC(C(C([C@H]2C(C)(C)CCC2)=C3)=CC=C3COC4=CC(F)=CC([C@H](CC)CC(O[H])=O)=C4)=C(F)C=C1,=,0.09,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-6226: A Potent and Orally Bioavailable GPR52 Full Agonist that Displays Efficacy in Non-Human Primates.,10.1021/acsmedchemlett.8b00213,Article,CHO,Unknown,EC50,COC1=CC(C(C([C@H]2C(C)(C)CCC2)=C3)=CC=C3COC4=C(F)C=CC([C@H](CC)CC(O[H])=O)=C4)=C(F)C=C1,=,0.74,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery of AM-6226: A Potent and Orally Bioavailable GPR53 Full Agonist that Displays Efficacy in Non-Human Primates.,10.1021/acsmedchemlett.8b00213,Article,CHO,Unknown,EC50,COC1=CC(C(C([C@H]2C(C)(C)CCC2)=C3)=CC=C3COC4=CC=CC([C@H](C5CC5)CC(O[H])=O)=C4F)=C(F)C=C1.F,=,0.1,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR40 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)O[C@@H]3C4=CC(C5=C(C)C=C(OCCCS(C)(=O)=O)C=C5C)=CC=C4,=,0.0559,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR41 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)O[C@H]3C4=CC(C5=C(C)C=C(OCCCS(C)(=O)=O)C=C5C)=CC=C4,=,0.282,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR42 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)O[C@H]3C4=CC(C5=C(C)C=C(OCCCS(C)(=O)=O)C=C5C)=CC=C4F,=,0.0675,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR43 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)O[C@@H]3C4=CC(C5=C(C)C=C(OCCCS(C)(=O)=O)C=C5C)=CC=C4F,=,0.0465,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR44 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)O[C@@H]3C4=CC(C5=C(C)C(F)=C(OCCCS(C)(=O)=O)C=C5C)=CC=C4,=,0.0824,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR45 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)O[C@H]3C4=CC(C5=C(C)C(F)=C(OCCCS(C)(=O)=O)C=C5C)=CC=C4,=,0.1207,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR46 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)O[C@H]3C4=CC(C5=CC=C(OCCCS(C)(=O)=O)C=C5Cl)=CC=C4,=,0.1452,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR47 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)O[C@@H]3C4=CC(C5=CC=C(OCCCS(C)(=O)=O)C=C5Cl)=CC=C4,=,0.0948,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR48 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)OC(C4=CC(C5=CC=C(OCCCS(C)(=O)=O)C=C5C)=CC=C4)CO3,=,0.1226,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR49 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)OC(C4=CC(C5=CC=C(OCCCS(C)(=O)=O)C=C5Cl)=CC=C4F)CO3,=,0.0562,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR50 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)OC(C4=CC(C5=CC=C(OCCCS(C)(=O)=O)C=C5Cl)=CC(F)=C4)CO3,=,0.2051,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR51 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)OC(C4=CC(C5=CC=C(OCCCS(C)(=O)=O)C=C5Cl)=C(F)C=C4)CO3,=,0.125,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR52 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)O[C@H](C4=CC(C5=C(C=CC=C5C)C)=CC=C4)CO3,=,0.0529,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR53 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)O[C@@H](C4=CC(C5=C(C=CC=C5C)C)=CC=C4)CO3,=,0.0301,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR54 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)O[C@H](C4=CC(C5=CC=CC=C5C)=CC=C4)CO3,=,0.0393,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR55 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)O[C@@H](C4=CC(C5=CC=CC=C5C)=CC=C4)CO3,=,0.0191,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR56 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)O[C@H](C4=CC(C5=CC=CC=C5Cl)=CC=C4)CO3,=,0.0667,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR57 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)O[C@@H](C4=CC(C5=CC=CC=C5Cl)=CC=C4)CO3,=,0.0567,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR58 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)OC(C4=CC(C5=CC=CC=C5)=CC=C4)CO3,=,0.0654,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR59 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)OC(C4=CC(C5=CC=C(F)C=C5C)=CC=C4)CO3,=,0.0359,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR60 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)OC(C4=CC(C5=CC=C(C)C=C5C)=CC=C4)CO3,=,0.0387,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR61 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)OC(C4=CC(C5=C(C)C=C(C)C=C5C)=CC=C4)CO3,=,0.0616,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR62 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)OC(C4=CC(C5=CC(C)=CC=C5C)=CC=C4)CO3,=,0.088,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR63 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)OC(C4=CC(C5=CC(C)=CC(C)=C5)=CC=C4)CO3,=,0.132,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR64 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H]1C2=CC3=C(OC(CO3)C4=CC(C5=CC=C(C=C5Cl)F)=CC=C4)C=C2OC1)O[H],=,0.0747,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR65 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)OC(C4=CC(C5=CC=CC=C5F)=CC=C4)CO3,=,0.0732,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR66 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)OC(C4=CC(C5=CC=CC=C5C(F)(F)F)=CC=C4)CO3,=,0.0745,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR67 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OCC(C3=CC(Br)=CC=C3)O4)=C4C=C2OC1,=,0.0547,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR68 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC[C@@H](C3=CC(Br)=CC=C3)O4)=C4C=C2OC1,=,0.0135,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR69 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC[C@H](C3=CC(Br)=CC=C3)O4)=C4C=C2OC1,=,0.1111,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR70 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC[C@@H](C3=CC(Cl)=CC=C3)O4)=C4C=C2OC1,=,0.0342,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR71 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC[C@H](C3=CC(Cl)=CC=C3)O4)=C4C=C2OC1,=,0.2198,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR72 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC[C@@H](C3=CC(Cl)=C(Cl)C=C3)O4)=C4C=C2OC1,=,0.016,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR73 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC[C@H](C3=CC(Cl)=C(Cl)C=C3)O4)=C4C=C2OC1,=,0.1905,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR74 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC[C@@H](C3=CC(C(F)(F)F)=CC=C3)O4)=C4C=C2OC1,=,0.0113,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR75 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC[C@H](C3=CC(C(F)(F)F)=CC=C3)O4)=C4C=C2OC1,=,0.0304,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR76 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC[C@H](C3=CC(C(F)(F)F)=CC(F)=C3)O4)=C4C=C2OC1,=,0.0637,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel orally bioavailable GPR77 agonists,10.1016/j.bmcl.2013.03.060,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC[C@H](C3=CC(Br)=CC(F)=C3)O4)=C4C=C2OC1,=,0.1051,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR40?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1C(SC(N1[H])=O)CC2=CC=C(OC(C=C3)=C(Cl)C=C3Cl)C=C2,=,0.101,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR41?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1C(OC(N1[H])=O)CC2=CC=C(OC(C=C3)=C(Cl)C=C3Cl)C=C2,=,4.017,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR42?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1C(CC(N1[H])=O)CC2=CC=C(OC(C=C3)=C(Cl)C=C3Cl)C=C2,=,6.451,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR43?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C(N1[H])C(SC1=O)CC2=CC=C(C=C2)OC3=C(C)C=CC=C3,=,0.124,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR44?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C(N1[H])C(SC1=O)CC2=CC=C(C=C2)OC3=CC(C)=CC=C3,=,0.203,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR45?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C(N1[H])C(SC1=O)CC2=CC=C(C=C2)OC3=CC=C(C)C=C3,=,0.547,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR46?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C(N1[H])C(SC1=O)CC2=CC=C(C=C2)OC3=CC(C)=CC(C)=C3,=,0.096,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR47?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C(N1[H])C(SC1=O)CC2=CC=C(C=C2)OC3=C(C)C(C)=CC=C3,=,0.334,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR48?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C(N1[H])C(SC1=O)CC2=CC=C(C=C2)OC3=C(C)C=C(C)C=C3,=,0.121,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR49?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C(N1[H])C(SC1=O)CC2=CC=C(C=C2)OC3=C(C)C=CC(C)=C3,=,0.238,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR50?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C(N1[H])C(SC1=O)CC2=CC=C(C=C2)OC3=CC(C)=C(C)C=C3,=,0.727,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR51?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C(N1[H])C(SC1=O)CC2=CC=C(C=C2)OC3=C(Cl)C=CC=C3,=,1.189,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR52?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C(N1[H])C(SC1=O)CC2=CC=C(C=C2)OC3=CC(Cl)=CC=C3,=,0.318,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR53?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C(N1[H])C(SC1=O)CC2=CC=C(C=C2)OC3=CC=C(Cl)C=C3,=,0.24,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR54?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C(N1[H])C(SC1=O)CC2=CC=C(C=C2)OC3=C(Cl)C=C(Cl)C=C3,=,0.101,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR55?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C(N1[H])C(SC1=O)CC2=CC=C(C=C2)OC3=CC(Cl)=CC(Cl)=C3,=,0.207,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR56?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C(N1[H])C(SC1=O)CC2=CC=C(C=C2)OC3=C(Cl)C=C(C(F)(F)F)C=C3,=,0.078,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR57?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C(N1[H])C(SC1=O)CC2=CC=C(C=C2)OC3=CC(C)=C(C#N)C(C)=C3,=,0.12,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR58?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=CC=C(OC3=CC=CC=C3)C=C2)=O,=,0.307,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR59?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=CC(OC3=CC=CC=C3)=CC=C2)=O,=,4.7,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR60?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=C(OC3=CC=CC=C3)C=CC=C2)=O,=,11.27,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR61?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=CC=C(SC3=CC=CC=C3)C=C2)=O,=,5.064,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR62?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=CC=C(CC3=CC=CC=C3)C=C2)=O,=,9.283,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR63?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=CC=C(/C=C\C3=CC=CC=C3)C=C2)=O,=,2.094,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR64?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=CC=C(CCC3=CC=CC=C3)C=C2)=O,=,1.082,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR65?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=CC=C(OCC3=CC=CC=C3)C=C2)=O,=,6.178,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR66?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=CC=C(C(C3=CC=CC=C3)=O)C=C2)=O,=,5.3,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR67?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=CC=C(C3=CC=CC=C3)C=C2)=O,=,2.219,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR68?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=CC=C(OC3=NC(C(F)(F)F)=CC=C3)C=C2)=O,=,2.287,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR69?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=CC=C(OC3=NC=C(C(F)(F)F)C=C3)C=C2)=O,=,0.237,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR70?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=CC=C(OC3=NC=CC(C(F)(F)F)=C3)C=C2)=O,=,0.558,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR71?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=CC=C(OC3=NC=CC=C3C(F)(F)F)C=C2)=O,=,1.635,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR72?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=CC=C(OC3=NC(C)=CC=C3)C=C2)=O,=,1.087,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR73?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=CC=C(OC3=NC=C(C)C=C3)C=C2)=O,=,4.282,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR74?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=CC=C(OC3=NC=CC(C)=C3)C=C2)=O,=,4.474,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR75?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=CC=C(OC3=NC=CC=C3C)C=C2)=O,=,2.62,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR76?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=CC=C(OC3=NC=CC(Cl)=C3)C=C2)=O,=,1.872,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR77?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=CC=C(OC3=NC=C(C(F)(F)F)C=C3C)C=C2)=O,=,0.218,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR78?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=CC=C(OC3=NC=C(C)C=C3C(F)(F)F)C=C2)=O,=,0.688,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR79?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=CC=C(OC3=NC(Cl)=CC(C(F)(F)F)=C3)C=C2)=O,=,0.069,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR80?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=CC=C(OC3=NC(Cl)=CC(Cl)=C3)C=C2)=O,=,0.09,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR81?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=C(C)C=C(OC3=NC=C(C(F)(F)F)C=C3Cl)C=C2)=O,=,0.01,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR82?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=C(C)C=C(OC3=CC=C(C(F)(F)F)C=C3Cl)C=C2)=O,=,0.018,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR83?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=C(Cl)C=C(OC3=NC=C(C(F)(F)F)C=C3Cl)C=C2)=O,=,0.026,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR84?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=C(Cl)C=C(OC3=NC=C(Cl)C=C3Cl)C=C2)=O,=,0.063,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR85?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=C(C(F)(F)F)C=C(OC3=CC=C(Cl)C=C3Cl)C=C2)=O,=,0.088,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR86?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=C(OC)C=C(OC3=CC=C(Cl)C=C3Cl)C=C2)=O,=,1.407,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR87?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=C(OC)C=C(OC3=NC=C(C(F)(F)F)C=C3Cl)C=C2)=O,=,13.85,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR88?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=C(C)C=C(OC3=NC=C(C(F)(F)F)C=C3Cl)C=C2C)=O,=,5.454,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Discovery of 5-aryloxy-2,4-thiazolidinediones as potent?GPR89?agonists",10.1016/j.bmcl.2009.10.052,Article,Unknown,FLIPR functional assay,EC50,O=C1N([H])C(C(S1)CC2=C(C=CC=C3)C3=C(OC4=NC=C(C(F)(F)F)C=C4Cl)C=C2)=O,=,23.587,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles,10.1021/ml300427u,Article,CHO,Unknown,EC50,COC1=CC(C(C(C2=CCCC2(C)C)=C3)=CC=C3COC4=CC=CC([C@H](C5CC5)CC(O[H])=O)=C4)=C(F)C=C1,=,0.16,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery and Optimization of Potent GPR41 Full Agonists Containing Tricyclic Spirocycles,10.1021/ml300427u,Article,CHO,Unknown,EC50,COC1=CC(C(C(C2=CCCC2(C)C)=C3)=CC=C3COC4=CC=CC(CCC(O[H])=O)=C4)=C(F)C=C1,=,0.79,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery and Optimization of Potent GPR42 Full Agonists Containing Tricyclic Spirocycles,10.1021/ml300427u,Article,CHO,Unknown,EC50,COC1=CC(C(C(C2=CCCC2(C)C)=C3)=CC=C3COC4=CC=C5C([C@@H](CC(O[H])=O)CC5)=C4)=C(F)C=C1,=,0.5,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery and Optimization of Potent GPR43 Full Agonists Containing Tricyclic Spirocycles,10.1021/ml300427u,Article,CHO,Unknown,EC50,COC1=CC(C(C(C2=CCCC2(C)C)=C3)=CC=C3COC4=CC=C5C([C@@]([C@H]6C(O[H])=O)([H])[C@@]6([H])C5)=C4)=C(F)C=C1,=,1.42,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery and Optimization of Potent GPR44 Full Agonists Containing Tricyclic Spirocycles,10.1021/ml300427u,Article,CHO,Unknown,EC50,COC1=CC(C(C(C2=CCCC2(C)C)=C3)=CC=C3COC4=CC=C(CC[C@@]5(C6)[C@]6([H])C(O[H])=O)C5=C4)=C(F)C=C1,=,0.18,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery and Optimization of Potent GPR45 Full Agonists Containing Tricyclic Spirocycles,10.1021/ml300427u,Article,CHO,Unknown,EC50,COC1=CC(C(C(C2=CCCC2(C)C)=C3)=CC=C3COC4=CC=CC([C@H](C5)[C@]5([H])C(O[H])=O)=C4)=C(F)C=C1,=,1.38,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery and Optimization of Potent GPR46 Full Agonists Containing Tricyclic Spirocycles,10.1021/ml300427u,Article,CHO,Unknown,EC50,COC1=CC(C(C(C2=CCCC2(C)C)=C3)=CC=C3COC4=CC=CC([C@@](C5)(C)[C@]5([H])C(O[H])=O)=C4)=C(F)C=C1,=,2.13,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery and Optimization of Potent GPR47 Full Agonists Containing Tricyclic Spirocycles,10.1021/ml300427u,Article,CHO,Unknown,EC50,COC1=CC(C(C(C2=CCCC2(C)C)=C3)=CC=C3COC4=CC=C5C([C@@]([C@]6([H])C(O[H])=O)(C6)CCC5)=C4)=C(F)C=C1,=,0.15,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery and Optimization of Potent GPR48 Full Agonists Containing Tricyclic Spirocycles,10.1021/ml300427u,Article,CHO,Unknown,EC50,COC1=CC(C(C(C2=CCCC2(C)C)=C3)=CC=C3COC4=CC=C5C([C@@]([C@]6([H])C(O[H])=O)(CC6)CCC5)=C4)=C(F)C=C1,=,0.35,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery and Optimization of Potent GPR49 Full Agonists Containing Tricyclic Spirocycles,10.1021/ml300427u,Article,CHO,Unknown,EC50,COC1=CC(C(C(C2=CCCC2(C)C)=C3)=CC=C3COC4=CC=C(CC5)C([C@]5(CC6)[C@]6([H])C(O[H])=O)=C4)=C(F)C=C1,=,0.52,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery and Optimization of Potent GPR50 Full Agonists Containing Tricyclic Spirocycles,10.1021/ml300427u,Article,CHO,Unknown,EC50,COC1=CC(C(C(C2=CCCC2(C)C)=C3)=CC=C3COC4=CC=C5C([C@]6([C@@]([H])(C6)C(O[H])=O)C5)=C4)=C(F)C=C1,=,0.82,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery and Optimization of Potent GPR51 Full Agonists Containing Tricyclic Spirocycles,10.1021/ml300427u,Article,CHO,Unknown,EC50,FC1C(C=C(OC)C=C1)C(C([C@@H]2CCCC2(C)C)=C3)=CC=C3COC4=CC=C5CC[C@]6(C[C@]6(C(O[H])=O)[H])C5=C4,=,0.081,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery and Optimization of Potent GPR52 Full Agonists Containing Tricyclic Spirocycles,10.1021/ml300427u,Article,CHO,Unknown,EC50,FC1=C(C=C(OC)C=C1)C(C([C@H]2CCCC2(C)C)=C3)=CC=C3COC4=CC=C5CC[C@]6(C[C@]6(C(O[H])=O)[H])C5=C4,=,0.212,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery and Optimization of Potent GPR53 Full Agonists Containing Tricyclic Spirocycles,10.1021/ml300427u,Article,CHO,Unknown,EC50,FC1=C(C=C(OC)C=C1)C(C([C@@H]2CCCC2(C)C)=C3)=CC=C3COC4=CC=C5C([C@]6(CCC5)C[C@]6(C(O[H])=O)[H])=C4,=,0.092,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery and Optimization of Potent GPR54 Full Agonists Containing Tricyclic Spirocycles,10.1021/ml300427u,Article,CHO,Unknown,EC50,FC1=C(C=C(OC)C=C1)C(C([C@@H]2CCCC2(C)C)=C3)=CC=C3COC4=CC=C5C([C@]6(CCC5)C[C@]6(C(O[H])=O)[H])=C4F,=,0.098,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery and Optimization of Potent GPR55 Full Agonists Containing Tricyclic Spirocycles,10.1021/ml300427u,Article,CHO,Unknown,EC50,FC1=C(C=C(OC)N=C1)C(C([C@@H]2CCCC2(C)C)=C3)=CC=C3COC4=CC=C5C([C@]6(CCC5)C[C@]6(C(O[H])=O)[H])=C4F,=,0.105,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR40 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,CC1=CC=CC=C1C(C2=C3)=CSC2=CC=C3COC(C=C4)=CC=C4[C@H](CC5=NN=NN5[H])C#CC,=,0.009,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR41 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,CC1=CC=CC=C1C(C2=C3)=C(C)SC2=CC=C3COC(C=C4)=CC=C4[C@H](CC5=NN=NN5[H])C#CC,=,0.02,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR42 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,CC1=CC=CC=C1C(C2=C3)=C(F)SC2=CC=C3COC(C=C4)=CC=C4[C@H](CC5=NN=NN5[H])C#CC,=,0.015,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR43 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,CC1=CC=CC=C1C(C2=C3)=C(Cl)SC2=CC=C3COC(C=C4)=CC=C4[C@H](CC5=NN=NN5[H])C#CC,=,0.02,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR44 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,CC1=CC=CC=C1C(C2=C3)=C(Br)SC2=CC=C3COC(C=C4)=CC=C4[C@H](CC5=NN=NN5[H])C#CC,=,0.019,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR45 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,CC1=CC=CC=C1C(C2=C3)=C(I)SC2=CC=C3COC(C=C4)=CC=C4[C@H](CC5=NN=NN5[H])C#CC,=,0.028,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR46 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,CC1=CC=CC=C1C(C2=C3)=C(C#N)SC2=CC=C3COC(C=C4)=CC=C4[C@H](CC5=NN=NN5[H])C#CC,=,0.016,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR47 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,CC1=CC=CC=C1C(C2=C3)=C(C(F)(F)F)SC2=CC=C3COC(C=C4)=CC=C4[C@H](CC5=NN=NN5[H])C#CC,=,0.015,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR48 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,CC1=CC=CC=C1C(C2=C3)=C(S(=O)(C)=O)SC2=CC=C3COC(C=C4)=CC=C4[C@H](CC5=NN=NN5[H])C#CC,=,0.672,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR49 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,CC1=CC=CC=C1C(C2=C3)=CSC2=C(C)C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC5=NN=NN5[H],=,0.134,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR50 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,CC1=CC=CC=C1C(C2=C3)=CSC2=C(F)C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC5=NN=NN5[H],=,0.023,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR51 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,CC1=CC(OC)=CC=C1C(C2=C3)=CSC2=C(F)C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC5=NN=NN5[H],=,0.01,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR52 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,CC1=CC(OC)=CC=C1C(C2=C3)=CSC2=C(Cl)C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC5=NN=NN5[H],=,0.025,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR53 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,CC1=CC=CC=C1C(C2=C3)=CSC2=C(Cl)C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC5=NN=NN5[H],=,0.063,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR54 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC=C4C(C(C5=CC=C(OCCOC)C=C5C)=CS4)=C3)=NN=N1,=,0.009,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR55 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC=C4C(C(C5=CC=CC(OCCOC)=C5C)=CS4)=C3)=NN=N1,=,0.054,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR56 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC=C4C(C(C5=C(C)C=CC(OCCOC)=C5)=CS4)=C3)=NN=N1,=,0.085,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR57 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC=C4C(C(C5=C(C)C=C(OCC(O[H])CO[H])C=C5)=CS4)=C3)=NN=N1,=,0.029,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR58 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC=C4C(C(C5=C(C)C=C(OCCC(C)(C)O[H])C=C5)=CS4)=C3)=NN=N1,=,0.008,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR59 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC=C4C(C(C5=C(C)C=C(OCCCS(C)(=O)=O)C=C5)=CS4)=C3)=NN=N1,=,0.012,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR60 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC=C4C(C(C5=C(C)C=C(OCC(C6)(C)CS6(=O)=O)C=C5)=CS4)=C3)=NN=N1,=,0.03,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR61 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC=C4C(C(C5=C(C(F)(F)F)C=CC=C5)=CS4)=C3)=NN=N1,=,0.013,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR62 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC=C4C(C(C5=C(C)N=CC=C5)=CS4)=C3)=NN=N1,=,0.088,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR63 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC=C4C(C(C5=C(C)N=CN=C5)=CS4)=C3)=NN=N1,=,0.037,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR64 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC=C4C(C(C5=CC=NN5C)=CS4)=C3)=NN=N1,=,0.067,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR65 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC=C4C(C(N5C(C)CCCC5)=CS4)=C3)=NN=N1,=,0.083,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR66 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC=C4C(C(C5CCCCC5)=CS4)=C3)=NN=N1,=,0.107,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR67 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC=C4C(C(C5CC5)=CS4)=C3)=NN=N1,=,0.858,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR68 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,CC(SC1=CC=C2COC(C=C3)=CC=C3[C@@H](C#CC)CC4=NN=NN4[H])=C(C1=C2)C5=CC=C(OCCOC)C=C5C,=,0.047,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR69 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,FC(SC1=CC=C2COC(C=C3)=CC=C3[C@@H](C#CC)CC4=NN=NN4[H])=C(C1=C2)C5=CC=C(OCCOC)C=C5C,=,0.018,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR70 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,ClC(SC1=CC=C2COC(C=C3)=CC=C3[C@@H](C#CC)CC4=NN=NN4[H])=C(C1=C2)C5=CC=C(OCCOC)C=C5C,=,0.039,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR71 agonists,10.1016/j.bmcl.2017.12.022,Article,CHO,Calcium flux assays,EC50,CC1=CC(OCCOC)=CC=C1C(C2=C3)=C(SC2=CC=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC5=NN=NN5[H])C(F)(F)F,=,0.013,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel?GPR40?agonists",10.1016/j.ejmech.2018.08.075,Article,HEK293,Calcium flux assay,EC50,O=C(C#CC1=CC=C(C=C1)OCC2=CC(C3=C(C)C=CC=C3C)=CC=C2)O[H],=,0.38,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel?GPR40?agonists",10.1016/j.ejmech.2018.08.075,Article,HEK293,Calcium flux assay,EC50,O=C(C#CC1=CC=C(C=C1)OCC2=CC(C3=C(C)C=C(C)C=C3C)=CC=C2)O[H],=,2.87,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel?GPR40?agonists",10.1016/j.ejmech.2018.08.075,Article,HEK293,Calcium flux assay,EC50,O=C(C#CC1=CC=C(C=C1)OCC2=CC(C3=CC=CC=C3C)=CC=C2)O[H],=,0.61,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel?GPR40?agonists",10.1016/j.ejmech.2018.08.075,Article,HEK293,Calcium flux assay,EC50,O=C(C#CC1=CC=C(C=C1)OCC2=CC(C3=CC=CC=C3)=CC=C2)O[H],=,3.77,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel?GPR40?agonists",10.1016/j.ejmech.2018.08.075,Article,HEK293,Calcium flux assay,EC50,O=C(C#CC1=CC=C(C=C1)OCC2=CC(C3=CC=CC=C3OC(F)(F)F)=CC=C2)O[H],=,2.85,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel?GPR40?agonists",10.1016/j.ejmech.2018.08.075,Article,HEK293,Calcium flux assay,EC50,O=C(C#CC1=CC=C(C=C1)OCC2=CC(C3=CC=CC=C3Cl)=CC=C2)O[H],=,0.69,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel?GPR40?agonists",10.1016/j.ejmech.2018.08.075,Article,HEK293,Calcium flux assay,EC50,O=C(C#CC1=CC=C(C=C1)OCC2=CC(C3=CC=CC=C3C(C)C)=CC=C2)O[H],=,3.98,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel?GPR40?agonists",10.1016/j.ejmech.2018.08.075,Article,HEK293,Calcium flux assay,EC50,O=C(C#CC1=CC=C(C=C1)OCC2=CC(C3=CC=CC(F)=C3)=CC=C2)O[H],=,1.8,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel?GPR40?agonists",10.1016/j.ejmech.2018.08.075,Article,HEK293,Calcium flux assay,EC50,O=C(C#CC1=CC=C(C=C1)OCC2=CC(C3=CC=CC(C)=C3)=CC=C2)O[H],>,10,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel?GPR40?agonists",10.1016/j.ejmech.2018.08.075,Article,HEK293,Calcium flux assay,EC50,O=C(C#CC1=CC=C(C=C1)OCC2=CC(C3=CC=CC(C(F)(F)F)=C3)=CC=C2)O[H],>,10,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel?GPR40?agonists",10.1016/j.ejmech.2018.08.075,Article,HEK293,Calcium flux assay,EC50,O=C(C#CC1=CC=C(C=C1)OCC2=CC(C3=CC=C(C(C)(C)C)C=C3)=CC=C2)O[H],>,10,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel?GPR40?agonists",10.1016/j.ejmech.2018.08.075,Article,HEK293,Calcium flux assay,EC50,O=C(C#CC1=CC=C(C=C1)OCC2=CC(C3=CC=C(S(=O)(C)=O)C=C3)=CC=C2)O[H],>,10,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel?GPR40?agonists",10.1016/j.ejmech.2018.08.075,Article,HEK293,Calcium flux assay,EC50,O=C(C#CC1=CC=C(C=C1)OCC2=CC(C3=CC=C(OC(F)(F)F)C=C3)=CC=C2)O[H],>,10,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel?GPR40?agonists",10.1016/j.ejmech.2018.08.075,Article,HEK293,Calcium flux assay,EC50,O=C(C#CC1=CC=C(C=C1)OCC2=CC(C3=CC=C(C)C=C3Cl)=CC=C2)O[H],=,8.08,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel?GPR40?agonists",10.1016/j.ejmech.2018.08.075,Article,HEK293,Calcium flux assay,EC50,O=C(C#CC1=CC=C(C=C1)OCC2=CC(C3=CC(F)=CC=C3F)=CC=C2)O[H],>,10,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel?GPR40?agonists",10.1016/j.ejmech.2018.08.075,Article,HEK293,Calcium flux assay,EC50,O=C(C#CC1=CC=C(C=C1)OCC2=CC(OC3=CC=CC=C3)=CC=C2)O[H],=,1.1,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel?GPR40?agonists",10.1016/j.ejmech.2018.08.075,Article,HEK293,Calcium flux assay,EC50,O=C(C#CC1=CC=C(C=C1)OCC2=CC=C(OC3=CC=CC=C3)C=C2)O[H],=,4.02,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel?GPR40?agonists",10.1016/j.ejmech.2018.08.075,Article,HEK293,Calcium flux assay,EC50,O=C(C#CC1=CC=C(C=C1)OCC2=CC(OCC3=CC=CC=C3)=CC=C2)O[H],>,10,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists,10.1016/j.bmcl.2014.04.065,Article,CHO,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CC(COC(C=C3)=CC=C3CCC(O[H])=O)=CC=C2,=,0.0067,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR41 agonists,10.1016/j.bmcl.2014.04.065,Article,CHO,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CC(COC(N=C3)=CC=C3CCC(O[H])=O)=CC=C2,=,0.0035,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR42 agonists,10.1016/j.bmcl.2014.04.065,Article,CHO,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CC(COC(C=N3)=CC=C3CCC(O[H])=O)=CC=C2,=,0.071,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR43 agonists,10.1016/j.bmcl.2014.04.065,Article,CHO,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CC(COC(S3)=CC=C3CCC(O[H])=O)=CC=C2,=,0.052,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR44 agonists,10.1016/j.bmcl.2014.04.065,Article,CHO,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CC(COC(S3)=NC=C3CCC(O[H])=O)=CC=C2,=,0.065,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR45 agonists,10.1016/j.bmcl.2014.04.065,Article,CHO,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CC(COC(N=C3)=CN=C3CCC(O[H])=O)=CC=C2,=,0.0038,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR46 agonists,10.1016/j.bmcl.2014.04.065,Article,CHO,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CC(COC(N=N3)=CC=C3CCC(O[H])=O)=CC=C2,=,0.42,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR47 agonists,10.1016/j.bmcl.2014.04.065,Article,CHO,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CC(COC(N=C3)=NC=C3CCC(O[H])=O)=CC=C2,=,0.13,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR48 agonists,10.1016/j.bmcl.2014.04.065,Article,CHO,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CC(COC(N=C3)=CC(C)=C3CCC(O[H])=O)=CC=C2,=,0.0093,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR49 agonists,10.1016/j.bmcl.2014.04.065,Article,CHO,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CC(COC(N=C3C)=CC=C3CCC(O[H])=O)=CC=C2,=,0.081,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR50 agonists,10.1016/j.bmcl.2014.04.065,Article,CHO,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CC(COC(N=C3)=C(C)C=C3CCC(O[H])=O)=CC=C2,=,2.5,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR51 agonists,10.1016/j.bmcl.2014.04.065,Article,CHO,Calcium flux assay,EC50,CC(C=CC=C1C)=C1C2=CC(COC3=CC=C(CC(C(O[H])=O)F)C=N3)=CC=C2,=,0.0086,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR52 agonists,10.1016/j.bmcl.2014.04.065,Article,CHO,Calcium flux assay,EC50,CC(C=CC=C1C)=C1C2=CC(COC3=CC=C(CC(C(O[H])=O)C)C=N3)=CC=C2,=,0.065,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR53 agonists,10.1016/j.bmcl.2014.04.065,Article,CHO,Calcium flux assay,EC50,CC(C=CC=C1C)=C1C2=CC(COC3=CC=C(CC(C(O[H])=O)OC)C=N3)=CC=C2,=,0.12,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR54 agonists,10.1016/j.bmcl.2014.04.065,Article,CHO,Calcium flux assay,EC50,CC(C=CC=C1C)=C1C2=CC(COC3=CC=C(C(F)CC(O[H])=O)C=N3)=CC=C2.F,=,0.018,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR55 agonists,10.1016/j.bmcl.2014.04.065,Article,CHO,Calcium flux assay,EC50,CC(C=CC=C1C)=C1C2=CC(COC3=CC=C(C(C)CC(O[H])=O)C=N3)=CC=C2.F,=,0.01,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR56 agonists,10.1016/j.bmcl.2014.04.065,Article,CHO,Calcium flux assay,EC50,CC(C=CC=C1C)=C1C2=CC(COC3=CC=C(C(OCC)CC(O[H])=O)C=N3)=CC=C2.F,=,0.014,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR57 agonists,10.1016/j.bmcl.2014.04.065,Article,CHO,Calcium flux assay,EC50,CC(C=CC=C1C)=C1C2=CC(COC3=CC4=C(C(CC(O[H])=O)OC4)C=N3)=CC=C2.F,=,0.049,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR58 agonists,10.1016/j.bmcl.2014.04.065,Article,CHO,Calcium flux assay,EC50,CC1=CC=CC=C1COC2=CC=C(C(CC(O[H])=O)OCC)C=N2,=,0.23,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR59 agonists,10.1016/j.bmcl.2014.04.065,Article,CHO,Calcium flux assay,EC50,CC1=CC=CC=C1COC2=CC=C(C(CC(O[H])=O)OCC)C=C2,=,0.02,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR60 agonists,10.1016/j.bmcl.2014.04.065,Article,CHO,Calcium flux assay,EC50,O=C(O[H])CC(OCC)C1=CC=C(C=C1)OCC2=CC=CC(C)=C2,=,0.035,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR61 agonists,10.1016/j.bmcl.2014.04.065,Article,CHO,Calcium flux assay,EC50,O=C(O[H])CC(OCC)C1=CC=C(C=C1)OCC2=CC=C(C)C=C2,=,0.37,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1558,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CC1=CC=CC=C1COC2=CC=C(C(C(F)(F)C(O[H])=O)OCC)C=C2,=,3.8,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1559,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CC1=CC=CC=C1COC2=CC=C(C(CC(N([H])S(=O)(C)=O)=O)OCC)C=C2,=,0.58,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1560,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C=C1)N(C(C2=CC=CC=C2C)=O)[H],=,1.6,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1561,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C=C1)N(CC2=CC=C(Cl)C(Cl)=C2)[H],=,0.027,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1562,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C(F)=C1)OCC2=CC=C(Cl)C(Cl)=C2,=,0.21,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1563,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C(C)=C1)OCC2=CC=C(Cl)C(Cl)=C2,=,1.5,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1564,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C=C1F)OCC2=CC=C(Cl)C(Cl)=C2,=,0.012,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1565,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C=C1Cl)OCC2=CC=C(Cl)C(Cl)=C2,=,0.098,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1566,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C=C1OC)OCC2=CC=C(Cl)C(Cl)=C2,=,0.97,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1567,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C=C1)OCC2=CC=CC(C)=C2,=,0.035,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1568,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C=C1)OCC2=CC=C(C)C=C2,=,0.37,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1569,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C=C1)OCC2=CC=CC(F)=C2,=,0.03,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1570,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C=C1)OCC2=CC=CC(Cl)=C2,=,0.019,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1571,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C=C1)OCC2=CC=CC(OC)=C2,=,0.089,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1572,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C=C1)OCC2=CC=CC(OC3=CC=CC=C3)=C2,=,0.023,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1573,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C=C1)OCC2=CC=CC(C#N)=C2,=,0.053,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1574,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C=C1)OCC2=CC=C(Cl)C=C2,=,0.012,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1575,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C=C1)OCC2=CC=C(C(F)(F)F)C=C2,=,0.0072,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1576,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C=C1)OCC2=CC=C(Cl)C(Cl)=C2,=,0.0062,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1577,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C=C1)OCC2CCCCC2,=,0.035,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1578,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C=C1)OCC2=CC=CN=C2C,=,2.1,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1579,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C=C1)OCC2=C3C(C=CC=C3)=C(F)C=C2,=,0.013,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1580,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C=C1)OCCC2=CC=C(Cl)C(Cl)=C2,=,0.065,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1581,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C=C1)OC2=CC(Cl)=C(Cl)C=C2,=,0.049,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1582,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C=C1)OC2=C3C(C=CC=C3)=C(Cl)C=C2,=,0.56,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1583,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,CCOC(CC(O[H])=O)C1=CC=C(C=C1)OCC2=CC(Cl)=C(Cl)C=C2,=,0.147,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1584,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H](OCC)C1=CC=C(C=C1)OCC2=CC=C(C(F)(F)F)C=C2)O[H],=,0.0053,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1585,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H](OCC)C1=CC=C(C=C1)OCC2=CC=C(C(F)(F)F)C=C2F)O[H],=,0.013,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1586,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H](OCC)C1=CC=C(C=C1)OCC2=CC=C(OC(F)(F)F)C(F)=C2)O[H],=,0.0075,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1587,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H](OCC)C1=CC=C(C=C1)O[C@@H]2C(C=CC=C3)=C3CC2)O[H],=,0.069,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1588,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H](OCC)C1=CC=C(C=C1)O[C@H]2C(C=CC=C3)=C3CC2)O[H],=,0.031,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1589,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H](OCC)C1=CC=C(C=C1)O[C@@H]2CCCC3=C2C=CC=C3)O[H],=,0.062,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1590,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H](OCC)C1=CC=C(C=C1)OC2CC3=C(C=CC=C3)C2)O[H],=,0.082,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1591,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H](OCC)C1=CC=C(C=C1)OC2C3=C(N=CC=C3)CC2)O[H],=,5.6,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1592,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H](OCC)C1=CC=C(C=C1)OC2=NOC3=C2C=CC=C3C)O[H],=,0.12,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1593,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H](OCC)C1=CC=C(C=C1)O[C@H]2C3=C(C(C)=CC=C3)CC2)O[H],=,0.029,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1594,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H](OCC)C1=CC=C(C=C1)O[C@H]2C3=C(C(CC)=CC=C3)CC2)O[H],=,0.012,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1595,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H](OCC)C1=CC=C(C=C1)O[C@H]2C3=C(C(C(C)C)=CC=C3)CC2)O[H],=,0.012,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1596,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H](OCC)C1=CC=C(C=C1)O[C@H]2C3=C(C(C4CC4)=CC=C3)CC2)O[H],=,0.013,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1597,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H](OCC)C1=CC=C(C=C1)OC2C3=C(C(OC)=CC=C3)CC2)O[H],=,0.19,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1598,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H](OCC)C1=CC=C(C=C1)O[C@H]2C3=C(C(OCC)=CC=C3)CC2)O[H],=,0.063,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1599,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H](OCC)C1=CC=C(C=C1)O[C@H]2C3=C(C(Cl)=CC=C3)CC2)O[H],=,0.005,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1600,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H](OCC)C1=CC=C(C=C1)O[C@H]2C3=C(C(OC(F)(F)F)=CC=C3)CC2)O[H],=,0.0099,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1601,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H](OCC)C1=CC=C(C=C1)O[C@H]2C3=C(C(C(F)(F)F)=CC=C3)CC2)O[H],=,0.0037,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1602,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H](OCC)C1=CC=C(C=C1)O[C@H]2C3=C(C=C(C(F)(F)F)C=C3)CC2)O[H],=,0.013,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1603,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H](OCC)C1=CC=C(C=C1)O[C@H]2C3=C(C(C(F)(F)F)=CC=C3)OC2)O[H],=,0.021,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1604,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H](OCC)C1=CC=C(N=C1)O[C@H]2C3=C(C(C(F)(F)F)=CC=C3)CC2)O[H],=,0.02,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1605,10.1016/j.bmc.2015.07.028,Article,CHO,Calcium flux assay,EC50,O=C(C[C@H](OCC)C1=CC=C(N=C1)O[C@H]2C3=C(C(C(F)(F)F)=CC=C3)OC2)O[H],=,0.036,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,SAR Studies of Indole-5-propanoic Acid Derivatives To Develop Novel?GPR40?Agonists,10.1021/acsmedchemlett.7b00460,Article,CHO,Luciferase reporter assay,EC50,[H]N(C(C1=C(C)C=CC=C1)=C2)C3=C2C=C(C=C3)CCC(O[H])=O,=,0.447,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,SAR Studies of Indole-5-propanoic Acid Derivatives To Develop Novel?GPR40?Agonists,10.1021/acsmedchemlett.7b00460,Article,CHO,Luciferase reporter assay,EC50,[H]N(C(C1=C(Cl)C=CC=C1)=C2)C3=C2C=C(C=C3)CCC(O[H])=O,=,0.0546,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,SAR Studies of Indole-5-propanoic Acid Derivatives To Develop Novel?GPR41?Agonists,10.1021/acsmedchemlett.7b00460,Article,CHO,Luciferase reporter assay,EC50,[H]N(C(C1=CC=CC(Cl)=C1)=C2)C3=C2C=C(C=C3)CCC(O[H])=O,=,0.0378,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,SAR Studies of Indole-5-propanoic Acid Derivatives To Develop Novel?GPR42?Agonists,10.1021/acsmedchemlett.7b00460,Article,CHO,Luciferase reporter assay,EC50,[H]N(C(C1=CC=C(Cl)C=C1)=C2)C3=C2C=C(C=C3)CCC(O[H])=O,=,0.778,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,SAR Studies of Indole-5-propanoic Acid Derivatives To Develop Novel?GPR43?Agonists,10.1021/acsmedchemlett.7b00460,Article,CHO,Luciferase reporter assay,EC50,[H]N(C(C1=CC=CC(Br)=C1)=C2)C3=C2C=C(C=C3)CCC(O[H])=O,=,1.8,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,SAR Studies of Indole-5-propanoic Acid Derivatives To Develop Novel?GPR44?Agonists,10.1021/acsmedchemlett.7b00460,Article,CHO,Luciferase reporter assay,EC50,[H]N(C(C1=CC=CC=C1C(F)(F)F)=C2)C3=C2C=C(C=C3)CCC(O[H])=O,=,1.308,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,SAR Studies of Indole-5-propanoic Acid Derivatives To Develop Novel?GPR45?Agonists,10.1021/acsmedchemlett.7b00460,Article,CHO,Luciferase reporter assay,EC50,[H]N(C(C1=CC=CC=C1OC(F)(F)F)=C2)C3=C2C=C(C=C3)CCC(O[H])=O,=,1.016,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,SAR Studies of Indole-5-propanoic Acid Derivatives To Develop Novel?GPR46?Agonists,10.1021/acsmedchemlett.7b00460,Article,CHO,Luciferase reporter assay,EC50,[H]N(C(C1=CC=CC=C1F)=C2)C3=C2C=C(C=C3)CCC(O[H])=O,=,1.207,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,SAR Studies of Indole-5-propanoic Acid Derivatives To Develop Novel?GPR47?Agonists,10.1021/acsmedchemlett.7b00460,Article,CHO,Luciferase reporter assay,EC50,[H]N(C(C1=CC=CC=C1Br)=C2)C3=C2C=C(C=C3)CCC(O[H])=O,=,0.0094,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists,10.1016/j.bmcl.2011.03.114,Article,human cells,FLIPR based functional assay,EC50,CC#CC(CC(O[H])=O)C1=CC=C(OC2=C(C)C=C(C(F)(F)F)C=C2)C=C1,=,0.094,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR41 agonists,10.1016/j.bmcl.2011.03.114,Article,human cells,FLIPR based functional assay,EC50,CC#CC(CC(O[H])=O)C1=CC=C(OC2=C(OC(C)(F)F)C=C(C(F)(F)F)C=C2)C=C1,=,0.071,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR42 agonists,10.1016/j.bmcl.2011.03.114,Article,human cells,FLIPR based functional assay,EC50,CC#CC(CC(O[H])=O)C1=CC=C(OC2=C(Cl)C=C(C#N)C=C2)C=C1,=,0.042,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR43 agonists,10.1016/j.bmcl.2011.03.114,Article,human cells,FLIPR based functional assay,EC50,CC#CC(CC(O[H])=O)C1=CC=C(OC2=C(Br)C=C(C#N)C=C2)C=C1,=,0.085,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR44 agonists,10.1016/j.bmcl.2011.03.114,Article,human cells,FLIPR based functional assay,EC50,CC#CC(CC(O[H])=O)C1=CC=C(OC2=C(C=CC=C3)C3=C(C#N)C=C2)C=C1,=,0.053,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR45 agonists,10.1016/j.bmcl.2011.03.114,Article,human cells,FLIPR based functional assay,EC50,CC#CC(CC(O[H])=O)C1=CC=C(OC2=C(C=CC=C3)C3=C(C(F)(F)F)C=C2)C=C1,=,1.401,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR46 agonists,10.1016/j.bmcl.2011.03.114,Article,human cells,FLIPR based functional assay,EC50,CC#CC(CC(O[H])=O)C1=CC=C(OC2=C(Cl)C=C(C(F)(F)F)C=N2)C=C1,=,0.108,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR47 agonists,10.1016/j.bmcl.2011.03.114,Article,human cells,FLIPR based functional assay,EC50,CC#CC(CC(O[H])=O)C1=CC=C(OC2=NC=C(Br)C=N2)C=C1,=,1.568,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR48 agonists,10.1016/j.bmcl.2011.03.114,Article,human cells,FLIPR based functional assay,EC50,CC#CC(CC(O[H])=O)C1=CC=C(OC2=C(C#N)N=CC=N2)C=C1,=,1.578,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR49 agonists,10.1016/j.bmcl.2011.03.114,Article,human cells,FLIPR based functional assay,EC50,CC#CC(CC(O[H])=O)C1=CC=C(OC2=C(C=CC=C3)C3=CC=N2)C=C1,=,0.394,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR50 agonists,10.1016/j.bmcl.2011.03.114,Article,human cells,FLIPR based functional assay,EC50,CC#CC(CC(O[H])=O)C1=CC=C(OC2CCCC3=C2SC(C4=CC=C(C)C=C4)=N3)C=C1,=,0.051,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR51 agonists,10.1016/j.bmcl.2011.03.114,Article,human cells,FLIPR based functional assay,EC50,CC#CC(CC(O[H])=O)C1=CC=C(OC2=CC=C(C(F)(F)F)C=C2OC(C)(F)F)C=C1F,=,0.113,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR52 agonists,10.1016/j.bmcl.2011.03.114,Article,human cells,FLIPR based functional assay,EC50,CC#CC(CC(O[H])=O)C1=CC=C(OC2CCCC2)C=C1,=,0.114,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Identification of an Orally Efficacious GPR40/ FFAR1 Receptor Agonist,10.1021/acsmedchemlett.6b00331,Article,Unknown,Luciferase transactivation assay,EC50,O=C(C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(CNCC3=CC=NC=C3)=CC=C2)O[H],>,1000,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Identification of an Orally Efficacious GPR40/ FFAR2 Receptor Agonist,10.1021/acsmedchemlett.6b00331,Article,Unknown,Luciferase transactivation assay,EC50,O=C(C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(CNCC3=CSC=C3)=CC=C2)O[H],=,0.1183,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Identification of an Orally Efficacious GPR40/ FFAR3 Receptor Agonist,10.1021/acsmedchemlett.6b00331,Article,Unknown,Luciferase transactivation assay,EC50,O=C(C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(CN(C)CC3=CSC=C3)=CC=C2)O[H],=,0.038,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Identification of an Orally Efficacious GPR40/ FFAR4 Receptor Agonist,10.1021/acsmedchemlett.6b00331,Article,Unknown,Luciferase transactivation assay,EC50,O=C(C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=CC2)=CC2CN(CC3=CSC=C3)CC(F)(F)F)O[H],=,0.0008,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Identification of an Orally Efficacious GPR40/ FFAR5 Receptor Agonist,10.1021/acsmedchemlett.6b00331,Article,Unknown,Luciferase transactivation assay,EC50,O=C(C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=CC2)=CC2CN(CC3=CSC=C3)CCO[H])O[H],=,0.012,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Identification of an Orally Efficacious GPR40/ FFAR6 Receptor Agonist,10.1021/acsmedchemlett.6b00331,Article,Unknown,Luciferase transactivation assay,EC50,O=C(C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=CC2)=CC2CN(CC3=CSC=C3)CCCOC)O[H],=,0.0086,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Identification of an Orally Efficacious GPR40/ FFAR7 Receptor Agonist,10.1021/acsmedchemlett.6b00331,Article,Unknown,Luciferase transactivation assay,EC50,O=C(C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=CC2)=CC2CN(CC3=CSC=C3)C(C)C)O[H],=,0.0086,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Identification of an Orally Efficacious GPR40/ FFAR8 Receptor Agonist,10.1021/acsmedchemlett.6b00331,Article,Unknown,Luciferase transactivation assay,EC50,O=C(C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=CC2)=CC2CN(CC3=CSC=C3)CC(C)C)O[H],=,0.0014,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Identification of an Orally Efficacious GPR40/ FFAR9 Receptor Agonist,10.1021/acsmedchemlett.6b00331,Article,Unknown,Luciferase transactivation assay,EC50,O=C(C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=CC2)=CC2CN(CC3=CSC=C3)CC4CC4)O[H],=,0.0161,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Identification of an Orally Efficacious GPR40/ FFAR10 Receptor Agonist,10.1021/acsmedchemlett.6b00331,Article,Unknown,Luciferase transactivation assay,EC50,O=C(C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=CC2)=CC2CN(CC3=CSC=C3)C4CC4)O[H],=,0.0019,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Identification of an Orally Efficacious GPR40/ FFAR11 Receptor Agonist,10.1021/acsmedchemlett.6b00331,Article,Unknown,Luciferase transactivation assay,EC50,O=C(C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=CC2)=CC2CN(CC3=CSC=C3)C4CCCC4)O[H],=,0.0046,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Identification of an Orally Efficacious GPR40/ FFAR12 Receptor Agonist,10.1021/acsmedchemlett.6b00331,Article,Unknown,Luciferase transactivation assay,EC50,O=C(C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=CC2)=CC2CN(CC3=CSC=C3)C4CCCCC4)O[H],=,0.002,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Identification of an Orally Efficacious GPR40/ FFAR13 Receptor Agonist,10.1021/acsmedchemlett.6b00331,Article,Unknown,Luciferase transactivation assay,EC50,O=C(C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=CC2)=CC2CN(CC3=CSC=C3)C4CCOCC4)O[H],=,0.0077,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Identification of an Orally Efficacious GPR40/ FFAR14 Receptor Agonist,10.1021/acsmedchemlett.6b00331,Article,Unknown,Luciferase transactivation assay,EC50,O=C(C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=CC2)=CC2CN(CC3=CSC=C3)C4CCSCC4)O[H],=,0.0079,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Identification of an Orally Efficacious GPR40/ FFAR15 Receptor Agonist,10.1021/acsmedchemlett.6b00331,Article,Unknown,Luciferase transactivation assay,EC50,O=C(C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=CC2)=CC2CN(CC3=CSC=C3)C(CC4)CCS4(=O)=O)O[H],=,0.0167,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Identification of an Orally Efficacious GPR40/ FFAR16 Receptor Agonist,10.1021/acsmedchemlett.6b00331,Article,Unknown,Luciferase transactivation assay,EC50,O=C(C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=CC2)=CC2CN(CC3=CSC=C3)C4CCN(C)CC4)O[H],=,0.14,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Identification of an Orally Efficacious GPR40/ FFAR17 Receptor Agonist,10.1021/acsmedchemlett.6b00331,Article,Unknown,Luciferase transactivation assay,EC50,O=C(C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=CC2)=CC2CN(CC3=CSC=C3)CC4=CC=CC=C4)O[H],=,0.0044,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Identification of an Orally Efficacious GPR40/ FFAR18 Receptor Agonist,10.1021/acsmedchemlett.6b00331,Article,Unknown,Luciferase transactivation assay,EC50,O=C(C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=CC2)=CC2CN(CC3=CSC=C3)CC4=CC=NC=C4)O[H],=,0.0019,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Identification of an Orally Efficacious GPR40/ FFAR19 Receptor Agonist,10.1021/acsmedchemlett.6b00331,Article,Unknown,Luciferase transactivation assay,EC50,O=C(C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=CC2)=CC2CN(CC3=CSC=C3)CC4=CSC=C4)O[H],=,0.0021,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Identification of an Orally Efficacious GPR40/ FFAR20 Receptor Agonist,10.1021/acsmedchemlett.6b00331,Article,Unknown,Luciferase transactivation assay,EC50,O=C(C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=CC2)=CC2CN(CC3=CSC=C3)S(CC)(=O)=O)O[H],=,0.007,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Identification of an Orally Efficacious GPR40/ FFAR21 Receptor Agonist,10.1021/acsmedchemlett.6b00331,Article,Unknown,Luciferase transactivation assay,EC50,O=C(C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=CC2)=CC2CN(CC3=CSC=C3)S(C4CC4)(=O)=O)O[H],=,0.01,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Identification of an Orally Efficacious GPR40/ FFAR22 Receptor Agonist,10.1021/acsmedchemlett.6b00331,Article,Unknown,Luciferase transactivation assay,EC50,O=C(C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=CC2)=CC2CN(C(C)=O)CC3=CSC=C3)O[H],=,0.0296,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery?of?a?GPR40?Superagonist:?The?Impact?of?Aryl?Propionic?Acid alpha-Fluorination,10.1021/acsmedchemlett.8b00444,Article,HEK293,FLIPR based intracellular calcium mobilization assay,EC50,FC1=C(C=C(OC)C=C1)C2CC[C@@H](COC3=CC=CC([C@@H](CC(O[H])=O)C4CC4)=C3)CC2,=,0.00094,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery?of?a?GPR40?Superagonist:?The?Impact?of?Aryl?Propionic?Acid alpha-Fluorination,10.1021/acsmedchemlett.8b00444,Article,HEK293,FLIPR based intracellular calcium mobilization assay,EC50,FC1=C(C=C(OC)C=C1)C2CC[C@@H](COC3=CC=CC([C@@H]([C@@](C)([H])C(O[H])=O)C4CC4)=C3)CC2,=,0.0002,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery?of?a?GPR41?Superagonist:?The?Impact?of?Aryl?Propionic?Acid alpha-Fluorination,10.1021/acsmedchemlett.8b00444,Article,HEK293,FLIPR based intracellular calcium mobilization assay,EC50,FC1=C(C=C(OC)C=C1)C2CC[C@@H](COC3=CC=CC([C@@H]([C@@]([H])(C)C(O[H])=O)C4CC4)=C3)CC2,=,0.0022,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery?of?a?GPR42?Superagonist:?The?Impact?of?Aryl?Propionic?Acid alpha-Fluorination,10.1021/acsmedchemlett.8b00444,Article,HEK293,FLIPR based intracellular calcium mobilization assay,EC50,FC1=C(C=C(OC)C=C1)C2CC[C@@H](COC3=CC=CC([C@@H]([C@@](F)([H])C(O[H])=O)C4CC4)=C3)CC2,=,0.054,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery?of?a?GPR43?Superagonist:?The?Impact?of?Aryl?Propionic?Acid alpha-Fluorination,10.1021/acsmedchemlett.8b00444,Article,HEK293,FLIPR based intracellular calcium mobilization assay,EC50,FC1=C(C=C(OC)C=C1)C2CC[C@@H](COC3=CC=CC([C@@H]([C@@]([H])(F)C(O[H])=O)C4CC4)=C3)CC2,=,0.0011,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery?of?a?GPR44?Superagonist:?The?Impact?of?Aryl?Propionic?Acid alpha-Fluorination,10.1021/acsmedchemlett.8b00444,Article,HEK293,FLIPR based intracellular calcium mobilization assay,EC50,FC1=C(C=C(OC)C=C1)C2CC[C@@H](COC3=CC=CC([C@@H]([C@@](C)(F)C(O[H])=O)C4CC4)=C3)CC2,=,0.25,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery?of?a?GPR45?Superagonist:?The?Impact?of?Aryl?Propionic?Acid alpha-Fluorination,10.1021/acsmedchemlett.8b00444,Article,HEK293,FLIPR based intracellular calcium mobilization assay,EC50,FC1=C(C=C(OC)C=C1)C2CC[C@@H](COC3=CC=CC([C@@H]([C@@](F)(C)C(O[H])=O)C4CC4)=C3)CC2,=,0.0061,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery?of?a?GPR46?Superagonist:?The?Impact?of?Aryl?Propionic?Acid alpha-Fluorination,10.1021/acsmedchemlett.8b00444,Article,HEK293,FLIPR based intracellular calcium mobilization assay,EC50,FC1=C(C=C(OC)C=C1)C2CC[C@@H](COC3=CC=CC([C@@H](C(C)(C)C(O[H])=O)C4CC4)=C3)CC2,=,0.00011,¦ÌM
ACS MEDICINAL CHEMISTRY LETTERS,Discovery?of?a?GPR47?Superagonist:?The?Impact?of?Aryl?Propionic?Acid alpha-Fluorination,10.1021/acsmedchemlett.8b00444,Article,HEK293,FLIPR based intracellular calcium mobilization assay,EC50,FC1=C(C=C(OC)C=C1)C2CC[C@@H](COC3=CC=CC([C@@H](C(F)(F)C(O[H])=O)C4CC4)=C3)CC2,=,0.016,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Structure-Activity?Relationship?Study?and?Biological?Evaluation?of?2-(Disubstituted?phenyl)-indole-5-propanoic?Acid?Derivatives?as?GPR40?Full?Agonists,10.1021/acs.jmedchem.1c00031,Article,CHO,Luciferase reporter assay,EC50,O=C(CCC(C=C1)=CC2=C1N([H])C(C3=CC=CC(Cl)=C3Cl)=C2)O[H],=,4.78,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Structure-Activity?Relationship?Study?and?Biological?Evaluation?of?2-(Disubstituted?phenyl)-indole-5-propanoic?Acid?Derivatives?as?GPR40?Full?Agonists,10.1021/acs.jmedchem.1c00031,Article,CHO,Luciferase reporter assay,EC50,O=C(CCC(C=C1)=CC2=C1N([H])C(C3=CC=C(Cl)C=C3Cl)=C2)O[H],=,20.59,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Structure-Activity?Relationship?Study?and?Biological?Evaluation?of?2-(Disubstituted?phenyl)-indole-5-propanoic?Acid?Derivatives?as?GPR41?Full?Agonists,10.1021/acs.jmedchem.1c00031,Article,CHO,Luciferase reporter assay,EC50,O=C(CCC(C=C1)=CC2=C1N([H])C(C3=CC(Cl)=CC=C3Cl)=C2)O[H],,NA,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Structure-Activity?Relationship?Study?and?Biological?Evaluation?of?2-(Disubstituted?phenyl)-indole-5-propanoic?Acid?Derivatives?as?GPR42?Full?Agonists,10.1021/acs.jmedchem.1c00031,Article,CHO,Luciferase reporter assay,EC50,O=C(CCC(C=C1)=CC2=C1N([H])C(C3=C(Cl)C=CC=C3Cl)=C2)O[H],=,2.41,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Structure-Activity?Relationship?Study?and?Biological?Evaluation?of?2-(Disubstituted?phenyl)-indole-5-propanoic?Acid?Derivatives?as?GPR43?Full?Agonists,10.1021/acs.jmedchem.1c00031,Article,CHO,Luciferase reporter assay,EC50,O=C(CCC(C=C1)=CC2=C1N([H])C(C3=CC=CC(Cl)=C3F)=C2)O[H],,NA,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Structure-Activity?Relationship?Study?and?Biological?Evaluation?of?2-(Disubstituted?phenyl)-indole-5-propanoic?Acid?Derivatives?as?GPR44?Full?Agonists,10.1021/acs.jmedchem.1c00031,Article,CHO,Luciferase reporter assay,EC50,O=C(CCC(C=C1)=CC2=C1N([H])C(C3=CC=C(Cl)C=C3F)=C2)O[H],,NA,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Structure-Activity?Relationship?Study?and?Biological?Evaluation?of?2-(Disubstituted?phenyl)-indole-5-propanoic?Acid?Derivatives?as?GPR45?Full?Agonists,10.1021/acs.jmedchem.1c00031,Article,CHO,Luciferase reporter assay,EC50,O=C(CCC(C=C1)=CC2=C1N([H])C(C3=CC=CC(Cl)=C3C)=C2)O[H],=,0.38,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Structure-Activity?Relationship?Study?and?Biological?Evaluation?of?2-(Disubstituted?phenyl)-indole-5-propanoic?Acid?Derivatives?as?GPR46?Full?Agonists,10.1021/acs.jmedchem.1c00031,Article,CHO,Luciferase reporter assay,EC50,O=C(CCC(C=C1)=CC2=C1N([H])C(C3=CC=C(Cl)C=C3C)=C2)O[H],=,0.25,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Structure-Activity?Relationship?Study?and?Biological?Evaluation?of?2-(Disubstituted?phenyl)-indole-5-propanoic?Acid?Derivatives?as?GPR47?Full?Agonists,10.1021/acs.jmedchem.1c00031,Article,CHO,Luciferase reporter assay,EC50,O=C(CCC(C=C1)=CC2=C1N([H])C(C3=CC(Cl)=CC=C3C)=C2)O[H],=,16.26,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Structure-Activity?Relationship?Study?and?Biological?Evaluation?of?2-(Disubstituted?phenyl)-indole-5-propanoic?Acid?Derivatives?as?GPR48?Full?Agonists,10.1021/acs.jmedchem.1c00031,Article,CHO,Luciferase reporter assay,EC50,O=C(CCC(C=C1)=CC2=C1N([H])C(C3=CC=C(Br)C=C3C)=C2)O[H],=,0.73,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Structure-Activity?Relationship?Study?and?Biological?Evaluation?of?2-(Disubstituted?phenyl)-indole-5-propanoic?Acid?Derivatives?as?GPR49?Full?Agonists,10.1021/acs.jmedchem.1c00031,Article,CHO,Luciferase reporter assay,EC50,O=C(CCC(C=C1)=CC2=C1N([H])C(C3=CC=C(F)C=C3C)=C2)O[H],=,0.04,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Structure-Activity?Relationship?Study?and?Biological?Evaluation?of?2-(Disubstituted?phenyl)-indole-5-propanoic?Acid?Derivatives?as?GPR50?Full?Agonists,10.1021/acs.jmedchem.1c00031,Article,CHO,Luciferase reporter assay,EC50,O=C(CCC(C=C1)=CC2=C1N([H])C(C3=CC=C(N([H])[H])C=C3Cl)=C2)O[H],,NA,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Structure-Activity?Relationship?Study?and?Biological?Evaluation?of?2-(Disubstituted?phenyl)-indole-5-propanoic?Acid?Derivatives?as?GPR51?Full?Agonists,10.1021/acs.jmedchem.1c00031,Article,CHO,Luciferase reporter assay,EC50,O=C(CCC(C=C1)=CC2=C1N([H])C(C3=CC=C(Cl)C=C3C(F)(F)F)=C2)O[H],,NA,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Structure-Activity?Relationship?Study?and?Biological?Evaluation?of?2-(Disubstituted?phenyl)-indole-5-propanoic?Acid?Derivatives?as?GPR52?Full?Agonists,10.1021/acs.jmedchem.1c00031,Article,CHO,Luciferase reporter assay,EC50,O=C(CCC(C=C1)=CC2=C1N([H])C(C3=CC=C(C)C=C3C)=C2)O[H],=,0.41,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Structure-Activity?Relationship?Study?and?Biological?Evaluation?of?2-(Disubstituted?phenyl)-indole-5-propanoic?Acid?Derivatives?as?GPR53?Full?Agonists,10.1021/acs.jmedchem.1c00031,Article,CHO,Luciferase reporter assay,EC50,O=C(CCC(C=C1)=CC2=C1N([H])C(C3=CC(C)=CC=C3C)=C2)O[H],=,0.417,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Structure-Activity?Relationship?Study?and?Biological?Evaluation?of?2-(Disubstituted?phenyl)-indole-5-propanoic?Acid?Derivatives?as?GPR54?Full?Agonists,10.1021/acs.jmedchem.1c00031,Article,CHO,Luciferase reporter assay,EC50,O=C(CCC(C=C1)=CC2=C1N([H])C(C3=C(C)C=CC=C3C)=C2)O[H],=,0.729,¦ÌM
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY,"Novel agonists of free fatty acid receptor 1 (GPR40) based on 3-(1,3,4-thiadiazol-2-yl)propanoic acid scaffold",10.3109/14756366.2016.1142984,Article,CHO,Calcium flux FLIPR platform,EC50,O=C(O[H])CCC(S1)=NN=C1C(N([H])C2=CC=CC(Cl)=C2)=O,=,3.32,¦ÌM
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY,"Novel agonists of free fatty acid receptor 1 (GPR40) based on 3-(1,3,4-thiadiazol-3-yl)propanoic acid scaffold",10.3109/14756366.2016.1142984,Article,CHO,Calcium flux FLIPR platform,EC50,O=C(O[H])CCC(S1)=NN=C1C(N([H])C2=CC=CC(C)=C2)=O,=,5.93,¦ÌM
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY,"Novel agonists of free fatty acid receptor 1 (GPR40) based on 3-(1,3,4-thiadiazol-4-yl)propanoic acid scaffold",10.3109/14756366.2016.1142984,Article,CHO,Calcium flux FLIPR platform,EC50,O=C(O[H])CCC(S1)=NN=C1C(N([H])C(S2)=NN=C2C)=O,=,24.2,¦ÌM
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY,"Novel agonists of free fatty acid receptor 1 (GPR40) based on 3-(1,3,4-thiadiazol-5-yl)propanoic acid scaffold",10.3109/14756366.2016.1142984,Article,CHO,Calcium flux FLIPR platform,EC50,O=C(O[H])CCC(S1)=NN=C1C(N([H])C2=CC=C(F)C(F)=C2)=O,=,9.85,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR40) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N([H])C1=CC=C(CCC(O[H])=O)C=C1)C2=NN=C(COC3=CC=C(F)C=C3)S2,=,5.39,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR41) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N([H])C1=CC=C(CCC(O[H])=O)C=C1)C2=NN=C(COC3=C(C)C=CC(C)=C3)S2,=,1.53,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR42) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N([H])C1=CC=C(CCC(O[H])=O)C=C1)C2=NN=C(COC3=CC(CCC4)=C4C=C3)S2,=,1.38,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR43) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N([H])C1=CC=C(CCC(O[H])=O)C=C1)C2=NN=C(COC3=CC(Cl)=CC=C3)S2,=,1.57,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR44) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N([H])C1=CC=C(CCC(O[H])=O)C=C1)C2=NN=C(COC3=CC(C)=C(C)C=C3)S2,=,1.13,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR45) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N([H])C1=CC=C(CCC(O[H])=O)C=C1)C2=NN=C(COC3=C(C)C=C(C)C=C3)S2,=,2.54,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR46) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N([H])C1=CC=C(CCC(O[H])=O)C=C1)C2=NN=C(COC3=CC(C(F)(F)F)=CC=C3)S2,=,3.09,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR47) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N([H])C1=CC=C(CCC(O[H])=O)C=C1)C2=NN=C(COC3=CC(C)=CC=C3)S2,=,3.26,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR48) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N([H])C1=CC=C(CCC(O[H])=O)C=C1)C2=NN=C(COC3=CC=C(CC)C=C3)S2,=,1.17,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR49) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N([H])C1=CC=C(CCC(O[H])=O)C=C1)C2=NN=C(COC3=CC=C(C)C=C3)S2,=,2.17,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR50) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N([H])C1=CC=C(CCC(O[H])=O)C=C1)C2=NN=C(COC3=CC=C(OC)C=C3)S2,=,2.43,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR51) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N([H])C1=CC=C(CCC(O[H])=O)C=C1)C2=NN=C(COC3=C(C)C=CC=C3)S2,=,1.52,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR52) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N([H])C1=CC=C(CCC(O[H])=O)C=C1)C2=NN=C(CC(C3=CC=CC=C3)C4=CC=C(Cl)C=C4)S2,=,2.71,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR53) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N([H])C1=CC=C(CCC(O[H])=O)C=C1)C2=NN=C(CC(C3=CC=CC=C3)C4=CC=C(OC)C=C4)S2,=,1.35,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR54) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N([H])C1=CC=C(CCC(O[H])=O)C=C1)C2=NN=C(CC(C3=C(F)C=CC=C3)C4=CC=CC=C4)S2,=,1.02,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR55) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N([H])C1=CC=C(CCC(O[H])=O)C=C1)C2=NN=C(CC(C3=CC=CC=C3)C4=CC=C5C(OCO5)=C4)S2,=,4.12,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR56) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N([H])C1=CC=C(CCC(O[H])=O)C=C1)C2=NN=C(CC3=CC=CC=C3)S2,=,3.67,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR57) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N([H])C1=CC=C(CCC(O[H])=O)C=C1)C2=NN=C(CC3=CC=CC(Cl)=C3)S2,=,2.39,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR58) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N([H])C1=CC=C(CCC(O[H])=O)C=C1)C2=NN=C(CC3=CC=CC(F)=C3)S2,=,5.02,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR59) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N([H])C1=CC=C(CCC(O[H])=O)C=C1)C2=NN=C(CC3=CC=C(Cl)C=C3)S2,=,2.39,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR60) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N(C1=C(OC)C=CC(C)=C1)[H])C2=NN=C(CC3=CC=C(OCC(O[H])=O)C=C3)S2,>,10,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR61) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N(C1=C(F)C=C(F)C=C1)[H])C2=NN=C(CC3=CC=C(OCC(O[H])=O)C=C3)S2,>,10,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR62) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N(C1=CC=C(C)C=C1)[H])C2=NN=C(CC3=CC=C(OCC(O[H])=O)C=C3)S2,>,10,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR63) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N(C1=C(F)C=CC=C1)[H])C2=NN=C(CC3=CC=C(OCC(O[H])=O)C=C3)S2,>,10,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR64) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N(C1=CC=CC(C)=C1)[H])C2=NN=C(CC3=CC=C(OCC(O[H])=O)C=C3)S2,>,10,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR65) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N(C1=CC=C(F)C=C1)[H])C2=NN=C(CC3=CC=C(OCC(O[H])=O)C=C3)S2,>,10,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR66) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N(C1=CC=C(Cl)C=C1)[H])C2=NN=C(CC3=CC=C(OCC(O[H])=O)C=C3)S2,>,10,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR67) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N(C1=CC=CC(OC)=C1)[H])C2=NN=C(CC3=CC=C(OCC(O[H])=O)C=C3)S2,>,10,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR68) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N(C1=CC(F)=C(F)C=C1)[H])C2=NN=C(CC3=CC=C(OCC(O[H])=O)C=C3)S2,>,10,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR69) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N(C1=CC(C)=C(C)C=C1)[H])C2=NN=C(CC3=CC=C(OCC(O[H])=O)C=C3)S2,>,10,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR70) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N(C1=C(C)C(C)=CC=C1)[H])C2=NN=C(CC3=CC=C(OCC(O[H])=O)C=C3)S2,>,10,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR71) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N(C1=CC=CC=C1)[H])C2=NN=C(CC3=CC=C(OCC(O[H])=O)C=C3)S2,>,10,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR72) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N(C1=C(C)C=CC=C1)[H])C2=NN=C(CC3=CC=C(OCC(O[H])=O)C=C3)S2,>,10,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR73) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N(C1=CC=CC(C(OCC)=O)=C1)[H])C2=NN=C(CC3=CC=C(OCC(O[H])=O)C=C3)S2,>,10,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR74) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N(C1=CC=C(C(OCC)=O)C=C1)[H])C2=NN=C(CC3=CC=C(OCC(O[H])=O)C=C3)S2,>,10,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR75) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N(C1=CC=C(Br)C=C1)[H])C2=NN=C(CC3=CC=C(OCC(O[H])=O)C=C3)S2,>,10,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR76) agonists",10.1016/j.ejmech.2017.09.019,Article,CHO,Calcium flux assay,EC50,O=C(N(C1=NN=C(C)S1)[H])C2=NN=C(CC3=CC=C(OCC(O[H])=O)C=C3)S2,>,10,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,FC1=CC(OCC2OC3=CC(OC)=CC=C3CC2)=CC=C1CCC(O[H])=O,=,2.11,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR41 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,FC1=CC(OCC2OC3=CC(OCCCS(C)(=O)=O)=CC=C3CC2)=CC=C1CCC(O[H])=O,=,36.27,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR42 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,FC1=CC(OCC2OC3=CC(OCCOC)=CC=C3CC2)=CC=C1CCC(O[H])=O,=,2.37,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR43 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,FC1=CC(OCC2OC3=CC(OC)=CC=C3OC2)=CC=C1CCC(O[H])=O,=,1.47,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR44 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,FC1=CC(OCC2OC3=CC(Cl)=CC=C3OC2)=CC=C1CCC(O[H])=O,=,0.83,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR45 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,FC1=CC(OCC2OC3=CC(Br)=CC=C3OC2)=CC=C1CCC(O[H])=O,=,2.24,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR46 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,FC1=CC(OCC2OC3=CC=C(Br)C=C3OC2)=CC=C1CCC(O[H])=O,=,0.98,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR47 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,FC1=CC(N([H])CC2OC3=CC(Cl)=CC=C3OC2)=CC=C1CCC(O[H])=O,=,13.57,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR48 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,ClC1=CC=C2OCC(COC(C=C3)=CC=C3C(C#CC)CC(O[H])=O)OC2=C1,=,0.1,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR49 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,ClC1=CC=C2OCC(COC(C=C3)=CC=C3C(OCC)CC(O[H])=O)OC2=C1,=,0.64,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR50 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,ClC1=CC=C2OCC(COC(C=C3)=CC=C3C(C4=CN=CO4)CC(O[H])=O)OC2=C1,=,1.03,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR51 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,ClC1=CC=C2OCC(COC(C=C3)=CC=C3C(C4=NC=CN4C)CC(O[H])=O)OC2=C1,=,5.88,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR52 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,ClC1=CC=C2OCC(COC(C=C3)=CC=C3C(C4=CN=NN4C)CC(O[H])=O)OC2=C1,=,3.87,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR53 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,ClC1=CC=C2OCC(COC(C=C3)=CC=C3C(C4=CN=CN4C)CC(O[H])=O)OC2=C1,=,3.06,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR54 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,ClC1=CC=C2OCC(COC(C=C3)=CC=C3C(C4=CC=C(F)C=C4)CC(O[H])=O)OC2=C1,=,4.31,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR55 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,ClC1=CC=C2OCC(COC(C=C3)=CC=C3C(C4=CC=NC=C4)CC(O[H])=O)OC2=C1,=,1.17,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR56 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,ClC1=CC=C2OCC(COC(C=C3)=CC=C3C4(COC4)CC(O[H])=O)OC2=C1,=,8.06,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR57 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,ClC1=CC=C2OC[C@H](COC(C=C3)=CC=C3[C@@H](C#CC)CC(O[H])=O)OC2=C1,=,0.05,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR58 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,ClC1=CC=C2OC[C@H](COC(C=C3)=CC=C3[C@H](C#CC)CC(O[H])=O)OC2=C1,=,3.4,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR59 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,ClC1=CC=C2OC[C@@H](COC(C=C3)=CC=C3[C@H](C#CC)CC(O[H])=O)OC2=C1,=,5.04,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR60 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,ClC1=CC=C2OC[C@@H](COC(C=C3)=CC=C3[C@@H](C#CC)CC(O[H])=O)OC2=C1,=,0.26,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR61 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OC[C@@H]2OC3=CC=CC(Cl)=C3OC2,=,0.17,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR62 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OC[C@@H]2OC3=CC=C(Cl)C=C3OC2,=,0.11,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR63 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OC[C@@H]2OC3=C(Cl)C=CC=C3OC2,=,0.52,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR64 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OC[C@@H]2OC3=CC=CC=C3OC2)C=C1,=,0.09,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR65 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OC[C@@H]2OC3=CC(F)=CC=C3OC2)C=C1,=,0.21,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR66 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OC[C@@H]2OC3=CC(Br)=CC=C3OC2)C=C1,=,0.21,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR67 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OC[C@@H]2OC3=CC(C)=CC=C3OC2)C=C1,=,0.12,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR68 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OC[C@@H]2OC3=CC(OC)=CC=C3OC2)C=C1,=,0.13,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR69 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OC[C@@H]2OC3=CC(OC(F)(F)F)=CC=C3OC2)C=C1,=,0.7,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR70 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OC[C@@H]2OC3=CC(C#N)=CC=C3OC2)C=C1,=,2.1,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR71 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OC[C@@H]2OC3=CC(S(C)(=O)=O)=CC=C3OC2)C=C1,=,27.2,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR72 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OC[C@@H]2OC3=CC(CO[H])=CC=C3OC2)C=C1,>,30,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR73 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OC[C@@H]2OC3=CC(C(C)=O)=CC=C3OC2)C=C1,>,30,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR74 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OC[C@@H]2OC3=CC(C(N(C)C)=O)=CC=C3OC2)C=C1,>,30,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR75 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OC[C@@H]2OC3=CC(C(N4CCOCC4)=O)=CC=C3OC2)C=C1,>,50,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR76 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OC[C@@H]2OC3=CC(Cl)=C(F)C=C3OC2)C=C1,=,0.21,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR77 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OC[C@@H]2OC3=CC(Cl)=C(Cl)C=C3OC2)C=C1,=,0.15,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR78 agonists with improved pharmacokinetic and safety profiles",10.1016/j.bmc.2018.10.019,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OC[C@@H]2OC3=CC(Cl)=C(Br)C=C3OC2)C=C1,=,0.2,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,5-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=CC=CC(COC3=CC(F)=C(CCC(O[H])=O)C=C3)=C2,=,0.0248,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,6-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=CC(C)=CC(COC3=CC(F)=C(CCC(O[H])=O)C=C3)=C2,=,0.012,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,7-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=CC(F)=CC(COC3=CC(F)=C(CCC(O[H])=O)C=C3)=C2,=,0.0332,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,8-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=CC(Cl)=CC(COC3=CC(F)=C(CCC(O[H])=O)C=C3)=C2,=,0.0389,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,9-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=CC(C(F)(F)F)=CC(COC3=CC(F)=C(CCC(O[H])=O)C=C3)=C2,=,0.114,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,10-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=CC=C(F)C(COC3=CC(F)=C(CCC(O[H])=O)C=C3)=C2,=,0.0111,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,11-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=CC=C(Cl)C(COC3=CC(F)=C(CCC(O[H])=O)C=C3)=C2,=,0.0093,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,12-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=CC=C(OC)C(COC3=CC(F)=C(CCC(O[H])=O)C=C3)=C2,=,0.0243,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,13-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=CC=CC(COC3=CC(F)=C(CCC(O[H])=O)C=C3)=C2F,=,0.0259,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,14-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=C(F)C=CC(COC3=CC(F)=C(CCC(O[H])=O)C=C3)=C2,=,0.0252,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,15-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=C(Cl)C=CC(COC3=CC(F)=C(CCC(O[H])=O)C=C3)=C2,=,0.0159,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,16-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=C(OC)C=CC(COC3=CC(F)=C(CCC(O[H])=O)C=C3)=C2,=,0.0229,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,17-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=CC(OC)=CC(COC3=CC(F)=C(CCC(O[H])=O)C=C3)=C2,=,0.0531,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,18-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=CC(OCC)=CC(COC3=CC(F)=C(CCC(O[H])=O)C=C3)=C2,=,0.0691,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,19-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=CC(OCCC)=CC(COC3=CC(F)=C(CCC(O[H])=O)C=C3)=C2,=,0.0967,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,20-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=CC(OC(C)C)=CC(COC3=CC(F)=C(CCC(O[H])=O)C=C3)=C2,=,0.0792,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,21-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=CC(OCCCC)=CC(COC3=CC(F)=C(CCC(O[H])=O)C=C3)=C2,=,0.0893,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,22-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=CC(OCC(C)C)=CC(COC3=CC(F)=C(CCC(O[H])=O)C=C3)=C2,=,0.143,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,23-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=CC(OCC3CC3)=CC(COC4=CC(F)=C(CCC(O[H])=O)C=C4)=C2,=,0.0909,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,24-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=CC(OC3CCCC3)=CC(COC4=CC(F)=C(CCC(O[H])=O)C=C4)=C2,=,0.102,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,25-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=CC=CC(COC3=CC(F)=C(CCC(O[H])=O)C=C3)=N2,=,0.506,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,26-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=CN=CC(COC3=CC(F)=C(CCC(O[H])=O)C=C3)=C2,=,4.98,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,27-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=NC=CC(COC3=CC(F)=C(CCC(O[H])=O)C=C3)=C2,=,0.862,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,28-dimethylisoxazole",10.1016/j.ejmech.2016.03.054,Article,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=CC=NC(COC3=CC(F)=C(CCC(O[H])=O)C=C3)=C2,=,1.93,¦ÌM
CHEMISTRYSELECT,Discovery of Novel G-Protein-Coupled Receptor 40 Agonist with Phenylacetic Acid Scaffold for the Treatment of Type 2 Diabetes,10.1002/slct.202101589,Article,Unknown,FLIPR assay,EC50,O=C(N([H])C1=CCC(CC(O[H])=O)C=C1)C2=C(C)C=CC=C2,=,13.16,¦ÌM
CHEMISTRYSELECT,Discovery of Novel G-Protein-Coupled Receptor 40 Agonist with Phenylacetic Acid Scaffold for the Treatment of Type 3 Diabetes,10.1002/slct.202101589,Article,Unknown,FLIPR assay,EC50,O=C(N([H])C1=CCC(CC(O[H])=O)C=C1)C2=CC(C)=CC=C2,=,7.34,¦ÌM
CHEMISTRYSELECT,Discovery of Novel G-Protein-Coupled Receptor 40 Agonist with Phenylacetic Acid Scaffold for the Treatment of Type 4 Diabetes,10.1002/slct.202101589,Article,Unknown,FLIPR assay,EC50,O=C(N([H])C1=CCC(CC(O[H])=O)C=C1)C2=C(C)C(OCC)=CC=C2,=,21.37,¦ÌM
CHEMISTRYSELECT,Discovery of Novel G-Protein-Coupled Receptor 40 Agonist with Phenylacetic Acid Scaffold for the Treatment of Type 5 Diabetes,10.1002/slct.202101589,Article,Unknown,FLIPR assay,EC50,O=C(N([H])C1=CCC(CC(O[H])=O)C=C1)C2=C(C)C(OCCO[H])=CC=C2,=,24.82,¦ÌM
CHEMISTRYSELECT,Discovery of Novel G-Protein-Coupled Receptor 40 Agonist with Phenylacetic Acid Scaffold for the Treatment of Type 6 Diabetes,10.1002/slct.202101589,Article,Unknown,FLIPR assay,EC50,O=C(N([H])C1=CCC(CC(O[H])=O)C=C1)C2=CC(C3=CC=CC=C3)=CC=C2,=,3.25,¦ÌM
CHEMISTRYSELECT,Discovery of Novel G-Protein-Coupled Receptor 40 Agonist with Phenylacetic Acid Scaffold for the Treatment of Type 7 Diabetes,10.1002/slct.202101589,Article,Unknown,FLIPR assay,EC50,O=C(N([H])C1=CCC(CC(O[H])=O)C=C1)C2=CC(C3=C(C)C=CC=C3)=CC=C2,=,2.09,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,COC1=CC(N2CCC(OC3=CC=C(N4CC([H])C[C@@H]4CC(O[H])=O)C=C3)CC2)=C(F)C=C1,=,1.4,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR41 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,COC1=CC(N2CCC(OC3=CC=C(N4C[C@H](C(F)(F)F)C[C@@H]4CC(O[H])=O)C=C3)CC2)=C(F)C=C1,=,0.21,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR42 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,COC1=CC(N2CCC(CC3=CC=C(N4C[C@H](C(F)(F)F)C[C@@H]4CC(O[H])=O)C=C3)CC2)=C(F)C=C1,=,0.53,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR43 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,COC1=CC(N2CCC(CC3=CC=C(N4C[C@H](C(F)(F)F)C[C@@H]4CC(O[H])=O)C=C3)C2)=C(F)C=C1,=,2.83,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR44 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,COC1=CC(N2CC[C@H](COC3=CC=C(N4C[C@H](C(F)(F)F)C[C@@H]4CC(O[H])=O)C=C3)C2)=C(F)C=C1,=,0.94,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR45 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,COC1=CC(N2CC[C@@H](COC3=CC=C(N4C[C@H](C(F)(F)F)C[C@@H]4CC(O[H])=O)C=C3)C2)=C(F)C=C1,=,0.63,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR46 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=CC=CC=C4)C=C2,=,1.93,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR47 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=C(F)C=CC(OC)=C4)C=C2,=,0.11,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR48 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=C(Cl)C=CC=C4)C=C2,=,0.45,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR49 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=C(C)C=CC=C4)C=C2,=,0.5,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR50 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=C(CC)C=CC=C4)C=C2,=,1.18,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR51 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=CC(OC)=CC=C4)C=C2,=,0.62,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR52 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=CC=C(Cl)C=C4)C=C2,=,6.27,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR53 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=CC=C(F)C=C4)C=C2,=,2.73,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR54 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=CC(F)=C(OC)C=C4)C=C2,=,3.62,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR55 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=C(F)C=CC=C4OC)C=C2,=,5.9,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR56 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=C(F)C=CC=C4C)C=C2,=,0.8,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR57 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=C(C)C=CC=C4C)C=C2,=,1.34,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR58 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=C(C)C=C(OC)C=C4C)C=C2,=,3.06,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR59 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=C(F)C=CC(OCC)=C4)C=C2,=,0.22,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR60 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=C(F)C=CC(C)=C4)C=C2,=,0.44,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR61 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=C(F)C=CC(CC)=C4)C=C2,=,0.45,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR62 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=C(F)C=CC(C(C)C)=C4)C=C2,=,0.6,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR63 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=C(F)C=CC(Cl)=C4)C=C2,=,0.51,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR64 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=C(Cl)C=CC(F)=C4)C=C2,=,0.36,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR65 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=C(Cl)C=CC(Cl)=C4)C=C2,=,0.25,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR66 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=C(F)C=CC(F)=C4)C=C2,=,0.48,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR67 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=C(Cl)C=CC(OC)=C4)C=C2,=,0.1,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR68 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=C(Cl)C=CC(C)=C4)C=C2,=,0.36,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR69 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=C(C#N)C=CC(OC)=C4)C=C2,=,0.68,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR70 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=CC=CC=N4)C=C2,=,2.61,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR71 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=CC=CC(F)=N4)C=C2,=,0.39,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR72 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=C(C)C=CC(F)=N4)C=C2,=,0.37,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR73 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=CC=CN=C4)C=C2,=,7.68,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR74 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=C(OC)C=NC(F)=C4)C=C2,=,0.15,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR75 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1N(N=C(C(F)(F)F)[C@H]1C)C2=CC=C(OC3CCN(CC3)C4=C(OC)C=NC(Cl)=C4)C=C2,=,0.11,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR76 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@H]1[C@H](C)C(C(F)(F)F)=NN1C2=CC=C(C=C2)OC(CC3)[C@H](F)CN3C4=C(F)C=CC(OC)=C4,=,0.07,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR77 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@H]1[C@H](C)C(C(F)(F)F)=NN1C2=CC=C(C=C2)OC(CC3)[C@H](F)CN3C4=C(Cl)C=NC(OC)=C4,=,0.18,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR78 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@H]1[C@H](C)C(C(F)(F)F)=NN1C2=CC=C(C=C2)OC(CC3)[C@H](C)CN3C4=C(Cl)C=CC(OCC)=C4,=,0.15,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR79 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@H]1[C@H](C)C(C(F)(F)F)=NN1C2=CC=C(C=C2)OC(CC3)[C@H](C)CN3C4=C(F)C=NC(OCC)=C4,=,0.28,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR80 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@H]1[C@H](C)C(C(F)(F)F)=NN1C2=CC=C(C=C2)OC(CC3)[C@H](C)CN3C4=C(Cl)C=NC(OCC)=C4,=,0.25,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR81 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@H]1[C@H](C)C(C(F)(F)F)=NN1C2=CC=C(C=C2)OC(CC3)[C@H](C)CN3C4=C(Cl)C=NC(OC)=C4,=,0.07,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR82 Agonists,10.1021/acs.jmedchem.7b00982,Article,CHOA12 cells,Calcium flux assay,EC50,O=C(O[H])C[C@H]1[C@H](C)C(C(F)(F)F)=NN1C2=CC=C(C=C2)O[C@H]3CCN(C[C@@H]3C)C4=C(Cl)C=NC(OC)=C4,=,0.32,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Synthesis and Biological Evaluation of 3-Aryl-3-(4-phenoxy)-propionic Acid as a Novel Series of G Protein-Coupled Receptor 40 Agonists,10.1021/jm070130j,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C1=CC=CC=C1)C2=CC=C(OCCC)C=C2,=,4.8,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Synthesis and Biological Evaluation of 3-Aryl-3-(4-phenoxy)-propionic Acid as a Novel Series of G Protein-Coupled Receptor 40 Agonists,10.1021/jm070130j,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C1=CC=CC=C1)C2=CC=C(OCCCC)C=C2,=,1.2,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Synthesis and Biological Evaluation of 3-Aryl-3-(4-phenoxy)-propionic Acid as a Novel Series of G Protein-Coupled Receptor 40 Agonists,10.1021/jm070130j,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C1=CC=CC=C1)C2=CC=C(OCCCCC)C=C2,=,2.97,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Synthesis and Biological Evaluation of 3-Aryl-3-(4-phenoxy)-propionic Acid as a Novel Series of G Protein-Coupled Receptor 40 Agonists,10.1021/jm070130j,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C1=CC=CC=C1)C2=CC=C(OCCCCCC)C=C2,=,2.88,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Synthesis and Biological Evaluation of 3-Aryl-3-(4-phenoxy)-propionic Acid as a Novel Series of G Protein-Coupled Receptor 40 Agonists,10.1021/jm070130j,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C1=CC=CC=C1)C2=CC=C(OCCCCCCC)C=C2,=,4.26,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Synthesis and Biological Evaluation of 3-Aryl-3-(4-phenoxy)-propionic Acid as a Novel Series of G Protein-Coupled Receptor 40 Agonists,10.1021/jm070130j,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C1=CC=CC=C1)C2=CC=C(OCCCC(F)(F)F)C=C2,=,3.16,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Synthesis and Biological Evaluation of 3-Aryl-3-(4-phenoxy)-propionic Acid as a Novel Series of G Protein-Coupled Receptor 40 Agonists,10.1021/jm070130j,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C1=CC=CC=C1)C2=CC=C(OC/C=C/C)C=C2,=,2.71,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Synthesis and Biological Evaluation of 3-Aryl-3-(4-phenoxy)-propionic Acid as a Novel Series of G Protein-Coupled Receptor 40 Agonists,10.1021/jm070130j,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C1=CC=CC=C1)C2=CC=C(OCCCOC)C=C2,=,7.58,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Synthesis and Biological Evaluation of 3-Aryl-3-(4-phenoxy)-propionic Acid as a Novel Series of G Protein-Coupled Receptor 40 Agonists,10.1021/jm070130j,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C1=CC=CC=C1)C2=CC=C(OCCC(C)=C)C=C2,=,2.71,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Synthesis and Biological Evaluation of 3-Aryl-3-(4-phenoxy)-propionic Acid as a Novel Series of G Protein-Coupled Receptor 40 Agonists,10.1021/jm070130j,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C1=CC=CC=C1)C2=CC=C(OCCC(C)C)C=C2,=,1.86,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Synthesis and Biological Evaluation of 3-Aryl-3-(4-phenoxy)-propionic Acid as a Novel Series of G Protein-Coupled Receptor 40 Agonists,10.1021/jm070130j,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C1=CC=CC=C1)C2=CC=C(OCC(C)CC)C=C2,=,0.3,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Synthesis and Biological Evaluation of 3-Aryl-3-(4-phenoxy)-propionic Acid as a Novel Series of G Protein-Coupled Receptor 40 Agonists,10.1021/jm070130j,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C1=CC=CC=C1)C2=CC=C(OCC(CC)CC)C=C2,=,0.64,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Synthesis and Biological Evaluation of 3-Aryl-3-(4-phenoxy)-propionic Acid as a Novel Series of G Protein-Coupled Receptor 40 Agonists,10.1021/jm070130j,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C1=CC(F)=CC=C1)C2=CC=C(OCCCC)C=C2,=,1.44,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Synthesis and Biological Evaluation of 3-Aryl-3-(4-phenoxy)-propionic Acid as a Novel Series of G Protein-Coupled Receptor 40 Agonists,10.1021/jm070130j,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C1=CC(C(F)(F)F)=CC=C1)C2=CC=C(OCCCC)C=C2,=,2.84,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Synthesis and Biological Evaluation of 3-Aryl-3-(4-phenoxy)-propionic Acid as a Novel Series of G Protein-Coupled Receptor 40 Agonists,10.1021/jm070130j,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C1=CC=C(C(F)(F)F)C=C1)C2=CC=C(OCCCC)C=C2,>,10,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Synthesis and Biological Evaluation of 3-Aryl-3-(4-phenoxy)-propionic Acid as a Novel Series of G Protein-Coupled Receptor 40 Agonists,10.1021/jm070130j,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C1=CC=CS1)C2=CC=C(OCCCC)C=C2,=,1.29,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Synthesis and Biological Evaluation of 3-Aryl-3-(4-phenoxy)-propionic Acid as a Novel Series of G Protein-Coupled Receptor 40 Agonists,10.1021/jm070130j,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C1=CC=CC=C1O[H])C2=CC=C(OCCCC)C=C2,=,4.8,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Synthesis and Biological Evaluation of 3-Aryl-3-(4-phenoxy)-propionic Acid as a Novel Series of G Protein-Coupled Receptor 40 Agonists,10.1021/jm070130j,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C1=CC=CC=C1)C2=CC=CC(OCCCCC)=C2,>,10,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Synthesis and Biological Evaluation of 3-Aryl-3-(4-phenoxy)-propionic Acid as a Novel Series of G Protein-Coupled Receptor 40 Agonists,10.1021/jm070130j,Article,HEK293,Calcium flux assay,EC50,CCCCOC1=CC=C(C(C2=CC=CC=C2)CCCC(O[H])=O)C=C1,>,10,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,FC(F)(C1=CC=C(C=C1)C2=CC=CC(COC3=CC=C(C(CC(O[H])=O)C#CC)C=C3)=C2)F,=,0.025,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,FC(F)(C1=CC=C(C=C1)C2=CC=CC(COC3=CC=C(C(C4=CC=CC=C4)CC(O[H])=O)C=C3)=C2)F,=,0.33,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,FC(F)(C1=CC=C(C=C1)C2=CC=CC(COC3=CC=C(C(C4=CC=CC=N4)CC(O[H])=O)C=C3)=C2)F,=,0.33,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,FC(F)(C1=CC=C(C=C1)C2=CC=CC(COC3=CC=C(C(C4=CC=CN=C4)CC(O[H])=O)C=C3)=C2)F,=,0.4,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,FC(F)(C1=CC=C(C=C1)C2=CC=CC(COC3=CC=C(C(C4=CC=NC=C4)CC(O[H])=O)C=C3)=C2)F,=,0.19,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,FC(F)(C1=CC=C(C=C1)C2=CC=CC(COC3=CC=C(C(C4=CC=CS4)CC(O[H])=O)C=C3)=C2)F,=,0.19,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,FC(F)(C1=CC=C(C=C1)C2=CC=CC(COC3=CC=C(C(C4=NC=CS4)CC(O[H])=O)C=C3)=C2)F,=,0.12,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,FC(F)(C1=CC=C(C=C1)C2=CC=CC(COC3=CC=C(C(C4=NC=CN4C)CC(O[H])=O)C=C3)=C2)F,=,0.13,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](C1=NC=CN1C)C2=CC=C(C=C2)OCC3=CC(C4=CC=CC=C4S(C)(=O)=O)=CC=C3,=,23,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](C1=NC=CN1C)C2=CC=C(C=C2)OCC3=CC(C4=CC=CC=C4C#N)=CC=C3,=,0.69,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](C1=NC=CN1C)C2=CC=C(C=C2)OCC3=CC(C4=CC=CC=C4OC)=CC=C3,=,0.41,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](C1=NC=CN1C)C2=CC=C(C=C2)OCC3=CC(C4=CC=CC(OC)=C4)=CC=C3,=,0.75,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](C1=NC=CN1C)C2=CC=C(C=C2)OCC3=CC(C4=CC=C(OC)C=C4)=CC=C3,=,0.44,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](C1=NC=CN1C)C2=CC=C(C=C2)OCC3=CC(C4=CC=CC=C4OC(F)(F)F)=CC=C3,=,0.112,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](C1=NC=CN1C)C2=CC=C(C=C2)OCC3=CC(C4=CC=CC=C4C)=CC=C3,=,0.043,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](C1=NC=CN1C)C2=CC=C(C=C2)OCC3=CC(C4=CC=CC=C4Cl)=CC=C3,=,0.043,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](C1=NC=CN1C)C2=CC=C(C=C2)OCC3=CC(C4=CC=CC=C4CC)=CC=C3,=,0.048,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](C1=NC=CN1C)C2=CC=C(C=C2)OCC3=CC(C4=C(C)C=CC=C4C)=CC=C3,=,0.058,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](C1=NC=CN1C)C2=CC=C(C=C2)OCC3=CC(C4=CC=C(Cl)C=C4C)=CC=C3,=,0.033,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](C1=NC=CN1C)C2=CC=C(C=C2)OCC3=CC(C4=CC=CC(Cl)=C4C)=CC=C3,=,0.061,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](C1=NC=CN1C)C2=CC=C(C=C2)OCC3=CC(C4=CC=C(F)C=C4C)=CC=C3,=,0.059,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](C1=NC=CN1C)C2=CC=C(C=C2)OCC3=CC(C4=CC(F)=CC=C4C)=CC=C3,=,0.036,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](C1=NC=CN1C)C2=CC=C(C=C2)OCC3=CC(C4=CC=C(Cl)C=C4Cl)=CC=C3,=,0.069,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](C1=NC=CN1C)C2=CC=C(C=C2)OCC3=C(C)C(C4=CC=C(Cl)C=C4C)=CC=C3,=,0.24,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Discovery of the imidazole-derived GPR40 agonist AM-3189,10.1016/j.bmcl.2015.11.050,Article,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](C1=NC=CN1C)C2=CC=C(C=C2)OCC3=CC(C4=CC=C(Cl)C=C4C)=C(C)C=C3,=,0.097,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,CC#CC(CC(O[H])=O)C1=CC=C(OCC2=CC=C(C(N3CCC4(C=CC5=C4C=CC=C5)CC3)=O)C=C2)C=C1,=,0.179,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,CC#CC(CC(O[H])=O)C1=CC=C(OCC2=CC=C(S2)C(N3CCC4(C=CC5=C4C=CC=C5)CC3)=O)C=C1,=,0.172,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,CC#CC(CC(O[H])=O)C1=CC=C(OCC2=CC=C(S2)C(N3CCN(C4=CC=CC=C4)CC3)=O)C=C1,=,0.072,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,CC#CC(CC(O[H])=O)C1=CC=C(OCC2=CC=C(S2)C(N3CCN(CC4=CC=CC=C4)CC3)=O)C=C1,=,0.155,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,CC#CC(CC(O[H])=O)C1=CC=C(OCC2=CC=C(S2)C(N3CCN(C)CC3)=O)C=C1,>,5,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,CC#CC(CC(O[H])=O)C1=CC=C(OCC2=CC=C(S2)C(N3CCN(C4CCCCC4)CC3)=O)C=C1,=,0.82,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,CC#CC(CC(O[H])=O)C1=CC=C(OCC2=CC=C(S2)C(N3CCN(C4=CC=NC=C4)CC3)=O)C=C1,>,5,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,CC#CC(CC(O[H])=O)C1=CC=C(OCC2=CC=C(S2)C(N3CCN(C4=CN=CC=C4)CC3)=O)C=C1,=,1.136,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,CC#CC(CC(O[H])=O)C1=CC=C(OCC2=CC=C(S2)C(N3CCN(C4=NC=CC=C4)CC3)=O)C=C1,=,0.138,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])CC(C#CC)C1=CC=C(C=C1)OCC2=CC=C(S2)C(N3CCN(C4=CC=C(C)C=C4)CC3)=O,=,0.211,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])CC(C#CC)C1=CC=C(C=C1)OCC2=CC=C(S2)C(N3CCN(C4=CC=C(C(C)(C)C)C=C4)CC3)=O,=,0.417,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])CC(C#CC)C1=CC=C(C=C1)OCC2=CC=C(S2)C(N3CCN(C4=CC=C(OC)C=C4)CC3)=O,=,0.289,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])CC(C#CC)C1=CC=C(C=C1)OCC2=CC=C(S2)C(N3CCN(C4=CC=C(Cl)C=C4)CC3)=O,=,0.133,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])CC(C#CC)C1=CC=C(C=C1)OCC2=CC=C(S2)C(N3CCN(C4=CC=C(F)C=C4)CC3)=O,=,0.54,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])CC(C#CC)C1=CC=C(C=C1)OCC2=CC=C(S2)C(N3CCN(C4=CC(F)=CC=C4)CC3)=O,=,0.097,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])CC(C#CC)C1=CC=C(C=C1)OCC2=CC=C(S2)C(N3CCN(C4=C(F)C=CC=C4)CC3)=O,=,0.113,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])CC(C#CC)C1=CC=C(C=C1)OCC2=CC=C(S2)C(N3C4=C(C=CC=C4)CCC3)=O,=,0.08,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])CC(C#CC)C1=CC=C(C=C1)OCC2=CC=C(S2)C(N3CC(C=CC=C4)=C4CC3)=O,=,0.057,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,O=C(O[H])CC(C#CC)C1=CC=C(C=C1)OCC2=CC=C(S2)C(N(C3CCCC4=C3C=CC=C4)[H])=O,=,0.109,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,FC1=CC=C(C=C1)N(CC2)CCN2C(C3=CC=C(COC4=CC=C(CCC(O[H])=O)C=C4)S3)=O,=,0.61,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,FC1=CC=C(C=C1)N(CC2)CCN2C(C3=CC=C(COC4=CC=C(C(C5CC5)CC(O[H])=O)C=C4)S3)=O,>,1.667,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,FC1=CC=C(C=C1)N(CC2)CCN2C(C3=CC=C(COC4=CC=C([C@@H](C#CC)CC(O[H])=O)C=C4)S3)=O,=,0.047,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,FC1=CC=C(C=C1)N(CC2)CCN2C(C3=CC=C(COC4=CC=C([C@H](C#CC)CC(O[H])=O)C=C4)S3)=O,>,5,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,FC1=CC=C(C=C1)N(CC2)CCN2C(C3=CC=C(COC4=CC=C(C(CC(O[H])=O)CO5)C5=C4)S3)=O,>,1.667,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,FC1=CC=C(C=C1)N(CC2)CCN2C(C3=CC=C(COC4=CC=C(C(CC(O[H])=O)CO5)C5=C4)C=C3)=O,=,0.114,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,FC1=CC=C(C=C1)N(CC2)CCN2C(C3=NC=C(COC4=CC=C(C(CC(O[H])=O)CO5)C5=C4)S3)=O,=,0.203,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,FC1=CC=C(C=C1)N(CC2)CCN2C(C3=CC=C(COC4=CC=C(C(CC(O[H])=O)CO5)C5=C4)O3)=O,=,0.308,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,O=C(C1=CC=C(COC2=CC=C(C(CC(O[H])=O)CO3)C3=C2)O1)N4CCC5=C(C=CC=C5)C4,=,0.5,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,O=C(C1=NC=C(COC2=CC=C(C(CC(O[H])=O)CO3)C3=C2)S1)N4CCC5=C(C=CC=C5)C4,=,0.531,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,O=C(C1=CC=C(COC2=CC=C(C(CC(O[H])=O)CO3)C3=C2)C=C1)N4CCC5=C(C=CC=C5)C4,=,0.106,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,[H]N(C1C2=C(C=CC=C2)CCC1)C(C3=CC=C(COC4=CC=C(C(CC(O[H])=O)CO5)C5=C4)C=C3)=O,=,0.042,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,[H]N(C1C2=C(C=CC=C2)CCC1)C(C3=NC=C(COC4=CC=C(C(CC(O[H])=O)CO5)C5=C4)S3)=O,=,0.114,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis and Structure?activity Relationship Studies of GPR40 Agonists Containing Amide Linker",10.1016/j.ejmech.2018.04.023,Article,HEK293,Calcium mobilization assay,EC50,[H]N(C1C2=C(C=CC=C2)CCC1)C(C3=CC=C(COC4=CC=C(C(CC(O[H])=O)CO5)C5=C4)O3)=O,=,0.133,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Design, synthesis and biological evaluation of a series of novel GPR40 agonists containing nitrogen heterocyclic rings",10.1016/j.bmcl.2018.07.048,Article,HEK293E,Luciferase activity,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)OCC3=CC=CC(C4=C5C(CN(CC6=CC=CC=C6)CC5)=CC=C4)=C3,=,5.4,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Design, synthesis and biological evaluation of a series of novel GPR40 agonists containing nitrogen heterocyclic rings",10.1016/j.bmcl.2018.07.048,Article,HEK293E,Luciferase activity,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)OCC3=CC=CC(C4=C5C(CN(C(C6=CC=CC=C6)=O)CC5)=CC=C4)=C3,=,2.2,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Design, synthesis and biological evaluation of a series of novel GPR40 agonists containing nitrogen heterocyclic rings",10.1016/j.bmcl.2018.07.048,Article,HEK293E,Luciferase activity,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)OCC3=CC=CC(C(C=C4)=CC5=C4CN(CC6=CC=CC=C6)CC5)=C3,=,1.2,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Design, synthesis and biological evaluation of a series of novel GPR40 agonists containing nitrogen heterocyclic rings",10.1016/j.bmcl.2018.07.048,Article,HEK293E,Luciferase activity,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)OCC3=CC=CC(C(C=C4)=CC5=C4CN(CCC6=CC=CC=C6)CC5)=C3,=,4,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Design, synthesis and biological evaluation of a series of novel GPR40 agonists containing nitrogen heterocyclic rings",10.1016/j.bmcl.2018.07.048,Article,HEK293E,Luciferase activity,EC50,O=C(O[H])C[C@@H]1COC2=CC(OCC3=CC=CC(C(C=C4)=CC5=C4CCN(CC6=CC=CC=C6)C5)=C3)=CC=C12,=,0.8,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Design, synthesis and biological evaluation of a series of novel GPR40 agonists containing nitrogen heterocyclic rings",10.1016/j.bmcl.2018.07.048,Article,HEK293E,Luciferase activity,EC50,O=C(C[C@@H]1COC2=CC(OCC3=CC=CC(C4=CC5=C(C=C4)CN(CC6=CC=CC=C6)C5)=C3)=CC=C12)O[H],=,3,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Design, synthesis and biological evaluation of a series of novel GPR40 agonists containing nitrogen heterocyclic rings",10.1016/j.bmcl.2018.07.048,Article,HEK293E,Luciferase activity,EC50,O=C(O[H])CC(C)(C)C1=CC=C(C=C1)OCC2=CC=CC(C3=C4C(CN(CC5=CC=CC=C5)CC4)=CC=C3)=C2,=,0.8,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,ClC1=CC=C(COC(C=C2)=CC=C2N3[C@@H](CC3)CC(O[H])=O)C(Cl)=C1,=,0.26,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,ClC1=CC=C(COC(C=C2)=CC=C2N3[C@H](CC3)CC(O[H])=O)C(Cl)=C1,=,13,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,ClC1=CC=C(COC(C=C2)=CC=C2N(CCC3)[C@@H]3CC(O[H])=O)C(Cl)=C1,=,0.34,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,ClC1=CC=C(COC(C=C2)=CC=C2N(CCC3)[C@H]3CC(O[H])=O)C(Cl)=C1,=,0.88,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,ClC1=CC=C(COC(C=C2)=CC=C2N(CCCC3)[C@@H]3CC(O[H])=O)C(Cl)=C1,>,33,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,ClC1=CC=C(COC(C=C2)=CC=C2N(CCCC3)[C@H]3CC(O[H])=O)C(Cl)=C1,>,17,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,ClC1=CC=C(COC(C=C2)=CC=C2N(CCCCC3)[C@@H]3CC(O[H])=O)C(Cl)=C1,=,6.4,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,ClC1=CC=C(COC(C=C2)=CC=C2N(CCCCC3)[C@H]3CC(O[H])=O)C(Cl)=C1,=,11,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,ClC1=CC=C(COC(C=N2)=CC=C2N(CCC3)[C@@H]3CC(O[H])=O)C(Cl)=C1,=,0.22,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,ClC1=CC=C(COC(C=C2C)=CC=C2N(CCC3)[C@@H]3CC(O[H])=O)C(Cl)=C1,=,8.9,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,CC1=CC=CC=C1COC(C=C2)=CC=C2N(CCC3)[C@@H]3CC(O[H])=O,=,0.19,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,CC1=CC=CC=C1COC(N=C2)=CC=C2N(CCC3)[C@@H]3CC(O[H])=O,=,0.45,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,CC1=CC=CC=C1COC(C(C)=C2)=CC=C2N(CCC3)[C@@H]3CC(O[H])=O,>,33,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)COC3=CC=CC=C3C)CCC1,=,0.19,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)CC3=C(C)C=CC=C3)CCC1,=,0.15,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=C(C)C=CC=C3)CCC1,=,0.74,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)SC3=C(C)C=CC=C3)CCC1,=,0.57,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)S(C3=C(C)C=CC=C3)(=O)=O)CCC1,>,33,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)C(C3=C(C)C=CC=C3)=O)CCC1,=,4.6,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=CC=CC=C3)CCC1,=,0.56,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=C(Cl)C=C(Cl)C=C3)CCC1,=,0.36,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=C(F)C=CC=C3)CCC1,=,0.15,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=C(OCC)C=CC=C3)CCC1,=,1.7,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=CC(C)=CC=C3)CCC1,=,0.26,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=C(C(C)(C)C)C=CC=C3)CCC1,=,6.5,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=C(C4=CC=CC=C4)C=CC=C3)CCC1,=,3.5,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=CC(Cl)=CC=C3)CCC1,=,0.68,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=CC(N(C)C)=CC=C3)CCC1,=,1.3,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=CC=C(C)C=C3)CCC1,=,0.49,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=CC=C(Cl)C=C3)CCC1,=,0.29,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=CC=C(OC)C=C3)CCC1,=,0.52,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@@]1(C)N(C2=CC=C(C=C2)CC3=C(C)C=CC=C3)CCC1,>,33,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)CC3=C(C)C=CC=C3)CC[C@@H]1C,=,0.12,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)CC3=C(C)C=CC=C3)CC[C@@H]1C4=CC=CC=C4,=,11,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)CC3=C(C)C=CC=C3)C[C@@H](C)C1,=,0.14,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)CC3=C(C)C=CC=C3)C[C@@H](F)C1,=,0.074,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)CC3=C(C)C=CC=C3)C[C@@H](C(F)(F)F)C1,=,0.067,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=C(C)C=CC=C3)C[C@@H](C(F)(F)F)C1,=,0.073,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=C(C)C=CC=C3)C[C@@H](OC)C1,=,2.3,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)CC3=C(C)C=CC=C3)C[C@@H](C4=CC=CC=C4)C1,>,17,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)CC3=C(C)C=CC=C3)[C@@H](C)CC1,=,6.2,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=C(C(F)(F)F)C=CC=C3)C[C@@H](C(F)(F)F)C1,=,0.31,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=C(OC(F)(F)F)C=CC=C3)C[C@@H](C(F)(F)F)C1,=,0.17,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=C(C)C=C(OCC4=CC=CC=C4)C=C3)C[C@@H](C(F)(F)F)C1,=,0.12,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=C(C)C=C(OC)C=C3)C[C@@H](C(F)(F)F)C1,=,0.055,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=C(C)C(C)=CC=C3)C[C@@H](C(F)(F)F)C1,=,0.11,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=C(C)C(Cl)=CC=C3)C[C@@H](C(F)(F)F)C1,=,0.082,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=C(C)C=CC=C3C)C[C@@H](C(F)(F)F)C1,=,0.082,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=C(C)C(C4=C(F)C=CC(OC)=C4)=CC=C3)CCC1,=,0.31,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)CC3=C(C)C=C(C4=CC(OC)=CC=C4F)C=C3)CCC1,=,0.22,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=C(C)C(C4=C(F)C=CC(OC)=C4)=CC=C3)C[C@@H](C(F)(F)F)C1,=,0.5,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode,10.1021/acs.jmedchem.6b01559,Article,CHO,Ca2+ FLIPR assay,EC50,O=C(O[H])C[C@H]1N(C2=CC=C(C=C2)OC3=C(C)C=C(C4=CC(OC)=CC=C4F)C=C3)C[C@@H](C(F)(F)F)C1,=,0.49,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC=C2)C=C1,=,0.51,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=C(C3=CC=CC=C3)C=C2)C=C1,=,0.3,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=C(OC3=CC=CC=C3)C=C2)C=C1,=,0.31,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC=C2C3=CC=CC=C3)C=C1,=,3.6,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC=C2OC3=CC=CC=C3)C=C1,=,1.1,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC(C3=CC=CC=C3)=C2)C=C1,=,0.26,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC(OC3=CC=CC=C3)=C2)C=C1,=,0.034,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC(OCC3=CC=CC=C3)=C2)C=C1,=,0.3,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC(OCCC3=CC=CC=C3)=C2)C=C1,=,0.26,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC(C3=NC=CC=C3)=C2)C=C1,=,2.7,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC(C3=CC=CS3)=C2)C=C1,=,0.53,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC(C3=NC=CS3)=C2)C=C1,=,2.7,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC(OC3=CC=C(C)C=C3)=C2)C=C1,=,0.04,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC(OC3=CC(C)=CC=C3)=C2)C=C1,=,0.045,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC(OC3=C(C)C=CC=C3)=C2)C=C1,=,0.038,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC(OC3=C(C)C=CC=C3C)=C2)C=C1,=,0.047,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC(C3=CC=C(C)C=C3)=C2)C=C1,=,0.12,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC(C3=CC(C)=CC=C3)=C2)C=C1,=,0.24,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC(C3=C(C)C=CC=C3)=C2)C=C1,=,0.027,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC(C3=C(OC)C=CC=C3)=C2)C=C1,=,0.082,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC(C3=C(F)C=CC=C3)=C2)C=C1,=,0.12,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC(C3=C(Cl)C=CC=C3)=C2)C=C1,=,0.02,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC(C3=C(C(C)C)C=CC=C3)=C2)C=C1,=,0.03,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC(C3=C(C)C=CC=C3C)=C2)C=C1,=,0.0088,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC(C3=C(C)C(C)=CC=C3)=C2)C=C1,=,0.019,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=CC(C3=C(C)C=C(C)C=C3)=C2)C=C1,=,0.0099,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,CC(C=CC=C1C)=C1C2=CC(CNC3=CC=C(CCC(O[H])=O)C=C3)=CC=C2,=,0.0063,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,CC(C=CC=C1C)=C1C2=CC(CN(C)C3=CC=C(CCC(O[H])=O)C=C3)=CC=C2,=,0.52,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,CC(C=CC=C1C)=C1C2=CC(CCC3=CC=C(CCC(O[H])=O)C=C3)=CC=C2,=,0.32,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,CC(C=CC=C1C)=C1C2=CC(CSC3=CC=C(CCC(O[H])=O)C=C3)=CC=C2,=,1.8,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,FC(C(O[H])=O)CC1=CC=C(OCC2=CC=CC(C(C(C)=CC=C3)=C3C)=C2)C=C1,=,0.17,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,CC(C(O[H])=O)CC1=CC=C(OCC2=CC=CC(C(C(C)=CC=C3)=C3C)=C2)C=C1,=,0.17,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,CC1=C(C(C)=CC=C1)C2=CC(COC(C=C3)=CC=C3C(C)CC(O[H])=O)=CC=C2,=,0.032,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,CC1=C(C(C)=CC=C1)C2=CC(COC(C=C3F)=CC=C3CCC(O[H])=O)=CC=C2,=,0.0057,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,CC1=C(C(C)=CC=C1)C2=CC(COC(C=C3C)=CC=C3CCC(O[H])=O)=CC=C2,=,0.03,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,CC1=C(C(C)=CC=C1)C2=CC(COC(C=C3OC)=CC=C3CCC(O[H])=O)=CC=C2,=,0.03,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists",10.1021/jm101405t,Article,CHO,Ca2+ Influx Activity,EC50,CC1=C(C(C)=CC=C1)C2=CC(COC(C=C3F)=CC(F)=C3CCC(O[H])=O)=CC=C2,=,0.035,¦ÌM
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY,Novel FFA1 (GPR40) agonists containing spirocyclic periphery: polar azine periphery as a driver of potency,10.1080/14756366.2016.1230110,Article,CHO,Calcium flux assay,EC50,O=C(CCC(C=C1)=CC=C1OCC2=CC=C(CN3CCC4(CC3)CC(CCO4)OC5=CC=CC=N5)C=C2)O[H],=,0.9,¦ÌM
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY,Novel FFA1 (GPR40) agonists containing spirocyclic periphery: polar azine periphery as a driver of potency,10.1080/14756366.2016.1230110,Article,CHO,Calcium flux assay,EC50,O=C(CCC1=CC=C(C=C1)OCC2=CC=C(CN3CCC4(CC3)CC(CCO4)OC5=NC=CC=N5)C=C2)O[H],=,1.62,¦ÌM
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY,Novel FFA1 (GPR40) agonists containing spirocyclic periphery: polar azine periphery as a driver of potency,10.1080/14756366.2016.1230110,Article,CHO,Calcium flux assay,EC50,O=C(CCC1=CC=C(C=C1)OCC2=CC=C(CN3CCC4(CC3)CC(CCO4)OC5=CN=CC=N5)C=C2)O[H],>,20,¦ÌM
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY,Novel FFA1 (GPR40) agonists containing spirocyclic periphery: polar azine periphery as a driver of potency,10.1080/14756366.2016.1230110,Article,CHO,Calcium flux assay,EC50,O=C(CCC1=CC=C(C=C1)OCC2=CC=C(CN3CCC4(CC3)CC(CCO4)OC5=CC=NC=C5)C=C2)O[H],>,20,¦ÌM
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY,Novel FFA1 (GPR40) agonists containing spirocyclic periphery: polar azine periphery as a driver of potency,10.1080/14756366.2016.1230110,Article,CHO,Calcium flux assay,EC50,O=C(CCC1=CC=C(C=C1)OCC2=CC=C(CN3CCC4(CC3)CC(N5CCCC5)CCO4)C=C2)O[H],>,20,¦ÌM
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY,Novel FFA1 (GPR40) agonists containing spirocyclic periphery: polar azine periphery as a driver of potency,10.1080/14756366.2016.1230110,Article,CHO,Calcium flux assay,EC50,O=C(CCC1=CC=C(C=C1)OCC2=CC=C(CN3CCC4(CC3)CC(N5CCOCC5)CCO4)C=C2)O[H],>,20,¦ÌM
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY,Novel FFA1 (GPR40) agonists containing spirocyclic periphery: polar azine periphery as a driver of potency,10.1080/14756366.2016.1230110,Article,CHO,Calcium flux assay,EC50,O=C(CCC1=CC=C(C=C1)OCC2=CC=C(CN3CCC4(CC3)CC(CC(NC)=O)CCO4)C=C2)O[H],>,20,¦ÌM
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY,Novel FFA1 (GPR40) agonists containing spirocyclic periphery: polar azine periphery as a driver of potency,10.1080/14756366.2016.1230110,Article,CHO,Calcium flux assay,EC50,O=C(CCC1=CC=C(C=C1)OCC2=CC=C(CN3CCC4(CC3)CC(CC(NCC5=CC=NC=C5)=O)CCO4)C=C2)O[H],>,20,¦ÌM
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY,Novel FFA1 (GPR40) agonists containing spirocyclic periphery: polar azine periphery as a driver of potency,10.1080/14756366.2016.1230110,Article,CHO,Calcium flux assay,EC50,O=C(CCC1=CC=C(C=C1)OCC2=CC=C(CN3CCC4(CC3)CC(CC(NCC5=CN=CC=C5)=O)CCO4)C=C2)O[H],>,20,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])CCC1=CC=C(C=C1F)OCC2=CC=C(C=C2)CN3CCC(C4=C5C=CC=C4)(C=C5)CC3,=,0.18,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])CCC1=CC=C(C=C1Cl)OCC2=CC=C(C=C2)CN3CCC(C4=C5C=CC=C4)(C=C5)CC3,=,0.14,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC=C(C=C2)CN3CCC(C4=C5C=CC=C4)(C=C5)CC3,=,0.0091,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@@H](C#CC)C1=CC=C(C=C1)OCC2=CC=C(C=C2)CN3CCC(C4=C5C=CC=C4)(C=C5)CC3,=,2.8,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1F)OCC2=CC=C(C=C2)CN3CCC(C4=C5C=CC=C4)(C=C5)CC3,=,0.018,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@@H](C#CC)C1=CC=C(C=C1F)OCC2=CC=C(C=C2)CN3CCC(C4=C5C=CC=C4)(C=C5)CC3,=,0.44,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(F)=C(C=C2)CN3CCC(C4=C5C=CC=C4)(C=C5)CC3,=,0.017,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(Cl)=C(C=C2)CN3CCC(C4=C5C=CC=C4)(C=C5)CC3,=,0.032,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(OC)=C(C=C2)CN3CCC(C4=C5C=CC=C4)(C=C5)CC3,=,0.017,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(C)=C(C=C2)CN3CCC(C4=C5C=CC=C4)(C=C5)CC3,=,0.023,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(C(F)(F)F)=C(C=C2)CN3CCC(C4=C5C=CC=C4)(C=C5)CC3,=,0.02,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC=C(CN3CCC(C4=C5C=CC=C4)(C=C5)CC3)O2,=,0.0016,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC=C(CN3CCC(C4=C5C=CC=C4)(C=C5)CC3)S2,=,0.012,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(C)=C(CN3CCC(C4=C5C=CC=C4)(C=C5)CC3)S2,=,0.0029,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=NC=C(CN3CCC(C4=C5C=CC=C4)(C=C5)CC3)S2,=,0.0028,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CN=C(CN3CCC(C4=C5C=CC=C4)(C=C5)CC3)S2,=,0.0044,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C(C)N=C(CN3CCC(C4=C5C=CC=C4)(C=C5)CC3)S2,=,0.017,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=NC(C)=C(CN3CCC(C4=C5C=CC=C4)(C=C5)CC3)S2,=,0.011,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC=C(C=C2)CN3CCC(C4=C5C=CC=C4)(CC5)CC3,=,0.019,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC=C(C=C2)CN3CCC(C4=C5C=CC=C4)(CN5C)CC3,=,0.055,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC=C(C=C2)CN3CCC(C4=C5C=CC=C4)(CN5C(C)C)CC3,=,0.024,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC=C(C=C2)CN3CCC(C4=C5C=CC=C4)(CN5C6=CC=CC=C6)CC3,=,0.021,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC=C(C=C2)CN3CCC(C4=C5C(Cl)=CC=C4)(CN5C)CC3,=,0.017,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC=C(C=C2)CN3CCC(C4=C5C=CC(C)=C4)(CN5C)CC3,=,0.061,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC=C(C=C2)CN3CCC(C4=C5C=CC(C(F)(F)F)=C4)(CN5C)CC3,=,0.014,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC=C(C=C2)CN3CCC(C4=C5C=CC(OC)=C4)(CN5C)CC3,=,0.13,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC=C(C=C2)CN3CCC(CC4=O)(OC5=C4C=CC=C5)CC3,=,0.065,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC=C(CN3CCC(C4=C5C=CC=C4)(CC5)CC3)S2,=,0.008,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C1=NOC=C1)C2=CC=C(C=C2)OCC3=CN4C(C=C3)=NC(C5=CC=CC=C5)=N4,=,0.014,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(C3=CC=C(C(F)(F)F)C=C3)=CC=C2,=,0.015,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,"The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)",10.1021/acs.jmedchem.6b00892,Article,HEK293,Calcium flux assay,EC50,[H]OC(C[C@H]1C2=C(OC1)C=C(C=C2)OCC3=CC(C4=C(C)C=C(OCCCS(C)(=O)=O)C=C4C)=CC=C3)=O,=,0.16,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,COC1=CC(C(C=CC(COC2=CC(C(CS(O[H])(=O)=O)C3CC3)=CC=C2)=C4)=C4CN(C(C)C)C(C)C)=C(F)C=N1,>,1,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,O=C(N([H])S(C)(=O)=O)[C@](C)(F)[C@@H](C1CC1)C2=CC=CC(OCC3=CC(CN(C(C)C)C(C)C)=C(C4=C(F)C=NC(OC)=C4)C=C3)=C2,<,0.05,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,COC1=CC(C(C=CC(COC2=CC(C(CP(OC)(O[H])=O)C3CC3)=CC=C2)=C4)=C4CN(C(C)C)C(C)C)=C(F)C=N1,>,1,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,CC(P(O[H])(O[H])=O)C(C1CC1)C2=CC=CC(OCC3=CC(CN(C(C)C)C(C)C)=C(C4=C(F)C=NC(OC)=C4)C=C3)=C2,>,1,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,CC(P(O[H])(OC)=O)C(C1CC1)C2=CC=CC(OCC3=CC(CN(C(C)C)C(C)C)=C(C4=C(F)C=NC(OC)=C4)C=C3)=C2,>,1,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,FC1=C(C=C(OC)N=C1)C(C=CC(COC2=CC(C(C3CC3)CP(O[H])(O[H])=O)=CC=C2)=C4)=C4CN(C(C)C)C(C)C,>,1,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,FC1=C(C=C(OC)N=C1)C(C=CC(OCC2=CC(C(C3CC3)CP(O[H])(O[H])=O)=CC=C2)=C4)=C4CN(C(C)C)C(C)C,>,1,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,O=S(C[C@@H](C1CC1)C2=CC=CC(OCC3=CC(CN(C(C)C)C(C)C)=C(C4=C(F)C=NC(OC)=C4)C=C3)=C2)(O[H])=O,>,1,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,O=S(C[C@H](C1CC1)C2=CC=CC(OCC3=CC(CN(C(C)C)C(C)C)=C(C4=C(F)C=NC(OC)=C4)C=C3)=C2)(O[H])=O,>,1,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,CC(C)N(CC1=CC(C2=C(F)C=NC(OC)=C2)=CC=C1COC3=CC(C(CP(C)(O[H])=O)C4CC4)=CC=C3)C(C)C,>,1,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,FC1=C(C(C=CC(OCC2=CC(C(CP(O[H])(C)=O)C3CC3)=CC=C2)=C4)=C4CN(C(C)C)C(C)C)C=C(OC)N=C1,<,0.25,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,FC1=C(C(C=CC(OCC2=CC(C(C(C)(C)P(O[H])(O[H])=O)C3CC3)=CC=C2)=C4)=C4CN(C(C)C)C(C)C)C=C(OC)N=C1,>,1,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,CCC(CP(O[H])([H])=O)C1=CC=CC(COC2=CC(CN(C(C)C)C(C)C)=C(C3=C(F)C=NC(OC)=C3)C=C2)=C1,>,1,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,CC(C)(C)[C@@H](C1=C(C=CC(COC2=CC([C@H](C3CC3)CP(C)(O[H])=O)=CC=C2)=C1)C4=C(F)C=CC(OC)=C4)OC,<,0.05,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,CC(C)(C)[C@@H](C1=C(C=CC(COC2=CC([C@H](C3CC3)CP(C)(O[H])=O)=CC=C2)=C1)C4=C(F)C=NC(OC)=C4)OC,<,0.05,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,CC(C)(C)[C@@H](C1=C(C=CC(COC2=CC([C@H](C3CC3)CP(C)(O[H])=O)=CC=C2)=C1)C4=C(F)C=CC(O[H])=C4)OC,<,0.05,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,CC(C)(C)[C@@H](C1=C(C=CC(COC2=CC([C@H](C3CC3)CP(C)(O[H])=O)=CC=N2)=C1)C4=C(F)C=CC(OC)=C4)OC,<,0.05,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,CC(C)(C)[C@@H](C1=C(C=CC(COC2=CC([C@H](C3CC3)CP(C)(O[H])=O)=CC=N2)=C1)C4=C(F)C=NC(OC)=C4)OC,<,0.05,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,CC(C)(C)[C@@H](C1=C(C=CC(COC2=CC([C@H](C3CC3)CP(C)(O[H])=O)=CC=C2)=C1)C4=CC=CC(OC)=C4)OC,<,0.05,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,CC(C)(C)[C@@H](C1=C(C=CC(COC2=CC([C@H](C3CC3)CP(C)(O[H])=O)=CC=N2)=C1)C4=CC=CC(OC)=C4)OC,<,0.05,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,CC(C)(C)[C@@H](C1=C(C=CC(COC2=CC([C@H](C3CC3)CP(C)(O[H])=O)=CC=N2)=C1)C4=C(F)C=CC(O[H])=C4)OC,<,0.05,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,CC(C)(C)[C@@H](C1=C(C=CC(COC2=CC(C[C@@H](C)P(C)(O[H])=O)=CC=C2)=C1)C3=C(F)C=NC(OC)=C3)OC,<,0.05,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,CC(C)(C)[C@@H](C1=C(C=CC(COC2=CC([C@@H](C)CP(C)(O[H])=O)=CC=C2)=C1)C3=C(F)C=CC(OC)=C3)OC,<,0.05,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,CC(C)(C)[C@@H](C1=C(C=CC(COC2=CC([C@H](C)CP(C)(O[H])=O)=CC=C2)=C1)C3=C(F)C=CC(OC)=C3)OC,<,0.05,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,CC(C)(C)[C@@H](C1=C(C=CC(COC2=CC(C(C)CP(C)(O[H])=O)=CC=C2)=C1)C3=C(F)C=NC(OC)=C3)OC,<,0.05,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,O=P(C)(O[H])C[C@@H](C)C1=CC=CC(OCC2=CC(CN(C(C)C)C(C)C)=C(C=C2)C3=C(F)C=NC(OC)=C3)=C1,<,0.25,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,O=P(C)(O[H])C[C@H](C)C1=CC=CC(OCC2=CC(CN(C(C)C)C(C)C)=C(C=C2)C3=C(F)C=NC(OC)=C3)=C1,>,1,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,O=P(C)(O[H])C[C@H](C)C1=CC=NC(OCC2=CC([C@@H](OC)C(C)(C)C)=C(C=C2)C3=C(F)C=NC(OC)=C3)=C1,<,0.05,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,O=P(C)(O[H])C[C@@H](C)C1=CC=NC(OCC2=CC([C@@H](OC)C(C)(C)C)=C(C=C2)C3=C(F)C=NC(OC)=C3)=C1,<,0.05,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,O=P(C)(O[H])CC(C)C1=CC=NC(OCC2=CC(CN(C(C)C)C(C)C)=C(C=C2)C3=C(F)C=NC(OC)=C3)=C1,>,1,¦ÌM
,Preparation of cyclopropylpyridinylbenzyloxyphenylethylphosphonate derivatives and analogs for use as GPR40?agonists,WO2021174046,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,O=P(C)(O[H])CC(C)C1=CC=NC(OCC2=CC([C@@H](OC)C(C)(C)C)=C(C=C2)C3=C(F)C=CC(OC)=C3)=C1,<,0.05,¦ÌM
,Gpr40?agonists,WO2021174048,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,FC(C([C@@]1([H])CC[C@@](COC2=CC(C(CP(O[H])(OC)=O)C3CC3)=CC=C2)([H])CC1)=C4)=CC=C4OC,<,1,¦ÌM
,Gpr40?agonists,WO2021174048,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,FC(C([C@@]1([H])CC[C@@](COC2=CC(C(CP(O[H])(O[H])=O)C3CC3)=CC=C2)([H])CC1)=C4)=CC=C4OC,>,1,¦ÌM
,Gpr40?agonists,WO2021174048,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,FC(C([C@@]1([H])CC[C@@](COC2=CC(C(CS(=O)(O[H])=O)C3CC3)=CC=C2)([H])CC1)=C4)=CC=C4OC,>,1,¦ÌM
,Gpr40?agonists,WO2021174048,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,FC(C([C@@]1([H])CC[C@@](COC2=CC(C(C(C)P(O[H])(O[H])=O)C3CC3)=CC=C2)([H])CC1)=C4)=CC=C4OC,>,1,¦ÌM
,Gpr40?agonists,WO2021174048,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,FC(C([C@@H]1CC[C@@H](COC2=CC([C@@H](CP(O[H])(C)=O)C3CC3)=CC=N2)CC1)=C4)=CC=C4OC,<,0.05,¦ÌM
,Gpr40?agonists,WO2021174048,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,O=P(O[H])(C)C[C@@H](C1CC1)C2=CC=CC(OCC3CCN(C4=CC(OC)=CC=C4CCCC(C)(C)C)CC3)=C2,<,0.05,¦ÌM
,Gpr40?agonists,WO2021174048,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,O=P(O[H])(C)C[C@@H](C1CC1)C2=CC=NC(OCC3CCN(C4=CC(OC)=CC=C4CCCC(C)(C)C)CC3)=C2,<,0.05,¦ÌM
,Gpr40?agonists,WO2021174048,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,O=P(OCC)(C)C[C@H](C)C1=CC=NC(OCC2CCN(C3=CC(OC)=CC=C3CCCC(C)(C)C)CC2)=C1,<,0.05,¦ÌM
,Gpr40?agonists,WO2021174048,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,OC1=CC=C(C(N2CCC(COC3=CC([C@H](C)CP(OCC)(C)=O)=CC=N3)CC2)=C1)CCCC(C)(C)C,<,1,¦ÌM
,Gpr40?agonists,WO2021174048,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,O=P(O[H])(C)C[C@H](C)C1=CC=CC(OCC2CCN(C3=C(CCCC(C)(C)C)C=CC(OC)=C3)CC2)=C1,<,0.25,¦ÌM
,Gpr40?agonists,WO2021174048,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,O=P(O[H])(C)C[C@@H](C)C1=CC=CC(OCC2CCN(C3=C(CCCC(C)(C)C)C=CC(OC)=C3)CC2)=C1,<,0.05,¦ÌM
,Gpr40?agonists,WO2021174048,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,O=P(O[H])(C)C(C)CC1=CC=CC(OCC2CCN(C3=CC(OC)=CC=C3CCCC(C)(C)C)CC2)=C1,>,1,¦ÌM
,Gpr40?agonists,WO2021174048,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,O=P(O[H])(C)[C@H](CC)CC1=CC=CC(OCC2CCN(C3=CC(OC)=CC=C3CCCC(C)(C)C)CC2)=C1,<,1,¦ÌM
,Gpr40?agonists,WO2021174048,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,O=P(O[H])(C)[C@@H](CC)CC1=CC=CC(OCC2CCN(C3=CC(OC)=CC=C3CCCC(C)(C)C)CC2)=C1,<,1,¦ÌM
,Gpr40?agonists,WO2021174048,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,O=P(O[H])(O[H])C[C@@H](C)C1=CC=CC(OCC2CCN(C3=CC(OC)=CC=C3CCCC(C)(C)C)CC2)=C1,<,1,¦ÌM
,Gpr40?agonists,WO2021174048,Patent,CHO-Kl,Inositol Phosphate Accumulation Assay,EC50,O=P(O[H])(O[H])C[C@H](C)C1=CC=CC(OCC2CCN(C3=CC(OC)=CC=C3CCCC(C)(C)C)CC2)=C1,>,1,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC=CC(OC(C3=CC=C(C4=CC(OC)=CC=C4F)C=C3)=O)=C2)O[H],<,0.1,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,FC(C=CC(OC)=C1)=C1C2=NOC=C2C(OC3=CC([C@H](C4CC4)CC(O[H])=O)=CC=C3)=O,>,0.5,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC=CC(OC(C3=CC(C4=C(F)C=CC(OC)=C4)=NO3)=O)=C2)O[H],>,0.5,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC=CC(OC(C3CCN(C(C)C4=C(C(F)(F)F)C=CC(C(F)(F)F)=C4)C3)=O)=C2)O[H],<,0.1,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC=CC(OC(C3=CC=C(C=C3C)C4=CC(OC)=NC=C4F)=O)=C2,<,0.5,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,CC(C)N(CC1=C(C2=CC(OC)=NC=C2F)C=C(C(C(OC3=CC([C@H](C4CC4)CC(O[H])=O)=CC=C3)=O)=C1)C)CC,<,0.5,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,CC(C)N(CC1=C(C2=CC(OC)=NC=C2F)C=CC(C(OC3=CC([C@@H](CC(O[H])=O)C4CC4)=CC=C3)=O)=C1)C(C)C,<,0.01,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,CC(C)N(CC1=C(C2=CC(OC)=NC=C2)C=C(F)C(C(OC3=CC([C@@H](CC(O[H])=O)C4CC4)=CC=C3)=O)=C1)C(C)C,<,0.01,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,O=C(C[C@@H](C1CC1)C2C=C(C=CC2)OC(N3CCN(CC3)C(C)C4=C(C(F)(F)F)C=CC(C(F)(F)F)=C4)=O)O[H],<,0.1,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,CC(C)N(CC1=C(C2=CC(OC)=NC=C2F)C=C(C(C(OC3=CC([C@@H]([C@H](C)C(O[H])=O)C4CC4)=CCC3)=O)=C1)C)C(C)C,<,0.01,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,O=C([C@@H](C)[C@@H](C1CC1)C2=CC=CC(OC(C3CCN(CC3)C(C)C4=C(C(F)(F)F)C=CC(C(F)(F)F)=C4)=O)=C2)O[H],<,0.01,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,CC(C)N(C(C)C)CC1=C(C=CC(C(OC2=CC([C@H](C3CC3)[C@H](C)C(O[H])=O)=CC=C2)=O)=C1)C4=CC(OC)=NC=C4F,<,0.01,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H](C)[C@@H](C1CC1)C2=CC(OC(C3=C(C)C=C(C4=CC(OC)=CC=C4C(N(C5=NC(C)=CC=C5)CC(C)(C)C)=O)C=C3)=O)=CC=C2,<,0.01,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,CC1(C)CCN(C1)CC2=C(C3=CC(OC)=NC=C3F)C=CC(C(OC4=CC([C@H](C5CC5)[C@H](C)C(O[H])=O)=CC=C4)=O)=C2,<,0.01,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,CC(C)N(CC)CC1=C(C2=CC(OC)=NC=C2F)C=CC(C(OC3=CC([C@H](C4CC4)[C@H](C)C(O[H])=O)=CC=C3)=O)=C1,<,0.01,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,CC(C)N(CC1=C(C2=CC(OC)=NC=C2F)C=CC(C(OC3=CC([C@H](C4CC4)[C@H](C)C(O[H])=O)=CC=C3)=O)=C1)C[C@H](O[H])[C@@H](O[H])[C@H](O[H])[C@H](O[H])CO[H],>,0.5,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,CC(C)N(C(C)C)CC(C=C(C(OC1=CC([C@H](C2CC2)[C@@](C)(F)C(O[H])=O)=CC=C1)=O)C=C3)=C3C4=CC(OC)=NC=C4F,<,0.01,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H](C)[C@H](C1=CC=CC(OC([C@H]2CC[C@@H](CC2)C3=CC(OC)=CC=C3F)=O)=C1)C4CC4,<,0.01,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])C1=CC([C@H](C2CC2)CC(O[H])=O)=CC=C1,>,0.5,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,O=C(OC1=C(C)C=C(C=C1)C2=CC(OC)=CC=C2F)C3=CC([C@H](C4CC4)CC(O[H])=O)=CC=C3,<,0.5,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,O=C(OC1CCN(CC1)C(C)C2=C(C(F)(F)F)C=CC(C(F)(F)F)=C2)C3=CC([C@H](C4CC4)CC(O[H])=O)=CC=C3,>,0.5,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,CC(C)N(CC1=C(C=C(C(OC(C2=CC([C@H](C3CC3)[C@H](C)C(O[H])=O)=CC=C2)=O)=C1)F)C4=CC(OC)=NC=C4)C(C)C,<,0.01,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,CC(C)N(C(C)C)CC1=C(C=CC(OC(C2=CC([C@H](C3CC3)[C@](C(O[H])=O)(F)C)=CC=C2)=O)=C1)C4=CC(OC)=NC=C4F,<,0.01,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,O=C([C@@]([C@@H](C1CC1)C2=CC=CC(OC(C3=CC(CN(C(C)C)C(C)C)=C(C4=C(F)C=NC(O[H])=C4)C=C3C)=O)=C2)(F)C)O[H],>,0.5,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,CC(O1)=C(COC([C@@H](C)[C@@H](C2CC2)C3=CC=CC(OC(C4=CC=C(C(CN(C(C)C)C(C)C)=C4)C5=CC(OC)=NC=C5F)=O)=C3)=O)OC1=O,<,0.01,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,FC1=CN=C(OC)C=C1C(C(CN(C(C)C)C(C)C)=C2)=CC=C2C(OC3=CC(C(CP(O[H])(C)=O)C4CC4)=CC=C3)=O,>,0.5,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,FC1=CN=C(OC)C=C1C2=CC=C(C(OC3=CC(C(CS(=O)(O[H])=O)C4CC4)=CC=C3)=O)C=C2CN(C(C)C)C(C)C,>,0.5,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,C[C@@H]([C@@H](C1CC1)C2=CC=CC(OC(C(C=C3)=CC(CN(C(C)C)C(C)C)=C3C4=C(F)C=NC(OC)=C4)=O)=C2)C(OCCP(O[H])(O[H])=O)=O,<,0.5,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,FC1=C(OC(C2=CC(CN(C(C)C)C(C)C)=C(C3=C(F)C=NC(OC)=C3)C=C2)=O)C=CC=C1[C@H](C4CC4)[C@H](C)C(O[H])=O,<,0.01,¦ÌM
,Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40?agonists,WO2020242943,Patent,CHO-Kl,InositolPhosphate Accumulation Assay,EC50,COC1=CC(C(C=C2C)=C(C=C2C(OC3=CC(C(CP(C)(O[H])=O)C4CC4)=CC=C3)=O)CN(C(C)C)C(C)C)=C(F)C=N1,>,0.5,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC1=NC(SCC2=NC=C(C3=C(Cl)C=CC(OC)=C3)O2)=NC(N([H])[H])=C1,=,0.0025,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,FC(F)C1=NC(N([H])[H])=NC(SCC2=NC=C(C3=C(Cl)C=CC(OC)=C3)O2)=N1,=,0.004,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC1=C(C=C(Cl)C=C1)C2=CN=C(CSC3=NC(N([H])[H])=NC(C(F)F)=N3)O2,=,0.004,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,NC1=NC(SCC(O2)=NC=C2C3=C(Cl)C=CC(OC)=C3)=NC(CF)=N1,=,0.0063,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC1=NC(SCC2=NC=C(C3=CC=CC(OC)=C3Cl)O2)=NC(N)=C1,=,0.0079,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC(C=CC(Cl)=C1)=C1C2=CN=C(CSC3=NC(N([H])[H])=NC(C)=N3)O2,=,0.0079,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,COC1=CC(C2=CN=C(CSC3=NC(N([H])[H])=NC(CC)=N3)O2)=C(Cl)C=C1,=,0.0079,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC1=NC(SCC2=NC=C(C(C=C(OC)C=C3)=C3Cl)O2)=NC(N([H])[H])=N1,=,0.01,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC1=NC(SCC2=NC=C(C3=CC(Cl)=C(C=C3)OC)O2)=NC(N)=N1,=,0.0126,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,[H]N([H])C1=NC(SCC2=NC=C(C3=C(Cl)C=CC(OC)=C3)O2)=NC(C(F)(F)F)=C1,=,0.0126,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC1=CC(C2=CN=C(CSC3=NC(CF)=NC(N([H])[H])=N3)O2)=C(Cl)C=C1,=,0.0126,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC1=NC(SCC2=NC=C(O2)C3=C(Cl)C=CC(Cl)=C3)=NC(N)=C1,=,0.0158,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC(C=CC(Cl)=C1)=C1C2=CN=C(CSC3=NC(N([H])[H])=NC(CC)=N3)O2,=,0.0158,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC1=NC(SCC2=NC=C(C3=CC(Cl)=C(C=C3)OC)O2)=NC(N([H])[H])=C1,=,0.02,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC1=NC(SCC2=NC=C(C3=CC=CC(OC)=C3Cl)O2)=NC(N)=N1,=,0.02,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC1=C(OC)C=CC(C2=CN=C(CSC3=NC(N([H])[H])=NC(CC)=N3)O2)=C1,=,0.02,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CCC1=NC(SCC2=NC=C(O2)C3=CC(OC)=CC=C3)=NC(N)=N1,=,0.0251,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,BrC(C=CC=C1)=C1C2=CN=C(CSC3=NC(N([H])[H])=CC(C)=N3)O2,=,0.0251,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,COC1=CC(C(O2)=CN=C2CSC3=NC(N)=CC(C)=N3)=CC=C1,=,0.0251,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC1=CC=CC(C2=CN=C(CSC3=NC(N([H])[H])=NC(C4=CC=NC=C4)=N3)O2)=C1,=,0.0251,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC1=CC(C2=CN=C(CSC3=NC(N([H])[H])=NC(CC)=N3)O2)=CC(OC)=C1,=,0.0251,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC1=CC=CC(C2=CN=C(CSC3=NC(N([H])[H])=NC(CC)=N3)O2)=C1,=,0.0316,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,FC(C=C1)=C(Cl)C=C1C2=CN=C(CSC3=NC(N([H])[H])=NC(C)=N3)O2,=,0.0316,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC1=NC(SCC2=NC=C(C3=CC=C(C=C3)C)O2)=NC(N([H])[H])=C1,=,0.0316,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC1=CC=CC(C2=CN=C(CSC3=NC(N([H])[H])=CC(C)=N3)O2)=C1,=,0.0316,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC1=CC=CC(C2=CN=C(CSC3=NC(N([H])[H])=NC(C4=CC=NN4C)=N3)O2)=C1,=,0.0316,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC1=NC(SCC2=NC=C(C3=CC(Cl)=C(OCCCS(=O)(C)=O)C=C3)O2)=NC(N([H])[H])=C1,=,0.0316,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC1=NC(SCC2=NC=C(C3=CC=CC(OCC)=C3)O2)=NC(N)=C1,=,0.0398,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC1=C(C=CC(C2=CN=C(CSC3=NC(N([H])[H])=CC(C)=N3)O2)=C1)F,=,0.0398,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC1=NC(SCC2=NC=C(C3=CC(Cl)=CC=C3)O2)=NC(N([H])[H])=N1,=,0.0398,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC(C=CC=C1)=C1C2=CN=C(CSC3=NC(N)=NC(C)=N3)O2,=,0.0398,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,COC1=CC(C2=CN=C(CSC3=NC(N)=NC(C)=N3)O2)=CC=C1,=,0.0398,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,[H]N([H])C1=CC(C)=NC(SCC2=NC=C(C3=CC(Cl)=CC(OC)=C3)O2)=N1,=,0.0398,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC1=CC=CC(C2=CN=C(CSC3=NC(N)=NC(CC)=N3)O2)=C1Cl,=,0.0501,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,FC(F)(F)C1=CC=CC(C2=CN=C(CSC3=NC(N)=CC(C)=N3)O2)=C1,=,0.0501,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC1=CC=CC(C2=CN=C(CSC3=NC(N)=CC(C)=N3)O2)=C1Cl,=,0.0501,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,FC(F)(F)C1=CC=CC(C2=CN=C(CSC3=NC(N([H])[H])=NC(C)=N3)O2)=C1,=,0.0501,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,BrC1=CC=CC(C2=CN=C(CSC3=NC(N([H])[H])=NC(C)=N3)O2)=C1,=,0.0501,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC1=NC(SCC2=NC=C(C3=CC=CC(OCC)=C3)O2)=NC(N([H])[H])=N1,=,0.0501,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC1=CC=CC(C2=CN=C(CSC3=NC(N([H])[H])=NC(C)=N3)O2)=C1Cl,=,0.0501,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC(C=CC(Cl)=C1)=C1C2=CN=C(CSC3=NC(C(F)(F)F)=CC(N([H])[H])=N3)O2,=,0.0501,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC1=CC=CC(C2=CN=C(CSC3=NC(N([H])[H])=NC(C(Cl)F)=N3)O2)=C1,=,0.0501,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC1=NC(SCC2=NC=C(C3=CC(Cl)=CC(OC)=C3)O2)=NC(N([H])[H])=N1,=,0.0501,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC(C=CC(Cl)=C1)=C1C2=CN=C(CSC3=NC(N([H])[H])=NC(N(C)C)=N3)O2,=,0.0501,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC(C=C1)=CC=C1C2=CN=C(O2)CSC3=NC(N([H])[H])=NC(C)=N3,=,0.0631,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC1=NC(SCC2=NC=C(O2)C3=C(Cl)C=CC=C3)=NC(N([H])[H])=C1,=,0.0631,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC1=NC(SCC(O2)=NC=C2C3=CC4=C(C=CC=C4)C=C3)=NC(N([H])[H])=N1,=,0.0631,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,FC(F)(F)C1=CC(N)=NC(SCC2=NC=C(C3=CC=CC(OC)=C3)O2)=N1,=,0.0631,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,FC(F)(OC1=CC=CC(C2=CN=C(CSC3=NC(N([H])[H])=NC(C)=N3)O2)=C1)F,=,0.0631,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC1=NC(SCC2=NC=C(C(C=C3)=CC=C3OC)O2)=NC(N([H])[H])=C1,=,0.0794,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC1=NC(SCC2=NC=C(C3=CC=C(C=C3)OC)O2)=NC(N([H])[H])=N1,=,0.0794,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC1=NC(SCC(O2)=NC=C2C3=CC4=C(C=CC=C4)C=C3)=NC(N([H])[H])=C1,=,0.0794,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC(C=CC=C1)=C1C2=CN=C(CSC3=NC(N([H])[H])=CC(C)=N3)O2,=,0.0794,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,FC(F)(F)C1=NC(SCC2=NC=C(O2)C3=CC(Cl)=CC=C3)=NC(N)=N1,=,0.0794,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,[H]N([H])C1=NC(SCC2=NC=C(C3=C(Cl)C=CC(OC)=C3)O2)=NC(N4CCOCC4)=N1,=,0.0794,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC1=CC(N([H])C)=NC(SCC2=NC=C(O2)C3=CC(OC)=CC=C3)=N1,=,0.1,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CCC(C=C1)=CC=C1C2=CN=C(O2)CSC3=NC(N([H])[H])=NC(C)=N3,=,0.1,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC(C=CC=C1)=C1C2=CN=C(CSC3=NC(C(F)(F)F)=CC(N([H])[H])=N3)O2,=,0.1,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC1=CC=CC(C2=CN=C(CSC3=NC(N([H])[H])=NC(C4=CC=CC=C4)=N3)O2)=C1,=,0.1,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC(C=CC(Cl)=C1)=C1C2=CN=C(CSC3=NC(N([H])[H])=NC(N4CCOCC4)=N3)O2,=,0.1,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC1=CC=CC(C2=CN=C(CSC3=NC(C(F)(F)F)=CC(N([H])[H])=N3)O2)=C1,=,0.1259,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,COC1=CC(C2=CN=C(CSC3=NC(C4CC4)=NC(N([H])[H])=N3)O2)=CC=C1,=,0.1259,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,FC(F)(F)C1=CC(N([H])[H])=NC(SCC2=NC=C(C3=CC(Cl)=CC(OC)=C3)O2)=N1,=,0.1259,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC1=CC=CC(C2=CN=C(CSC3=NC(C(F)(F)F)=CC(N([H])[H])=N3)O2)=C1Cl,=,0.1585,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,[H]N([H])C1=NC(C2=CSC=N2)=NC(SCC3=NC=C(O3)C4=CC(Cl)=CC=C4)=N1,=,0.1585,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC1=CC=CC(C2=CN=C(CSC3=NC(N)=NC(C4=CN(C)N=C4)=N3)O2)=C1,=,0.1585,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,FC1=CC=C(C=C1)C2=CN=C(CSC3=NC(N([H])[H])=NC(C)=N3)O2,=,0.1995,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,FC(F)(C1=CC(C2=CN=C(O2)CSC3=C4C=CSC4=NC=N3)=CC=C1)F,=,0.1995,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC1=CC=CC(C2=CN=C(CSC3=NC(N)=NC(C4(C)CC4)=N3)O2)=C1,=,0.1995,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC1=CC=CC(C2=CN=C(CSC3=NC(N)=NC(C(C4)CC4(F)F)=N3)O2)=C1,=,0.1995,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,NC1=CC(C)=NC(SCC2=NC=C(C3=CC(OC(F)(F)F)=CC=C3)O2)=N1,=,0.1995,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,NC1=NC(SCC2=NC=C(C3=CC(OC(F)(F)F)=CC=C3)O2)=NC(C(F)(F)F)=C1,=,0.1995,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,COC1=C(C=CC=C1)C2=CN=C(O2)CSC3=NC(N)=CC(C)=N3,=,0.2512,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC1=NC2=C(C=CC=N2)C(SCC(O3)=NC=C3C4=C(Cl)C=CC(Cl)=C4)=N1,=,0.2512,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,COC1=CC(C2=CN=C(CSC3=C(C=CS4)C4=NC=N3)O2)=CC=C1,=,0.2512,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,FC(F)(F)C1=CC(N)=NC(SCC2=NC=C(C3=CC=C(C=C3)C)O2)=N1,=,0.2512,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC1=CC=CC(C2=CN=C(CSC3=NC(N([H])[H])=NC(OC)=N3)O2)=C1,=,0.2512,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,FC(F)(F)OC1=CC=CC(C2=CN=C(CSC3=NC(N([H])[H])=NC(CC)=N3)O2)=C1,=,0.2512,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,[H]N([H])C1=CC(N)=NC(SCC2=NC=C(C3=CC=C(C=C3)OC)O2)=C1C#N,=,0.3162,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC1=CC=CC(C2=CN=C(CSC3=NC(N([H])C)=C4C=CC=CC4=N3)O2)=C1,=,0.3162,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,COCC1=NC(SCC2=NC=C(O2)C3=CC(Cl)=CC=C3)=NC(N)=N1,=,0.3162,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC(C=CC=C1)=C1C2=CN=C(CSC3=NC(N([H])[H])=NC(N)=N3)O2,=,0.3981,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC1=CC=CC(C2=NN=C(CSC3=NC(N([H])[H])=CC(C)=N3)O2)=C1,=,0.3981,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC(C=C(C=C1)C2=CN=C(CSC3=NC(C(F)(F)F)=CC(N([H])[H])=N3)O2)=C1F,=,0.3981,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC1=CC=CC(C2=NN=C(CSC3=NC(C(F)(F)F)=CC(N([H])[H])=N3)O2)=C1,=,0.3981,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC1=NC(SCC2=NC=C(C3=CC=CC(OC)=C3)O2)=C4C=CC=NC4=N1,=,0.3981,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,FC1=CC=C(C=C1)C2=CN=C(CSC3=NC(N([H])[H])=CC(C)=N3)O2,=,0.1585,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,ClC(C=C1)=CC=C1C2=CN=C(CSC3=NC(N([H])[H])=CC(C)=N3)O2,=,0.1585,¦ÌM
,Preparation of oxazole and oxadiazole derivatives useful as agonists of free fatty acid receptor 1,WO2020211956,Patent,HEK cells,the BRET assay,EC50,CC1=NC(SCC2=NC=C(C3=CC=CC=C3)O2)=NC(N([H])[H])=C1,=,0.2512,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(C1=CC=C(COC(C=C2)=CC3=C2C(CC(O[H])=O)CO3)S1)N4CCN(C5=C4C=CC=C5)C6CC6,=,0.24,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(CC(CO1)C2=C1C=C(OCC3=CC=C(C(N4CCC5=C(C4)C=CC=C5)=O)S3)C=C2)O[H],=,0.566,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(CC(C#CC)C1=CC=C(OCC2=CC=C(S2)C(N3CCN(CC3)CC4=CC=C(C(C)(C)C)C=C4)=O)C=C1)O[H],=,0.614,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(N1CCN(CC1)C2CCCCC2)C3=CC=C(S3)COC4=CC=C(C(CC(O[H])=O)C#CC)C=C4,=,0.789,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(CC(C#CC)C1=CC=C(C=C1)OCC2=CC=C(C(N([H])C3=CC=CC=C3N4CCOCC4)=O)S2)O[H],=,0.163,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C#CC)C(C=C1)=CC=C1OCC2=CC=C(C(N3CCN(CC3)C4=NC=CC=N4)=O)S2,=,0.172,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(N1CCN(CC1)C2=CC=CC=N2)C3=CC=C(COC4=CC=C(C(C#CC)CC(O[H])=O)C=C4)S3,=,0.119,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(N([H])C1CCCC2=CC=CC=C12)C3=CC=C(COC4=CC=C(C(C#CC)CC(O[H])=O)C=C4)S3,=,0.119,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(N1C2=C(C=CC=C2OC)CCC1)C3=CC=C(COC4=CC=C(C(C#CC)CC(O[H])=O)C=C4)S3,=,0.113,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(C1=CC=C(COC2=CC=C(C(CC(O[H])=O)C#CC)C=C2)S1)N3CCN(C4=C3C=CC=C4)C5CC5,=,0.196,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(CC(C#CC)C1=CC=C(OCC2=CC=C(C(N3CCN(CC3)C4=CC=CC=C4)=O)S2)C=C1)O[H],=,0.074,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(CC(C#CC)C1=CC=C(C=C1)OCC2=CC=C(S2)C(N3C4=C(CC3)C=CC=C4)=O)O[H],=,0.071,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(CC(C#CC)C1=CC=C(OCC2=CC=C(S2)C(N3CC(C(OC)=CC=C4)=C4CC3)=O)C=C1)O[H],=,0.066,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,FC(F)(F)C1=CC=C(C=C1)N(CC2)CCN2C(C3=CC=C(COC(C=C4)=CC=C4C(C#CC)CC(O[H])=O)S3)=O,=,0.382,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,COC(C=C1)=CC=C1CN2CCN(C(C3=CC=C(COC4=CC=C(C(C#CC)CC(O[H])=O)C=C4)S3)=O)CC2,=,0.125,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,ClC1=CC=C(C=C1)N(CC2)CCN2C(C3=CC=C(COC4=CC=C(C=C4)C(CC(O[H])=O)C#CC)S3)=O,=,0.133,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,CC1=C(N2CCN(C(C3=CC=C(COC(C=C4)=CC=C4C(C#CC)CC(O[H])=O)S3)=O)CC2)C(C)=CC=C1,=,0.236,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,N#CC1=CC(N(CC2)CCN2C(C3=CC=C(COC4=CC=C(C=C4)C(C#CC)CC(O[H])=O)S3)=O)=CC=C1,=,0.383,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(C1=CC=C(COC2=CC=C(C=C2)C(C#CC)CC(O[H])=O)S1)N3CCN(CC3)C(C=C4)=CC=C4OC,=,0.319,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,N#CC1=CC=C(N(CC2)CCN2C(C3=CC=C(COC(C=C4)=CC=C4C(C#CC)CC(O[H])=O)S3)=O)C=C1,=,0.258,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(N(CC1)CCN1C2=CC=CC=C2)C3=CSC(COC4=CC=C(C(C#CC)CC(O[H])=O)C=C4)=C3,=,0.036,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,FC1=CC=C(C=C1)N2CCN(C(C3=CC=C(COC4=CC=C(C=C4)C(CC(O[H])=O)C#CC)S3)=O)CC2,=,0.054,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,CC1=CC=C(C=C1)N(CC2)CCN2C(C3=CC=C(COC(C=C4)=CC=C4C(CC(O[H])=O)C#CC)S3)=O,=,0.21,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=[N+]([O-])C1=CC=CC=C1N(CC2)CCN2C(C3=CC=C(COC(C=C4)=CC=C4C(C#CC)CC(O[H])=O)S3)=O,=,0.093,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C#CC)C1=CC=C(C=C1)OCC(S2)=CC=C2C(N3CCN(CC4=CC=CC=C4)CC3)=O,=,0.12,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(C1=CC=C(COC2=CC=C(C(CC(O[H])=O)C#CC)C=C2)S1)N3CCC4(CC3)C5=CC=CC=C5C=C4,=,0.18,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,FC(C=CC=C1)=C1N2CCN(C(C3=CC=C(COC(C=C4)=CC=C4C(CC(O[H])=O)C#CC)S3)=O)CC2,=,0.113,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,N#CC1=C(C=CC=C1)N2CCN(C(C3=CC=C(COC4=CC=C(C=C4)C(C#CC)CC(O[H])=O)S3)=O)CC2,=,0.157,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,FC1=CC=CC(N2CCN(C(C3=CC=C(COC4=CC=C(C(C#CC)CC(O[H])=O)C=C4)S3)=O)CC2)=C1,=,0.114,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,CC(C=C1)=CN=C1N2CCN(C(C3=CC=C(COC4=CC=C(C=C4)C(C#CC)CC(O[H])=O)S3)=O)CC2,=,0.189,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(C1=CC=C(COC(C=C2)=CC=C2C(C#CC)CC(O[H])=O)S1)N3CCN(CC3)C4=NC=C(C=C4)OC,=,0.132,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,FC1=CN=C(C=C1)N2CCN(C(C3=CC=C(COC4=CC=C(C=C4)C(CC(O[H])=O)C#CC)S3)=O)CC2,=,0.127,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(CC(C#CC)C1=CC=C(C=C1)OCC2=CC=C(S2)C(N3CCN(CC3)C4=CC(OC)=CC=C4)=O)O[H],=,0.142,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,ClC1=C(C=CC=C1)N2CCN(C(C3=CC=C(COC4=CC=C(C=C4)C(C#CC)CC(O[H])=O)S3)=O)CC2,=,0.12,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C#CC)C1=CC=C(C=C1)OCC2=CC=C(S2)C(N3CCN(CC3)C(C=CC=C4)=C4OC)=O,=,0.177,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(C1=CC=C(COC(C=C2)=CC=C2C(C#CC)CC(O[H])=O)S1)N3CC4=C(C=CC=C4)C3,=,0.118,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(N1CCN(CC1)CC2=CC3=C(C=C2)OCO3)C4=CC=C(COC(C=C5)=CC=C5C(C#CC)CC(O[H])=O)S4,=,0.765,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(CC(C#CC)C1=CC=C(C=C1)OCC2=CC=C(C(N3CC(C=CC=C4)=C4CC3)=O)S2)O[H],=,0.044,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,FC(C=C1)=CC=C1CN2CCN(C(C3=CC=C(COC(C=C4)=CC=C4C(C#CC)CC(O[H])=O)S3)=O)CC2,=,0.24,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C#CC)C1=CC=C(C=C1)OCC2=CC=C(C=C2)C(N3CCN(CC4=CC=CC=C4)CC3)=O,=,0.14,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C#CC)C1=CC=C(OCC2=CC=C(C(N3CCC4(CC3)C(C=CC=C5)=C5C=C4)=O)C=C2)C=C1,=,0.14,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(C1=CC=C(C=C1)COC(C=C2)=CC=C2C(CC(O[H])=O)C#CC)N3CCN(CC3)CC4=CC=C(C=C4)CC,=,0.081,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(C(C=C1)=CC=C1COC2=CC=C(C=C2)C(C#CC)CC(O[H])=O)N(C3C4=C(C=CC=C4)CCC3)[H],=,0.036,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(C1=CC=C(COC2=CC=C(C(C#CC)CC(O[H])=O)C=C2)C=C1)N3CCC4=C(C3)C=CC=C4,=,0.105,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(C1=CC=C(C=C1)COC2=CC=C(C=C2)C(CC(O[H])=O)C#CC)N3CCN(C4=CC=CC=C4)CC3,=,0.088,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(C1=CSC(COC2=CC=C(C(CC(O[H])=O)C#CC)C=C2)=C1)N3CCN(CC4=CC=CC=C4)CC3,=,0.115,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(C1=CSC(COC2=CC=C(C(C#CC)CC(O[H])=O)C=C2)=C1)N(CC3)CCC43C5=CC=CC=C5C=C4,=,0.1,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(C1=CSC(COC2=CC=C(C=C2)C(CC(O[H])=O)C#CC)=C1)N(C3C4=C(CCC3)C=CC=C4)[H],=,0.039,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(CC(C#CC)C(C=C1)=CC=C1OCC2=CC(C(N3CCC4=C(C=CC=C4)C3)=O)=CS2)O[H],=,0.159,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(C1=CSC(COC2=CC=C(C(C#CC)CC(O[H])=O)C=C2)=C1)N([H])C(CC3)CCN3C4=CC=CC=C4,=,0.553,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C#CC)C1=CC=C(OCC2=CC=C(C(N3CC4=C(CC3)C=CC=C4)=O)O2)C=C1,=,0.05,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(N1CCN(CC1)C2=CC=CC=C2)C3=CC=C(COC4=CC=C(C(C#CC)CC(O[H])=O)C=C4)O3,=,0.141,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(C1=CC=C(COC2=CC=C(C(CC(O[H])=O)C#CC)C=C2)O1)N3CCC4(CC3)C=CC5=CC=CC=C54,=,0.197,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(N(C1C2=C(CCC1)C=CC=C2)[H])C3=CC=C(COC4=CC=C(C(C#CC)CC(O[H])=O)C=C4)O3,=,0.127,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(N([H])C1C2=C(C=CC=C2)CCC1)C3=NC=C(COC(C=C4)=CC=C4C(C#CC)CC(O[H])=O)S3,=,0.142,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(C1=CC=CC(COC(C=C2)=CC=C2C(C#CC)CC(O[H])=O)=C1)N3CC4=C(CC3)C=CC=C4,=,0.072,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(N1CCN(CC1)C2=CC=CC=C2)C3=CC=CC(COC(C=C4)=CC=C4C(C#CC)CC(O[H])=O)=C3,=,0.041,¦ÌM
,Preparation of amide compounds as GPR40?agonists,CN109666027,Patent,HEK293,Calcium flux assay,EC50,O=C(N([H])C1CCCC2=C1C=CC=C2)C3=CC=CC(COC4=CC=C(C(C#CC)CC(O[H])=O)C=C4)=C3,=,0.109,¦ÌM
,"Phenylpropargylic acid small-molecular organic compounds as GPR40?agonists?and their preparation, pharmaceutical compositions and use in the treatment of diabetes",CN109516914,Patent,HEK-293,Calcium flux assay,EC50,O=C(O[H])C#CC1=CC=C(C=C1)OCC(C=C2)=CC=C2OC3=CC=CC=C3,>,1,¦ÌM
,"Phenylpropargylic acid small-molecular organic compounds as GPR40?agonists?and their preparation, pharmaceutical compositions and use in the treatment of diabetes",CN109516914,Patent,HEK-293,Calcium flux assay,EC50,O=C(O[H])C#CC1=CC=C(C=C1)OCC2=CC(OCC3=CC=CC=C3)=CC=C2,>,10,¦ÌM
,"Phenylpropargylic acid small-molecular organic compounds as GPR40?agonists?and their preparation, pharmaceutical compositions and use in the treatment of diabetes",CN109516914,Patent,HEK-293,Calcium flux assay,EC50,CC(C1=CC=C(C=C1)C2=CC=CC(COC3=CC=C(C#CC(O[H])=O)C=C3)=C2)(C)C,>,10,¦ÌM
,"Phenylpropargylic acid small-molecular organic compounds as GPR40?agonists?and their preparation, pharmaceutical compositions and use in the treatment of diabetes",CN109516914,Patent,HEK-293,Calcium flux assay,EC50,FC(F)(C1=CC=C(C=C1)C2=CC=CC(COC3=CC=C(C#CC(O[H])=O)C=C3)=C2)F,>,10,¦ÌM
,"Phenylpropargylic acid small-molecular organic compounds as GPR40?agonists?and their preparation, pharmaceutical compositions and use in the treatment of diabetes",CN109516914,Patent,HEK-293,Calcium flux assay,EC50,CC1=C(C=CC=C1)C2=CC=CC(COC3=CC=C(C#CC(O[H])=O)C=C3)=C2,<,1,¦ÌM
,"Phenylpropargylic acid small-molecular organic compounds as GPR40?agonists?and their preparation, pharmaceutical compositions and use in the treatment of diabetes",CN109516914,Patent,HEK-293,Calcium flux assay,EC50,O=C(O[H])C#CC1=CC=C(C=C1)OCC2=CC(C3=C(OC(F)(F)F)C=CC=C3)=CC=C2,>,1,¦ÌM
,"Phenylpropargylic acid small-molecular organic compounds as GPR40?agonists?and their preparation, pharmaceutical compositions and use in the treatment of diabetes",CN109516914,Patent,HEK-293,Calcium flux assay,EC50,ClC1=C(C=CC=C1)C2=CC=CC(COC3=CC=C(C#CC(O[H])=O)C=C3)=C2,<,1,¦ÌM
,"Phenylpropargylic acid small-molecular organic compounds as GPR40?agonists?and their preparation, pharmaceutical compositions and use in the treatment of diabetes",CN109516914,Patent,HEK-293,Calcium flux assay,EC50,CC(C)C1=C(C2=CC=CC(COC3=CC=C(C#CC(O[H])=O)C=C3)=C2)C=CC=C1,>,1,¦ÌM
,"Phenylpropargylic acid small-molecular organic compounds as GPR40?agonists?and their preparation, pharmaceutical compositions and use in the treatment of diabetes",CN109516914,Patent,HEK-293,Calcium flux assay,EC50,CCC(C=CC=C1)=C1C2=CC=CC(COC(C=C3)=CC=C3C#CC(O[H])=O)=C2,>,1,¦ÌM
,"Phenylpropargylic acid small-molecular organic compounds as GPR40?agonists?and their preparation, pharmaceutical compositions and use in the treatment of diabetes",CN109516914,Patent,HEK-293,Calcium flux assay,EC50,CC1=CC=CC(C2=CC=CC(COC3=CC=C(C#CC(O[H])=O)C=C3)=C2)=C1,>,10,¦ÌM
,"Phenylpropargylic acid small-molecular organic compounds as GPR40?agonists?and their preparation, pharmaceutical compositions and use in the treatment of diabetes",CN109516914,Patent,HEK-293,Calcium flux assay,EC50,CCC1=CC=CC(C2=CC=CC(COC3=CC=C(C#CC(O[H])=O)C=C3)=C2)=C1,>,10,¦ÌM
,"Phenylpropargylic acid small-molecular organic compounds as GPR40?agonists?and their preparation, pharmaceutical compositions and use in the treatment of diabetes",CN109516914,Patent,HEK-293,Calcium flux assay,EC50,O=C(C#CC1=CC=C(C=C1)OCC2=CC(C3=CC(S(C)(=O)=O)=CC=C3)=CC=C2)O[H],>,10,¦ÌM
,"Phenylpropargylic acid small-molecular organic compounds as GPR40?agonists?and their preparation, pharmaceutical compositions and use in the treatment of diabetes",CN109516914,Patent,HEK-293,Calcium flux assay,EC50,FC(F)(F)C1=CC=CC(C2=CC=CC(COC3=CC=C(C#CC(O[H])=O)C=C3)=C2)=C1,>,10,¦ÌM
,"Phenylpropargylic acid small-molecular organic compounds as GPR40?agonists?and their preparation, pharmaceutical compositions and use in the treatment of diabetes",CN109516914,Patent,HEK-293,Calcium flux assay,EC50,FC1=CC=CC(C2=CC=CC(COC3=CC=C(C#CC(O[H])=O)C=C3)=C2)=C1,>,1,¦ÌM
,"Phenylpropargylic acid small-molecular organic compounds as GPR40?agonists?and their preparation, pharmaceutical compositions and use in the treatment of diabetes",CN109516914,Patent,HEK-293,Calcium flux assay,EC50,ClC1=CC=CC(C2=CC=CC(COC3=CC=C(C#CC(O[H])=O)C=C3)=C2)=C1,>,1,¦ÌM
,"Phenylpropargylic acid small-molecular organic compounds as GPR40?agonists?and their preparation, pharmaceutical compositions and use in the treatment of diabetes",CN109516914,Patent,HEK-293,Calcium flux assay,EC50,FC1=CC(C2=CC=CC(COC3=CC=C(C#CC(O[H])=O)C=C3)=C2)=C(F)C=C1,>,10,¦ÌM
,"Phenylpropargylic acid small-molecular organic compounds as GPR40?agonists?and their preparation, pharmaceutical compositions and use in the treatment of diabetes",CN109516914,Patent,HEK-293,Calcium flux assay,EC50,CC1=CC(Cl)=C(C=C1)C2=CC=CC(COC3=CC=C(C#CC(O[H])=O)C=C3)=C2,>,1,¦ÌM
,"Phenylpropargylic acid small-molecular organic compounds as GPR40?agonists?and their preparation, pharmaceutical compositions and use in the treatment of diabetes",CN109516914,Patent,HEK-293,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CC=CC(COC3=CC=C(C#CC(O[H])=O)C=C3)=C2,<,1,¦ÌM
,"Phenylpropargylic acid small-molecular organic compounds as GPR40?agonists?and their preparation, pharmaceutical compositions and use in the treatment of diabetes",CN109516914,Patent,HEK-293,Calcium flux assay,EC50,CC1=CC(C)=CC(C)=C1C2=CC=CC(COC3=CC=C(C#CC(O[H])=O)C=C3)=C2,>,1,¦ÌM
,"Furo[3,2-c]pyridine derivatives as GPR40 receptor modulators for the treatment of diabetes and their preparations",WO2018146008,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC(CCOC1=CC(C)=C(C(C)=C1)C2=CC=C(C3=C2CC[C@H]3N([H])C(C=C4OC5)=NC=C4[C@@H]5CC(O[H])=O)F)(C)O[H],=,0.015,¦ÌM
,"Furo[3,2-c]pyridine derivatives as GPR40 receptor modulators for the treatment of diabetes and their preparations",WO2018146008,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC(CCOC1=CC(C)=C(C(C)=C1)C2=CC=C(C3=C2CC[C@H]3N([H])C(C=C4OC5)=NC=C4[C@H]5CC(O[H])=O)F)(C)O[H],=,0.764,¦ÌM
,"Furo[3,2-c]pyridine derivatives as GPR40 receptor modulators for the treatment of diabetes and their preparations",WO2018146008,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC(CCOC1=CC(C)=C(C(C)=C1)C2=CC=CC3=C2CC[C@H]3N([H])C(C=C4OC5)=NC=C4[C@@H]5CC(O[H])=O)(C)O[H],=,0.021,¦ÌM
,"Furo[3,2-c]pyridine derivatives as GPR40 receptor modulators for the treatment of diabetes and their preparations",WO2018146008,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC(CCOC1=CC(C)=C(C(C)=C1)C2=CC=CC3=C2CC[C@H]3N([H])C(C=C4OC5)=NC=C4[C@H]5CC(O[H])=O)(C)O[H],=,0.751,¦ÌM
,"Furo[3,2-c]pyridine derivatives as GPR40 receptor modulators for the treatment of diabetes and their preparations",WO2018146008,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC(C=C1C2=NN(C)N=N2)=C(C(C)=C1)C3=CC=C(C4=C3CC[C@H]4N([H])C(C=C5OC6)=NC=C5[C@@H]6CC(O[H])=O)F,=,0.006,¦ÌM
,"Furo[3,2-c]pyridine derivatives as GPR40 receptor modulators for the treatment of diabetes and their preparations",WO2018146008,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC(C=C1C2=NN(C)N=N2)=C(C(C)=C1)C3=CC=C(C4=C3CC[C@H]4N([H])C(C=C5OC6)=NC=C5[C@H]6CC(O[H])=O)F,=,0.382,¦ÌM
,"Furo[3,2-c]pyridine derivatives as GPR40 receptor modulators for the treatment of diabetes and their preparations",WO2018146008,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC(C=C1C2=NN(C)N=N2)=C(C(C)=C1)C3=CC=CC4=C3CC[C@H]4N([H])C(C=C5OC6)=NC=C5[C@@H]6CC(O[H])=O,=,0.007,¦ÌM
,"Furo[3,2-c]pyridine derivatives as GPR40 receptor modulators for the treatment of diabetes and their preparations",WO2018146008,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC(C=C1C2=NN(C)N=N2)=C(C(C)=C1)C3=CC=CC4=C3CC[C@H]4N([H])C(C=C5OC6)=NC=C5[C@H]6CC(O[H])=O,=,0.378,¦ÌM
,"Furo[3,2-c]pyridine derivatives as GPR40 receptor modulators for the treatment of diabetes and their preparations",WO2018146008,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])C[C@H]1C2=CN=C(N[C@H](CC3)C4=C3C(C(C(C)=CC(O[C@H]5COCC5)=C6)=C6C)=CC=C4F)C=C2OC1,=,0.057,¦ÌM
,"Furo[3,2-c]pyridine derivatives as GPR40 receptor modulators for the treatment of diabetes and their preparations",WO2018146008,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])C[C@H]1C2=CN=C(N[C@H](CC3)C4=C3C(C(C(C)=CC(OC5COCC5)=C6)=C6C)=CC=C4F)C=C2OC1,=,0.056,¦ÌM
,"Furo[3,2-c]pyridine derivatives as GPR40 receptor modulators for the treatment of diabetes and their preparations",WO2018146008,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])C[C@H]1C2=CN=C(N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OCC6(COC6)C)C=C5C)C=C2OC1,=,0.037,¦ÌM
,"Furo[3,2-c]pyridine derivatives as GPR40 receptor modulators for the treatment of diabetes and their preparations",WO2018146008,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])C[C@H]1C(C(OC1)=C2)=CN=C2N([C@H](CC3)C4=C3C(C5=C(C)C=C(O[C@@H]6COCC6)C=C5C)=CC=C4F)[H],=,0.073,¦ÌM
,"Furo[3,2-c]pyridine derivatives as GPR40 receptor modulators for the treatment of diabetes and their preparations",WO2018146008,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])C[C@H]1C2=CN=C(C=C2OC1)N([C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OCC(O[H])(C)C)C=C5C)[H],=,0.035,¦ÌM
,"Furo[3,2-c]pyridine derivatives as GPR40 receptor modulators for the treatment of diabetes and their preparations",WO2018146008,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])C[C@H]1C2=CN=C(N([C@H](CC3)C4=C3C(C5=C(C)C=C(OCC6COCC6)C=C5C)=CC=C4F)[H])C=C2OC1,=,0.027,¦ÌM
,"Furo[3,2-c]pyridine derivatives as GPR40 receptor modulators for the treatment of diabetes and their preparations",WO2018146008,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC(O[H])(C)CN1N=NC(C2=CC(C)=C(C(C)=C2)C3=CC=C(C4=C3CC[C@H]4N([H])C(C=C5OC6)=NC=C5[C@@H]6CC(O[H])=O)F)=N1,=,0.009,¦ÌM
,"Furo[3,2-c]pyridine derivatives as GPR40 receptor modulators for the treatment of diabetes and their preparations",WO2018146008,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC(C=C1C(C=CN2C)=NC2=O)=C(C(C)=C1)C3=CC=C(C4=C3CC[C@H]4N([H])C5=NC=C(C(OC6)=C5)[C@@H]6CC(O[H])=O)F,=,0.027,¦ÌM
,"Furo[3,2-c]pyridine derivatives as GPR40 receptor modulators for the treatment of diabetes and their preparations",WO2018146008,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC(C=C1C(C=CN2C)=CC2=O)=C(C(C)=C1)C3=CC=C(C4=C3CC[C@H]4N([H])C5=NC=C(C(OC6)=C5)[C@@H]6CC(O[H])=O)F,=,0.012,¦ÌM
,"Furo[3,2-c]pyridine derivatives as GPR40 receptor modulators for the treatment of diabetes and their preparations",WO2018146008,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC(C=C1C(N=CN2C)=CC2=O)=C(C(C)=C1)C3=CC=C(C4=C3CC[C@H]4N([H])C5=NC=C(C(OC6)=C5)[C@@H]6CC(O[H])=O)F,=,0.014,¦ÌM
,"Furo[3,2-c]pyridine derivatives as GPR40 receptor modulators for the treatment of diabetes and their preparations",WO2018146008,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC(C=C1C(C=C2)=CN(C)C2=O)=C(C(C)=C1)C3=CC=C(C4=C3CC[C@H]4N([H])C5=NC=C(C(OC6)=C5)[C@@H]6CC(O[H])=O)F,=,0.027,¦ÌM
,"Furo[3,2-c]pyridine derivatives as GPR40 receptor modulators for the treatment of diabetes and their preparations",WO2018146008,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC(C=C1C2=CN=CC=N2)=C(C(C)=C1)C3=CC=C(C4=C3CC[C@H]4N([H])C(C=C5OC6)=NC=C5[C@@H]6CC(O[H])=O)F,=,0.009,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(OCCCS(C)(=O)=O)=CC(C)=C1C2=CC=CC(CN(C3=CC=C(N=C3)[C@H]4C[C@@H]4C(O[H])=O)[H])=C2,=,0.05,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(F)(F)C1=C(C=C(C=C1)CN(C2=CC=C([C@H]3C[C@@H]3C(O[H])=O)N=C2)[H])C4=CC=C(OCCC(O[H])(C)C)C=C4,=,0.017,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(F)(F)C1=C(C=C(C=C1)CN(C2=CC=C([C@H]3C[C@@H]3C(O[H])=O)N=C2)[H])C4=CC=C(OCC5CC5)C=C4,=,0.022,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(F)(F)C1=C(C=C(C=C1)CN(C2=CC=C([C@H]3C[C@@H]3C(O[H])=O)N=C2)[H])C4=CC=C(OC(F)(F)F)C=C4,=,0.044,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(F)(F)C1=C(C=C(C=C1)CN(C2=CC=C([C@H]3C[C@@H]3C(O[H])=O)N=C2)[H])C4=C(C)C=C(OCCC(C)(O[H])C)C=C4C,=,0.012,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=CC=C(C5=NN=C(OC)C=C5)C=C4)=C(F)C=C3F,=,0.064,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=CC=C(C5=NC=C(OC)C=C5)C=C4)=C(F)C=C3F,=,0.027,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=CC=C(N([H])[H])C=C4C)=C(F)C=C3F,=,0.127,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=CC=C(O[H])C(Cl)=C4)=C(F)C=C3F,=,0.943,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=CC(F)=C(O[H])C(F)=C4)=C(F)C=C3F,=,0.052,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(C5=NN(C)N=N5)C=C4C)=CC=C3F,=,0.008,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(OCC5=CC=CC=C5)C=C4C)=CC=C3F,=,0.044,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(OCC(C)(C#N)C)C=C4C)=CC=C3F,=,0.059,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(OCC(O[H])=O)C=C4C)=CC=C3F,=,4.517,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=CC=C(C5=CSC(C)=N5)C=C4)=CC=C3F,=,0.219,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(C(C=C5)=CN(C)C5=O)C=C4C)=CC=C3F,=,0.029,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(C(C=CN5C)=CC5=O)C=C4C)=CC=C3F,=,0.018,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(C(N=CN5C)=CC5=O)C=C4C)=CC=C3F,=,0.023,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(OCCC(C)(C)O[H])C=C4C)=CC=C3F,=,0.027,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(OC5CCOCC5)C=C4C)=CC=C3F,=,0.035,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(OCC(O[H])(C)C)C=C4C)=CC=C3F,=,0.101,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(O[H])C=C4C)=CC=C3F,=,0.206,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(F)C=C(F)C=C4F)=CC=C3F,=,0.505,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(O[C@H]5COCC5)C=C4C)=CC=C3F,=,0.044,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(O[C@@H]5COCC5)C=C4C)=CC=C3F,=,0.028,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(OCC5CCOC5)C=C4C)=CC=C3F,=,0.039,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(C(N([H])[H])=O)C=C4C)=CC=C3F,=,0.401,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(Cl)C(OC)=CC(OC)=C4Cl)=CC=C3F,=,0.03,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=CC=CC=C4C5(C#N)CC5)=CC=C3F,=,0.696,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(Cl)C=CC=C4Cl)=CC=C3F,=,0.034,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(OC)C=C(OC)C=C4OC)=CC=C3F,=,0.453,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=CC=C(C5=CN=CO5)C=C4)=CC=C3F,=,0.174,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(F)C=C(OC5CC5)C=C4F)=CC=C3F,=,0.297,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(F)C=C(N([H])[H])C=C4F)=CC=C3F,=,0.031,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(OC)C=C4C)=CC=C3F,=,0.049,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(Cl)C=CC(C)=C4Cl)=CC=C3F,=,0.035,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=CC=CC=C4C(F)(F)F)=CC=C3F,=,0.038,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C#N)C=CC=C4C#N)=CC=C3F,>,10,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(F)C=CC=C4F)=CC=C3F,=,0.435,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(F)C=C(OC)C=C4F)=CC=C3F,=,0.988,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=CC=C4C)=CC=C3F,=,0.041,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(C(N(C)C)=O)C=C4C)=CC=C3F,=,0.231,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(C(N([H])C)=O)C=C4C)=CC=C3F,=,0.358,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(OCC5CCOCC5)C=C4C)=CC=C3F,=,0.018,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(C(O[H])=O)C=C4C)=CC=C3F,=,3.662,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(OCC(CC5)(O[H])CCS5(=O)=O)C=C4C)=CC=C3F,=,0.171,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(C5=CC(OC)=NC=C5)C=C4C)=CC=C3F,=,0.005,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(OCC5(O[H])CCSCC5)C=C4C)=CC=C3F,=,0.056,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(OCC5(O[H])CCOCC5)C=C4C)=CC=C3F,=,0.147,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=CC=CC=C4C(C)C)=CC=C3F,=,0.081,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(C5=NC=C(C)C=N5)C=C4C)=CC=C3F,=,0.006,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(F)C(OC)=CC(OC)=C4F)=CC=C3F,=,0.836,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(CC)C=CC=C4CC)=CC=C3F,=,0.057,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(C5=NN(CC(C)(O[H])C)N=N5)C=C4C)=CC=C3F,=,0.01,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(C5=CC=NN5C)C=C4C)=CC=C3F,=,0.012,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(C(C=CN5C)=NC5=O)C=C4C)=CC=C3F,=,0.032,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138027,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,[H]N(C1=CC=C([C@H]2C[C@@H]2C(O[H])=O)N=C1)CC3=CC(C4=C(C)C=C(C#N)C=C4C)=CC=C3F,=,0.091,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(OCCCS(=O)(C)=O)=CC(C)=C1C2=CC=CC(CN(C(C=N3)=NC=C3[C@H]4C[C@@H]4C(O[H])=O)[H])=C2,=,0.036,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(C(C=C1)=C(C=C1CNC(C=N2)=NC=C2[C@H]3C[C@@H]3C(O[H])=O)C4=CC=C(OCCC(C)(C)O[H])C=C4)(F)F,=,0.006,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(C(C=C1)=C(C=C1CN(C(C=N2)=NC=C2[C@@H]3[C@@H](C(O[H])=O)C3)[H])C4=CC=C(OCC5CC5)C=C4)(F)F,=,0.028,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(C(C=C1)=C(C=C1CN(C(C=N2)=NC=C2[C@@H]3[C@@H](C(O[H])=O)C3)[H])C4=CC=C(OC(F)(F)F)C=C4)(F)F,=,0.009,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(F)(F)C1=C(C=C(C=C1)CN(C(C=N2)=NC=C2[C@H]3C[C@@H]3C(O[H])=O)[H])C4=C(C)C=C(OCCC(C)(C)O[H])C=C4C,=,0.31,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(C=C1F)=C(C=C1CN(C(C=N2)=NC=C2[C@H]3C[C@@H]3C(O[H])=O)[H])C4=CC=C(C5=CC=C(OC)C=N5)C=C4,=,0.019,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(C=C1F)=C(C=C1CN(C(C=N2)=NC=C2[C@H]3C[C@@H]3C(O[H])=O)[H])C4=CC=C(C5=NN=C(C=C5)OC)C=C4,=,0.038,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(C=C1F)=C(C=C1CN(C(C=N2)=NC=C2[C@H]3C[C@@H]3C(O[H])=O)[H])C4=C(C)C=C(N([H])[H])C=C4,=,0.126,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(C=C1F)=C(C=C1CN(C(C=N2)=NC=C2[C@H]3C[C@@H]3C(O[H])=O)[H])C4=CC=C(O[H])C(Cl)=C4,=,0.596,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(C=C1F)=C(C=C1CN(C(C=N2)=NC=C2[C@H]3C[C@@H]3C(O[H])=O)[H])C4=CC(F)=C(OC)C(F)=C4,=,0.053,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(OCC(C)(C)O[H])C=C2C)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,0.018,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(OCC(CC3)(O[H])CCS3(=O)=O)C=C2C)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,0.1,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(C(N([H])C)=O)C=C2C)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,0.224,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(C(N(C)C)=O)C=C2C)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,0.034,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(C(O[H])=O)C=C2C)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,0.024,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(C(C=C3)=CN(C)C3=O)C=C2C)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,0.021,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=CC=CC=C2C(C)C)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,0.154,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(OCC3CCOCC3)C=C2C)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,0.014,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(OCCC(C)(C)O[H])C=C2C)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,0.016,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(OC3CCOCC3)C=C2C)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,0.022,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(C(N=CN3C)=CC3=O)C=C2C)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,0.021,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(C(C=CN3C)=CC3=O)C=C2C)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,0.014,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(C3=CN=CC=N3)C=C2C)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,0.014,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(OCC(C)(C#N)C)C=C2C)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,0.034,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(OCC3=CC=CC=C3)C=C2C)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,0.023,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(C3=NN(C)N=N3)C=C2C)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,0.006,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(C3=CC=NN3C)C=C2C)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,0.072,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(C3=NN(CC(C)(O[H])C)N=N3)C=C2C)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,0.007,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(OCC3(O[H])CCOCC3)C=C2C)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,0.068,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(OCC3(O[H])CCSCC3)C=C2C)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,0.028,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(C3=CC(OC)=NC=C3)C=C2C)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,0.005,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=CC=C(C3=CSC(C)=N3)C=C2)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,0.02,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(OCC3(C)COC3)C=C2C)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,0.147,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(OCC(O[H])=O)C=C2C)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,0.104,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(C(C=CN3C)=NC3=O)C=C2C)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,0.278,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(CC)C=CC=C2CC)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,0.004,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(F)C(OC)=CC(OC)=C2F)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,0.047,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(C3=NC=C(C)C=N3)C=C2C)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,0.389,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(CO[H])C=C2C)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,4.282,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=CC=CC=C2C(F)(F)F)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,0.051,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(Cl)C=CC(C)=C2Cl)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,0.723,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(O[C@H]3COCC3)C=C2C)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,0.028,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(O[C@@H]3COCC3)C=C2C)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,0.025,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(OCC3CCOC3)C=C2C)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,1.924,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(F)C=C(F)C=C2F)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,0.034,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(Cl)C=CC=C2Cl)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,0.006,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(F)C=CC=C2F)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,0.579,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(OC)C=C2C)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,0.024,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(C(N([H])[H])=O)C=C2C)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,0.01,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(Cl)C(OC)=CC(OC)=C2Cl)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,1.388,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=CC=CC=C2C3(C#N)CC3)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,0.051,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=C(C#N)C=C2C)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,0.984,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(OC)C=C(OC)C=C2OC)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,0.887,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(F)C=C(OC3CC3)C=C2F)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,0.011,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(F)C=C(N([H])[H])C=C2F)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,0.189,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=CC=C(C3=CN=CO3)C=C2)C=C1CN(C4=NC=C([C@@H]5C[C@H]5C(O[H])=O)N=C4)[H],=,0.177,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C#N)C=CC=C2C#N)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],>,10,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(F)C=C(OC)C=C2F)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,0.896,¦ÌM
,Preparation of benzylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138028,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC=C(C2=C(C)C=CC=C2C)C=C1CN(C3=NC=C([C@@H]4C[C@H]4C(O[H])=O)N=C3)[H],=,0.024,¦ÌM
,Preparation of benzyloxypyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138030,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(C=C1F)=C(C=C1COC2=NC=C([C@H]3C[C@@H]3C(O[H])=O)N=C2)C4=C(C)C=C(OCCC(C)(C)O[H])C=C4C,=,0.006,¦ÌM
,Preparation of benzyloxypyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138030,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(C(N=N2)=NN2C)=CC(C)=C1C3=CC=CC(COC(C=N4)=NC=C4[C@H]5C[C@@H]5C(O[H])=O)=C3,=,0.003,¦ÌM
,Preparation of benzyloxypyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138030,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(F)(F)C1=CC=CC=C1C2=CC=CC(COC(C=N3)=NC=C3[C@H]4C[C@@H]4C(O[H])=O)=C2,=,0.024,¦ÌM
,Preparation of benzyloxypyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138030,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(OC)=CC(C)=C1C2=CC=CC(COC3=NC=C([C@H]4C[C@@H]4C(O[H])=O)N=C3)=C2,=,0.012,¦ÌM
,Preparation of benzyloxypyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138030,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1C[C@@H]1C2=CN=C(C=N2)OCC3=CC(C4=CC=C(C5=CN=CO5)C=C4)=CC=C3,=,0.067,¦ÌM
,Preparation of benzyloxypyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138030,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(O[C@@H]2COCC2)=CC(C)=C1C3=CC=CC(COC4=NC=C([C@H]5C[C@@H]5C(O[H])=O)N=C4)=C3,=,0.01,¦ÌM
,Preparation of benzyloxypyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138030,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(OC2CCOCC2)=CC(C)=C1C3=CC=CC(COC4=NC=C([C@H]5C[C@@H]5C(O[H])=O)N=C4)=C3,=,0.008,¦ÌM
,Preparation of benzyloxypyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138030,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(OCCC(C)(C)O[H])=CC(C)=C1C2=CC=CC(COC3=NC=C([C@H]4C[C@@H]4C(O[H])=O)N=C3)=C2,=,0.007,¦ÌM
,Preparation of benzyloxypyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138030,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(C(C=C2)=CN(C)C2=O)=CC(C)=C1C3=CC=CC(COC4=NC=C([C@H]5C[C@@H]5C(O[H])=O)N=C4)=C3,=,0.009,¦ÌM
,Preparation of benzyloxypyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138030,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(C2=CN=CC=N2)=CC(C)=C1C3=CC=CC(COC4=NC=C([C@@H](C5)[C@H]5C(O[H])=O)N=C4)=C3,=,0.013,¦ÌM
,Preparation of benzyloxypyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138030,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(C2=CC=NN2C)=CC(C)=C1C3=CC=CC(COC(C=N4)=NC=C4[C@H]5C[C@@H]5C(O[H])=O)=C3,=,0.006,¦ÌM
,Preparation of benzyloxypyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138030,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(C(N=N2)=NN2CC(C)(O[H])C)=CC(C)=C1C3=CC=CC(COC(C=N4)=NC=C4[C@H]5C[C@@H]5C(O[H])=O)=C3,=,0.008,¦ÌM
,Preparation of benzyloxypyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138030,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CCC1=CC=CC(CC)=C1C2=CC=CC(COC(C=N3)=NC=C3[C@H]4C[C@@H]4C(O[H])=O)=C2,=,0.02,¦ÌM
,Preparation of benzyloxypyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138030,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(OCC2OCCC2)=CC(C)=C1C(C=C3COC4=NC=C([C@H]5C[C@@H]5C(O[H])=O)N=C4)=CC=C3F,=,0.006,¦ÌM
,Preparation of benzyloxypyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138030,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,ClC1=CC=CC(Cl)=C1C(C=C2COC(C=N3)=NC=C3[C@H]4C[C@@H]4C(O[H])=O)=CC=C2F,=,0.008,¦ÌM
,Preparation of benzyloxypyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138030,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(C2=NC=C(C)C=N2)=CC(C)=C1C(C=C3COC4=NC=C([C@H]5C[C@@H]5C(O[H])=O)N=C4)=CC=C3F,=,0.003,¦ÌM
,Preparation of benzyloxypyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138030,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(C2=CC=NC(OC)=C2)=CC(C)=C1C3=CC=C(C(COC(C=N4)=NC=C4[C@H]5C[C@@H]5C(O[H])=O)=C3)F,=,0.007,¦ÌM
,Preparation of benzyloxypyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138030,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(OCCCS(=O)(C)=O)=CC(C)=C1C(C=C2COC3=NC=C([C@H]4C[C@@H]4C(O[H])=O)N=C3)=CC=C2F,=,0.007,¦ÌM
,Preparation of benzyloxypyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138030,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(OCC2CCOCC2)=CC(C)=C1C3=CC=C(C(COC4=NC=C([C@H]5C[C@@H]5C(O[H])=O)N=C4)=C3)F,=,0.006,¦ÌM
,Preparation of benzyloxypyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138030,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC(C1=CC=CC=C1C(C=C2COC(C=N3)=NC=C3[C@H]4C[C@@H]4C(O[H])=O)=CC=C2F)C,=,0.035,¦ÌM
,Preparation of benzyloxypyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138030,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(F)(F)C1=C(C=C(C=C1)COC(C=N2)=NC=C2[C@H]3C[C@@H]3C(O[H])=O)C4=CC=C(OCCC(C)(C)O[H])C=C4,=,0.003,¦ÌM
,Preparation of benzyloxypyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138030,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(F)(F)C(C=C1)=C(C=C1COC2=NC=C([C@H]3C[C@@H]3C(O[H])=O)N=C2)C4=CC=C(C5=NN=C(C)O5)C=C4,=,0.004,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC(C=C(C1=NN(C)N=N1)C=C2C)=C2C3=CC=CC(COC(C=C4)=CN=C4[C@H]5C[C@@H]5C(O[H])=O)=C3,=,0.005,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(C(N=C2)=NC=C2C)=CC(C)=C1C3=CC=CC(COC4=CC=C([C@H]5C[C@@H]5C(O[H])=O)N=C4)=C3,=,0.006,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(OCCC(C)(C)O[H])=CC(C)=C1C2=CC=CC(COC3=CC=C(N=C3)[C@H]4C[C@@H]4C(O[H])=O)=C2,=,0.019,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(C2=CN(C)C(C=C2)=O)=CC(C)=C1C3=CC=CC(COC4=CC=C(N=C4)[C@H]5C[C@@H]5C(O[H])=O)=C3,=,0.015,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(C2=CN=CC=N2)=CC(C)=C1C3=CC=CC(COC4=CC=C(N=C4)[C@H]5C[C@@H]5C(O[H])=O)=C3,=,0.011,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(C(N=N2)=NN2CC(C)(C)O[H])=CC(C)=C1C3=CC=CC(COC4=CC=C(N=C4)[C@H]5C[C@@H]5C(O[H])=O)=C3,=,0.009,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(C2=CC=NN2C)=CC(C)=C1C3=CC=CC(COC4=CC=C(N=C4)[C@H]5C[C@@H]5C(O[H])=O)=C3,=,0.011,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(C2=CC=NC(OC)=C2)=CC(C)=C1C3=CC=CC(COC4=CC=C(N=C4)[C@H]5C[C@@H]5C(O[H])=O)=C3,=,0.006,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CCC1=CC=CC(CC)=C1C2=CC=CC(COC3=CC=C(N=C3)[C@H]4C[C@@H]4C(O[H])=O)=C2,=,0.062,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(OCC2CCOCC2)=CC(C)=C1C3=CC=CC(COC4=CC=C(N=C4)[C@H]5C[C@@H]5C(O[H])=O)=C3,=,0.023,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(OCC2OCCC2)=CC(C)=C1C3=CC=CC(COC(C=N4)=CC=C4[C@@H]5[C@@H](C(O[H])=O)C5)=C3,=,0.032,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(O[C@H]2CCOC2)=CC(C)=C1C3=CC=CC(COC4=CC=C(N=C4)[C@H]5C[C@@H]5C(O[H])=O)=C3,=,0.027,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(OC2CCOCC2)=CC(C)=C1C3=CC=CC(COC4=CC=C(N=C4)[C@H]5C[C@@H]5C(O[H])=O)=C3,=,0.029,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(OC)=CC(C)=C1C2=CC=CC(COC3=CC=C(N=C3)[C@H]4C[C@@H]4C(O[H])=O)=C2,=,0.027,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,ClC1=CC=CC(Cl)=C1C2=CC=CC(COC3=CC=C(N=C3)[C@H]4C[C@@H]4C(O[H])=O)=C2,=,0.024,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(OCCCS(=O)(C)=O)=CC(C)=C1C2=CC=CC(COC3=CC=C(N=C3)[C@H]4C[C@@H]4C(O[H])=O)=C2,=,0.037,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(C(N=N2)=NN2C)=CC(C)=C1C(C=C3COC4=CC=C(N=C4)[C@H]5C[C@@H]5C(O[H])=O)=CC=C3F,=,0.003,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(C(N=N2)=NN2CC(C)(C)O[H])=CC(C)=C1C3=CC=C(F)C(COC4=CC=C(N=C4)[C@H]5C[C@@H]5C(O[H])=O)=C3,=,0.006,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(C2=NC=CN=C2)=CC(C)=C1C(C=C3COC4=CC=C([C@H]5C[C@@H]5C(O[H])=O)N=C4)=CC=C3F,=,0.007,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(C2=CC=NC(OC)=C2)=CC(C)=C1C3=CC=C(C(COC4=CC=C(N=C4)[C@H]5C[C@@H]5C(O[H])=O)=C3)F,=,0.005,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(C2=CC=NN2C)=CC(C)=C1C(C=C3COC4=CC=C(N=C4)[C@H]5C[C@@H]5C(O[H])=O)=CC=C3F,=,0.006,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(C2=NC=C(C)C=N2)=CC(C)=C1C3=CC=C(F)C(COC4=CC=C(N=C4)[C@H]5C[C@@H]5C(O[H])=O)=C3,=,0.004,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(OCC2(C)COC2)=CC(C)=C1C3=CC=C(F)C(COC(C=N4)=CC=C4[C@H]5C[C@@H]5C(O[H])=O)=C3,=,0.024,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(C(O[H])=O)=CC(C)=C1C2=CC=C(F)C(COC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)N=C3)=C2,=,2.214,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(OCC(O[H])(C)C)=CC(C)=C1C2=CC=C(C(COC3=CC=C(N=C3)[C@H]4C[C@@H]4C(O[H])=O)=C2)F,=,0.036,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(C=C1F)=C(C=C1COC2=CC=C([C@H]3C[C@@H]3C(O[H])=O)N=C2)C4=C(C)C=C(OCCC(C)(O[H])C)C=C4C,=,0.012,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(F)(F)C1=C(C=C(C=C1)COC2=CC=C(N=C2)[C@H]3C[C@@H]3C(O[H])=O)C4=CC=C(C5=NC=C(OC)C=N5)C=C4,=,0.004,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(C(C=C1)=C(C=C1COC2=CC=C(N=C2)[C@H]3C[C@@H]3C(O[H])=O)C4=CC=C(C5=NN=C(OC)C=C5)C=C4)(F)F,=,0.01,¦ÌM
,Preparation of benzyloxypyridylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,WO2018138029,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(C1=C(C=C(C=C1)COC2=CC=C(N=C2)[C@H]3C[C@@H]3C(O[H])=O)C4=CC=C(OCCC(O[H])(C)C)C=C4)(F)F,=,0.012,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(OCCC(O[H])(C)C)=CC(C)=C1C(C2=C3[C@H](NC4=CN=C([C@@H]5[C@H](C5)C(O[H])=O)C=N4)CC2)=CC=C3F,=,0.004,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(OCCC(O[H])(C)C)=CC(C)=C1C(C2=C3[C@H](NC4=CN=C([C@H]5[C@H](C(O[H])=O)C5)C=N4)CC2)=CC=C3F,=,0.164,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(OCCCS(=O)(C)=O)=CC(C)=C1C(C2=C3[C@H](NC4=CN=C([C@@H](C5)[C@H]5C(O[H])=O)C=N4)CC2)=CC=C3F,=,0.008,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(OCCCS(=O)(C)=O)=CC(C)=C1C(C2=C3[C@H](NC4=CN=C([C@H]5[C@H](C(O[H])=O)C5)C=N4)CC2)=CC=C3F,=,0.519,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(C2=NN(C)N=N2)=CC(C)=C1C3=CC=CC4=C3CC[C@H]4NC5=CN=C([C@@H]6[C@H](C6)C(O[H])=O)C=N5,=,0.003,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(OCCC(O[H])(C)C)=CC(C)=C1C2=CC=CC3=C2CC[C@H]3NC4=CN=C([C@H]5C[C@@H]5C(O[H])=O)C=N4,=,0.004,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC1=CC(C2=CC=CC3=C2CC[C@H]3NC4=CN=C([C@@H]5[C@H](C5)C(O[H])=O)C=N4)=CC=C1OC,=,0.163,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=NC=C(N[C@@H]3CCC4=C3C=CC=C4C5=CC=C(C6=NC=C(OC)N=C6)C=C5)N=C2)C1,=,0.035,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C(N([H])[H])=O)C=C5C)C=N2)C1,=,0.024,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C(N=CN6C)=CC6=O)C=C5C)C=N2)C1,=,0.006,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OCC(CC6)(O[H])CCS6(=O)=O)C=C5C)C=N2)C1,=,0.014,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OCC6CCOCC6)C=C5C)C=N2)C1,=,0.004,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C(O[H])=O)C=C5C)C=N2)C1,=,0.355,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=CC=C5C)C=N2)C1,=,0.007,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(F)C=CC=C5F)C=N2)C1,=,0.077,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=CC=CC=C5C(F)(F)F)C=N2)C1,=,0.023,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(F)C=C(N([H])[H])C=C5F)C=N2)C1,=,0.15,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OC6CC6)C=C5C)C=N2)C1,=,0.056,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C(N(C)C)=O)C=C5C)C=N2)C1,=,0.075,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(Cl)C=CC(C)=C5Cl)C=N2)C1,=,0.004,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OC)C=C5C)C=N2)C1,=,0.008,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=CC=C(C6=CN=CO6)C=C5)C=N2)C1,=,0.144,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(OC)C=C(OC)C=C5OC)C=N2)C1,=,0.128,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(Cl)C=CC=C5Cl)C=N2)C1,=,0.007,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=CC=CC=C5C6(C#N)CC6)C=N2)C1,=,0.367,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(O[C@H]6CCOC6)C=C5C)C=N2)C1,=,0.013,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(O[C@@H]6CCOC6)C=C5C)C=N2)C1,=,0.009,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(Cl)C(OC)=CC(OC)=C5Cl)C=N2)C1,=,0.005,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(CO[H])C=C5C)C=N2)C1,=,0.02,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OC6CCOCC6)C=C5C)C=N2)C1,=,0.009,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OCC6(C)COC6)C=C5C)C=N2)C1,=,0.007,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C(C=C6)=CN(C)C6=O)C=C5C)C=N2)C1,=,0.006,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OCC6=CC=CC=C6)C=C5C)C=N2)C1,=,0.009,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C6=NN(C)N=N6)C=C5C)C=N2)C1,=,0.002,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C6=CC=NN6C)C=C5C)C=N2)C1,=,0.012,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(F)C(OC)=CC(OC)=C5F)C=N2)C1,=,0.081,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C6=NC=C(C)C=N6)C=C5C)C=N2)C1,=,0.004,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C6=NN(CC(C)(C)O[H])N=N6)C=C5C)C=N2)C1,=,0.003,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=CC=CC=C5C(C)C)C=N2)C1,=,0.016,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OCC6(O[H])CCOCC6)C=C5C)C=N2)C1,=,0.011,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C6=CC(OC)=NC=C6)C=C5C)C=N2)C1,=,0.005,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OCC6CCOC6)C=C5C)C=N2)C1,=,0.018,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(F)C=C(OC)C=C5F)C=N2)C1,=,0.09,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C(NC)=O)C=C5C)C=N2)C1,=,0.023,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OCC(C)(O[H])C)C=C5C)C=N2)C1,=,0.009,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=CC=C(C6=CSC(C)=N6)C=C5)C=N2)C1,=,0.019,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OCC(O[H])=O)C=C5C)C=N2)C1,=,0.839,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(CC)C=CC=C5CC)C=N2)C1,=,0.004,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(F)C=C(F)C=C5F)C=N2)C1,=,0.074,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C#N)C=C5C)C=N2)C1,=,0.009,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OCC6(O[H])CCSCC6)C=C5C)C=N2)C1,=,0.01,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C#N)C=CC=C5C#N)C=N2)C1,=,4.256,¦ÌM
,Preparation of indanylaminopyrazinylcyclopropanecarboxylic acid derivatives for use as GPR40 receptor activity modulators,CN110214135,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@@H]1[C@@H](C2=CN=C(N[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C6=NC=CN=C6)C=C5C)C=N2)C1,=,0.004,¦ÌM
,Sulfinyl acetic acid or sulfonyl acetic acid derivative as GPR40?agonist?and its preparation,CN108059607,Patent,HEK293,Calcium flux assay,EC50,O=S(CC(O[H])=O)C1=CC=C(OCC2=CC(C3=C(C)C=CC=C3C)=CC=C2)C=C1,<,0.1,¦ÌM
,Sulfinyl acetic acid or sulfonyl acetic acid derivative as GPR40?agonist?and its preparation,CN108059607,Patent,HEK293,Calcium flux assay,EC50,CC1=C(C(C)=CC=C1)C2=CC=CC(COC3=CC(S(CC(O[H])=O)=O)=CC=C3)=C2,>,10,¦ÌM
,Sulfinyl acetic acid or sulfonyl acetic acid derivative as GPR40?agonist?and its preparation,CN108059607,Patent,HEK293,Calcium flux assay,EC50,O=S(CC(O[H])=O)C1=CC=C(OC2CCC3=C2C=CC=C3Cl)C=C1,>,10,¦ÌM
,Sulfinyl acetic acid or sulfonyl acetic acid derivative as GPR40?agonist?and its preparation,CN108059607,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CS(C1=CC=C(OCC2=CC(C3=C(C)C=CC=C3C)=CC=C2)C=C1)(=O)=O,<,1,¦ÌM
,Sulfinyl acetic acid or sulfonyl acetic acid derivative as GPR40?agonist?and its preparation,CN108059607,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CS(C1=CC=CC(OCC2=CC=C(C3=C(C)C=CC=C3C)C=C2)=C1)=O,>,10,¦ÌM
,Sulfinyl acetic acid or sulfonyl acetic acid derivative as GPR40?agonist?and its preparation,CN108059607,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CS(C1=CC=C(OCC2=C(C)C=CC=C2)C=C1)=O,>,10,¦ÌM
,Sulfinyl acetic acid or sulfonyl acetic acid derivative as GPR40?agonist?and its preparation,CN108059607,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CS(C1=CC=C(OCC2=C(C)C=CC=C2)C=C1)(=O)=O,<,10,¦ÌM
,Sulfinyl acetic acid or sulfonyl acetic acid derivative as GPR40?agonist?and its preparation,CN108059607,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CS(C1=CC=C(C#CC2=C(C)C=CC=C2)C=C1)=O,>,10,¦ÌM
,Sulfinyl acetic acid or sulfonyl acetic acid derivative as GPR40?agonist?and its preparation,CN108059607,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CS(C1=CC=C(C#CC2=C(C)C=CC=C2)C=C1)(=O)=O,<,10,¦ÌM
,Sulfinyl acetic acid or sulfonyl acetic acid derivative as GPR40?agonist?and its preparation,CN108059607,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CS(C1=CC=C(O[C@@H]2C3=C(C(C(F)(F)F)=CC=C3)CC2)C=C1)=O,>,10,¦ÌM
,Sulfinyl acetic acid or sulfonyl acetic acid derivative as GPR40?agonist?and its preparation,CN108059607,Patent,HEK293,Calcium flux assay,EC50,O=C(NO[H])CS(C1=CC=C(OCC2=CC(C3=C(C)C=CC=C3C)=CC=C2)C=C1)=O,<,10,¦ÌM
,Sulfinyl acetic acid or sulfonyl acetic acid derivative as GPR40?agonist?and its preparation,CN108059607,Patent,HEK293,Calcium flux assay,EC50,O=C(NCC(O[H])=O)CS(C1=CC=C(OCC2=CC(C3=C(C)C=CC=C3C)=CC=C2)C=C1)=O,>,10,¦ÌM
,Sulfinyl acetic acid or sulfonyl acetic acid derivative as GPR40?agonist?and its preparation,CN108059607,Patent,HEK293,Calcium flux assay,EC50,O=S(CC(O[H])=O)C1=CC=C(OCC2=CC=C(C3=C(C)C=CC=C3C)C=C2)C=C1,<,1,¦ÌM
,Sulfinyl acetic acid or sulfonyl acetic acid derivative as GPR40?agonist?and its preparation,CN108059607,Patent,HEK293,Calcium flux assay,EC50,O=S(CC(O[H])=O)C1=CC=C(OCC2=CC(C3=C(Cl)C=NC=C3)=CC=C2)C=C1,<,1,¦ÌM
,Sulfinyl acetic acid or sulfonyl acetic acid derivative as GPR40?agonist?and its preparation,CN108059607,Patent,HEK293,Calcium flux assay,EC50,O=S(CC(O[H])=O)C1=CC=C(OCC2=CC(C3=C(C)ON=C3C)=CC=C2)C=C1,<,10,¦ÌM
,Sulfinyl acetic acid or sulfonyl acetic acid derivative as GPR40?agonist?and its preparation,CN108059607,Patent,HEK293,Calcium flux assay,EC50,O=S(CC(O[H])=O)C1=CC=C(OCC2=CC(C3=CN(C)N=C3)=CC=C2)C=C1,>,10,¦ÌM
,Sulfinyl acetic acid or sulfonyl acetic acid derivative as GPR40?agonist?and its preparation,CN108059607,Patent,HEK293,Calcium flux assay,EC50,O=S(CC(O[H])=O)C1=CC=C(OCC2=C(C)N=C(C3=CC=C(F)C=C3)S2)C=C1,<,10,¦ÌM
,Sulfinyl acetic acid or sulfonyl acetic acid derivative as GPR40?agonist?and its preparation,CN108059607,Patent,HEK293,Calcium flux assay,EC50,O=S(CC(O[H])=O)C1=CC=C(S1)OCC2=CC(C3=C(C)C=CC=C3C)=CC=C2,<,1,¦ÌM
,Sulfinyl acetic acid or sulfonyl acetic acid derivative as GPR40?agonist?and its preparation,CN108059607,Patent,HEK293,Calcium flux assay,EC50,CC1=C(C(C)=NC=N1)C2=CC=CC(COC3=CC=C(S(CC(O[H])=O)=O)C=C3)=C2,<,10,¦ÌM
,Sulfinyl acetic acid or sulfonyl acetic acid derivative as GPR40?agonist?and its preparation,CN108059607,Patent,HEK293,Calcium flux assay,EC50,FC1=C(C=C(OC)C=C1)C2=CC=CC(COC3=CC=C(S(CC(O[H])=O)=O)C=C3)=C2,<,1,¦ÌM
,Sulfinyl acetic acid or sulfonyl acetic acid derivative as GPR40?agonist?and its preparation,CN108059607,Patent,HEK293,Calcium flux assay,EC50,O=S(CC(O[H])=O)C1=CC=C(C=C1)OCC2=CC(C3=CC=NC=C3)=CC=C2,<,1,¦ÌM
,Preparation of biphenyl carboxylic acid compounds useful for the treatment of diabetes and metabolic syndrome related diseases,CN108003074,Patent,HEK293,Calcium flux assay,EC50,CC1=C(C(C)=CC(OC(C)(C)C(O[H])=O)=C1)C2=CC(COC3=CC=CC(OCCCS(C)(=O)=O)=C3)=CC=C2,=,0.11,¦ÌM
,Preparation of biphenyl carboxylic acid compounds useful for the treatment of diabetes and metabolic syndrome related diseases,CN108003074,Patent,HEK293,Calcium flux assay,EC50,CC1=C(C(C)=CC(NC(C)(C)C(O[H])=O)=C1)C2=CC(COC3=CC=CC(OCCCS(C)(=O)=O)=C3)=CC=C2,=,0.09,¦ÌM
,Preparation of biphenyl carboxylic acid compounds useful for the treatment of diabetes and metabolic syndrome related diseases,CN108003074,Patent,HEK293,Calcium flux assay,EC50,CC1=C(C(C)=CC(OCCC(O[H])=O)=C1)C2=CC(COC3=CC=CC(OCCCS(C)(=O)=O)=C3)=CC=C2,=,0.078,¦ÌM
,Preparation of biphenyl carboxylic acid compounds useful for the treatment of diabetes and metabolic syndrome related diseases,CN108003074,Patent,HEK293,Calcium flux assay,EC50,CC1=C(C(C)=CC(SC(F)(F)C(O[H])=O)=C1)C2=CC(CNC3=CC=CC(OCCCS(C)(=O)=O)=C3)=CC=C2,=,0.053,¦ÌM
,Preparation of biphenyl carboxylic acid compounds useful for the treatment of diabetes and metabolic syndrome related diseases,CN108003074,Patent,HEK293,Calcium flux assay,EC50,CC1=C(C(C)=CC(OC(CCC)C(O[H])=O)=C1)C2=CC(COC3=CC=CC(OCCCS(C)(=O)=O)=C3C)=CC=C2,=,0.208,¦ÌM
,Preparation of biphenyl carboxylic acid compounds useful for the treatment of diabetes and metabolic syndrome related diseases,CN108003074,Patent,HEK293,Calcium flux assay,EC50,CC1=C(C(C)=CC(OC(F)(F)C(O[H])=O)=C1)C2=CC(CNC3=CC=CC(OCCCS(C)(=O)=O)=C3C)=CC=C2,=,0.023,¦ÌM
,Preparation of biphenyl carboxylic acid compounds useful for the treatment of diabetes and metabolic syndrome related diseases,CN108003074,Patent,HEK293,Calcium flux assay,EC50,CC1=C(C(C)=CC(OC(CCC)C(O[H])=O)=C1)C2=CC(C(CC3=CC=CC(OCCCS(C)(=O)=O)=C3)=O)=CC=C2,=,0.005,¦ÌM
,Preparation of biphenyl carboxylic acid compounds useful for the treatment of diabetes and metabolic syndrome related diseases,CN108003074,Patent,HEK293,Calcium flux assay,EC50,CC1=C(C(C)=CC(CCC(O[H])=O)=C1)C2=CC(NC(C3=CC=CC(OCCCS(C)(=O)=O)=C3)=O)=CC=C2,=,0.00087,¦ÌM
,Preparation of biphenyl carboxylic acid compounds useful for the treatment of diabetes and metabolic syndrome related diseases,CN108003074,Patent,HEK293,Calcium flux assay,EC50,CC1=C(C(C)=CC(/C=C/C(O[H])=O)=C1)C2=CC(C(NC3=CC=CC(OCCCS(C)(=O)=O)=C3)=O)=CC=C2,=,0.096,¦ÌM
,Preparation of biphenyl carboxylic acid compounds useful for the treatment of diabetes and metabolic syndrome related diseases,CN108003074,Patent,HEK293,Calcium flux assay,EC50,CC1=C(C(C)=CC(OCC(O[H])=O)=C1)C2=CC(COC3=CC=C(OCCCS(C)(=O)=O)C=C3F)=CC=C2,=,0.08,¦ÌM
,Preparation of biphenyl carboxylic acid compounds useful for the treatment of diabetes and metabolic syndrome related diseases,CN108003074,Patent,HEK293,Calcium flux assay,EC50,CC1=C(C(C)=CC(OC(C)(C)C(O[H])=O)=C1)C2=CC(COC3=CC=CC(OCCN(CC4)CCS4(=O)=O)=C3)=CC=C2,=,0.039,¦ÌM
,Preparation of biphenyl carboxylic acid compounds useful for the treatment of diabetes and metabolic syndrome related diseases,CN108003074,Patent,HEK293,Calcium flux assay,EC50,CC1=C(C(C)=CC(OC(C)(C)C(O[H])=O)=C1)C2=CC(OC(C)C3=CC=CC(OCCN4CCOCC4)=C3)=CC=C2,=,0.12,¦ÌM
,Preparation of biphenyl carboxylic acid compounds useful for the treatment of diabetes and metabolic syndrome related diseases,CN108003074,Patent,HEK293,Calcium flux assay,EC50,CC1=C(C(C)=CC(OC(C)(C)C(O[H])=O)=C1)C2=CC(OC(C)C3=CC=CC(OCCCS(C)(=O)=O)=C3)=CC=C2,=,0.000691,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OC[C@@H]3CC[C@H](CC3)C4=CC(OC)=CC=C4F)=CC=C2)O[H],=,0.0008,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OC[C@H]3CC[C@@](O[H])(CC3)C4=CC(OC)=CC=C4F)=CC=C2)O[H],=,0.0248,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])CC(C1CC1)C2=CC=NC(OC[C@H](CC3)CC[C@@H]3C4=CC(OC)=CC=C4F)=C2,=,0.0007,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])CC(C1CC1)C2=CC=NC(OC[C@H]3CC[C@H](CC3)C4=CC(OC)=CC=C4F)=C2,=,0.0756,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OC[C@@H]3CC[C@@](O[H])(CC3)C4=CC(OC)=CC=C4F)=CC=C2)O[H],=,0.3771,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])CC(C1CC1)C2=CC=NC(OC[C@H]3CC[C@H](CC3)C(C=C(N=C4)OC)=C4F)=C2,=,0.0347,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC1=C(C=C(N=C1)OC)[C@@H]2CC[C@@H](COC3=CC(C(CC(O[H])=O)C4CC4)=CC=N3)CC2,=,0.0005,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC1=C(C=C(OC)N=C1)[C@H]2CC[C@H](COC3=CC=CC([C@H](C4CC4)CC(O[H])=O)=C3)CC2,=,0.0005,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC1=C(C=C(OC)N=C1)[C@H]2CC[C@@H](COC3=CC=CC([C@H](C4CC4)CC(O[H])=O)=C3)CC2,=,0.0269,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(OC[C@H]3CC[C@@](OC)(CC3)C4=CC(OC)=CC=C4F)=CC=C2,=,0.0021,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(OC[C@@H]3CC[C@@](OC)(CC3)C4=CC(OC)=CC=C4F)=CC=C2,=,0.0138,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])CC(C1CC1)C2=NC(OC[C@@H]3CC[C@H](CC3)C4=CC(OC)=CC=C4F)=CC=C2,=,0.0327,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])CC(C1=NC(OC[C@@H](CC2)CC[C@@H]2C3=CC(OC)=CC=C3F)=CC=C1)C4CC4,=,1.5011,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])CC(C1CC1)C2=NC(OC[C@H](CC3)CC[C@@H]3C4=C(F)C=NC(OC)=C4)=CC=C2,=,0.1376,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])CC(C1=NC(OC[C@@H](CC2)CC[C@@H]2C(C=C(N=C3)OC)=C3F)=CC=C1)C4CC4,=,3.0818,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC=C(OC)C=C1[C@@H](CC2)CC[C@H]2COC3=CC=CC([C@H](C4CC4)CC5=NN=NN5[H])=C3,=,0.0443,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])CC(C1=CC(OC[C@@H](CC2)CC[C@@H]2C3=CC(OC)=CC=C3F)=CN=C1)C4CC4,=,0.2257,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OC[C@H](CC3)CC[C@@]3(F)C4=CC(OC)=CC=C4F)=CC=C2)O[H],=,0.0825,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OC[C@H]3CC[C@@](F)(CC3)C4=CC(OC)=CC=C4F)=CC=C2)O[H],=,0.0099,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])CC(C1=CC(OC[C@H](CC2)CC[C@@H]2C3=CC(OC)=CC=C3F)=CN=C1)C4CC4,=,0.012,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])CC(C1CC1)C2=CC(OC[C@H](CC3)CC[C@@H]3C4=C(F)C=NC(OC)=C4)=CN=C2,=,0.0176,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])CC(C1CC1)C2=CC(OC[C@H]3CC[C@H](CC3)C4=C(F)C=NC(OC)=C4)=CN=C2,=,0.3073,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC1=C(C=C(N=C1)OC)[C@H]2CC[C@H](COC3=CC([C@H](CC(O[H])=O)C4CC4)=CC=N3)CC2,=,0.0084,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC1=C(C=C(N=C1)OC)[C@H](CC2)CC[C@@H]2COC3=CC([C@H](C4CC4)CC(O[H])=O)=CC=N3,=,0.0053,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC=C(OC)C=C1[C@H]2CC[C@H](COC3=CC([C@H](CC(O[H])=O)C4CC4)=CC=N3)CC2,=,0.0109,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC=C(OC)C=C1[C@H]2CC[C@H](COC3=CC([C@@H](CC(O[H])=O)C4CC4)=CC=N3)CC2,=,0.0002,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC=C(OC)C=C1[C@H]2CC[C@H](/C=C/C3=CC=CC([C@H](C4CC4)CC(O[H])=O)=C3)CC2,=,0.0026,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,CC(CC1C(CCC(C1)C2=CC(OC)=CC=C2F)COC3=CC=CC([C@H](C4CC4)CC(O[H])=O)=C3)C,=,0.0179,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,CC(CC(C1)C(CCC1C2=C(F)C=NC(OC)=C2)COC3=CC=CC([C@H](C4CC4)CC(O[H])=O)=C3)C,=,0.0021,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])CC(C1CC1)C2=CC(OC[C@H](CC3)CC[C@@H]3C4=C(F)C=NC(OC)=C4)=CC=N2,=,0.0261,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])CC(C1=CC(OC[C@@H]2CC[C@H](C(C=C(N=C3)OC)=C3F)CC2)=CC=N1)C4CC4,=,0.059,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC1=C(C=C(OC)N=C1)C2CC(C(CC2)COC3=CC([C@@H](CC(O[H])=O)C4CC4)=CC=C3)C,=,0.0037,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])CC(C1CC1)C2=CC(OC[C@H](CC3)CC[C@@H]3C4=CC(OC)=CC=C4F)=CC=N2,=,0.0624,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])CC(C1CC1)C2=CC(OC[C@@H](CC3)CC[C@@H]3C4=CC(OC)=CC=C4F)=CC=N2,=,1.8399,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC=C(OC)C=C1[C@H]2CC[C@@H](CC2)CCC3=CC=CC([C@H](C4CC4)CC(O[H])=O)=C3,=,0.0017,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])C[C@H](C1CC1)C2=CC(OC[C@@H](CC3)CC[C@@H]3C4=CC(OC)=CC=C4F)=CC=C2,=,0.6868,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])C[C@@H](C1=CC(OC[C@H](CC2)CC[C@@H]2C3=CC(OC)=CC=C3F)=CC=C1)C4CC4,=,0.0062,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC=C(OC)C=C1[C@H]2CC[C@H](CC2)COC3=CC=CC([C@@H](CC4=NN=NN4[H])C5CC5)=C3,=,0.5999,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC=C(OC)C=C1[C@H]2CC[C@H](CNC3=CC=CC([C@H](C4CC4)CC(O[H])=O)=C3)CC2,=,0.022,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC=C(OC)C=C1[C@H]2CC[C@H](CC2)COC3=CC([C@H](CC(O[H])=O)C4CC4)=CC=N3,=,0.018,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(CC(C1=CC=CC(OC[C@@H](CC2)CC[C@@H]2C3=CC(OC)=CC=C3F)=C1)C#CC)O[H],=,3.1031,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC1=C([C@H]2CC[C@H](COC3=CC([C@@H](CC4=NN=NN4[H])C5CC5)=CC=N3)CC2)C=C(OC)N=C1,=,0.281,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC1=C([C@@](CC[C@@H]2COC3=CC([C@H](C4CC4)CC(O[H])=O)=CC=N3)(CC2)OC)C=C(N=C1)OC,=,0.0099,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,COC1=CC([C@]2(OC)CC[C@H](COC3=CC([C@H](C4CC4)CC(O[H])=O)=CC=N3)CC2)=C(C=N1)F,=,0.2576,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC=NC(OCC3CCC(CC3)C4=NC(OC)=CN=C4)=C2,=,5.8036,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC1=C(C=C(N=C1)OCC)[C@H]2CC[C@H](CC2)COC3=CC([C@H](C4CC4)CC(O[H])=O)=CC=N3,=,0.2121,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])C[C@H](C1=CC=NC(OCC2CCC(CC2)C3=NC(OC)=CC=N3)=C1)C4CC4,=,0.2442,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])CC(OCC)C1=CC=CC(OC[C@H]2CC[C@H](CC2)C3=CC(OC)=CC=C3F)=C1,=,0.5001,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])[C@@H](C)[C@H](C1=CC=CC(OC[C@@H](CC2)CC[C@@H]2C3=C(F)C=CC(OC)=C3)=C1)C4CC4,=,0.002,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])[C@@H](C)[C@@H](C1CC1)C2=CC(OC[C@H](CC3)CC[C@@H]3C4=C(F)C=CC(CC)=C4)=CC=C2,=,0.0005,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC([C@H](C1=CC(OC[C@H]2CC[C@H](C3=CC(OC)=CC=C3F)CC2)=CC=C1)C4CC4)(C(O[H])=O)C,=,0.0003,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,F[C@@]([C@H](C1=CC(OC[C@@H]2CC[C@H](CC2)C3=CC(OC)=CC=C3F)=CC=C1)C4CC4)(C)C(O[H])=O,=,0.00027,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,F[C@]([C@H](C1=CC(OC[C@@H]2CC[C@H](CC2)C3=CC(OC)=CC=C3F)=CC=C1)C4CC4)(C)C(O[H])=O,=,0.00605,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC(C)(C(O[H])=O)[C@H](C1=CC(OC[C@@H]2CC[C@H](CC2)C3=C(F)C=NC(OC)=C3)=CC=C1)C4CC4,=,0.00025,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,F[C@@](C)(C(O[H])=O)[C@H](C1=CC(OC[C@@H]2CC[C@H](CC2)C3=C(F)C=NC(OC)=C3)=CC=C1)C4CC4,=,0.00025,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,F[C@](C)(C(O[H])=O)[C@H](C1=CC(OC[C@@H]2CC[C@H](CC2)C3=C(F)C=NC(OC)=C3)=CC=C1)C4CC4,=,0.0326,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,F[C@@](C)(C(O[H])=O)[C@H](C1=CC(OCC2CCC(CC2)C3=CC(OC)=CC=C3Cl)=CC=C1)C4CC4,=,0.00019,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC(C)(C(O[H])=O)[C@H](C1=CC(OCC2CCC(CC2)C3=CC(CC)=CC=C3Cl)=CC=C1)C4CC4,=,0.00059,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC(C)(C(O[H])=O)[C@H](C1=CC(OCC2CCC(CC2)C3=CC(OC)=CC=C3)=CC=C1)C4CC4,=,0.00025,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,CC(F)(C(O[H])=O)[C@@H](C1=CC(OCC2CCC(CC2)C3=CC(F)=NC=C3F)=CC=C1)C4CC4,=,0.0017,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC(C)(C(O[H])=O)[C@H](C1=CC(OC[C@@H]2CC[C@H](CC2)C3=CC(CC)=CC=C3F)=CC=C1)C4CC4,=,0.00027,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC(C)(C(O[H])=O)[C@H](C1=CC(OCC2CCC(C3=CC=NC(OC)=C3)CC2)=CC=C1)C4CC4,=,0.0012,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC(C)(C(O[H])=O)[C@H](C1=CC(OCC2CCC(C3=CC(OC)=CC=C3C)CC2)=CC=C1)C4CC4,=,0.00016,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC(C)(C(O[H])=O)[C@H](C1=CC(OCC2CCC(CC2)C3=CC(OC)=CC=C3C(N([H])C4=CC=CC=N4)=O)=CC=C1)C5CC5,=,0.0019,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC([C@H](C1=CC(/C=C/[C@H](CC2)CC[C@@H]2C3=CC(OC)=CC=C3F)=CC=C1)C4CC4)(C(O[H])=O)C,=,0.00188,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC([C@H](C1=CC(CC[C@H](CC2)CC[C@@H]2C3=CC(OC)=CC=C3F)=CC=C1)C4CC4)(C(O[H])=O)C,=,0.00022,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,F[C@]([C@H](C1=CC(OC[C@@H](CC2)CC[C@H]2C3=C(F)C=CC(OC(F)(F)F)=C3)=CC=C1)C4CC4)(C(O[H])=O)C,=,0.01408,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,CC([C@@H](C1CC1)C2=CC(OCC3CCC(C4=CC(F)=CC=C4F)CC3)=CC=C2)(C(O[H])=O)F,=,0.00044,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,F[C@@](C)(C(O[H])=O)[C@@H](C1CC1)C2=CC(OCC3CCC(C4=CC(OC)=CC=C4F)=CC3)=CC=C2,=,0.00018,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC(C)(C(O[H])=O)[C@@H](C1CC1)C2=CC(NC[C@H](CC3)CC[C@@H]3C4=CC(OC)=CC=C4F)=CC=C2,=,0.00172,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC(C)(C(O[H])=O)[C@@H](C1CC1)C2=CC(COC3CCC(C4=CC(OC)=CC=C4F)CC3)=CC=C2,=,0.0022,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,FC(C=CC(OC)=C1)=C1[C@H]2CC[C@H](COC3=CC([C@@H](C(F)(C(O[H])=O)C)C4CC4)=CC=N3)CC2,=,0.013,¦ÌM
,Preparation of cyclohexyl derivatives as GPR40?agonists?for the treatment of type II diabetes,WO2018081047,Patent,HEK293,Calcium Flux Assay,EC50,CC(F)(C(O[H])=O)[C@H](C1=CC=NC(OC[C@H](CC2)CC[C@@H]2C3=CC(OC)=NC=C3F)=C1)C4CC4,=,0.079,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(OCCC(O[H])(C)C)=CC(C)=C1C(C=C2CN(C3=NC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)[H])=CC=C2F,=,0.045,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(C=C1F)=C(C=C1CN(C2=NC=C([C@@H]3[C@H](C3)C(O[H])=O)C=C2)[H])C(C(C)=CC(OCCC(O[H])(C)C)=C4)=C4C,=,0.042,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(C=C1F)=C(C=C1CN(C2=NC=C([C@H]3C[C@@H]3C(O[H])=O)C=C2)[H])C4=C(F)C=CC(CN([H])[H])=C4,>,10,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(C(C=C1)=C(C=C1CN(C2=NC=C([C@@H]3[C@H](C3)C(O[H])=O)C=C2)[H])C4=CC=C(OCCC(C)(O[H])C)C=C4)(F)F,=,0.015,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(C1=C(C=C(C=C1)CN([H])C2=NC=C([C@H]3C[C@@H]3C(O[H])=O)C=C2)C4=C(C)C=C(OCCC(O[H])(C)C)C=C4C)(F)F,=,0.012,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(F)(F)C(C=CC(CN(C1=NC=C([C@H]2C[C@@H]2C(O[H])=O)C=C1)[H])=C3)=C3C4=CC=C(OC(F)(F)F)C=C4,=,0.038,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,FC(C1=C(C=C(C=C1)CN(C2=NC=C([C@@H]3[C@H](C3)C(O[H])=O)C=C2)[H])C4=CC=C(OCC5CC5)C=C4)(F)F,=,0.034,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,CC1=CC(OCCCS(C)(=O)=O)=CC(C)=C1C2=CC=CC(CN(C3=NC=C([C@@H]4[C@@H](C(O[H])=O)C4)C=C3)[H])=C2,=,0.05,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(C5=CSC(C)=N5)C=C4C)=CC=C3F)C1)O[H],=,0.256,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(C5=CN=CO5)C=C4C)=CC=C3F)C1)O[H],=,0.022,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(C5=NC=CN=C5)C=C4C)=CC=C3F)C1)O[H],=,0.021,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(OCCCS(C)(=O)=O)C=C4C)=CC=C3F)C1)O[H],>,10,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(C(C=C5)=CN(C)C5=O)C=C4C)=CC=C3F)C1)O[H],=,0.017,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(C5=NN(CC(C)(O[H])C)N=N5)C=C4C)=CC=C3F)C1)O[H],=,0.011,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(O[H])C=C4C)=CC=C3F)C1)O[H],=,0.026,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(OCC5(O[H])CCSCC5)C=C4C)=CC=C3F)C1)O[H],=,0.064,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(OCC(O[H])=O)C=C4C)=CC=C3F)C1)O[H],=,0.353,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=CC=C4C)=CC=C3F)C1)O[H],=,0.131,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(F)C=C(OC)C=C4F)=CC=C3F)C1)O[H],=,2.097,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(F)C=CC=C4F)=CC=C3F)C1)O[H],=,2.295,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C(F)(F)F)C=CC=C4C(F)(F)F)=CC=C3F)C1)O[H],=,0.834,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(F)C(F)=C(OC)C(F)=C4F)=CC=C3F)C1)O[H],=,0.477,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C#N)C=CC=C4C#N)=CC=C3F)C1)O[H],>,10,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=CC=CC=C4C(F)(F)F)=CC=C3F)C1)O[H],=,0.204,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(Cl)C=CC(C)=C4Cl)=CC=C3F)C1)O[H],=,0.041,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(OC)C=C4C)=CC=C3F)C1)O[H],=,0.079,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(C(O[H])=O)C=C4C)=CC=C3F)C1)O[H],>,10,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(F)C=C(N([H])[H])C=C4F)=CC=C3F)C1)O[H],=,6.725,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(F)C=C(OC5CC5)C=C4F)=CC=C3F)C1)O[H],=,0.57,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(OC)C=C(OC)C=C4OC)=CC=C3F)C1)O[H],=,0.877,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(Cl)C=CC=C4Cl)=CC=C3F)C1)O[H],=,0.105,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=CC=CC=C4C5(C#N)CC5)=CC=C3F)C1)O[H],=,1.944,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(Cl)C(OC)=CC(OC)=C4Cl)=CC=C3F)C1)O[H],=,0.128,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(C(N([H])[H])=O)C=C4C)=CC=C3F)C1)O[H],=,0.612,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(C#N)C=C4C)=CC=C3F)C1)O[H],=,0.137,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(OCC5CCOC5)C=C4C)=CC=C3F)C1)O[H],=,0.085,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(O[C@H]5COCC5)C=C4C)=CC=C3F)C1)O[H],=,0.063,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(O[C@@H]5COCC5)C=C4C)=CC=C3F)C1)O[H],=,0.094,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(F)C=C(F)C=C4F)=CC=C3F)C1)O[H],=,1.444,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(CO[H])C=C4C)=CC=C3F)C1)O[H],=,0.443,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(OCC(C)(O[H])C)C=C4C)=CC=C3F)C1)O[H],=,0.081,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(OC5CCOCC5)C=C4C)=CC=C3F)C1)O[H],=,0.1,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(C(N=CN5C)=CC5=O)C=C4C)=CC=C3F)C1)O[H],=,0.054,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(C(C=CN5C)=CC5=O)C=C4C)=CC=C3F)C1)O[H],=,0.032,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(OCC5(C)COC5)C=C4C)=CC=C3F)C1)O[H],=,0.147,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(OCC(C)(C#N)C)C=C4C)=CC=C3F)C1)O[H],=,0.096,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(OCC5=CC=CC=C5)C=C4C)=CC=C3F)C1)O[H],=,0.107,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(C5=NN(C)N=N5)C=C4C)=CC=C3F)C1)O[H],=,0.02,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(C(C=CN5C)=NC5=O)C=C4C)=CC=C3F)C1)O[H],=,0.072,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(C5=CC=NN5C)C=C4C)=CC=C3F)C1)O[H],=,0.025,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(CC)C=CC=C4CC)=CC=C3F)C1)O[H],=,0.106,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(F)C(OC)=CC(OC)=C4F)=CC=C3F)C1)O[H],=,1.344,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(C5=NC=C(C)C=N5)C=C4C)=CC=C3F)C1)O[H],=,0.015,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=CC=CC=C4C(C)C)=CC=C3F)C1)O[H],=,0.317,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(OCC5(O[H])CCOCC5)C=C4C)=CC=C3F)C1)O[H],=,0.22,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(C5=CC(OC)=NC=C5)C=C4C)=CC=C3F)C1)O[H],=,0.012,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(OCC(CC5)(O[H])CCS5(=O)=O)C=C4C)=CC=C3F)C1)O[H],=,0.422,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(OCC5CCOCC5)C=C4C)=CC=C3F)C1)O[H],=,0.043,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(C(NC)=O)C=C4C)=CC=C3F)C1)O[H],=,0.375,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(C(N(C)C)=O)C=C4C)=CC=C3F)C1)O[H],=,0.55,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=CC=C4C)=C(F)C=C3F)C1)O[H],=,0.036,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(F)C=C(OC)C=C4F)=C(F)C=C3F)C1)O[H],=,0.668,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(F)C=CC=C4F)=C(F)C=C3F)C1)O[H],=,0.931,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(F)C(F)=C(OC)C(F)=C4F)=C(F)C=C3F)C1)O[H],=,0.123,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C#N)C=CC=C4C#N)=C(F)C=C3F)C1)O[H],>,10,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=CC=CC=C4C(F)(F)F)=C(F)C=C3F)C1)O[H],=,0.048,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(Cl)C=CC(C)=C4Cl)=C(F)C=C3F)C1)O[H],=,0.031,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C([C@H]1[C@H](C2=CN=C(C=C2)N([H])CC3=CC(C4=C(C)C=C(OC)C=C4C)=C(F)C=C3F)C1)O[H],=,0.059,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(C(O[H])=O)C=C4C)=C(F)C=C3F)C1,=,5.964,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(F)C=C(N([H])[H])C=C4F)=C(F)C=C3F)C1,=,3.629,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(F)C=C(OC5CC5)C=C4F)=C(F)C=C3F)C1,=,0.14,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(OC)C=C(OC)C=C4OC)=C(F)C=C3F)C1,=,0.838,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(Cl)C=CC=C4Cl)=C(F)C=C3F)C1,=,0.04,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=CC=CC=C4C5(C#N)CC5)=C(F)C=C3F)C1,=,1.338,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(Cl)C(OC)=CC(OC)=C4Cl)=C(F)C=C3F)C1,=,0.05,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(C(N([H])[H])=O)C=C4C)=C(F)C=C3F)C1,=,0.34,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(C#N)C=C4C)=C(F)C=C3F)C1,=,0.083,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(OCC5CCOC5)C=C4C)=C(F)C=C3F)C1,=,0.005,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(O[C@@H]5COCC5)C=C4C)=C(F)C=C3F)C1,=,0.042,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(O[C@H]5COCC5)C=C4C)=C(F)C=C3F)C1,=,0.059,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(F)C=C(F)C=C4F)=C(F)C=C3F)C1,=,0.491,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(OCC(C)(O[H])C)C=C4C)=C(F)C=C3F)C1,=,0.104,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(OC5CCOCC5)C=C4C)=C(F)C=C3F)C1,=,0.057,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(C(N=CN5C)=CC5=O)C=C4C)=C(F)C=C3F)C1,=,0.025,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(C(C=CN5C)=CC5=O)C=C4C)=C(F)C=C3F)C1,=,0.029,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(OCC5(C)COC5)C=C4C)=C(F)C=C3F)C1,=,0.089,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(OCC(C)(C#N)C)C=C4C)=C(F)C=C3F)C1,=,0.081,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(OCC5=CC=CC=C5)C=C4C)=C(F)C=C3F)C1,=,0.065,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(C5=NN(C)N=N5)C=C4C)=C(F)C=C3F)C1,=,0.008,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(C(C=CN5C)=NC5=O)C=C4C)=C(F)C=C3F)C1,=,0.043,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(C5=CC=NN5C)C=C4C)=C(F)C=C3F)C1,=,0.016,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(CC)C=CC=C4CC)=C(F)C=C3F)C1,=,0.072,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(F)C(OC)=CC(OC)=C4F)=C(F)C=C3F)C1,=,1.319,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(C5=NC=C(C)C=N5)C=C4C)=C(F)C=C3F)C1,=,0.011,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=CC=CC=C4C(C)C)=C(F)C=C3F)C1,=,0.114,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(OCC5(O[H])CCOCC5)C=C4C)=C(F)C=C3F)C1,=,0.189,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(OCC5(O[H])CCSCC5)C=C4C)=C(F)C=C3F)C1,=,0.102,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(C5=CC(OC)=NC=C5)C=C4C)=C(F)C=C3F)C1,=,0.008,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(OCC(CC5)(O[H])CCS5(=O)=O)C=C4C)=C(F)C=C3F)C1,=,0.101,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(OCC5CCOCC5)C=C4C)=C(F)C=C3F)C1,=,0.039,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(C(NC)=O)C=C4C)=C(F)C=C3F)C1,=,0.42,¦ÌM
,Preparation of benzylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators useful in treating metabolic diseases,CN110088089,Patent,1321N1,InositolPhosphate Accumulation Assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CN=C(C=C2)NCC3=CC(C4=C(C)C=C(C(N(C)C)=O)C=C4C)=C(F)C=C3F)C1,=,0.462,¦ÌM
,Preparation of pyrazine ring-containing phenylpropionic acid compound,CN107556252,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC(COC2=NC(C(C=C3)=C(C)C=C3F)=CN=C2)=CC=C1CCC(O[H])=O,<,0.02,¦ÌM
,Preparation of pyrazine ring-containing phenylpropionic acid compound,CN107556252,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC(COC2=CN=CC(C3=C(C)C=C(C)C=C3C)=N2)=CC=C1CCC(O[H])=O,<,0.01,¦ÌM
,Preparation of pyrazine ring-containing phenylpropionic acid compound,CN107556252,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC(COC2=CN=CC(C(C(C)=C3)=C(C)C=C3OCC)=N2)=CC=C1CCC(O[H])=O,<,0.005,¦ÌM
,Preparation of pyrazine ring-containing phenylpropionic acid compound,CN107556252,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC(COC2=CN=CC(C(C(C)=C3)=C(C)C=C3OCOC)=N2)=CC=C1CCC(O[H])=O,<,0.005,¦ÌM
,Preparation of pyrazine ring-containing phenylpropionic acid compound,CN107556252,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC(COC2=CN=CC(C(C(C)=C3)=C(C)C=C3OCCOC)=N2)=CC=C1CCC(O[H])=O,<,0.01,¦ÌM
,Preparation of pyrazine ring-containing phenylpropionic acid compound,CN107556252,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC(COC2=CN=CC(C(C(C)=C3)=C(C)C=C3N4CCOCC4)=N2)=CC=C1CCC(O[H])=O,<,0.005,¦ÌM
,Preparation of pyrazine ring-containing phenylpropionic acid compound,CN107556252,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC(COC2=CN=CC(C3=C(C)C=C(C=C3C)OC4CCOCC4)=N2)=CC=C1CCC(O[H])=O,<,0.05,¦ÌM
,Preparation of pyrazine ring-containing phenylpropionic acid compound,CN107556252,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC(COC2=CN=CC(C(C(C)=C3)=C(C)C=C3OC4CCCCC4)=N2)=CC=C1CCC(O[H])=O,<,0.05,¦ÌM
,Preparation of pyrazine ring-containing phenylpropionic acid compound,CN107556252,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC(COC2=NC(C3=C(OC)C=CC=C3OC)=CN=C2)=CC=C1CCC(O[H])=O,<,0.05,¦ÌM
,Preparation of pyrazine ring-containing phenylpropionic acid compound,CN107556252,Patent,HEK293,Calcium Flux Assay,EC50,FC(C(F)=CC(C1=CN=CC(OCC(C=C2F)=CC=C2CCC(O[H])=O)=N1)=C3)=C3F,<,1,¦ÌM
,Preparation of pyrazine ring-containing phenylpropionic acid compound,CN107556252,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC(COC2=CN=CC(C3=CC=CN=C3OC)=N2)=CC=C1CCC(O[H])=O,<,0.1,¦ÌM
,Preparation of pyrazine ring-containing phenylpropionic acid compound,CN107556252,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC(COC2=NC(C3=CSC=C3)=CN=C2)=CC=C1CCC(O[H])=O,<,0.05,¦ÌM
,Preparation of pyrazine ring-containing phenylpropionic acid compound,CN107556252,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC(COC2=CN=CC(C(C=N3)=CN3CCC)=N2)=CC=C1CCC(O[H])=O,<,1,¦ÌM
,Preparation of pyrazine ring-containing phenylpropionic acid compound,CN107556252,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC(COC2=CN=CC(C3=C(C)ON=C3C)=N2)=CC=C1CCC(O[H])=O,<,0.5,¦ÌM
,Preparation of pyrazine ring-containing phenylpropionic acid compound,CN107556252,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC(COC2=NC(C3=CC(OC)=CC=C3F)=CN=C2)=CC=C1CCC(O[H])=O,<,0.5,¦ÌM
,Preparation of pyrazine ring-containing phenylpropionic acid compound,CN107556252,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC(COC2=NC(C3=CC=C(F)N=C3C)=CN=C2)=CC=C1CCC(O[H])=O,<,0.5,¦ÌM
,Preparation of pyrazine ring-containing phenylpropionic acid compound,CN107556252,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC(COC2=NC(C3=CC=CC=C3F)=CN=C2)=CC=C1CCC(O[H])=O,<,0.05,¦ÌM
,Preparation of pyrazine ring-containing phenylpropionic acid compound,CN107556252,Patent,HEK293,Calcium Flux Assay,EC50,FC1=CC(COC2=NC(C3=CC(OC)=CC=C3F)=C(N=C2)C)=CC=C1CCC(O[H])=O,<,0.5,¦ÌM
,Preparation of heterocyclic fused phenylpropionic acid derivatives useful as GPR40 receptor agonists,CN107266413,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])CCC1=CC(SCC(C2=CC(C3=C(C)C=CC=C3C)=CC=C2)O4)=C4C=C1,=,7.816,¦ÌM
,Preparation of heterocyclic fused phenylpropionic acid derivatives useful as GPR40 receptor agonists,CN107266413,Patent,HEK293,Calcium Flux Assay,EC50,CC1=C(C(C)=CC=C1)C2=CC=CC(C3OC4=C(SC3)C=C(C5C(C(O[H])=O)C5)C=C4)=C2,=,1.258,¦ÌM
,Preparation of heterocyclic fused phenylpropionic acid derivatives useful as GPR40 receptor agonists,CN107266413,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])C1C(C1)C2=CC(SCC(C3=CC(C(F)(F)F)=CC=C3)O4)=C4C=C2,=,6.005,¦ÌM
,Preparation of heterocyclic fused phenylpropionic acid derivatives useful as GPR40 receptor agonists,CN107266413,Patent,HEK293,Calcium Flux Assay,EC50,FC(F)(F)C1=CC=CC(C2=CC3=C(O2)C=CC(CCC(O[H])=O)=C3)=C1,=,4.016,¦ÌM
,Preparation of heterocyclic fused phenylpropionic acid derivatives useful as GPR40 receptor agonists,CN107266413,Patent,HEK293,Calcium Flux Assay,EC50,FC(F)(F)C1=CC=CC(C2OC3=C(C2)C=C(CCC(O[H])=O)C=C3)=C1,=,2.384,¦ÌM
,Preparation of heterocyclic fused phenylpropionic acid derivatives useful as GPR40 receptor agonists,CN107266413,Patent,HEK293,Calcium Flux Assay,EC50,FC(F)(F)C1=CC=CC(C2OC3=C(C2)C=C(C(C#CC)CC(O[H])=O)C=C3)=C1,=,2.327,¦ÌM
,Preparation of heterocyclic fused phenylpropionic acid derivatives useful as GPR40 receptor agonists,CN107266413,Patent,HEK293,Calcium Flux Assay,EC50,FC(F)(F)C1=CC=CC(C2OC3=C(C2)C=C(C(OCC)CC(O[H])=O)C=C3)=C1,=,4.558,¦ÌM
,Preparation of heterocyclic fused phenylpropionic acid derivatives useful as GPR40 receptor agonists,CN107266413,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])C1C(C1)C2=CC3=C(OC(C4=CC(C(F)(F)F)=CC=C4)CC3)C=C2,=,0.553,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,CC1=CC=CC=C1C2=CSC(C=C3)=C2C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC5=NN=NN5[H],=,0.002,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,CC1=CC=CC=C1C2=C(Cl)SC(C=C3)=C2C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC5=NN=NN5[H],=,0.02,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,CC1=CC=CC=C1C2=C(F)SC(C=C3)=C2C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC5=NN=NN5[H],=,0.022,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,BrC1=CC=CC=C1C2=CSC(C=C3)=C2C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC5=NN=NN5[H],=,0.02,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,CC1=CN=C(Cl)C=C1C2=CSC(C=C3)=C2C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC5=NN=NN5[H],=,0.065,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OCC(CC2)(O[H])CCS2(=O)=O)=CC=C1C3=C(Cl)SC(C=C4)=C3C=C4COC(C=C5)=CC=C5[C@@H](C#CC)CC6=NN=NN6[H],=,0.19,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OCCC(O[H])(C)C)=CC=C1C2=CSC(C=C3)=C2C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC5=NN=NN5[H],=,0.17,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OCCOC)=CC=C1C2=CSC(C=C3)=C2C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC5=NN=NN5[H],=,0.009,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OC2CCOCC2)=CC=C1C3=CSC(C=C4)=C3C=C4COC(C=C5)=CC=C5[C@@H](C#CC)CC6=NN=NN6[H],=,0.27,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,CC1=C(OCCOC)C=CC=C1C2=CSC(C=C3)=C2C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC5=NN=NN5[H],=,0.054,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,CC1=NC=CC=C1C2=CSC(C=C3)=C2C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC5=NN=NN5[H],=,0.088,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OCC(C2)(C)CS2(=O)=O)=CC=C1C3=CSC(C=C4)=C3C=C4COC(C=C5)=CC=C5[C@@H](C#CC)CC6=NN=NN6[H],=,0.03,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC=C4C5=CC=CC=C5C(F)(F)F)=NN=N1,=,0.013,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(S(=O)(C)=O)=CC=C1C2=CSC(C=C3)=C2C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC5=NN=NN5[H],=,0.13,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,CC1=CC=C(OCCOC)C=C1C2=CSC(C=C3)=C2C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC5=NN=NN5[H],=,0.085,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OCCCS(C)(=O)=O)=CC=C1C2=CSC(C=C3)=C2C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC5=NN=NN5[H],=,0.023,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(C(CC2)CCS2(=O)=O)=CC=C1C3=CSC(C=C4)=C3C=C4COC(C=C5)=CC=C5[C@@H](C#CC)CC6=NN=NN6[H],=,0.097,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OC(CC2)CCS2(=O)=O)=CC=C1C3=C(C)SC(C=C4)=C3C=C4COC(C=C5)=CC=C5[C@@H](C#CC)CC6=NN=NN6[H],=,0.08,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,CC1=CC=CC=C1C2=C(C)SC(C=C3)=C2C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC5=NN=NN5[H],=,0.028,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CSC(C=C3)=C2C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC5=NN=NN5[H],=,0.024,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC=C4C5=CN=C(OCCOC)C=C5C)=NN=N1,=,0.051,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC=C4C5=CC=NN5C)=NN=N1,=,0.067,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC=C4C5=NC=NN5C)=NN=N1,=,1.74,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC=C4C5=NC=CN=C5C)=NN=N1,=,0.55,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC=C4C5=CN=CN=C5C)=NN=N1,=,0.037,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC=C4C5=NC=C(OCCOC)C=C5C)=NN=N1,=,0.034,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC=C4C5=CC=CC6=C5OCCO6)=NN=N1,=,0.061,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC=C4C5=CC=CC6=C5CCN6C(CC)=O)=NN=N1,=,0.027,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC=C4C5=CC(NS(=O)(C)=O)=CC=C5C)=NN=N1,=,0.42,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC=C4C5=CC=CC6=C5CCC(C)(C)O6)=NN=N1,=,0.43,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC=C4C5=CC=C(OCC(O[H])CO[H])C=C5C)=NN=N1,=,0.029,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC=C4C5=CC=CC=C5Cl)=NN=N1,=,0.011,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC=C4C5=CC(OCCOC)=CC=C5C)=NN=N1,=,0.008,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC(Br)=C4C5=CC=CC=C5C)=NN=N1,=,0.019,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC(I)=C4C5=CC=CC=C5C)=NN=N1,=,0.028,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC(C(F)(F)F)=C4C5=CC=CC=C5C)=NN=N1,=,0.015,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC(C(F)(F)F)=C4C5CC5)=NN=N1,=,0.59,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC(C#N)=C4C5=CC=CC=C5C)=NN=N1,=,0.016,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC(S(=O)(C)=O)=C4C5=CC=CC=C5C)=NN=N1,=,0.67,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(N=C2)OCC3=CC4=C(C=C3)SC=C4C5=CC=CC=C5C)=NN=N1,=,0.058,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(N=C2)OCC3=CC4=C(C=C3)SC=C4C5=CC=C(OCCOC)C=C5C)=NN=N1,=,0.019,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CN=C(C=C2)OCC3=CC4=C(C=C3)SC=C4C5=CC=C(OCCOC)C=C5C)=NN=N1,=,0.12,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CN=C(C=C2)OCC3=CC4=C(C=C3)SC=C4C5=CC=C(OCCC(C)(C)O[H])C=C5C)=NN=N1,=,0.13,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC(F)=C4C5=CC=C(OCCOC)C=C5C)=NN=N1,=,0.018,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC(Cl)=C4C5=CC=C(OCCOC)C=C5C)=NN=N1,=,0.039,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC(C)=C4C5=CC=C(OCCOC)C=C5C)=NN=N1,=,0.047,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC(C(F)(F)F)=C4C5=CC=C(OCCOC)C=C5C)=NN=N1,=,0.013,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC4=C(C=C3)SC=C4N5CCCCC5C)=NN=N1,=,0.083,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CN=C4SC=C(C5=CC=CC=C5C)C4=C3)=NN=N1,=,0.01,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CN=C4SC=C(C5=CC=C(OC)C=C5C)C4=C3)=NN=N1,=,0.052,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=NC=C4SC=C(C5=CC=CC=C5C)C4=C3)=NN=N1,=,0.003,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=NC=C4SC=C(C5=CC=C(OC)C=C5C)C4=C3)=NN=N1,=,0.001,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC=C4SC=C(C5=CC=CC=C5C)C4=N3)=NN=N1,=,0.17,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC=C4SC=C(C5=CC=C(OC)C=C5C)C4=N3)=NN=N1,=,0.18,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC=C4SC=C(C5CCCCC5)C4=C3)=NN=N1,=,0.11,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC=C4SC=C(C5CCCC5)C4=C3)=NN=N1,=,0.054,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC=C4SC=C(C5CC5)C4=C3)=NN=N1,=,0.86,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC=C4SC=C(C(C)C)C4=C3)=NN=N1,=,0.1,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC=C4SC=C(CCC)C4=C3)=NN=N1,=,0.13,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC=C4SC=CC4=C3)=NN=N1,=,0.11,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(CC(C#CC)C2=CC=C(C=C2)OCC3=CC=C4SC=C(C5=CC=CC=C5C)C4=C3)=NN=N1,=,0.034,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@@H](C#CC)C2=CC=C(C=C2)OCC3=CC=C4SC=C(C5=CC=CC=C5C)C4=C3)=NN=N1,=,0.91,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC(C)=C4SC=C(C5=CC=CC=C5C)C4=C3)=NN=N1,=,0.13,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC(C)=C4SC=C(CCCC)C4=C3)=NN=N1,=,0.33,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC(C)=C4SC=C(C5CCCC5)C4=C3)=NN=N1,=,0.44,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC(C)=C4SC=C(C5CCCCC5)C4=C3)=NN=N1,=,1.12,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC(Cl)=C4SC=C(C5=CC=CC=C5C)C4=C3)=NN=N1,=,0.063,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC(Cl)=C4SC=C(C5=CC=C(OC)C=C5C)C4=C3)=NN=N1,=,0.025,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC(F)=C4SC=C(C5=CC=CC=C5C)C4=C3)=NN=N1,=,0.023,¦ÌM
,Preparation of substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type ll diabetes,US20170291908,Patent,HEK293,Calcium flux assay,EC50,[H]N1C(C[C@H](C#CC)C2=CC=C(C=C2)OCC3=CC(F)=C4SC=C(C5=CC=C(OC)C=C5C)C4=C3)=NN=N1,=,0.01,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC=CC=C1C2=CSC3=C2C=C(COC(C=C4)=CC=C4CCC(O[H])=O)C=C3,=,0.007,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC=CC=C1C2=CSC3=C2C=C(COC(C=C4)=CC=C4[C@@H](C#CC)CC(O[H])=O)C=C3,=,0.005,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OCC(CC2)(O[H])CCS2(=O)=O)=CC=C1C3=CSC4=CC=C(C=C34)COC5=CC=C(C=C5)[C@@H](C#CC)CC(O[H])=O,=,0.005,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OCCCS(C)(=O)=O)=CC=C1C(C2=C3)=CSC2=CC=C3COC(C=C4)=CC=C4[C@H](CC(O[H])=O)C#CC,=,0.003,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=S(CCN1C(C2=CC=C(C(C)=C2)C3=CSC4=CC=C(C=C34)COC5=CC=C(C=C5)[C@H](CC(O[H])=O)C#CC)=O)(CC1)=O,=,0.023,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(C(CC2)=CCS2(=O)=O)=CC=C1C3=CSC4=CC=C(C=C34)COC5=CC=C(C=C5)[C@H](CC(O[H])=O)C#CC,=,0.015,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(O[H])=CC=C1C2=CSC3=CC=C(C=C23)COC4=CC=C(C=C4)[C@H](CC(O[H])=O)C#CC,=,0.007,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(C(CC2)CCS2(=O)=O)=CC=C1C(C3=C4)=CSC3=CC=C4COC5=CC=C(C=C5)[C@@H](C#CC)CC(O[H])=O,=,0.02,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OC(CC2)CCS2(=O)=O)=CC=C1C(C3=C4)=C(C)SC3=CC=C4COC5=CC=C(C=C5)[C@@H](C#CC)CC(O[H])=O,=,0.017,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C(C2=C3)=CSC2=CC=C3COC4=CC=C(C=C4)[C@@H](C#CC)CC(O[H])=O,=,0.041,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C3C(C(C(C(C)=C4)=CC=C4OCCC5(O[H])CC5)=CS3)=C2)C=C1,=,0.016,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C3C(C(C(C(C)=C4)=CC=C4OCCC(C)(O[H])C)=CS3)=C2)C=C1,=,0.009,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,[H]OC(COC1=CC=C(C(C)=C1)C(C2=C3)=CSC2=CC=C3COC4=CC=C(C=C4)[C@@H](C#CC)CC(O[H])=O)CO[H],=,0.007,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@@H](C1=CC=C(OCC2=CC=C3SC=C(C4=CC=C(OCC5(C)COC5)C=C4C)C3=C2)C=C1)C#CC,=,0.009,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@@H](C1=CC=C(OCC2=CC=C3SC=C(C4=CC=C(OC5CCOCC5)C=C4C)C3=C2)C=C1)C#CC,=,0.002,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@@H](C1=CC=C(OCC2=CC=C3SC=C(C4=CC=C(OCCOC)C=C4C)C3=C2)C=C1)C#CC,=,0.005,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@@H](C1=CC=C(OCC2=CC=C3SC=C(C4=CC=C(OCC(CC5)CCS5(=O)=O)C=C4C)C3=C2)C=C1)C#CC,=,0.006,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@@H](C1=CC=C(OCC2=CC=C3SC=C(C4=CC=C(OCC(C5)(C)CS5(=O)=O)C=C4C)C3=C2)C=C1)C#CC,=,0.011,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@@H](C1=CC=C(OCC2=CC=C3SC=C(C4=CC=CC=C4Cl)C3=C2)C=C1)C#CC,=,0.008,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@@H](C1=CC=C(OCC2=CC=C3SC=C(C4=CC=CC=C4Br)C3=C2)C=C1)C#CC,=,0.005,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@@H](C1=CC=C(OCC2=CC=C3SC=C(C4=CC=CC=C4C(F)(F)F)C3=C2)C=C1)C#CC,=,0.008,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@@H](C1=CC=C(OCC2=CC=C3SC=C(C4=CC=CN=C4C)C3=C2)C=C1)C#CC,=,0.008,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@@H](C1=CC=C(COC2=CC=C3SC=C(C4=CC=CC=C4C)C3=C2)C=C1)C#CC,=,0.01,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OCCCS(C)(=O)=O)=CC=C1C2=CSC3=CC=C(C=C23)OCC(C=C4)=CC=C4[C@@H](C#CC)CC(O[H])=O,=,0.009,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(C(CC2)=CCS2(=O)=O)=CC=C1C3=CSC4=CC=C(C=C34)OCC(C=C5)=CC=C5[C@@H](C#CC)CC(O[H])=O,=,0.024,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(C(CC2)CCS2(=O)=O)=CC=C1C3=CSC4=CC=C(C=C34)OCC(C=C5)=CC=C5[C@@H](C#CC)CC(O[H])=O,=,0.018,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CSC3=CC=C(C=C23)OCC(C=C4)=CC=C4[C@@H](C#CC)CC(O[H])=O,=,0.02,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(C(CC2)=CCS2(=O)=O)=CC=C1C3=CSC4=CC=C(C=C34)COC5=CC=C(C=C5)C6(CC(C6)=O)CC(O[H])=O,=,0.012,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(C(CC2)CCS2(=O)=O)=CC=C1C3=CSC4=CC=C(C=C34)COC5=CC=C(C=C5)C6(CC(C6)=O)CC(O[H])=O,=,0.034,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC=CC=C1C2=CSC3=CC=C(C=C23)COC4=CC=C(C(CC(O[H])=O)(C5)CC5=O)C=C4,=,0.006,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(CC1=O)(C1)C2=CC=C(OCC3=CC=C4SC=C(C5=CC=C(OCCOCC)C=C5C)C4=C3)C=C2,=,0.036,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OC2CCS(CC2)(=O)=O)=CC=C1C3=CSC4=CC=C(C=C34)COC5=CC=C(C(CC(O[H])=O)(C6)CC6=O)C=C5,=,0.015,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OC2CCOCC2)=CC=C1C3=CSC4=CC=C(C=C34)COC5=CC=C(C(CC(O[H])=O)(C6)CC6=O)C=C5,=,0.025,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=NC=CC=C1C2=CSC3=CC=C(C=C23)COC4=CC=C(C(CC(O[H])=O)(C5)CC5=O)C=C4,=,0.019,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(N2CC(S3(=O)=O)(CC3)C2)=CC=C1C4=CSC5=CC=C(C=C45)COC6=CC=C(C(CC(O[H])=O)(C7)CC7=O)C=C6,=,0.015,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC=C(C=C1C2=CSC(C=C3)=C2C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC(O[H])=O)S(=O)(C)=O,=,0.021,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(S(=O)(C)=O)=CC=C1C2=CSC(C=C3)=C2C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC(O[H])=O,=,0.012,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC=C(NS(=O)(C)=O)C=C1C2=CSC(C=C3)=C2C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC(O[H])=O,=,0.031,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC=CC(NS(C)(=O)=O)=C1C2=CSC(C=C3)=C2C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC(O[H])=O,=,0.022,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC=CC=C1C2=CSC(C=C3)=C2C=C3COC(C=C4)=NC=C4C(C#CC)CC(O[H])=O,=,0.013,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OC2CCOCC2)=CC=C1C3=CSC(C=C4)=C3C=C4COC(C=C5)=NC=C5C(C#CC)CC(O[H])=O,=,0.018,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OCCOC)=CC=C1C2=CSC(C=C3)=C2C=C3COC(C=C4)=NC=C4C(C#CC)CC(O[H])=O,=,0.02,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OCCOC)=CN=C1C2=CSC(C=C3)=C2C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC(O[H])=O,=,0.01,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=NC=C(OCCOC)C=C1C2=CSC(C=C3)=C2C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC(O[H])=O,=,0.009,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=NC(OCCOC)=CC=C1C2=CSC(C=C3)=C2C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC(O[H])=O,=,0.012,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OCCOC)=NC=C1C2=CSC(C=C3)=C2C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC(O[H])=O,=,0.006,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CN=C(Cl)C=C1C2=CSC(C=C3)=C2C=C3COC(C=C4)=CC=C4[C@@H](C#CC)CC(O[H])=O,=,0.019,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC=CC=C1C2=CSC(C=C3)=C2C=C3OCC(C=C4)=CC=C4CCC(O[H])=O,=,0.89,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC(CCOC1=CC=C(C(C)=C1)C(C2=C3)=CSC2=CC=C3OCC(C=C4)=CC=C4[C@@H](C#CC)CC(O[H])=O)(C)O[H],=,0.044,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OCC(O[H])CO[H])=CC=C1C(C2=C3)=CSC2=CC=C3OCC(C=C4)=CC=C4[C@@H](C#CC)CC(O[H])=O,=,0.033,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OCC2(C)COC2)=CC=C1C(C3=C4)=CSC3=CC=C4OCC(C=C5)=CC=C5[C@@H](C#CC)CC(O[H])=O,=,0.034,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OC2CCOCC2)=CC=C1C(C3=C4)=CSC3=CC=C4OCC(C=C5)=CC=C5[C@@H](C#CC)CC(O[H])=O,=,0.017,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OCCOC)=CC=C1C(C2=C3)=CSC2=CC=C3OCC(C=C4)=CC=C4[C@@H](C#CC)CC(O[H])=O,=,0.014,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OCC(CC2)CCS2(=O)=O)=CC=C1C(C3=C4)=CSC3=CC=C4OCC(C=C5)=CC=C5[C@@H](C#CC)CC(O[H])=O,=,0.014,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@@H](C1=CC=C(COC2=CC=C3C(C(C(C(C)=C4)=CC=C4OCC(C5)(C)CS5(=O)=O)=CS3)=C2)C=C1)C#CC,=,0.07,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C1=CC=C(OCC2=CC=C3C(C(C(C(C)=C4)=CC=C4OCCC(C)(O[H])C)=CS3)=C2)N=C1)C#CC,=,0.016,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C1=CC=C(OCC2=CC=C3C(C(C(C(C)=C4)=CC=C4OCC(O[H])CO[H])=CS3)=C2)N=C1)C#CC,=,0.01,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C1=CC=C(OCC2=CC=C3C(C(C(C(C)=C4)=CC=C4OCC(CC5)CCS5(=O)=O)=CS3)=C2)N=C1)C#CC,=,0.01,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C1=CC=C(OCC2=CC=C3C(C(C(C(C)=C4)=CC=C4OCC(C5)(C)CS5(=O)=O)=CS3)=C2)N=C1)C#CC,=,0.021,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@@H](C1=CC=C(OCC2=CC=C3C(C(C4=CC(OCCOC)=CC=C4C)=CS3)=C2)C=C1)C#CC,=,0.011,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@@H](C1=CC=C(OCC2=CC=C3C(C(C4=C(OCCOC)C=CC=C4C)=CS3)=C2)C=C1)C#CC,=,0.014,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@@H](C1=CC=C(OCC2=CC=C3C(C(C4=CC=CC(OCCOC)=C4C)=CS3)=C2)C=C1)C#CC,=,0.009,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@@H](C1=CC=C(OCC2=CC=C3C(C(C4=C(OCCOC)C=CC=C4)=CS3)=C2)C=C1)C#CC,=,0.019,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@@H](C1=CC=C(OCC2=CC=C3C(C(C4=C(S(=O)(C)=O)C=CC=C4)=CS3)=C2)C=C1)C#CC,=,0.015,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@@H](C#CC)C1=CC=C(OCC2=CC=C3SC=C(C(C(C)=C4)=CC=C4OCCC(C)(O[H])C)C3=C2)N=C1,=,0.5,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C3SC=C(C(C(C)=C4)=CC=C4OCCC(C)(O[H])C)C3=C2)N=C1,=,0.012,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@@H](C#CC)C1=CC=C(OCC2=CC=C3SC=C(C(C(C)=C4)=CC=C4OCC5CCOCC5)C3=C2)N=C1,=,1.33,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C3SC=C(C(C(C)=C4)=CC=C4OCC5CCOCC5)C3=C2)N=C1,=,0.013,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OCC2CCS(CC2)(=O)=O)=CC=C1C(C3=C4)=CSC3=CC=C4COC(N=C5)=CC=C5[C@@H](CC(O[H])=O)C#CC,=,0.18,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,CC1=CC(OCC2CCS(CC2)(=O)=O)=CC=C1C(C3=C4)=CSC3=CC=C4COC(N=C5)=CC=C5[C@H](CC(O[H])=O)C#CC,=,0.007,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@@H](C#CC)C1=CC=C(OCC2=CC=C3SC=C(C(C(C)=C4)=CC=C4OCCOC)C3=C2)N=C1,=,0.83,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C3SC=C(C(C(C)=C4)=CC=C4OCCOC)C3=C2)N=C1,=,0.016,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C3C(C(C4=CC=CN=C4OC)=CS3)=C2)C=C1,=,0.009,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C3C(C(C4=CC=CC=C4OC)=CS3)=C2)C=C1,=,0.028,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C3C(C(C4=CC=C(OC)N=C4C)=CS3)=C2)C=C1,=,0.02,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C3C(C(C4=C(OC)C=CN=C4)=CS3)=C2)C=C1,=,0.011,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C3C(C(C4=C(C)C=C(OC)N=C4)=CS3)=C2)C=C1,=,0.037,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C3C(C(C4=C(OC)C=NC=C4)=CS3)=C2)C=C1,=,0.01,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C3C(C(C4=C(C)C=C(OC)C=N4)=CS3)=C2)C=C1,=,0.052,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CN=C(OCC2=CC=C3C(C(C4=CC=CC=C4C)=CS3)=C2)C=C1,=,0.007,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(COC2=CC=C3C(C(C4=CC=C(OC5CCOC5)C=C4C)=CS3)=C2)C=C1,=,0.008,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CN=C(OCC2=CC=C3C(C(C4=C(C)C=CC(OCCOC)=C4)=CS3)=C2)C=C1,=,0.011,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CN=C(OCC2=CC=C3C(C(C4=CC=CC(OCCOC)=C4C)=CS3)=C2)C=C1,=,0.008,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CN=C(OCC2=CC=C3C(C(C4=NC=C(OCCOC)C=C4C)=CS3)=C2)C=C1,=,0.02,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C3C(C(C4=C(C)C=NC(Cl)=C4)=CS3)=C2)N=C1,=,0.015,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C3C(C(C4=C(OC)C=CC=N4)=CS3)=C2)C=C1,=,0.017,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C3C(C(C4=CC(OCCOC)=CN=C4C)=CS3)=C2)N=C1,=,0.013,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C3C(C(C4=NC(Cl)=CC=C4C)=CS3)=C2)C=C1,=,0.015,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C3C(C(C4=C(C)C=CC(OC)=N4)=CS3)=C2)C=C1,=,0.015,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C3C(C(C4=C(C)C=C(CC5CCNCC5)C=C4)=CS3)=C2)C=C1,=,0.004,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C3C(C(C4=C(C)C=C(C5CCNCC5)C=C4)=CS3)=C2)C=C1,=,0.008,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC(C#CC)C1=CC=C(OCC2=CC=C3C(C(C4=CC=CC=C4C)=CS3)=C2)C=C1,=,0.004,¦ÌM
,Preparation of benzothienyl compounds as Gpr40 agonists useful in anti-diabetic drug combinations,US20170290800,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@@H](C#CC)C1=CC=C(OCC2=CC=C3C(C(C4=CC=CC=C4C)=CS3)=C2)C=C1,=,0.16,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,FC1=C(C2=C(C(COC3=CC=CC([C@H](C4CC4)CC(O[H])=O)=C3)=NO2)OC5CC(C)(C)C(C)(C)C5)C=C(OC)N=C1,=,0.005,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,CC1(C)CC(COC(C(COC2=CC=CC([C@H](C3CC3)CC(O[H])=O)=C2)=NO4)=C4C5=CC(OC)=CC=C5F)C1,=,0.037,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])CC(C1=CC(/C=C/C2=NOC(C3=CC(OC)=CC=C3F)=C2C4CC4)=CC=C1)C5CC5,=,0.021,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])CC(C1=CC(CCC2=NOC(C3=CC(OC)=CC=C3F)=C2C4CC4)=CC=C1)C5CC5,=,0.024,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,CC(C1)(C)CC1COC(C(COC2=CC=CC([C@H](C3CC3)CC(O[H])=O)=C2)=NO4)=C4C(C=C5OC)=C(C=N5)F,=,0.113,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,FC(C(C1=C(C(COC(N=C2)=CC(C(CC(O[H])=O)C3CC3)=C2Cl)=NO1)C4=CCCC4(C)C)=C5)=CC=C5OC,=,0.053,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(OCC3=CSC(C4=CC(OC)=CC5=C4C=CS5)=C3C6=CCCC6(C)C)=CC=C2,=,0.053,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,CC1(C)C(C1(C)C)COC(C(COC2=CC=CC([C@H](C3CC3)CC(O[H])=O)=C2)=NO4)=C4C5=CC(OC)=CC=C5F,=,0.058,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,CC(C)CC1=C(C2=C(F)C=NC(OC)=C2)ON=C1COC3=CC=CC([C@H](C4CC4)CC(O[H])=O)=C3,=,1.266,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=CSC(C4=CC(OC)=CC=C4F)=C3C5=CCCC5(C)C)=CC=C2)O[H],=,0.087,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(OCC3=CSC(C4=CC(OC)=CC=C4F)=C3C5CC5)=CC=C2,=,0.108,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=NOC(C4=CC(OC)=CC=C4F)=C3C5=CCCC5(C)C)=CC=C2)O[H],=,0.018,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(OCC3=CSC(C4=CSC=C4)=C3C5=CCCC5(C)C)=CC=C2,=,0.087,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=CSC(C4=CC(N(C)C)=CC=C4)=C3C5=CCCC5(C)C)=CC=C2)O[H],=,0.242,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,CC1(C)CCC=C1C2=C(C3=CC=C(C=C3F)OC)SC=C2COC4=CC=CC([C@H](C5CC5)CC(O[H])=O)=C4,=,0.305,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=CSC(C4=CC(OC)=CC=C4F)=C3C(C)C(F)(F)F)=CC=C2)O[H],=,0.253,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(OCC3=CSC(C4=CC=CC=C4)=C3C5=CCCC(C)5C)=CC=C2,=,0.079,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(OCC3=CSC(C4=CC=CC=C4F)=C3C5=CCCC5(C)C)=CC=C2,=,0.11,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(OCC3=CSC(C4=CC=CC=C4OC)=C3C5=CCCC5(C)C)=CC=C2,=,0.047,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=CSC(C4=CC(OC)=CC(OC)=C4)=C3C5=CCCC5(C)C)=CC=C2)O[H],=,0.016,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=CSC(C4=CC=CC5=C4C=CN5[H])=C3C6=CCCC6(C)C)=CC=C2)O[H],=,0.068,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=CSC(C4=CC=CC5=C4C=CO5)=C3C6=CCCC6(C)C)=CC=C2)O[H],=,0.101,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=CSC(C4=CC(OC)=CC=C4)=C3C5=CCCC5(C)C)=CC=C2)O[H],=,0.026,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=CSC(C4=C(F)C=NC(OC)=C4)=C3C5=CCCC(C)5C)=CC=C2)O[H],=,0.053,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=CSC(C4=CC(OC)=CN=C4)=C3C5=CCCC5(C)C)=CC=C2)O[H],=,0.083,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC(C(C(C)C(F)(F)F)=C(C3=CC(OC)=CC=C3F)S4)=C4Cl)=CC=C2)O[H],=,0.32,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,FC(C(C1=C(C(COC2=CC=CC([C@H](C3CC3)CC(O[H])=O)=C2)=NS1)C4=CCCC4(C)C)=C5)=CC=C5OC,=,0.032,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=CSC(C4=CC=NC(OC)=C4)=C3C5=CCCC5(C)C)=CC=C2)O[H],=,0.258,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=NOC(C4=CC(OC)=CC=C4F)=C3C5=CC=C(C)S5)=CC=C2)O[H],=,0.031,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=NOC(C4=CC(OC)=CC=C4F)=C3C5=C(C=CS5)C)=CC=C2)O[H],=,0.215,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(OCC3=NOC(C4=CC(OC)=CC=C4F)=C3C5=CC=CC=C5)=CC=C2,=,0.168,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=NOC(C4=CC(OC)=CC=C4F)=C3CC(C)C)=CC=C2)O[H],=,0.008,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=NOC(C4=CC(OC)=CC=C4F)=C3/C=C(C)\C)=CC=C2)O[H],=,0.03,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=NOC(C4=CC(OC)=CC=C4F)=C3C5CC5)=CC=C2)O[H],=,0.065,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@H](C1CC1)C2=CC(OCC3=CSC(C4=CC(C#N)=CC=C4F)=C3C5=CCCC(C)5C)=CC=C2)O[H],=,0.115,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,CC(C)COC(C(COC1=CC=CC([C@H](C2CC2)CC(O[H])=O)=C1)=NO3)=C3C4=CC(OC)=CC=C4F,=,0.005,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=NOC(C4=CC(OC)=CC=C4F)=C3OC5CCCC5)=CC=C2)O[H],=,0.008,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=NOC(C4=CC(OC)=CC=C4F)=C3OCC5CC5)=CC=C2)O[H],=,0.014,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=NOC(C4=CC(OC)=CC=C4F)=C3OC(C)C)=CC=C2)O[H],=,0.019,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=NOC(C4=CC(OC)=CC=C4F)=C3OC5CCC5)=CC=C2)O[H],=,0.011,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=NOC(C4=CC(OC)=CC=C4F)=C3C5=CC=C(C(C)(C)C)S5)=CC=C2)O[H],=,0.023,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=NOC(C4=CC(OC)=CC=C4F)=C3OC5CCCCC5)=CC=C2)O[H],=,0.007,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,CC(C)COC(C(COC1=CC=CC([C@H](C2CC2)CC(O[H])=O)=C1)=NO3)=C3C4=C(F)C=NC(OC)=C4,=,0.02,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=NOC(C4=C(F)C=NC(OC)=C4)=C3OC5CCCCC5)=CC=C2)O[H],=,0.024,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,FC(CCOC(C(COC1=CC=CC([C@H](C2CC2)CC(O[H])=O)=C1)=NO3)=C3C4=CC(OC)=CC=C4F)(F)F,=,0.067,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(OCC3=NOC(C4=CC(OC)=CC=C4F)=C3OCC)=CC=C2,=,0.11,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(OCC3=NOC(C4=CC(OC)=NC=C4F)=C3OCC)=CC=C2,=,0.18,¦ÌM
,Preparation of GPR40 agonists for the treatment of type ll diabetes,WO2017027309,Patent,HEK293,Calcium Flux Assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(OCC3=NOC(C4=C(F)C=NC(OC)=C4)=C3/C=C(C)\C)=CC=C2)O[H],=,0.051,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,CC1=CC(C(N=N2)=NN2C)=CC(C)=C1C3=CC=CC4=C3CC[C@H]4NC5=NC=C([C@H]6C[C@@H]6C(O[H])=O)C=C5,=,0.007,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,CC1=CC(OCCC(O[H])(C)C)=CC(C)=C1C2=CC=CC3=C2CC[C@H]3N([H])C4=NC=C([C@H]5C[C@@H]5C(O[H])=O)C=C4,=,0.011,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,CC1=CC(C2=NN(C)N=N2)=CC(C)=C1C(C3=C4[C@H](NC5=NC=C([C@@H]6[C@H](C6)C(O[H])=O)C=C5)CC3)=CC=C4F,=,0.004,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,CC1=CC(OCCC(O[H])(C)C)=CC(C)=C1C(C(CC2)=C3[C@@H]2N([H])C4=NC=C([C@@H]5[C@H](C5)C(O[H])=O)C=C4)=CC=C3F,=,0.008,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,CC1=CC(C2=NN(C)N=N2)=CC(C)=C1C3=CC=CC4=C3CC[C@H]4N(C5=NC=C([C@@H]6C[C@H]6C(O[H])=O)C=C5)[H],=,0.259,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,CC1=CC(OCCC(O[H])(C)C)=CC(C)=C1C2=CC=CC3=C2CC[C@H]3NC4=NC=C([C@@H]5C[C@H]5C(O[H])=O)C=C4,=,0.497,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,CC1=CC(OCCC(O[H])(C)C)=CC(C)=C1C2=CC=C(F)C3=C2CC[C@H]3NC4=NC=C([C@@H]5C[C@H]5C(O[H])=O)C=C4,=,0.568,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,FC1=CC=C(C2=C1[C@@H](CC2)N(C3=NC=C([C@@H]4[C@H](C4)C(O[H])=O)C=C3)[H])C5=C(C)C=C(O[C@H]6CCOC6)C=C5C,=,0.027,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,FC1=CC=C(C2=C1[C@@H](CC2)N(C3=NC=C([C@@H]4[C@H](C4)C(O[H])=O)C=C3)[H])C5=C(C)C=C(C6=NN(CC(C)(O[H])C)N=N6)C=C5C,=,0.004,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,FC1=CC=C(C2=C1[C@@H](CC2)N(C3=NC=C([C@@H]4[C@H](C4)C(O[H])=O)C=C3)[H])C5=C(C)C=C(OC6CCOCC6)C=C5C,=,0.018,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C=CC=C4C5=C(C)C=C(OC6CCOCC6)C=C5C)C1)O[H],=,0.02,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OCC6CCOC6)C=C5C)C1)O[H],=,0.011,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=CC=C5C)C1)O[H],=,0.013,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OC)C=C5C)C1)O[H],=,0.016,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C#N)C=C5C)C1)O[H],=,0.018,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C(N([H])[H])=O)C=C5C)C1)O[H],=,0.06,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(O[C@@H]6CCOC6)C=C5C)C1)O[H],=,0.027,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(CC)C=CC=C5CC)C1)O[H],=,0.005,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C6=NN=NN6CC(C)(C)O[H])C=C5C)C1)O[H],=,0.318,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C6=NN=NN6)C=C5C)C1)O[H],=,0.177,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C6=NOC(C)=N6)C=C5C)C1)O[H],=,0.004,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(CO[H])C=C5C)C1)O[H],=,0.071,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OCC(C)(O[H])C)C=C5C)C1)O[H],=,0.017,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C=CC=C4C5=C(C)C=C(OCC(C)(O[H])C)C=C5C)C1)O[H],=,0.023,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C6=CC=NN6C)C=C5C)C1)O[H],=,0.031,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OCC6=CC=CC=C6)C=C5C)C1)O[H],=,0.035,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OCC6(C)COC6)C=C5C)C1)O[H],=,0.014,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OCC(O[H])=O)C=C5C)C1)O[H],=,4.13,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OCC(C)(C#N)C)C=C5C)C1)O[H],=,0.023,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C=CC=C4C5=C(C)C=C(OCC(C)(C#N)C)C=C5C)C1)O[H],=,0.022,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C(C=CN6C)=CC6=O)C=C5C)C1)O[H],=,0.006,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C=CC=C4C5=C(C)C=C(C(C=CN6C)=CC6=O)C=C5C)C1)O[H],=,0.008,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C=CC=C4C5=C(C)C=C(C(C=C6)=CN(C)C6=O)C=C5C)C1)O[H],=,0.018,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C(C=C6)=CN(C)C6=O)C=C5C)C1)O[H],=,0.011,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C(O[H])=O)C=C5C)C1)O[H],=,0.94,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(O[H])C=C5C)C1)O[H],=,0.033,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C#N)C=CC=C5C#N)C1)O[H],=,4.13,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C(N=CN6C)=CC6=O)C=C5C)C1)O[H],=,0.005,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C=CC=C4C5=C(C)C=C(C(N=CN6C)=CC6=O)C=C5C)C1)O[H],=,0.008,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=CC=CC=C5C6(C#N)CC6)C1)O[H],=,0.629,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=CC=CC=C5C(C)C)C1)O[H],=,0.026,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(OC)C=C(OC)C=C5OC)C1)O[H],=,0.427,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(Cl)C=CC=C5Cl)C1)O[H],=,0.013,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(Cl)C=CC(C)=C5Cl)C1)O[H],=,0.007,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(Cl)C(OC)=CC(OC)=C5Cl)C1)O[H],=,0.013,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(F)C=CC=C5F)C1)O[H],=,0.208,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(F)C=C(OC)C=C5F)C1)O[H],=,0.151,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C=CC=C4C5=C(F)C=C(OC)C=C5F)C1)O[H],=,0.212,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(F)C(OC)=CC(OC)=C5F)C1)O[H],=,0.107,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(F)C=C(N([H])[H])C=C5F)C1)O[H],=,0.462,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(F)C=C(OC6CC6)C=C5F)C1)O[H],=,0.061,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OCC6CCOCC6)C=C5C)C1)O[H],=,0.005,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OCC6(O[H])CCOCC6)C=C5C)C1)O[H],=,0.02,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OCC(CC6)(O[H])CCS6(=O)=O)C=C5C)C1)O[H],=,0.029,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C(NC)=O)C=C5C)C1)O[H],=,0.039,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C(C=CN6C)=NC6=O)C=C5C)C1)O[H],=,0.006,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C6=CC(OC)=NC=C6)C=C5C)C1)O[H],=,0.006,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(OCC6(O[H])CCSCC6)C=C5C)C1)O[H],=,0.017,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=CC=CC=C5C(F)(F)F)C1)O[H],=,0.049,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C=CC=C4C5=CC=CC=C5C(F)(F)F)C1)O[H],=,0.091,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(C)C=C(C(N(C)C)=O)C=C5C)C1)O[H],=,0.186,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C=CC=C4C5=C(C)C=C(C(N(C)C)=O)C=C5C)C1)O[H],=,0.174,¦ÌM
,Preparation of indanylaminopyridylcyclopropanecarboxylic acids as GPR40 receptor modulators for treatment of metabolic diseases,US2017037040,Patent,1321N1,IP1 accumulation measurements,EC50,O=C([C@@H]1[C@@H](C2=CN=C(C=C2)N([H])[C@@H]3CCC4=C3C(F)=CC=C4C5=C(F)C(F)=C(OC)C(F)=C5F)C1)O[H],=,0.003,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,FC(F)(F)C(C=CC=C1)=C1C(C2=C3C=CC(COC4=NC=C5C(C[C@H]6[C@H](C(O[H])=O)[C@H]65)=C4)=C2)CC73CC7,=,0.01143,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,FC(F)(F)C(C=CC=C1)=C1C(C2=C3C=CC(COC4=NC=C5C(C[C@H]6[C@H](C(O[H])=O)[C@H]65)=C4)=C2)CC3=O,=,0.04736,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,FC(F)(F)C(C=CC=C1)=C1C2CC(C)(C)C3=C2C=C(COC4=NC=C5C(C[C@H]6[C@H](C(O[H])=O)[C@H]65)=C4)C=C3,=,0.7688,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(C5=CC=CC=C5C(F)(F)F)=CC6(C)C)=C6C=C4)O[H],=,0.01798,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CC5C)C6=CC=CC=C6C(F)(F)F)=C5C=C4)O[H],=,0.02158,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CC56CCC6)C7=CC=CC=C7C(F)(F)F)=C5C=C4)O[H],=,0.02258,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CC56COC6)C7=C(C(F)(F)F)C=CC=C7)=C5C=C4)O[H],=,0.03534,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CC56COC(C)(C)OC6)C7=C(C(F)(F)F)C=CC=C7)=C5C=C4)O[H],=,0.02113,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CC5(C)C)C6=CC=CC=C6)=C5C=C4)O[H],=,0.02238,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CC5(C)C)C6=C(F)C=CC=C6F)=C5C=C4)O[H],=,0.03893,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CC5(C)C)C6=C(Cl)C=CC=C6)=C5C=C4)O[H],=,0.03511,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CC5(C)C)C6=CC=CC=C6C(F)(F)F)=C5C=C4)O[H],=,0.07042,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CC5(C)C)C6=C(S(=O)(C)=O)C=CC=C6)=C5C=C4)O[H],=,0.04057,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CC5(C)C)C6=CC=CN=C6OC)=C5C=C4)O[H],=,0.02178,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CC5(C)C)C6=C(C)C=CN=C6OC)=C5C=C4)O[H],=,0.007767,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CC5(C)C)C6=CC=CC7=C6N(C)C=N7)=C5C=C4)O[H],=,0.02771,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CC5(C)C)C6=C(F)C=CC=C6)=C5C=C4)O[H],=,0.04366,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CC5)C6=C(C(F)(F)F)C=CC=C6)=C5C=C4F)O[H],=,0.01028,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CC5)(O[H])C6=CC=CC=C6C(F)(F)F)=C5C=C4)O[H],=,0.0166,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2(F)F)=C3)=CN=C3OCC4=CC(C(CC5(C)C)C6=C(C(F)(F)F)C=CC=C6)=C5C=C4F)O[H],=,0.05297,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CC5(C)C)C6=C(C(F)(F)F)C=NC=C6)=C5C=C4F)O[H],=,0.006912,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CC5(C)C)C6=C(C(F)(F)F)N=CC=C6)=C5C=C4F)O[H],=,0.02079,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CC5(C)C)C6=CC=CN=C6OC)=C5C=C4F)O[H],=,0.01556,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CC5(C)C)C6=CC=C(OCCCS(C)(=O)=O)C=C6C(F)(F)F)=C5C=C4F)O[H],=,0.04117,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CC5(C)C)C6=C(C(F)(F)F)C=C(OCCC(C)(C)O[H])C=C6)=C5C=C4F)O[H],=,0.01683,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CCC5)C6=CC=C(OCCC(O[H])(C)C)N=C6C)=C5C=C4)O[H],=,0.03502,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CCC5)C6=C(C)N=C(OCCC(C)=C)C=C6)=C5C=C4)O[H],=,0.2143,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(N5C6=C(C(F)(F)F)C=CC=C6)=C(C(C)(C)C5)C=C4F)O[H],=,0.009958,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(N5C6=CC=CC=C6C(F)(F)F)=C(CC5)C=C4)O[H],=,0.02618,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(N5C6=CC=CC=C6C(F)(F)F)=C(C=C5)C=C4)O[H],=,0.02324,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(N5C6=CC=CC=C6)=C(CC5)C=C4)O[H],=,0.1679,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(N5C6=CC=CC=C6C(F)(F)F)=C(C(Br)=C5)C=C4)O[H],=,0.04757,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(N5C6=CC=CC=C6C(F)(F)F)=C(C(C7CC7)=C5)C=C4)O[H],=,0.09153,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C5C6=C(C(F)(F)F)C=CC=C6)=C(C(C)(C)N5C)C=C4)O[H],=,0.01185,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C5C6=C(C(F)(F)F)C=CC=C6)=C(C(C)(C)N5)C=C4)O[H],=,0.01541,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C5(C)C6=CC=CC=C6C(F)(F)F)=C(CO5)C=C4)O[H],=,0.4308,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C5C6=C(C(F)(F)F)C=CC=C6)=C(C(C)(C)O5)C=C4F)O[H],=,0.001985,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CCC5)C6=C(C(F)(F)F)C=CC=C6)=C5C=C4)O[H],=,0.00987,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(C)C(C(CCC5)C6=C(C(F)(F)F)C=CC=C6)=C5C=C4)O[H],=,0.07077,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CCC5)C6=C(C(F)(F)F)C=CC=C6)=C5C=C4F)O[H],=,0.06795,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C5C6=C(F)C=CC(OC)=C6)=C(C(C)(C)C5)C=C4F)O[H],=,0.2227,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(C(C)CC5)C6=C(C(F)(F)F)C=CC=C6)=C5C=C4)O[H],=,0.07962,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(C5=C(C(F)(F)F)C=CC=C5)=C(C)CC6)=C6C=C4)O[H],=,0.2362,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CCO5)C6=C(C(F)(F)F)C=CC=C6)=C5C=C4)O[H],=,0.03615,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CCO5)(O[H])C6=C(C(F)(F)F)C=CC=C6)=C5C=C4)O[H],=,0.0961,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(OCC5)C6=C(C(F)(F)F)C=CC=C6)=C5C=C4)O[H],=,0.01504,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C(N(CCC5(C)C)C6=C(C(F)(F)F)C=CC=C6)=C5C=C4)O[H],=,0.02966,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(N(CCC5(C)C)C6=C(C(F)(F)F)C=CC=C6)=C5C=C4F)O[H],=,0.03918,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(N(C(CC5(C)C)=O)C6=C(C(F)(F)F)C=CC=C6)=C5C=C4F)O[H],=,0.5617,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(CCC5(C)C)C6=C(C(F)(F)F)C=CC=C6)=C5C=C4F)O[H],=,0.07021,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(N(C5)C6=C(F)C=CC(OC)=C6)=C(C5(C)C)C=C4F)O[H],=,0.04384,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(N5C6=CC=CC=C6)=C(OCC5)C=C4)O[H],=,0.6534,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(N(CCCC5)C6=CC=CC=C6)=C5C=C4)O[H],=,0.04291,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(C5=CC=CC=C5C(F)(F)F)=CN6C7=CC=CC=C7)=C6C=C4F)O[H],=,0.02824,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CC=C3OCC4=CC(N(CCC5)C6=CC=CC=N6)=C5C=C4)O[H],=,0.1695,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CC=C3OCC4=CC(N(CCC5)C6=C(C)C=CC=C6)=C5C=C4)O[H],=,0.06489,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C(C(NCC5(C)C)C6=C(C(F)(F)F)C=CC=C6)=C5C=C4)O[H],=,0.004992,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@]1(C)C(C(C2)=C3)=CN=C3OCC4=CC(C(C5)C6=C(C(F)(F)F)C=CC=C6)=C(C5(C)C)C=C4F)O[H],=,0.1574,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(C)(C)CC5(C)C)=C5C=C4F)O[H],=,0.01729,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(N5C6=C(C(F)(F)F)C=CC=C6)=C(C=N5)C=C4F)O[H],=,0.007085,¦ÌM
,Preparation of tricyclic compounds as GPR 40 agonists and their use as antidiabetic agents,WO2015176640,Patent,HEK,Inositol Phosphate Turnover Assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(N5CC6=C(C(F)(F)F)C=CC=C6)=C(C=C5)C=C4F)O[H],=,0.195,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,CS(=O)(CCCOC1=CC=C(C(C=C2)=CC(COC3=CC=C4[C@@]5([H])[C@@]([C@@H]5C(O[H])=O)([H])CC4=C3)=C2F)C(C)=N1)=O,=,0.046,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,FC(C=CC(C1=CC=C(OC(CC2)CCS2(=O)=O)N=C1C)=C3)=C3COC4=CC=C5[C@@]6([H])[C@@]([C@@H]6C(O[H])=O)([H])CC5=C4,=,0.0702,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])[C@H]1[C@@H]2CC(C=C(C=C3)OCC4=CC=CC(C5=CC=C(N6CCC(CC6)S(=O)(C)=O)N=C5C)=C4)=C3[C@@H]21,=,0.0599,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])[C@H]1[C@@H]2CC(C=C(C=C3)OCC4=CC=CC(C5=C(C)C=C(OCCCS(C)(=O)=O)N=C5C)=C4)=C3[C@@H]21,=,0.0891,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,CC1=C(C2=CC(COC3=CC=C4C(C[C@@H]5[C@H]4[C@H]5C(O[H])=O)=C3)=CC=C2)C=NC(OCCCS(=O)(C)=O)=C1,=,0.0585,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,CC1=C(C2=CC(COC3=CC=C4C(C[C@@H]5[C@H]4[C@H]5C(O[H])=O)=C3)=C(F)C=C2)C(C)=NC(OCCCS(=O)(C)=O)=C1,=,0.0574,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,CC1=C(C2=C(C)C(COC3=CC=C4C(C[C@@H]5[C@H]4[C@H]5C(O[H])=O)=C3)=CC=C2)C(C)=NC(OCCCS(=O)(C)=O)=C1,=,0.098,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,CC1=C(C2=C(C)C(COC3=CC=C4C(C[C@@H]5[C@H]4[C@H]5C(O[H])=O)=C3)=CC=C2)C=NC(OCCCS(=O)(C)=O)=C1,=,0.2323,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,CC1=C(C2=CC(COC3=CC=C4C(C[C@@H]5[C@H]4[C@H]5C(O[H])=O)=C3)=C(F)C=C2)C(C)=NC(OC(CC6)CCS6(=O)=O)=C1,=,0.099,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,CC1=C(C2=CC(COC3=CC=C4C(C[C@@H]5[C@H]4[C@H]5C(O[H])=O)=C3)=C(F)C=C2)C=NC(OC(CC6)CCS6(=O)=O)=C1,=,0.0931,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])[C@H]1[C@H]2[C@@H]1C3=CC=C(C=C3C2)OCC4=C(F)C=CC(C5=CC=C(NCCCS(C)(=O)=O)N=C5C)=C4,=,0.0559,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])[C@H]1[C@H]2[C@@H]1C3=CC=C(C=C3C2)OCC4=CC=CC(C5=CC=C(NCCCS(C)(=O)=O)N=C5C)=C4,=,0.1227,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])[C@H]1[C@H]2[C@@H]1C3=CC=C(C=C3C2)OCC4=CC=CC(C5=C(C)C=C(OC(CC6)CCS6(=O)=O)N=C5C)=C4,=,0.1021,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])[C@H]1[C@H]2[C@@H]1C3=CC=C(C=C3C2)OCC4=C(F)C=CC(C5=C(C)C=C(NCCCS(C)(=O)=O)N=C5)=C4,=,0.1448,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])[C@H]1[C@H]2[C@@H]1C3=CC=C(C=C3C2)OCC4=CC=CC(C5=C(C)C=C(NCCCS(C)(=O)=O)N=C5)=C4,=,0.3166,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])[C@H]1[C@H]2[C@@H]1C3=CC=C(C=C3C2)OCC4=CC=CC(C5=C(C)C=C(NCCCS(C)(=O)=O)N=C5)=C4C,=,4.283,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])[C@H]1[C@H]2[C@@H]1C3=CC=C(C=C3C2)OCC4=CC=CC(C5=CC=C(OC(CC6)CCS6(=O)=O)N=C5C)=C4C,=,252.1,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])[C@H]1[C@H]2[C@@H]1C3=CC=C(C=C3C2)OCC4=CC=CC(C5=CC=C(OCCCS(=O)(C)=O)N=C5CO[H])=C4,=,0.206,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])[C@H]1[C@H]2[C@@H]1C3=CC=C(C=C3C2)OCC4=C(F)C=CC(C5=CC=C(OCCCS(C)(=O)=O)N=C5C)=C4F,=,0.1786,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])[C@H]1[C@H]2[C@@H]1C3=CC=C(C=C3C2)OCC4=C(F)C=CC(C5=C(C)C=C(OCCCS(C)(=O)=O)N=C5C)=C4F,=,0.0474,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])[C@H]1[C@H]2[C@@H]1C3=CC=C(C=C3C2)OCC4=C(F)C=CC(C5=C(C)C=C(OCCCS(C)(=O)=O)N=C5)=C4F,=,0.0589,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C([C@H]1[C@@H]2CC3=CC(OCC4=CC=C(C)C(C(C=N5)=CC6=C5N(C=C6)CCCS(=O)(C)=O)=C4)=CC=C3[C@H]12)O[H],=,0.0742,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C([C@H]1[C@@H]2CC3=CC(OCC4=C(F)C=CC(C(C=N5)=CC6=C5NC=C6)=C4)=CC=C3[C@H]12)O[H],=,0.0733,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=S([C@H]1[C@@H](CCCC1)COC(N=C2C)=CC=C2C3=CC(COC4=CC=C5C(C[C@H]6[C@H](C(O[H])=O)[C@H]65)=C4)=C(F)C=C3)(C)=O,=,0.0679,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,FC(C=CC(C1=CC=C(OCC2(O[H])CCCCC2O[H])N=C1C)=C3)=C3COC4=CC=C5C(C[C@H]([C@@H]65)[C@@H]6C(O[H])=O)=C4,=,0.0838,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,FC(C=CC(C1=CC=C(OCC2CCC[C@H](O[H])[C@@H]2O[H])N=C1C)=C3)=C3COC4=CC=C5C(C[C@H]([C@@H]65)[C@@H]6C(O[H])=O)=C4,=,0.0489,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,FC(C=CC(C1=CC=C(OCC2CCOCC2)N=C1C)=C3)=C3COC4=CC=C5C(C[C@H]([C@@H]65)[C@@H]6C(O[H])=O)=C4,=,0.0185,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,FC(C=CC(C1=CC=C(OCCCCN2N=CC=N2)N=C1C)=C3)=C3COC4=CC=C5C(CC(C65)C6C(O[H])=O)=C4,=,0.0161,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,FC(C=CC(C1=C(C)C=C(OCCC2(COC2)O[H])N=C1)=C3)=C3COC4=CC=C5C(C[C@H]([C@@H]65)[C@@H]6C(O[H])=O)=C4,=,0.0492,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C([C@@H]1[C@H]2C3=CC=C(C=C3C[C@@H]12)OCC4=C(C=CC(C5=CC=C(O[C@@H]6CO[C@]7([H])[C@@H](O[H])CO[C@]67[H])N=C5C)=C4)F)O[H],=,0.0309,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])[C@@H]1[C@@H]2[C@H]1CC3=C2C=CC(OCC4=C(F)C=CC(C(C=NC(OCCCS(=O)(C)=O)=N5)=C5C(F)(F)F)=C4)=C3,=,0.0307,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])[C@@H]1[C@@H]2[C@H]1CC3=C2C=CC(OC(C)C4=C(F)C=CC(C(C(C)=N5)=CC=C5OC(CC6)CCS6(=O)=O)=C4)=C3,=,0.0778,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,FC(C=CC(C(C(C)=N1)=CC=C1OCCCN2C(CCC2)=O)=C3)=C3COC4=CC=C5C(C[C@@H]6[C@H]5[C@H]6C(O[H])=O)=C4,=,0.0199,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,FC(C=CC(C1=CC=C(N=C1C)OCCCC2(O[H])CC2)=C3)=C3COC(C=C4C[C@H]56)=CC=C4[C@@H]5[C@H]6C(O[H])=O,=,0.0166,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,FC(C=CC(C1=CC=C(N=C1C)OC2CCC(C(C)(C)O[H])CC2)=C3)=C3COC(C=C4C[C@H]56)=CC=C4[C@@H]5[C@H]6C(O[H])=O,=,0.0741,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,[H][C@@]1(N2C3=NC(C)=C(C(C=C4)=CC(COC(C=C5C[C@H]67)=CC=C5[C@@H]6[C@H]7C(O[H])=O)=C4F)C=C3)CC(O[H])C[C@@]2([H])CC1,=,0.0476,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C([C@@H]1[C@H]2C3=CC=C(C=C3C[C@H]21)OCC4=C(C=CC(C5=CC=C(N6CCC7(C=CC8=C7C=CC=C8)CC6)N=C5C)=C4)F)O[H],=,0.032,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C([C@@H]1[C@H]2C3=CC=C(C=C3C[C@H]21)OCC4=C(C=CC(C5=CC=C(N6CCC(O[H])CC6)N=C5C)=C4)F)O[H],=,0.0224,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C([C@@H]1[C@H]2C3=CC=C(C=C3C[C@H]21)OCC4=C(C=CC(C5=CC=C(N6CCC(C(F)(F)F)CC6)N=C5C)=C4)F)O[H],=,0.0128,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C([C@@H]1[C@H]2C3=CC=C(C=C3C[C@H]21)OCC4=C(C=CC(C5=CC=C(N6CCC(O[H])(C)CC6)N=C5C)=C4)F)O[H],=,0.0755,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C([C@@H]1[C@H]2C3=CC=C(C=C3C[C@H]21)OCC4=C(C=CC(C5=C(C)N=C(N6CCC(C#N)(C7=CC=CC=C7)CC6)N=C5C)=C4)F)O[H],=,0.0232,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C([C@@H]1[C@H]2C3=CC=C(C=C3C[C@H]21)OCC4=C(C=CC(C5=C(C)N=C(N6CCC(C7=CC=CC=C7)CC6)N=C5C)=C4F)F)O[H],=,0.0294,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C([C@@H]1[C@H]2C3=CC=C(C=C3C[C@H]21)OCC4=C(C=CC(C5=C(C)N=C(N6CCC(C7=CC=CC=C7)(C#N)CC6)N=C5C)=C4F)F)O[H],=,0.0387,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,CS(=O)(N([H])CC1CCN(C2=NC(C)=C(C3=CC(COC4=CC=C(C(C[C@H]56)=C4)[C@@H]5[C@H]6C(O[H])=O)=C(F)C=C3)C=C2)C1)=O,=,0.0178,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C([C@H]1[C@@H]2CC3=CC(OCC4=CC=CC(C(C=C5)=C(C)N=C5N6CCN(S(=O)(C)=O)CC6)=C4)=CC=C3[C@@H]21)O[H],=,0.0767,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,O=C([C@H]1[C@@H]2CC3=CC(OCC4=C(F)C=CC(C(C=C5)=C(C)N=C5OC6CCN(S(=O)(C)=O)CC6)=C4)=CC=C3[C@H]12)O[H],=,0.0289,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,FC(C=CC(C1=C(C)N=C(C=C1)N(CC2)CCC2CS(C)(=O)=O)=C3)=C3COC4=CC=C5[C@H]6[C@H]([C@@H]6C(O[H])=O)CC5=C4,=,0.058,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,FC(C=CC(C(C=CC(N(C1)CC1S(C)(=O)=O)=N2)=C2C)=C3)=C3COC4=CC=C5[C@H]6[C@H]([C@@H]6C(O[H])=O)CC5=C4,=,0.0233,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,CC1=C2SC(C3=CC=NC=C3)=NC2=CC=C1C4=CC(COC5=CC=C6[C@@H]7[C@@H](C(O[H])=O)[C@@H]7CC6=C5)=C(F)C=C4,=,0.0354,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,FC(F)(F)C1=C(OCCCS(=O)(C)=O)N=CC(C(C=C2)=CC(COC3=CC(C[C@H]4[C@H](C(O[H])=O)[C@@H]54)=C5C=C3)=C2F)=C1,=,0.0507,¦ÌM
,Preparation of tetrahydrocyclopropaindene derivatives as GPR40 agonists for treatment of diabetes and related conditions,WO2015089809,Patent,CHO,Calcium mobilization assay,EC50,FC(F)(F)C(C=C(N([H])CC1CCOCC1)N=C2)=C2C3=CC(COC4=CC=C5[C@]6([H])[C@H]([C@](CC5=C4)6[H])C(O[H])=O)=C(F)C=C3,=,0.0354,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C=C(C=C4)C5=C(F)C=CC(OC)=C5)=CC=C2)O[H],=,0.0002,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C([C@@H](C)[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C=C(C=C4)C5=C(F)C=CC(OC)=C5)=CC=C2)O[H],=,0.0004,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(C[C@@H](C1CC1)C2=C(F)C(O[C@H](CC3)C4=C3C=C(C=C4)C5=C(F)C=CC(OC)=C5)=CC=C2)O[H],=,0.003,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,FC(C(O[C@H](CC1)C2=C1C=C(C=C2)C3=C(F)C=CC(OC)=C3)=CC=C4)=C4[C@H](C5CC5)[C@H](C)C(O[H])=O,=,0.0002,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,FC(C(O[C@H](CC1)C2=C1C=C(C=C2)C3=C(F)C=CC(OC)=C3)=CC=C4)=C4[C@H](C5CC5)[C@@H](C)C(O[H])=O,=,0.008,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C(C5=C(F)C=C(OC)C=C5)=C(C=C4)C6=C(F)C=CC(OC)=C6)=CC=C2,=,0.001,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C(Cl)=C(C=C4)C5=C(F)C=CC(OC)=C5)=CC=C2,=,0.007,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])[C@@H](C)[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C=C(C=C4)C5=C(F)C=NC(OC)=C5)=CC=C2,=,0.004,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C=C(C=C4)C5=CC(Cl)=CC=C5)=CC=C2,=,0.019,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C=C(C=C4)C5=C(F)C(OC)=CC=C5)=CC=C2,=,0.008,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C(C5=C(N(C)C=C6)C6=CC=C5)=C(C=C4)C7=C(F)C=CC(OC)=C7)=CC=C2,=,0.0008,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C(C5=CC=C(C(F)(F)F)C=C5)=C(C=C4)C6=C(F)C=CC(OC)=C6)=CC=C2,=,0.0004,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C(C5=CC=NN5C)=C(C=C4)C6=C(F)C=CC(OC)=C6)=CC=C2,=,0.102,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C(C5=CC=NN5C(C)C)=C(C=C4)C6=C(F)C=CC(OC)=C6)=CC=C2,=,0.002,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C(C5=CSC(N6CCCC6)=N5)=C(C=C4)C7=C(F)C=CC(OC)=C7)=CC=C2,=,0.013,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C(/C=C(C)/C)=C(C=C4)C5=C(F)C=CC(OC)=C5)=CC=C2,=,0.0006,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C(C5CCCC5)=C(C=C4)C6=C(F)C=CC(OC)=C6)=CC=C2,=,0.003,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C(C5=CC(C(F)(F)F)=NN5C)=C(C=C4)C6=C(F)C=CC(OC)=C6)=CC=C2,=,0.004,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C(C(C)=C)=C(C=C4)C5=C(F)C=CC(OC)=C5)=CC=C2,=,0.006,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C(/C=C/C5CCCCC5)=C(C=C4)C6=C(F)C=CC(OC)=C6)=CC=C2,=,0.0005,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])[C@@H](C)[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C(C5=C(C)C=NN5C)=C(C=C4)C6=C(F)C=CC(OC)=C6)=CC=C2,=,0.001,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])[C@@H](C)[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C(C5=C6N(C=CC=C6)N=C5)=C(C=C4)C7=C(F)C=CC(OC)=C7)=CC=C2,=,0.0008,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])[C@@H](C)[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C(C5=CN(C)N=N5)=C(C=C4)C6=C(F)C=CC(OC)=C6)=CC=C2,=,0.022,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])[C@@H](C)[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C(C5=NN(C)C=C5)=C(C=C4)C6=C(F)C=CC(OC)=C6)=CC=C2,=,0.102,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C(/C=C/C(C)(C)C)=C(C=C4)C5=C(F)C=CC(OC)=C5)=CC=C2,=,0.004,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C(C5=CSC=C5)=C(C=C4)C6=C(F)C=CC(OC)=C6)=CC=C2,=,0.0007,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C(COC(C)(C)C)=C(C=C4)C5=C(F)C=CC(OC)=C5)=CC=C2,=,0.001,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(O[H])C[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C(C5CC5)=C(C=C4)C6=C(F)C=CC(OC)=C6)=CC=C2,=,0.0008,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(O[C@H](CC3)C4=C3C(C#N)=C(C=C4)C5=C(F)C=CC(OC)=C5)=CC=C2)O[H],=,0.022,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(O[C@H]3C(C(F)=CC(C4=C(F)C=CC(OC)=C4)=C5)=C5CC3)=CC=C2)O[H],=,0.036,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C([C@@H](C)[C@@H](C1CC1)C2=CC(O[C@H]3C(C=CC(C4=C(F)C=CC(OC)=C4)=C5F)=C5CC3)=CC=C2)O[H],=,0.0004,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(O[C@H]3C(C=C(F)C(C4=C(F)C=CC(OC)=C4)=C5)=C5CC3)=CC=C2)O[H],=,0.012,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(O[C@H]3C(C=CC(C4=C(F)C=CC(OC)=C4)=C5F)=C5CC3)=CC=C2)O[H],=,0.004,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C([C@@H](C)[C@@H](C1CC1)C2=CC(O[C@H]3C(C=CC(C4=C(F)C=CC(O[H])=C4)=C5)=C5CC3)=CC=C2)O[H],=,0.0002,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,O=C(C[C@@H](C1CC1)C2=CC(O[C@H]3C(C=CC(C4=C(F)C=CC(OC)=C4)=C5Cl)=C5CC3)=CC=C2)O[H],=,0.007,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,COC1=CC(C(C=CC2=C3CC[C@H]2OC4=CC=CC([C@H](C5CC5)[C@H](C)C(O[H])=O)=C4)=C3C6=CC=CC(C=C7)=C6N7C)=C(F)C=C1,=,0.001,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,COC1=CC(C2=NC3=C([C@H](OC4=CC=CC([C@H](C5CC5)CC(O[H])=O)=C4)CC3)C=C2)=C(F)C=C1,=,0.017,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,COC1=CC(C2=NC3=C([C@H](OC4=CC=CC([C@H](C5CC5)[C@H](C)C(O[H])=O)=C4)CC3)C=C2)=C(F)C=C1,=,0.005,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,COC1=CC(C2=CC3=C([C@H](OC4=CC=CC([C@H](C5CC5)[C@H](C)C(O[H])=O)=C4)CC3)N=C2)=C(F)C=C1,=,0.002,¦ÌM
,Preparation of bicyclic compounds useful as GPR40 agonists for treatment of diabetes,WO2015084692,Patent,CHO,Calcium mobilization assay,EC50,COC1=CC(C2=CC3=C([C@H](OC4=CC=CC([C@H](C5CC5)[C@H](C)C(O[H])=O)=C4)CC3)C=N2)=C(F)C=C1,<,0.0002,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC1=CC=C(C2=C1[C@H](OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)CC2)OC5=CC=C(OCC6=CC=CC=C6)C=C5,=,0.006,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC1=CC=C(C2=C1[C@H](OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)CC2)OC5=CC=C(OCC6=CC=C(O[H])C=C6)C=C5,=,0.006,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC1=CC=C(C2=C1[C@H](OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)CC2)OC5=CC=C(OCC6=CC=CC=C6)C(F)=C5,=,0.005,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC1=CC=C(C2=C1[C@H](OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)CC2)OC5=CC=C(OCCC(C)(C)O[H])C=C5,=,0.005,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(OCC6(O[H])CCOCC6)C=C5,=,0.007,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(OC6CCOCC6)C=C5,=,0.002,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(OCCCS(C)(=O)=O)C=C5,=,0.004,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(OCCOC)C=C5,=,0.005,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(OCC(C)(C)O[H])C=C5,=,0.005,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(OCCO[H])C=C5,=,0.007,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC(F)=C(OCCC(C)(C)O[H])C=C5,=,0.003,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC(F)=C(OC6CCOCC6)C=C5,=,0.004,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC(F)=C(OCCOC)C=C5,=,0.008,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(OCCN6CCOCC6)C=C5,=,0.003,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC(F)=C(OCCCS(C)(=O)=O)C=C5,=,0.008,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(C(O[H])=O)C=C5,=,0.092,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(C(NC)=O)C=C5,=,0.009,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(C(NCC6CC6)=O)C=C5,=,0.006,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(C(N(C)CCO[H])=O)C=C5,=,0.048,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(C(N(C)C)=O)C=C5,=,0.011,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(C(NC6CCOCC6)=O)C=C5,=,0.003,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(C(N6CCOCC6)=O)C=C5,=,0.027,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(C(NCC)=O)C=C5,=,0.012,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(C#N)C=C5,=,0.002,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(C#N)C=C5C,=,0.002,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(C#N)C=C5F,=,0.019,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC(OC)=C(C#N)C=C5,=,0.002,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC(F)=C2OC5=CC=C(C#N)C=C5,=,0.001,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(C6=NN(C)N=N6)C=C5,=,0.003,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(N6N=C(C(C)C)C=C6)C=C5,=,0.008,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC(C)=C(OCCC(C)(C)O[H])C(C)=C5,=,0.009,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(C6=NC(C)=NO6)C=C5,=,0.004,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(C6=NN(C)C(C)=N6)C=C5,=,0.005,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(C(NCC(C)(C)O[H])=O)C=C5,=,0.016,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(C6=NOC(C)=N6)C=C5,=,0.003,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC6=C(C=NN6C)C=C5,=,0.002,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC6=C(N=C(C)S6)C=C5,=,0.002,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC=C(S(C)(=O)=O)C=C5,=,0.027,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,FC(C1=C2CC[C@H]1OC3=CC=C([C@H]4C[C@@H]4C(O[H])=O)C=C3)=CC=C2OC5=CC6=CC=C(C)N=C6C=C5,=,0.006,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])[C@H]1C[C@@H]1C2=CC=C(C=C2)O[C@@H]3CCC4=C3C=CC(C#N)=C4OC5=CN=C(Cl)C=C5,=,0.045,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])[C@H]1C[C@@H]1C2=CC=C(C=C2)O[C@@H]3CCC4=C3C=CC=C4S(C5=C(C)C=C(C#N)C=C5C)(=O)=O,=,0.012,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])[C@H]1C[C@@H]1C2=CC=C(C=C2)O[C@@H]3CCC4=C3C=CC=C4S(C5=C(C)C=CC=C5C)(=O)=O,=,0.004,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(C1C(C2=CC=C(C=C2)O[C@H]3C4=C(CC3)C(S(C5=CC=CC=C5)(=O)=O)=CC=C4)C1)O[H],=,0.037,¦ÌM
,(Indanyloxyphenyl)cyclopropanecarboxylic acids as GPR40 agonists and their preparation and use for the treatment of GPR40-associated diseases,US2015148347,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(C1C(C2=CC=C(C=C2)O[C@H]3C4=C(CC3)C(S(C5=CC=CC=C5)=O)=CC=C4)C1)O[H],=,0.197,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OCC5CN(C5)S(=O)(C)=O)=C3)C=C2OC1,=,0.121,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OC[C@@H]5CCCN5S(=O)(C)=O)=C3)C=C2OC1,=,0.108,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OC[C@H]5CCCN5S(=O)(C)=O)=C3)C=C2OC1,=,0.093,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OC[C@H]5CCCN5S(=O)(C)=O)=C3)C=C2OC1,=,0.025,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OC[C@H]5CN(S(C)(=O)=O)CC5)=C3)C=C2OC1,=,0.093,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OC[C@@H]5CN(S(C)(=O)=O)CC5)=C3)C=C2OC1,=,0.095,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OC[C@@H]5CN(S(C)(=O)=O)CC5)=C3)C=C2OC1,=,0.043,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OCC5=CC=C(S(C)(=O)=O)S5)=C3)C=C2OC1,=,0.062,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OCC5N(S(=O)(C)=O)CCCC5)=C3)C=C2OC1,=,0.117,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OCC5(C)CN(S(C)(=O)=O)CC5)=C3)C=C2OC1,=,0.072,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OCC5(F)CN(S(C)(=O)=O)CC5)=C3)C=C2OC1,=,0.158,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OCC[C@@H]5N(S(C)(=O)=O)CCC5)=C3)C=C2OC1,=,0.076,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OCCCN(C5CCCC5)S(C)(=O)=O)=C3)C=C2OC1,=,0.147,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OCCCN(C5=CC=CC=C5)S(C)(=O)=O)=C3)C=C2OC1,=,0.129,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OCC5CCC(O[H])CC5)=C3)C=C2OC1,=,0.053,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OCC5CCC(C(F)(F)F)CC5)=C3)C=C2OC1,=,0.201,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OCC5CCC(F)(F)CC5)=C3)C=C2OC1,=,0.1,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OCC5CCCCO5)=C3)C=C2OC1,=,0.119,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OCC5CCOCC5)=C3)C=C2OC1,=,0.059,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OCC5CCCO5)=C3)C=C2OC1,=,0.1,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OCC5CC(C)=C(C)CO5)=C3)C=C2OC1,=,0.105,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OCC5CCC(O[H])CO5)=C3)C=C2OC1,=,0.038,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OC[C@@H]5C[C@@H](O[H])[C@@H](O[H])CO5)=C3)C=C2OC1,=,0.055,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OC[C@@H]5C[C@H](O[H])[C@H](O[H])CO5)=C3)C=C2OC1,=,0.053,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OC[C@@H]5C[C@@H](O[H])[C@@H](O[H])CO5)=C3)C=C2OC1,=,0.025,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OC[C@@H]5C[C@H](O[H])[C@H](O[H])CO5)=C3)C=C2OC1,=,0.024,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OC[C@H]5C[C@H](O[H])[C@H](O[H])CO5)=C3)C=C2OC1,=,0.028,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OC[C@H]5C[C@@H](O[H])[C@@H](O[H])CO5)=C3)C=C2OC1,=,0.029,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OC[C@@H]5C[C@@H](O[H])[C@H](O[H])CO5)=C3)C=C2OC1,=,0.052,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OC[C@@H]5C[C@H](O[H])[C@@H](O[H])CO5)=C3)C=C2OC1,=,0.044,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OC[C@H]5C[C@H](O[H])[C@@H](O[H])CO5)=C3)C=C2OC1,=,0.065,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OC[C@H]5C[C@@H](O[H])[C@H](O[H])CO5)=C3)C=C2OC1,=,0.062,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OCC5CC(C)(O[H])C(O[H])(C)CO5)=C3)C=C2OC1,=,0.02,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OC[C@@H]5COCCO5)=C3)C=C2OC1,=,0.015,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=C(F)C(C(C(C)=C4)=C(C)C=C4OC[C@@H]5C[C@@H](O[H])[C@@H](O[H])CO5)=C3)C=C2OC1,=,0.015,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=C(F)C(C(C(C)=C4)=C(C)C=C4OC[C@@H]5C[C@H](O[H])[C@H](O[H])CO5)=C3)C=C2OC1,=,0.02,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4NCC5CCOCC5)=C3)C=C2OC1,=,0.094,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4NC(C5CCOCC5)=O)=C3)C=C2OC1,=,0.038,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OCC5C(C6)CCC6C5)=C3)C=C2OC1,=,0.104,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OCC5CC(O[H])C(O[H])CC5)=C3)C=C2OC1,=,0.048,¦ÌM
,Benzofuran derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes and metabolic diseases,WO2015062486,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(OCC3=CC=CC(C(C(C)=C4)=C(C)C=C4OCC5COCC5)=C3)C=C2OC1,=,0.066,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,COCC#CC1=CC=CC(COC2=CC(OC3)=C(C=C2)C3CC(O[H])=O)=C1,=,0.055,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,C#CC1=CC=CC(COC2=CC(OC3)=C(C=C2)C3CC(O[H])=O)=C1,=,0.041,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])CC1C2=C(OC1)C=C(OCC3=CC(C#CC4=CC=CC=C4)=CC=C3)C=C2,=,0.053,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])CC1C2=C(OC1)C=C(OCC3=CC(C#CC4=CC=CC(CO[H])=C4)=CC=C3)C=C2,=,0.076,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])CC1C2=C(OC1)C=C(OCC3=CC(C#CC4=CC=C5C(C=NN5)=C4)=CC=C3)C=C2,=,0.101,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])CC1C2=C(OC1)C=C(OCC3=CC(C#CCOC)=CC=C3F)C=C2,=,0.077,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,C#CC1=CC=C(F)C(COC2=CC(OC3)=C(C=C2)C3CC(O[H])=O)=C1,=,0.046,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])CC1C2=C(OC1)C=C(OCC3=CC(C#CC4=CC=CC=C4)=CC=C3F)C=C2,=,0.059,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])CC1C2=C(OC1)C=C(OCC3=CC(C#CC4=CC=C(N([H])[H])C=C4)=CC=C3)C=C2,=,0.052,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])CC1C2=C(OC1)C=C(OCC3=CC(C#CC4=CC=C(O[H])C=C4)=CC=C3)C=C2,=,0.035,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])CC1C2=C(OC1)C=C(OCC3=CC(C#CC4=CC=C(O[H])C=C4)=CC=C3F)C=C2,=,0.079,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])CC1C2=C(OC1)C=C(OCC3=CC(C#CC4=CC=C(N(C(C)=O)[H])C=C4)=CC=C3)C=C2,=,0.095,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])CC1C2=C(OC1)C=C(OCC3=CC(C#CC4=CC=C(OC(C)=O)C=C4)=CC=C3)C=C2,=,0.064,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,FC1=CC=C(C#CC2=CC=C(OCCCS(C)(=O)=O)C=C2)C=C1COC3=CC4=C(C(CC(O[H])=O)CO4)C=C3,=,0.02,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,FC1=CC=C(C#CC2=CC=CC(OCCCS(C)(=O)=O)=C2)C=C1COC3=CC4=C(C(CC(O[H])=O)CO4)C=C3,=,0.028,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,FC1=CC=C(C#CC2=CC=CC(O[H])=C2)C=C1COC3=CC4=C(C(CC(O[H])=O)CO4)C=C3,=,0.067,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])CC1C2=C(OC1)C=C(C=C2)OCC3=CC(C#CC4=CC=CC(N([H])[H])=C4)=CC=C3,=,0.091,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])CC1C2=C(OC1)C=C(C=C2)OCC3=CC(C#CC4=CC=CC(OCCCS(C)(=O)=O)=C4)=CC=C3,=,0.082,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])CC1C2=C(OC1)C=C(C=C2)OCC3=CC(C#CC4=CC=C(OCCCS(C)(=O)=O)C=C4)=CC=C3,=,0.03,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,FC(C=CC(C#CC1=CC=CC(N([H])[H])=C1)=C2)=C2COC(C=C3OC4)=CC=C3C4CC(O[H])=O,=,0.037,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(C=C2OC1)OCC3=CC=CC(C#CC4=CC=CC(COCCCS(C)(=O)=O)=C4)=C3,=,0.107,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(C=C2OC1)OCC3=CC=CC(C#CC4=CC=CC=C4N([H])[H])=C3,=,0.094,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,O=S(C)(COCCC#CC1=CC=CC(COC(C=C2OC3)=CC=C2C3CC(O[H])=O)=C1)=O,=,0.04,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,O=C(OC)CC1C2=CC=C(C=C2OC1)OCC3=CC(C#CCCS(C)(=O)=O)=CC=C3,=,0.102,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,O=S(C)(CCCCC#CC1=CC=CC(COC(C=C2OC3)=CC=C2C3CC(O[H])=O)=C1)=O,=,0.09,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,FC1=CC=C(C#CC2=CC=C(S(=O)(C)=O)C=C2)C=C1COC3=CC=C4C(OCC4CC(O[H])=O)=C3,=,0.11,¦ÌM
,GPR40 agonist and its application,CN104250238,Patent,CHO,Calcium flux assay,EC50,O=C(OC)CC1C2=CC=C(C=C2OC1)OCC3=CC(C#CC4=CC=C(S(C)(=O)=O)C=C4)=CC=C3,=,0.038,¦ÌM
,Preparation of fused ring compounds for regulating GPR40 receptors,WO2014146604,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(C=C2OC1)OCC3=CC=CC(C(C(C)=C4)=C(C=C4OCCCP(C)(C)=O)C)=C3,=,0.01,¦ÌM
,Preparation of fused ring compounds for regulating GPR40 receptors,WO2014146604,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(C=C2OC1)OCC3=CC=CC(C(C(C)=C4)=C(C=C4OCCNS(C)(=O)=O)C)=C3,=,0.0033,¦ÌM
,Preparation of fused ring compounds for regulating GPR40 receptors,WO2014146604,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(C=C2OC1)OCC3=CC=CC(C(C(C)=C4)=C(C=C4OCCNS(CC)(=O)=O)C)=C3,=,0.057,¦ÌM
,Preparation of fused ring compounds for regulating GPR40 receptors,WO2014146604,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(C=C2OC1)OCC3=CC=CC(C(C(C)=C4)=C(C=C4OCCNS(C5CC5)(=O)=O)C)=C3,=,0.0129,¦ÌM
,Preparation of fused ring compounds for regulating GPR40 receptors,WO2014146604,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(C=C2OC1)OCC3=CC=CC(C(C(C)=C4)=C(C=C4OCCN5S(CCC5)(=O)=O)C)=C3,=,0.0067,¦ÌM
,Preparation of fused ring compounds for regulating GPR40 receptors,WO2014146604,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(C=C2OC1)OCC3=CC=CC(C(C(C)=C4)=C(C=C4OCCCS(N(C)C)(=O)=O)C)=C3,=,0.0187,¦ÌM
,Preparation of fused ring compounds for regulating GPR40 receptors,WO2014146604,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(C=C2OC1)OCC3=CC=CC(C(C(C)=C4)=C(C=C4OCCCS(N([H])C)(=O)=O)C)=C3,=,0.0043,¦ÌM
,Preparation of fused ring compounds for regulating GPR40 receptors,WO2014146604,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(C=C2OC1)NCC3=CC=CC(C(C(C)=C4)=C(C=C4OCCN(CCC5)S5(=O)=O)C)=C3,=,0.0085,¦ÌM
,Preparation of fused ring compounds for regulating GPR40 receptors,WO2014146604,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(C=C2OC1)NCC3=CC=CC(C(C(C)=C4)=C(C=C4OCCCP(C)(C)=O)C)=C3,=,0.0744,¦ÌM
,Preparation of fused ring compounds for regulating GPR40 receptors,WO2014146604,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(C=C2OC1)OCC3=CC=CC(C4=C(C=C(N5CCN(S(C)(=O)=O)CC5)C=C4C)C)=C3,=,0.0076,¦ÌM
,Preparation of fused ring compounds for regulating GPR40 receptors,WO2014146604,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)OCC3=CC=CC(C4=C(C=C(OCCN5S(CCC5)(=O)=O)C=C4C)C)=C3,=,0.0061,¦ÌM
,Preparation of fused ring compounds for regulating GPR40 receptors,WO2014146604,Patent,HEK293,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(C#CC3=CC=CC(C4=C(C=C(OCCCS(C)(=O)=O)C=C4C)C)=C3)C=C2OC1,=,0.0319,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CC(C3CCC(C=C4CCC(O[H])=O)=C(C=C4)O3)=CC=C2,=,0.102,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])CCC1=CC2=C(C=C1)OC(C3=CC=CC=C3)CC2,=,10,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])CCC1=CC2=C(C=C1)OC(C3=C(F)C=CC(C4=C(C)C=CC=C4C)=N3)CC2,=,0.292,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,CC(C=C1OCCS(=O)(C)=O)=C(C(C)=C1)C2=CC(C3OC(C=CC(CCC(O[H])=O)=C4)=C4CC3)=CC=C2,=,0.185,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CC=CC(C(OC3=C4C=C(CCC(O[H])=O)C=C3)CC4=O)=C2,=,10,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,FC1(CC(OC(C=C2)=C1C=C2CCC(O[H])=O)C3=CC=CC(C4=C(C)C=CC=C4C)=C3)F,=,0.349,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,CC(C=CC=C1C)=C1C2=CC(C3OC(C=CC(CCC(O[H])=O)=N4)=C4CC3)=CC=C2,=,1.309,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CC(C3CCC(C=C4C(C#CC)CC(O[H])=O)=C(C=C4)O3)=CC=C2,=,0.027,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=NC(C3CCC(C=C4C(C#CC)CC(O[H])=O)=C(C=C4)O3)=C(F)C=C2,=,0.076,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,FC(F)(C1=C(C2=NC(C3CCC(C=C4C(C#CC)CC(O[H])=O)=C(C=C4)O3)=C(F)C=C2)C=CC=C1)F,=,0.061,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,ClC1=CC(C2CCC(C=C3C(C#CC)CC(O[H])=O)=C(C=C3)O2)=CC=C1C(F)(F)F,=,1.535,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,CC1=NC(OC)=CC=C1C2=NC(C3CCC(C=C4C(CC(O[H])=O)C#CC)=C(C=C4)O3)=C(F)C=C2,=,0.106,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,FC(F)(F)C1=NC=CC=C1C2=NC(C3CCC(C=C4C(C#CC)CC(O[H])=O)=C(C=C4)O3)=C(F)C=C2,=,0.172,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CC(C3CCC(C=C([C@H](CC(O[H])=O)C#CC)C=C4)=C4O3)=C(F)C=C2,=,0.026,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,CC(ON=C1C)=C1C2=CC(C3CCC4=C(C=CC(C(C#CC)CC(O[H])=O)=C4)O3)=CC=C2,=,0.151,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])CC(C#CC)C1=CC2=C(C=C1)OC(C3=CC=CC(OC(C=C4)=CC=C4C#N)=C3)CC2,=,0.04,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,CC1=NC(OC)=CC=C1C2=CC(C3CCC(C=C4C(C#CC)CC(O[H])=O)=C(C=C4)O3)=C(F)C=C2,=,0.057,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,CC1=NC(OC)=CC(C)=C1C2=CC(C3CCC(C=C4C(C#CC)CC(O[H])=O)=C(C=C4)O3)=C(F)C=C2,=,0.033,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,CC1=NC=CC=C1C2=CC=CC(C3CCC(C=C4C(CC(O[H])=O)C#CC)=C(C=C4)O3)=C2,=,0.244,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,FC(F)(F)C1=CC=CC=C1C2=CC=CC(C3OC(C=C4)=C(CC3)C=C4C(C#CC)CC(O[H])=O)=C2,=,0.052,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,BrC(C=C1)=CC(C2OC3=C(CC2)C=C(C(C#CC)CC(O[H])=O)C=C3)=C1F,=,0.115,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,FC(F)(F)C1=CC=C(C2=CC(C3CCC(C=C([C@@H](C#CC)CC(O[H])=O)C=C4)=C4O3)=C(F)C=C2)C=C1,=,0.162,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,FC(C=CC(OC)=C1)=C1C2=CC(C3OC(C=C4)=C(CC3)C=C4[C@H](CC(O[H])=O)C#CC)=C(F)C=C2,=,0.128,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,FC(F)(F)C1=NC=CC=C1C2=CC(C3CCC(C=C4[C@@H](C#CC)CC(O[H])=O)=C(C=C4)O3)=C(F)C=C2,=,0.095,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,FC(F)(F)C1=NN(C)C2=C1C(C3=CC(C4CCC(C=C([C@@H](C#CC)CC(O[H])=O)C=C5)=C5O4)=CC=C3)=CC=C2,=,0.057,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC2=C(C=C1)OC(C(C=C(C3=CCCC3(C)C)C=C4)=C4F)CC2,=,0.114,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CC=CC(C3OC(C=C4)=C(CC3)C=C4C(CC(O[H])=O)C5=CC=CC=N5)=C2,=,0.734,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CC=CC(C3CCC(C=C4C(C5CC5)CC(O[H])=O)=C(C=C4)O3)=C2,=,2.036,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,C/C(C)=C\C(CC(O[H])=O)C1=CC2=C(C=C1)OC(C3=CC(C4=C(C)C=CC=C4C)=CC=C3)CC2,=,0.069,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CC=CC(C3CCC(C=C4C(CC(O[H])=O)C5=C(OC)C=CC=C5)=C(C=C4)O3)=C2,=,10,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CC=CC(C3CCC(C=C4C(CC(O[H])=O)C5=CC=CC(OC)=C5)=C(C=C4)O3)=C2,=,10,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CC=CC(C3OC4=C(CC3)C=C(C=C4)C(C5=CC=C(OC)C=C5)CC(O[H])=O)=C2,=,10,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,FC1=C(C=C(OC)C=C1)C2=C(C3=CCCC3(C)C)C=C(C4OC5=C(CC4)C=CC(CCC(O[H])=O)=C5)C=C2,=,0.012,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,CC1=C(SC(C2=CC=CC=C2)=N1)C(CC3)OC4=C3C=C([C@@H](C#CC)CC(O[H])=O)C=C4,=,0.045,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,COC1=CC(C2=CC=C(C=C2)C3CCC4=C(C=CC([C@H](CC(O[H])=O)C#CC)=C4)O3)=C(F)C=C1,=,0.105,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,CC1=CC=CC(C)=C1C2=CC(C3CCC(C=C4[C@@H]5CC(O[H])=O)=C(C=C4OC5)O3)=CC=C2,=,0.247,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,CC1=C(C=CC=C1)C2=CC(C3CCC(C=C4[C@@H]5CC(O[H])=O)=C(C=C4OC5)O3)=C(F)C=C2,=,0.117,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,CC1=C(C=CC=C1)C2=CC(F)=C(C=C2)C3CCC(C=C4[C@@H]5CC(O[H])=O)=C(C=C4OC5)O3,=,1.047,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,CC1=CC=CC=C1C2=CC=CC(C3CCC4=C(C=C(OC5)C([C@@H]5CC(O[H])=O)=C4)O3)=C2F,=,1.036,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,CHO,Calcium flux assay,EC50,CC1=CC=CC=C1C2=CC(C3CCC(C=C4[C@@H]5CC(O[H])=O)=C(C=C4OC5)O3)=C(F)C=C2C6=C(C)C=CC=C6,=,0.051,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,COC(C=C1)=CC(C(C=C2)=CC=C2C3OC(C=C(C=C4)C(CC(O[H])=O)C5CC5)=C4CC3)=C1F,=,0.025,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,[H]OC(C=C1)=CC(C(C=C2)=CC=C2C3OC(C=C(C=C4)[C@@H](CC(O[H])=O)C5CC5)=C4CC3)=C1F,=,0.391,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,FC1=C(C=C(OC(F)(F)F)C=C1)C(C=C2)=CC=C2C3OC(C=C(C=C4)[C@@H](CC(O[H])=O)C5CC5)=C4CC3,=,0.934,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,FC1=C(C=C(OC)N=C1)C(C=C2)=CC=C2C3OC(C=C(C=C4)[C@@H](CC(O[H])=O)C5CC5)=C4CC3,=,0.011,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC=C(C=C4)C5=CC(F)=CC(OC)=C5)O[H],=,0.116,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC=C(C=C4)C5=CC=CC(OCC(F)(F)F)=C5)O[H],=,1.198,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC=C(C=C4)C5=CC=NC(OC)=C5)O[H],=,0.019,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC=C(C=C4)C5=CC=CC(OC)=N5)O[H],=,0.304,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC=C(C=C4)C5=C(F)C=CC(OC(F)(F)F)=C5)O[H],=,0.65,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC=C(C=C4)C5=CN=CC(OC)=N5)O[H],=,0.92,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC=C(C=C4)C5=CC=CC(OC6CC6)=C5)O[H],=,1.7,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC=C(C=C4)C5=CC=CC(OC)=C5)O[H],=,0.022,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC=C(C=C4)C5=CC=CC=C5)O[H],=,0.13,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC=C(C=C4)C5=CC=CC(SC)=C5)O[H],=,0.165,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC=C(C=C4)C5=C(F)C=CC(OC)=C5F)O[H],=,0.054,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC=C(C=C4)C5=CC=C(F)C(OCC)=C5)O[H],=,1.52,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC=C(C=C4F)C5=CC(OC)=CN=C5)O[H],=,0.363,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC=C(C=C4F)C5=CC(OCCN6C)=C6C=C5)O[H],=,1.393,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC=C(C=C4F)C5=C(F)C=CC(OC)=C5)O[H],=,0.0065,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC=C(C=C4F)C5=CC=CC(OC)=C5)O[H],=,0.0106,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC=C(C=C4F)C5=C(F)C=NC(OC)=C5)O[H],=,0.0036,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC=C(C=C4F)C5=C(Cl)C=CC(OC)=C5)O[H],=,0.019,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC=C(C=C4F)C5=CN=CC(OC)=N5)O[H],=,0.488,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC=C(C=C4F)C5=C(F)C=C(F)C(OC)=C5)O[H],=,0.218,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC=C(C=C4F)C5=CC=NC(OC)=C5)O[H],=,0.014,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=NC=C(C=C4F)C5=C(F)C=CC(OC)=C5)O[H],=,0.084,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC(OC(F)(F)F)=C(C=C4)C5=C(F)C=CC(OC)=C5)O[H],=,0.029,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C([C@@H](C)[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC(OC(F)(F)F)=C(C=C4)C5=C(F)C=CC(OC)=C5)O[H],=,0.032,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC([C@@H]5C(C)(C)CCC5)=C(C=C4)C6=C(F)C=CC(OC)=C6)O[H],=,0.066,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC([C@H]5C(C)(C)CCC5)=C(C=C4)C6=C(F)C=CC(OC)=C6)O[H],=,0.0062,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C(C[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=NC=C(C=C4)C5=C(F)C=CC(OC)=C5)O[H],=,0.016,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C([C@@H](C)[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=NC=C(C=C4)C5=C(F)C=CC(OC)=C5)O[H],=,0.132,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C([C@@H](C)[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=NC(C5=CCCC5(C)C)=C(C=C4)C6=C(F)C=CC(OC)=C6)O[H],=,0.0088,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C([C@@H](C)[C@@H](C1CC1)C(C=C2)=CC3=C2CCC(O3)C4=CC=C(N=C4C(F)(F)F)C5=C(F)C=CC(OC)=C5)O[H],=,0.017,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,COC(C1=C(C2=C(F)C=CC(OC)=C2)C=CC(C3OC4=C(CC3)C=CC([C@H](C5CC5)CC(O[H])=O)=C4)=C1)C6CC6,=,0.0141,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,COC(C1=C(C2=C(F)C=CC(OC)=C2)C=CC(C3OC4=C(CC3)C=CC([C@H](C5CC5)CC(O[H])=O)=C4)=C1)C(F)(F)F,=,0.0415,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,COC(C1=C(C2=C(F)C=CC(OC)=C2)C=CC(C3OC4=C(CC3)C=CC([C@H](C5CC5)[C@H](C)C(O[H])=O)=C4)=C1)C(C)(C)C,=,0.0032,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,COC(C1=C(C2=CC=NC(OC)=C2)C=CC(C3OC4=C(CC3)C=CC([C@H](C5CC5)[C@H](C)C(O[H])=O)=C4)=C1)C(C)(C)C,=,0.0005,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,COC(C1=C(C2=C(F)C=NC(OC)=C2)C=CC(C3OC4=C(CC3)C=CC([C@H](C5CC5)[C@H](C)C(O[H])=O)=C4)=C1)C6CC6,=,0.0009,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,COC1=CC(C(C=C2)=C(N3CCC3)N=C2C4OC5=C(CC4)C=CC([C@H](C6CC6)[C@H](C)C(O[H])=O)=C5)=C(F)C=C1,=,0.018,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,COC1=CC(C(C=C2F)=CC=C2C3OC4=C(CC3)C=CC([C@H](C5CC5)[C@H](C)C(O[H])=O)=C4)=CC=N1,=,0.0012,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,COC1=CC(C(C=C2)=CC=C2C3OC4=C(CC3)C=CC(C(C5CC5)CC(O[H])=O)=N4)=C(F)C=C1,=,0.217,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,COC1=CC(C(C=C2)=CC=C2C3OC4=C(CC3)C=CC([C@H](C5CC5)[C@H](C)C(O[H])=O)=N4)=C(F)C=C1,=,0.454,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C([C@@H](C)[C@@H](C1CC1)C(C=C2)=CC3=C2OC[C@@H](C4=CC=C(C5=C(F)C=CC(OC)=C5)N=C4C(F)(F)F)O3)O[H],=,0.0082,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C([C@@H](C)[C@@H](C1CC1)C(C=C2)=CC3=C2OC[C@@H](C4=CC(C(C(C)(C)C)OC)=C(C5=C(F)C=CC(OC)=C5)C=C4)O3)O[H],=,0.0021,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C([C@@H](C)[C@@H](C1CC1)C(C=C2)=CC3=C2OC[C@@H](C4=NC(C(F)(F)F)=C(C5=C(F)C=CC(OC)=C5)C=C4)O3)O[H],=,0.0082,¦ÌM
,Preparation of biphenylchromane derivatives and analogs for use as GPR40 agonists,WO2014130608,Patent,HEK,Inositol phophate turnover assay,EC50,O=C([C@@H](C)[C@@H](C1CC1)C(C=C2)=C(F)C3=C2OCC(C4=NC=C(C5=C(F)C=CC(OC)=C5)C=C4)O3)O[H],=,0.0026,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(OC)C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=CC6=C(C=C5)C(C)=NO6)=CC=C4F,=,0.004,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(O[C@H](CC3)C4=C3C(OC5=CC(OC)=CC=C5)=CC=C4F)C=C2OC1,=,0.006,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(O[C@H](CC3)C4=C3C(OC5=CC=C(OC)C=C5)=CC=C4F)C=C2OC1,=,0.003,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(O[C@H](CC3)C4=C3C(OC5=C(C)C=CC=C5)=CC=C4F)C=C2OC1,=,0.006,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(O[C@H](CC3)C4=C3C(OC5=C(C)C=CC=C5C)=CC=C4F)C=C2OC1,=,0.07,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(O[C@H](CC3)C4=C3C(OC5=CN=CC=C5)=CC=C4F)C=C2OC1,=,0.033,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(O[C@@H]3CCC4=C3C(F)=CC=C4OC5=NC=CC=C5)C=C2OC1,=,0.032,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=CC=C(C#N)C=C5)=CC=C4F,=,0.004,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(O[C@H](CC3)C4=C3C(OC5=NC(C)=NC=C5)=CC=C4F)C=C2OC1,=,0.155,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C(C(OC1)=C2)=CC=C2O[C@H](CC3)C4=C3C(OC5=NC=CN=C5)=CC=C4F,=,0.035,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=CC=NC=C5)=CC=C4F,=,0.018,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=NC6=C(S5)C=CC=C6)=CC=C4F,=,0.012,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@@H]1COC2=CC(O[C@H](CC3)C4=C3C(OC5=NC6=C(N5C)C=CC=C6)=CC=C4F)=CC=C12,=,0.216,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H]3C4=C(CC3)C(OC(N=C5)=CC=C5C(F)(F)F)=CC=C4F,=,0.026,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,CC1=NC(OC(C2=C3[C@H](OC(C=C4OC5)=CC=C4[C@@H]5CC(O[H])=O)CC2)=CC=C3F)=CC=C1,=,0.031,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=CC=C(OC)N=N5)=CC=C4F,=,0.138,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=CC=CC=C5C#N)=CC=C4F,=,0.004,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@@H]1COC2=CC(O[C@H](CC3)C4=C3C(OC5=CC=C(S(C)(=O)=O)C=C5)=CC=C4F)=CC=C12,=,0.041,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=NC6=C(O5)C=CC=C6)=CC=C4F,=,0.013,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(O[C@@H]3CCC4=C3C(F)=CC=C4OC(C=C5)=CC6=C5N=CC=C6)C=C2OC1,=,0.006,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=CC=C(C(C)=C5)C#N)=CC=C4F,=,0.004,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC(C=C5)=C(F)C=C5C#N)=CC=C4F,=,0.003,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=C(C#N)C=C(C)C=C5)=CC=C4F,=,0.007,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H]3C4=C(C(OC(C=C5)=C(C)C=C5C#N)=CC=C4F)CC3,=,0.003,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@@H]1COC2=CC(O[C@H](CC3)C4=C3C(OC5=CC=C(OC(F)F)C=N5)=CC=C4F)=CC=C12,=,0.013,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,N#CC(C=C(OC(F)(F)F)C=C1)=C1OC(C(CC2)=C3[C@@H]2OC(C=C4OC5)=CC=C4[C@@H]5CC(O[H])=O)=CC=C3F,=,0.03,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@@H]1COC2=CC(O[C@H]3C4=C(CC3)C(OC5=CC(C#N)=CC=C5)=CC=C4F)=CC=C12,=,0.007,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(O[C@H](CC3)C4=C3C(OC5=CC(F)=C(CO[H])C=C5)=CC=C4F)C=C2OC1,=,0.008,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=CC=C(C#N)C(F)=C5)=CC=C4F,=,0.006,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)C[C@H](CC3)C4=C3C(OC5=C(C#N)C=CC(F)=C5)=CC=C4F,=,0.011,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=CN=C(N(C)C)C=C5)=CC=C4F,=,0.12,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,FC(F)(F)C1=NC=CC(OC(C(CC2)=C3[C@@H]2OC(C=C4OC5)=CC=C4[C@@H]5CC(O[H])=O)=CC=C3F)=C1,=,0.006,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,FC1=CC=C(OC2=NC=C(F)C=N2)C(CC3)=C1[C@@H]3OC(C=C4OC5)=CC=C4[C@@H]5CC(O[H])=O,=,0.031,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,FC1=CC=C(OC2=CC=C(OC)N=C2)C(CC3)=C1[C@@H]3OC(C=C4OC5)=CC=C4[C@@H]5CC(O[H])=O,=,0.005,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,FC1=CC=C(OC2=CN=C(OC)N=C2)C(CC3)=C1[C@@H]3OC(C=C4OC5)=CC=C4[C@@H]5CC(O[H])=O,=,0.079,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(O[C@H](CC3)C4=C3C(OC5=CC(OC)=NC=C5)=CC=C4F)C=C2OC1,=,0.004,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(O[C@H](CC3)C4=C3C(OC5=CC(OC)=C(C#N)C=C5)=CC=C4F)C=C2OC1,=,0.005,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(O[C@H](CC3)C4=C3C(OC5=CC6=C(N(C)C=C6)C=C5)=CC=C4F)C=C2OC1,=,0.006,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=C6C(C=CC=N6)=CC=C5)=CC=C4F,=,0.021,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=NC6=CC=CC=C6C=C5)=CC=C4F,=,0.022,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=CC=C(C#N)C=C5C#N)=CC=C4F,=,0.017,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(O[C@H](CC3)C4=C3C(OC5=CC6=C(N(C)C=N6)C=C5)=CC=C4F)C=C2OC1,=,0.891,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C(C(OC1)=C2)=CC=C2O[C@H](CC3)C4=C3C(OC5=NC6=CC=CC=C6C=N5)=CC=C4F,=,0.034,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C(C(OC1)=C2)=CC=C2O[C@H](CC3)C4=C3C(OC5=NC=C(OC)C=C5)=CC=C4F,=,0.019,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=CC6=C(N(C)N=C6)C=C5)=CC=C4F,=,0.007,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=CC6=C(C=NN6C)C=C5)=CC=C4F,=,0.003,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=CC6=C(N(C)N=C6)C=C5C)=CC=C4F,=,0.026,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=CC6=C(SC(C)=N6)C=C5)=CC=C4F,=,0.007,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=CC(C)=C(C#N)C(C)=C5)=CC=C4F,=,0.012,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=C(C#N)C=CC(Br)=C5)=CC=C4F,=,0.006,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=C(F)C=C(C#N)C=C5F)=CC=C4F,=,0.018,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=C(OC)C=C(C#N)C=C5)=CC=C4F,=,0.006,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=C(C)C6=C(N(C)N=C6)C=C5)=CC=C4F,=,0.069,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=C(F)C=CC(C#N)=C5)=CC=C4F,=,0.029,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=CC(N=C(C)O6)=C6C=C5)=CC=C4F,=,0.006,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=C(F)C=C(OC)C=C5)=CC=C4F,=,0.006,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=CC(F)=C(OC)C(F)=C5)=CC=C4F,=,0.007,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=CC6=C(N=C(C)O6)C=C5)=CC=C4F,=,0.003,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=CC6=C(N=C(C)S6)C=C5)=CC=C4F,=,0.005,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=CC6=C(ON=C6C)C=C5)=CC=C4F,=,0.003,¦ÌM
,Preparation of indanyloxydihydrobenzofuranylacetic acids as modulators of GPR40 receptor for treating metabolic diseases,US2014148462,Patent,1321N1,IP1 accumulation measurement,EC50,O=C(O[H])C[C@H]1C2=CC=C(C=C2OC1)O[C@H](CC3)C4=C3C(OC5=CC6=C(C(C)=NO6)C=C5)=CC=C4F,=,0.003,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@@H]2CC3=CC(OCC4=CC=CC(C5=C(C)C=C(CC6(C)COC6)C=C5C)=C4)=NC=C3[C@@H]21)O[H],=,0.043,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@@H]2CC3=CC(OCC4=C(F)C=CC(C5=C(C)C=C(OCC6(C)COC6)C=C5C)=C4)=NC=C3[C@@H]21)O[H],=,0.027,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@@H]2CC3=CC(OCC4=CC=CC(C5=C(C)C=C(OCCC6(CC6)O[H])C=C5C)=C4)=NC=C3[C@@H]21)O[H],=,0.027,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@@H]2CC3=CC(OCC4=C(F)C=CC(C5=C(C)C=C(OCCC6(CC6)O[H])C=C5C)=C4)=NC=C3[C@@H]21)O[H],=,0.03,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@@H]2CC3=CC(OCC4=CC=CC(C5=C(C)C=C(OCCC(O[H])(C)C)C=C5C)=C4)=NC=C3[C@@H]21)O[H],=,0.022,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@@H]2CC3=CC(OCC4=C(F)C=CC(C5=C(C)C=C(OCCC(O[H])(C)C)C=C5C)=C4)=NC=C3[C@@H]21)O[H],=,0.021,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@@H]2CC3=CC(OCC4=C(F)C=CC(C5=C(C(F)(F)F)C=C(OCCC(O[H])(C)C)C=C5)=C4)=NC=C3[C@@H]21)O[H],=,0.015,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@@H]2CC3=CC(OCC4=CC=CC(C5=C(C(F)(F)F)C=C(OCCC(O[H])(C)C)C=C5)=C4)=NC=C3[C@@H]21)O[H],=,0.014,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@@H]2CC3=CC(OCC4=C(F)C=CC(C5=C(C)C=C(OC[C@@H](O[H])C)C=C5C)=C4)=NC=C3[C@@H]21)O[H],=,0.04,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@@H]2CC3=CC(OCC4=CC=CC(C5=CC=C(OCCC(C)(O[H])C)N=C5C)=C4)=NC=C3[C@@H]21)O[H],=,0.042,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1C2C1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=CC=C(OCCC(O[H])(C)C)N=C5C)=C4)O[H],=,0.065,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=CC=C(OCCC(C)(O[H])C)N=C5C)=C4)O[H],=,0.015,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=CC=C(OCCCC(O[H])(C)C)N=C5C)=C4)O[H],=,0.023,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=CC=C(OCCOCC(C)(C)O[H])N=C5C)=C4)O[H],=,0.035,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(C(F)(F)F)C=C(OCCC6(CC6)O[H])C=C5)=C4)O[H],=,0.026,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC=CC(C5=C(C(F)(F)F)C=C(OCCC6(CC6)O[H])C=C5)=C4)O[H],=,0.041,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(C)C=C(OCC6(F)CCOCC6)C=C5C)=C4)O[H],=,0.019,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC=CC(C5=C(C)C=C(OCC6(F)CCOCC6)C=C5C)=C4)O[H],=,0.023,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(C(F)(F)F)C=C(OCCCS(C)(=O)=O)C=C5F)=C4)O[H],=,0.018,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC=CC(C5=C(C)C=C(OCCCS(C)(=O)=O)C=C5C)=C4)O[H],=,0.042,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@@H]1[C@@H]2[C@H]1C(C(C2)=C3)=CN=C3OCC4=CC=CC(C5=C(C)C=C(OCCCS(C)(=O)=O)C=C5C)=C4)O[H],=,0.078,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(C)C=C(OCCCS(C)(=O)=O)C=C5C)=C4)O[H],=,0.025,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C(C1C2C1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(C(F)(F)F)C=C(OCCCS(C)(=O)=O)C=C5)=C4)O[H],=,0.043,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(C(F)(F)F)C=C(OCCCS(C)(=O)=O)C=C5)=C4)O[H],=,0.019,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=CC(CCCCS(C)(=O)=O)=CC=C5OC(F)(F)F)=C4)O[H],=,0.034,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C(C1C2C1C(C(C2)=C3)=CN=C3OCC4=CC=CC(C5=C(C)C(I)=C(OCCCS(=O)(C)=O)C=C5C)=C4)O[H],=,0.064,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC=C(C)C(C5=CC(OC)=NC=C5)=C4)O[H],=,0.017,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC(C(F)(F)F)=CC(C5=CC=C(OCCCS(C)(=O)=O)N=C5C)=C4)O[H],=,0.027,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=C(F)C(C5=C(C)C=C(OCCCS(C)(=O)=O)C=C5C)=C4)O[H],=,0.026,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC=C(C(F)(F)F)C(C5=CC=C(OCCCS(C)(=O)=O)N=C5C)=C4)O[H],=,0.036,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC=CC(C5=C(C(F)(F)F)C=C(OCC(O[H])(C)C)N=C5)=C4)O[H],=,0.078,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(C(F)(F)F)C=C(OCC(O[H])(C)C)N=C5)=C4)O[H],=,0.059,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(C)C=C(OCC(O[H])CO[H])C=C5C)=C4)O[H],=,0.032,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(C)C=C(OCC(O[H])(C)CO[H])C=C5C)=C4)O[H],=,0.046,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC=CC(C5=C(C)C=C(OCC6CC(F)(F)C6)C=C5C)=C4)O[H],=,0.02,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(C)C=C(OCCC6CC(F)(F)C6)C=C5C)=C4)O[H],=,0.019,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC=CC(C5=C(C)C=C(OCCC6CC(F)(F)C6)C=C5C)=C4)O[H],=,0.015,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC=CC(C5=C(C)C=C(OCCC/C(C)=N/OC)C=C5C)=C4)O[H],=,0.013,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC=CC(C5=CC=C(OCCC/C(C)=N/OC)C=C5C)=C4)O[H],=,0.013,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC=CC(C5=C(C)C=C(OCCCN6CC(F)(F)C6)C=C5C)=C4)O[H],=,0.016,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(C)C=C(CCC(C)(C)O[H])C=C5C)=C4)O[H],=,0.02,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(C)C=C(CCCCS(=O)(C)=O)C=C5C)=C4)O[H],=,0.16,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(C)C=C(CCCC(C)(C)O[H])C=C5C)=C4)O[H],=,0.036,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C(C1C2C1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(C(F)(F)F)C=C(OCCC(C)(C)O[H])N=C5)=C4)O[H],=,0.076,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC=CC(C5=C(C(F)(F)F)C=C(OCCC(C)(C)O[H])N=C5)=C4)O[H],=,0.019,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(C(F)(F)F)C=C(OCCC(C)(C)O[H])N=C5)=C4)O[H],=,0.023,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=CC=C(OC6CCC(C(C)(C)O[H])CC6)N=C5C)=C4)O[H],=,0.099,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=CN=C(OCCCC(C)(C)O[H])C=C5C(F)(F)F)=C4)O[H],=,0.011,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC=CC(C5=CN=C(OCCCC(C)(C)O[H])C=C5C(F)(F)F)=C4)O[H],=,0.015,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(C)C=CC=C5C)=C4)O[H],=,0.049,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C(C1C2C1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=CC=CC=C5C(F)(F)F)=C4)O[H],=,0.036,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C(C1C2C1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=CC=C(C(F)(F)F)C=C5)=C4)O[H],=,0.054,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C(C1C2C1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=CC=CC(C(F)(F)F)=C5)=C4)O[H],=,0.047,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C(C1C2C1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(F)C=CC=C5C(F)(F)F)=C4)O[H],=,0.087,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C(C1C2C1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=CC(Cl)=CC(C(F)(F)F)=C5)=C4)O[H],=,0.067,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C(C1C2C1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(C(F)(F)F)N=CC=C5)=C4)O[H],=,0.048,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C(C1C2C1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(C(F)(F)F)C=CC=N5)=C4)O[H],=,0.095,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(C)C=C(OCCCS(=O)(C)=O)N=C5)=C4)O[H],=,0.026,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C(C1C2C1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=CC=C(OC(CC6)CCS6(=O)=O)N=C5C)=C4)O[H],=,0.097,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=CC=C(OCCCS(C)(=O)=O)N=C5C)=C4)O[H],=,0.046,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=CC=CC(C5=C(C)C=C(OCCCS(C)(=O)=O)N=C5C)=C4)O[H],=,0.05,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(C)C=C(OCCCS(C)(=O)=O)N=C5C)=C4)O[H],=,0.035,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C(C1C2C1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(C)N=C(OCCCS(C)(=O)=O)N=C5C)=C4)O[H],=,0.077,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C(C1C2C1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C(S5)=C(C)N=C5OCCCS(C)(=O)=O)=C4)O[H],=,0.018,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C(C1C2C1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(C)N=C(OCCCN6C(CCC6)=O)C=C5)=C4)O[H],=,0.038,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=C(OC(F)F)C=C(OCCCS(C)(=O)=O)N=C5)=C4)O[H],=,0.058,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C(C1C2C1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(C5=CC=C(OCC(F)(F)C(F)(F)F)N=C5C)=C4)O[H],=,0.01,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C1C2C1CC3=CC(N([H])CC4=C(C=CC(C5=CC=C(N=C5C)OCCCS(=O)(C)=O)=C4)F)=NC=C23,=,0.096,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(OC5=CC=CC=C5C(F)(F)F)=C4)O[H],=,0.035,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(OC5=CC=CC=C5)=C4)O[H],=,0.034,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@H]1[C@H]2[C@@H]1C(C(C2)=C3)=CN=C3OCC4=C(F)C=CC(OC5=CC=C(C(F)(F)F)C=C5Cl)=C4)O[H],=,0.049,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C(C1C2C1CC3=CC(OCC4=C(F)C=CC(C5=C(C)C=CC=C5C)=N4)=NC=C23)O[H],=,0.042,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C(C1C2C1CC3=CC(OCC4=C(F)C=NC(C5=C(C)C=CC=C5C)=C4)=NC=C23)O[H],=,0.028,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@@H]1[C@@H]2[C@H]1CC3=CC(OCC4=NC(C5=C(C(F)(F)F)C=C(OCCCS(C)(=O)=O)C=C5)=CC=C4F)=NC=C23)O[H],=,0.07,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@@H]1[C@@H]2[C@H]1CC3=CC(OCC4=NC(C5=CC=C(N6CCN(S(C)(=O)=O)CC6)N=C5C)=CC=C4F)=NC=C23)O[H],=,0.09,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@@H]1[C@@H]2[C@H]1CC3=CC(OCC4=C(C)C(C5=C(C)C=CC=C5C)=CC=C4)=NC=C23)O[H],=,0.0081,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C(C1C2C1CC3=CC(OCC4=C(C)C(C5=C(C(F)(F)F)C=CC=C5)=CC=C4)=NC=C23)O[H],=,0.03,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@@H]1[C@@H]2[C@H]1CC3=CC(OCC4=CC(C5=C(C)C=C(OCCCC(C)(C)C#N)C=C5C)=CC=C4)=NC=C23)O[H],=,0.024,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@@H]1[C@@H]2[C@H]1CC3=CC(OCC4=CC(C5=C(C)C=C(OCCCC6(CC6)C#N)C=C5C)=CC=C4)=NC=C23)O[H],=,0.04,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@@H]1[C@@H]2[C@H]1CC3=CC(OCC4=CC(C5=C(C)C=C(O[C@]6([H])C[C@@](C#N)(C)C6)C=C5C)=CC=C4)=NC=C23)O[H],=,0.054,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@@H]1[C@@H]2[C@H]1CC3=CC(OC(C)C4=CC(C5=C(C)C=C(OCCCS(C)(=O)=O)C=C5C)=CC=C4F)=NC=C23)O[H],=,0.045,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@@H]1[C@@H]2[C@H]1CC3=CC(OCC4=CC(C5=C(C)N=C(N6CC(CS(=O)(C)=O)C6)C=C5)=CC=C4F)=NC=C23)O[H],=,0.051,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C(C1C2C1CC3=CC(OCC4=CC(C5=C(C)N=C(N6CCC(CS(C)(=O)=O)C6)C=C5)=CC=C4F)=NC=C32)O[H],=,0.076,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C(C1C2C1CC3=CC(OCC4=CC(C5=C(C)N=C(N6CCOCC6)N=C5C)=CC=C4F)=NC=C32)O[H],=,0.086,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C(C1C2C1CC3=CC(OCC4=CC(C5=C(C)N=C(N6CCC7(C=CC8=CC=CC=C78)CC6)N=C5C)=CC=C4F)=NC=C32)O[H],=,0.045,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C(C1C2C1CC3=CC(OCC4=CC(C5=CC=C(N6CC(NS(C)(=O)=O)CC6)N=C5C)=CC=C4F)=NC=C32)O[H],=,0.044,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,O=C([C@@H]1[C@@H]2[C@H]1CC3=CC(OCC4=CC(C5=CC=C(N6CCN(S(C)(=O)=O)CC6)N=C5C)=CC=C4F)=NC=C32)O[H],=,0.069,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,FC(F)(F)C1=NC(C=CC(F)=C2F)=C2N1C(C=CC=C3COC4=NC=C5C(C[C@H]6[C@H](C(O[H])=O)[C@@H]56)=C4)=C3C,=,0.034,¦ÌM
,Preparation of tricyclic compounds as GPR40 agonists for use in treating diabetes and associated conditions,WO2014022528,Patent,CHO,Calcium flux assay,EC50,CC1=C(C=CC=C1COC2=NC=C3C(C[C@H]4[C@H](C(O[H])=O)[C@@H]34)=C2)N5C(CC)=NC6=C5C(F)=C(F)C=C6,=,0.03,¦ÌM
,"Derivatives of(S)-2-(2,3-dihydrobenzofur-3-yl)acetic acid as GPR40O/FFAR1 receptor agonists and their preparation, pharmaceutical compositions and use in the treatment of diabetes mellitus",CN103145663,Patent,HEK293,Calcium flux assay,EC50,O=C(C[C@H]1C2=CC=C(C=C2OC1)OCC3=CC(C(C(C)=C4)=C(C)C=C4CN([H])CCS(C)(=O)=O)=CC=C3)O[H],=,0.302,¦ÌM
,"Derivatives of(S)-2-(2,3-dihydrobenzofur-3-yl)acetic acid as GPR40O/FFAR1 receptor agonists and their preparation, pharmaceutical compositions and use in the treatment of diabetes mellitus",CN103145663,Patent,HEK293,Calcium flux assay,EC50,O=C(C[C@H]1C2=C(F)C=C(C=C2OC1)OCC3=CC(C(C(C)=C4)=C(C)C=C4OCCCS(C)(=O)=O)=CC=C3)O[H],=,1.484,¦ÌM
,"Derivatives of(S)-2-(2,3-dihydrobenzofur-3-yl)acetic acid as GPR40O/FFAR1 receptor agonists and their preparation, pharmaceutical compositions and use in the treatment of diabetes mellitus",CN103145663,Patent,HEK293,Calcium flux assay,EC50,O=C(C[C@H]1C2=CC=C(C=C2OC1)OCC3=CC(C(C(C)=C4)=C(C)C=C4CCCCS(C)(=O)=O)=CC=C3)O[H],=,0.3485,¦ÌM
,"Derivatives of(S)-2-(2,3-dihydrobenzofur-3-yl)acetic acid as GPR40O/FFAR1 receptor agonists and their preparation, pharmaceutical compositions and use in the treatment of diabetes mellitus",CN103145663,Patent,HEK293,Calcium flux assay,EC50,O=C(C[C@H]1C2=CC=C(C=C2OC1)O[C@@H](C)C3=CC(C(C(C)=C4)=C(C)C=C4OCCCS(C)(=O)=O)=CC=C3)O[H],=,1.38,¦ÌM
,"Derivatives of(S)-2-(2,3-dihydrobenzofur-3-yl)acetic acid as GPR40O/FFAR1 receptor agonists and their preparation, pharmaceutical compositions and use in the treatment of diabetes mellitus",CN103145663,Patent,HEK293,Calcium flux assay,EC50,O=C(C[C@H]1C2=CC=C(C=C2OC1)O[C@H](C)C3=CC(C(C(C)=C4)=C(C)C=C4OCCCS(C)(=O)=O)=CC=C3)O[H],=,0.4099,¦ÌM
,"Derivatives of(S)-2-(2,3-dihydrobenzofur-3-yl)acetic acid as GPR40O/FFAR1 receptor agonists and their preparation, pharmaceutical compositions and use in the treatment of diabetes mellitus",CN103145663,Patent,HEK293,Calcium flux assay,EC50,CC(C=C1OCCN2CCOCC2)=C(C(C)=C1)C3=CC=CC(COC4=CC=C5[C@H](CC(O[H])=O)COC5=C4)=C3,=,0.2408,¦ÌM
,"Derivatives of(S)-2-(2,3-dihydrobenzofur-3-yl)acetic acid as GPR40O/FFAR1 receptor agonists and their preparation, pharmaceutical compositions and use in the treatment of diabetes mellitus",CN103145663,Patent,HEK293,Calcium flux assay,EC50,O=C(C[C@H]1C2=CC=C(C=C2OC1)OCC3=CC(C(C(C)=C4)=C(C)C=C4COCCS(C)(=O)=O)=CC=C3)O[H],=,0.1517,¦ÌM
,"Derivatives of(S)-2-(2,3-dihydrobenzofur-3-yl)acetic acid as GPR40O/FFAR1 receptor agonists and their preparation, pharmaceutical compositions and use in the treatment of diabetes mellitus",CN103145663,Patent,HEK293,Calcium flux assay,EC50,O=C(C[C@H]1C2=CC=C(C=C2OC1)OCC3=CC(C(C(C)=C4)=C(C)C=C4OCCCN5CCOCC5)=CC=C3)O[H],=,0.3399,¦ÌM
,"Derivatives of(S)-2-(2,3-dihydrobenzofur-3-yl)acetic acid as GPR40O/FFAR1 receptor agonists and their preparation, pharmaceutical compositions and use in the treatment of diabetes mellitus",CN103145663,Patent,HEK293,Calcium flux assay,EC50,CC(C=C1CN(C)CCS(=O)(C)=O)=C(C(C)=C1)C2=CC=CC(COC(C=C3OC4)=CC=C3[C@@H]4CC(O[H])=O)=C2,=,0.5408,¦ÌM
,"Derivatives of(S)-2-(2,3-dihydrobenzofur-3-yl)acetic acid as GPR40O/FFAR1 receptor agonists and their preparation, pharmaceutical compositions and use in the treatment of diabetes mellitus",CN103145663,Patent,HEK293,Calcium flux assay,EC50,CC(C=C1NCCCS(=O)(C)=O)=C(C(C)=C1)C2=CC=CC(COC(C=C3OC4)=CC=C3[C@@H]4CC(O[H])=O)=C2,=,0.6224,¦ÌM
,"Derivatives of(S)-2-(2,3-dihydrobenzofur-3-yl)acetic acid as GPR40O/FFAR1 receptor agonists and their preparation, pharmaceutical compositions and use in the treatment of diabetes mellitus",CN103145663,Patent,HEK293,Calcium flux assay,EC50,CC(C=C1NCCCS(=O)(C)=O)=C(C(C)=C1)C2=CC=CC(COC(C=C3OC4)=CC(F)=C3[C@@H]4CC(O[H])=O)=C2,=,0.4412,¦ÌM
,"Derivatives of(S)-2-(2,3-dihydrobenzofur-3-yl)acetic acid as GPR40O/FFAR1 receptor agonists and their preparation, pharmaceutical compositions and use in the treatment of diabetes mellitus",CN103145663,Patent,HEK293,Calcium flux assay,EC50,CC(C=C1OCCCS(=O)(C)=O)=C(C(C)=C1)C2=CC=CC(NCC(C=C3OC4)=CC=C3[C@@H]4CC(O[H])=O)=C2,=,0.4646,¦ÌM
,"Derivatives of(S)-2-(2,3-dihydrobenzofur-3-yl)acetic acid as GPR40O/FFAR1 receptor agonists and their preparation, pharmaceutical compositions and use in the treatment of diabetes mellitus",CN103145663,Patent,HEK293,Calcium flux assay,EC50,CC(C=C1OCCCS(=O)(C)=O)=C(C(C)=C1)C2=CC=CC(OCC(C=C3OC4)=CC=C3[C@@H]4CC(O[H])=O)=C2,=,0.4066,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)O[C@@H]3C4=CC(C(C(C)=CC(OCCCS(=O)(C)=O)=C5)=C5C)=CC=C4,=,0.054,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)O[C@H]3C4=CC(C(C(C)=CC(OCCCS(=O)(C)=O)=C5)=C5C)=CC=C4,=,0.156,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)OC3C4=CC(Br)=CC=C4,=,0.054,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)OC3C4=CC(C5CC5)=CC=C4,=,0.036,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)OC3C4=CC(C5=C(C)C=C(C)C=C5C)=CC=C4,=,0.061,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)OC3C4=CC(C5=C(C)C=CC=C5C)=CC=C4,=,0.025,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)O[C@@H]3C4=CC(C5=C(C)C=CC=C5C)=CC=C4,=,0.052,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)O[C@@H]3C4=CC(C5=C(C)C=CC=C5)=CC=C4,=,0.039,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)O[C@H]3C4=CC(C5=C(C)C=CC=C5C)=CC=C4,=,0.03,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)O[C@H]3C4=CC(C5=C(C)C=CC=C5)=CC=C4,=,0.019,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C(C(OC1)=C2)=CC(OC3)=C2OC3C4=CC(C(C=CC(OCCCS(=O)(C)=O)=C5)=C5C)=CC=C4,=,0.122,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C(C(OC1)=C2)=CC(OC3)=C2OC3C4=CC(C(C=CC(OCCCS(=O)(C)=O)=C5)=C5Cl)=CC=C4,=,0.064,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])CCC1=CC(OC2)=C(C=C1)OC2C3=CC(C(C(C)=CC(OCCCS(=O)(C)=O)=C4)=C4C)=CC=C3,=,0.071,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])CCC1=CC(OC2)=C(C=C1)O[C@@H]2C3=CC(C(C(C)=CC(OCCCS(=O)(C)=O)=C4)=C4C)=CC=C3,=,0.045,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])CCC1=CC(OC2)=C(C=C1)O[C@H]2C3=CC(C(C(C)=CC(OCCCS(=O)(C)=O)=C4)=C4C)=CC=C3,=,0.062,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])CCC1=CC(OC2)=C(C=C1F)OC2C3=CC(C(C(C)=CC(OCCCS(=O)(C)=O)=C4)=C4C)=CC=C3,=,0.08,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])CC(C#CC)C1=CC(OC[C@H](C2=CC(C(C(C)=CC(OCCCS(=O)(C)=O)=C3)=C3C)=CC=C2)O4)=C4C=C1,=,0.116,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@@H](C#CC)C1=CC(OC[C@H](C2=CC(C(C(C)=CC(OCCCS(=O)(C)=O)=C3)=C3C)=CC=C2)O4)=C4C=C1,=,0.064,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,FC1=CC2=C(OC[C@@H](C3=CC(C(C(C)=CC(OCCCS(=O)(C)=O)=C4)=C4C)=CC=C3)O2)C=C1CCC(O[H])=O,=,0.035,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,FC1=CC2=C(OC[C@H](C3=CC(C(C(C)=CC(OCCCS(=O)(C)=O)=C4)=C4C)=CC=C3)O2)C=C1CCC(O[H])=O,=,0.099,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(C(C1)C1C2=CC3=C(C=C2)OC(C4=CC(C5=CC=CC=C5C)=CC=C4)CO3)O[H],=,0.035,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)OC(C4=CC(Br)=CC(F)=C4)CO3,=,0.047,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC[C@H]3C4=CC(Br)=CC=C4)=C(O3)C=C2OC1,=,0.32,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)OC3C4=CC(C5=C(C)ON=C5C)=CC=C4,=,0.089,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)OC3C4=CC(C5=CC=CC=C5Cl)=CC=C4,=,0.031,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OCC(C3=CC(C(F)(F)F)=CC=C3)O4)=C4C=C2OC1,=,0.044,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)OC(C4=CC(Cl)=CC=C4)CO3,=,0.037,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OCC3C4=CC(C(C(Cl)=C5)=CC=C5F)=CC=C4)=C(O3)C=C2OC1,=,0.074,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)OC3C4=CC(C5=C(F)C=CC=C5)=CC=C4,=,0.073,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1COC2=CC(O3)=C(OCC3C4=CC(C5=CC=CC=C5C(F)(F)F)=CC=C4)C=C12,=,0.074,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OCC(C3=CC(C4=CN=CC=C4C)=CC=C3)O5)=C5C=C2OC1,=,0.136,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)OC(C4=CC(Cl)=C(C=C4)Cl)CO3,=,0.036,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)O[C@@H]3C4=CC=CC(C(F)(F)F)=C4,=,0.011,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)O[C@H]3C4=CC=CC(C(F)(F)F)=C4,=,0.03,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC(OC3)=C(C=C2OC1)O[C@H]3C4=CC=CC(Cl)=C4,=,0.023,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)O[C@H](C4=CC=C(Cl)C(Cl)=C4)CO3,=,0.015,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,[H]OC(CC(C#CC)C1=CC2=C(C=C1)O[C@H](C3=CC(C)=CC(C4=C(C)C=C(CCCCS(C)(=O)=O)C=C4C)=C3)CO2)=O,=,0.128,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,ClC1=C(C=CC(OCCCS(C)(=O)=O)=C1)C2=CC([C@H]3OC4=C(OC3)C=C5C(OC[C@H]5CC(O[H])=O)=C4)=CC=C2,=,0.094,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,CS(CCCOC1=CC(C)=C(C(C)=C1F)C2=CC(C3OC4=C(OC3)C=C5C(OC[C@H]5CC(O[H])=O)=C4)=CC=C2)(=O)=O,=,0.056,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,CS(CCCOC1=CC(C)=C(C(C)=C1)C2=CC([C@H]3OC4=C(OC3)C=C5C(OC[C@H]5CC(O[H])=O)=C4)=C(F)C=C2)(=O)=O,=,0.046,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,CS(CCCOC1=CC(C)=C(C(C)=C1F)C2=CC([C@H]3OC4=C(OC3)C=C5C(OC[C@H]5CC(O[H])=O)=C4)=CC=C2)(=O)=O,=,0.12,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)O[C@H](C4=CC=CC(C5=C(Cl)C=CC=C5)=C4)CO3,=,0.066,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)O[C@@H](C4=CC=CC(C5=C(Cl)C=CC=C5)=C4)CO3,=,0.056,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@@H]1C2=CC3=C(C=C2OC1)OC(C4=CC=CC(Br)=C4)CO3,=,0.062,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)O[C@@H](C4=CC(F)=CC=C4)CO3,=,0.1,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)O[C@@H](C4=CC=C(C(C)(C)CCC5(C)C)C5=C4)CO3,=,0.101,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)O[C@@H](C4=CC=CC(C5=C(C)C=C(F)C=C5)=C4)CO3,=,0.033,¦ÌM
,Preparation of benzodioxane derivatives as GPR40 agonists for treating diabetes and metabolic diseases,CN103030646,Patent,CHO,Calcium flux assay,EC50,O=C(O[H])C[C@H]1C2=CC3=C(C=C2OC1)OC(C4=CC=CC(C5=C(Cl)C=CC=C5)=C4C)CO3,=,0.125,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,O=C(CCC(C=C1)=CC=C1OCC2=CC(/C(C3=CC=CC=C3)=N\OC)=CC=C2)O[H],<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,O=C(CCC(C=C1)=CC=C1NCC2=CC(/C(C3=CC=CC=C3)=N\OC)=CC=C2)O[H],<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,O=C(O[H])CCC1=CC=C(N([H])CC2=CC=C(C=C2)OC/C(C3=CC=CC=C3)=N\OC)C=C1,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,CO/N=C(COC1=CC=C(CN([H])C2=CC=C(C=C2)CCC(O[H])=O)C=C1)/C3=CC=CC=C3C,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,O=C(O[H])CCC(C=C1)=CC=C1OCC(C=C2)=CC=C2OC/C(C3=CC=CC=C3)=N\OC,<,0.01,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,O=C(O[H])[C@H]1[C@H](C2=CC=C(C=C2)N([H])CC3=CC(/C(C4=CC=CC=C4)=N/OC)=CC=C3)C1,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,CO/N=C(COC1=CC=C(CN([H])C(C=C2)=CC=C2[C@H]3[C@H](C(O[H])=O)C3)C=C1)\C4=CC=CC=C4,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,CC(C=CC=C1)=C1/C(COC(C=C2)=CC=C2CN([H])C(C=C3)=CC=C3[C@H]4[C@H](C(O[H])=O)C4)=N/OC,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,N#CC(CC(O[H])=O)C1=CC=C(C=C1)OCC2=CC=C(C=C2)OC/C(C3=CC=CC=C3)=N\OC,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,O=C(O[H])CC(C1=CC=C(OCC2=CC=C(C=C2)OC/C(C3=CC=CC=C3)=N\OC)C=C1)C4=NOC=C4,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,N#CC(C1=CC=C(OCC(C=C2)=CC(F)=C2OC/C(C3=CC=CC=C3)=N\OC)C=C1)CC(O[H])=O,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,N#CC(CC(O[H])=O)C1=CC=C(C=C1)OCC(C=C2)=CC=C2OC/C(C3=CC=C(F)C=C3)=N\OC,<,0.01,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,O=C(CC(C#N)C1=CC=C(OCC2=C(F)C=C(C=C2)OC/C(C3=CC=CC=C3)=N\OC)C=C1)O[H],<,0.01,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,CC1=CC(/C(COC2=CC=C(C=C2)COC(C=C3)=CC=C3C(C4=NOC=C4)CC(O[H])=O)=N/OC)=CC=C1,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,O=C(CC(C#N)C1=CC=C(OCC2=CC=C(C=C2)OC/C(C3=CC=C(C=C3)OC)=N\OC)C=C1)O[H],<,0.01,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,O=C(O[H])CC(C#N)C1=CC=C(C=C1)OCC2=CC(OC)=C(C=C2)OC/C(C3=CC=CC=C3)=N\OC,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,CC1=CC(/C(COC2=CC=C(C=C2)COC(C=C3)=CC=C3C(C#N)CC(O[H])=O)=N/OC)=CC=C1,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,N#CC(C=C1)=CC=C1/C(COC(C=C2)=CC=C2COC3=CC=C(CCC(O[H])=O)C=C3)=N/OC,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,O=C(O[H])CC(C#N)C1=CC=C(C=C1)OCC2=CC=C(C=C2)OC/C(C3=CC=C(C#N)C=C3)=N\OC,<,0.01,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,O=C(O[H])CC(C#N)C1=CC=C(C=C1)OCC2=CC=C(C=C2)OC/C(C3=CC=C(F)C=C3)=N\OC,<,0.01,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,O=C(O[H])CC(C#N)C1=CC=C(C=C1)OCC2=CC=C(C=C2)OC/C(C3=CC=CC(F)=C3)=N\OC,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,FC(C=C(OCC1=CC=C(C=C1)OC/C(C2=CC=CC=C2)=N\OC)C=C3)=C3CCC(O[H])=O,<,0.01,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,O=C(O[H])CCC1=C(F)C=C(C=C1)OCC2=CC=C(C=C2)OC/C(C3=CC=C(C#N)C=C3)=N\OC,<,0.01,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,O=C(O[H])CCC1=C(F)C=C(C=C1)OCC2=CC=C(C=C2)OC/C(C3=CC=C(C=C3)OC)=N\OC,<,0.01,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,O=C(O[H])CCC(C=CC(OCC1=CC(OC)=C(C=C1)OC/C(C2=CC=CC=C2)=N\OC)=C3)=C3F,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,O=C(O[H])C1C(C2=CC=C(OCC3=CC=C(C=C3)OC/C(C4=CC=C(C#N)C=C4)=N\OC)C=C2)C1,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,COC1=CC=C(/C(COC2=CC=C(COC(C=C3)=CC=C3C(C4)C4C(O[H])=O)C=C2)=N/OC)C=C1,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,CC(C=C(C=C1)OCC2=CC=C(C=C2)OC/C(C3=CC=CC=C3)=N\OC)=C1C(C#N)CC(O[H])=O,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,N#CC1=CC=C(C=C1)/C(COC2=CC=C(COC3=CC=C(C=C3)[C@H]4C[C@@H]4C(O[H])=O)C=C2)=N/OC,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,COC1=CC=C(C=C1)/C(COC2=CC=C(C=C2)COC3=CC=C(C=C3)C(C#N)CC(O[H])=O)=N/OC,<,0.01,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,O=C(O[H])CC1C2=CC=C(C=C2OC1)OCC3=CC=C(C=C3)OC/C(C4=CC=CC=C4)=N\OC,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,O=C(O[H])/C=C(C#N)/C1=CC=C(C=C1)OCC(C=C2)=CC=C2OC/C(C3=CC=CC=C3)=N\OC,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,FC1=C(C(C#N)CC(O[H])=O)C=CC(OCC2=CC=C(C=C2)OC/C(C3=CC=CC=C3)=N\OC)=C1,<,0.01,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,N#CC(C1=CC=C(OCC(C=C2)=CC=C2OC/C(C3=CC=CC=C3)=N\O[H])C=C1)CC(O[H])=O,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,N#CC(CC(O[H])=O)C(C(OC)=C1)=CC=C1OCC2=CC=C(C=C2)OC/C(C3=CC=CC=C3)=N\OC,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,O=C(O[H])CC(C#CC)C(C=C1)=CC=C1OCC2=CC=C(C=C2)OC/C(C3=CC=CC=C3)=N\OC,<,0.01,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,O=C(O[H])CC(C#N)C1=CC=C(OCC2=CC=C(C=C2)OC/C(C3=CC=CC=C3)=N/OC)C=C1,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,N#CC(CC(O[H])=O)C1=CC=C(C=C1)OCC2=CC=C(C=C2)OC/C(C3=CC4=C(C=CC=C4)C3)=N\OC,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,N#CC(CC(O[H])=O)C1=CC=C(C=C1)OCC2=CC=C(C=C2)OC/C(C3=CC=C4OCCC4=C3)=N\OC,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,N#CC(C1=CC=C(OCC(C=C2)=CC=C2OC/C(C3=CC(CCC4)=C4C=C3)=N\OC)C=C1)CC(O[H])=O,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,N#CC(CC(O[H])=O)C1=CC=C(C=C1)OCC2=CC=C(C=C2)OC/C(C3=CC=CC=C3)=N\OC4=CC=CC=C4,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,O=C(O[H])CCC1=CC=C(OCC2=CC=C(C=C2)OC/C(C3=CC=CC=C3)=N\OCC4=CC=CC=C4)C=C1,<,0.1,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,O=C(O[H])CCC1=CC=C(C=C1)OCC(C=C2)=CC=C2OC/C(C3=CC=CC=C3)=N\OCC=C,<,0.01,¦ÌM
,Preparation of methoxyiminophenylethyloxybenzyloxyphenylpropanoic acid derivatives and analogs for use as GPR40 agonists,WO2012011125,Patent,CHO-K,Calcium flux assay,EC50,N#CC(C1=CC=C(C=C1)OCC2=CC=C(C=C2)OC/C(C3=CC=CC=C3)=N\OC4CCCCC4)CC(O[H])=O,<,0.1,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(CCC1=CC=C(N([H])CC(C=C2)=CC3=C2C=CN3C(C)C)C=C1)O[H],=,0.1,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=CC=C1N([H])CC(C=C2)=CC3=C2C=CN3CC4=CC=CC=C4,=,0.03,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(CCC(C=C1)=CC=C1N([H])CC2=CC3=C(C=C2)C=CN3C4=CSC=C4)O[H],=,0.01,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(CCC(C=C1)=CC=C1N([H])CC2=CC3=C(C=C2)C=CN3CCC4=CC=CC=C4)O[H],=,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(CCC(C=C1)=CC=C1N([H])CC2=CC3=C(C=C2)C(Cl)=CN3CC4=CC=CC=C4)O[H],=,0.03,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(CCC(C=C1)=CC=C1N([H])CC2=CC3=C(C=C2)C(Cl)=C(Cl)N3CC4=CC=CC=C4)O[H],=,0.1,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(CCC(C=C1)=CC=C1N([H])CC2=C(Cl)C3=C(C=C2)C=CN3CC4=CC=CC=C4)O[H],=,0.02,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(CCC(C=C1)=CC=C1N([H])CC2=C(Cl)C3=C(C=C2)C=CN3C4=CC=C(F)C=C4)O[H],=,0.3,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(CCC(C=C1)=CC=C1N([H])CC2=CC3=C(C=C2)C=CN3C4=CC=C(F)C=C4)O[H],=,0.7,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(CCC(C=C1)=CC=C1N([H])CC2=C(Cl)C3=C(C=C2)C=CN3CC4CCCCC4)O[H],=,0.4,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,ClC1=CN(CC2=CC=CC=C2)C3=C1C=CC(COC4=CC(OCC5CC(O[H])=O)=C5C=C4)=C3,=,0.16,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=CC=C1OCC2=CC3=C(C=C2)C=CN3C4=CSC=C4,=,0.02,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=CC=C1OCC2=C(C)C3=C(C=C2)C=CN3C4=CC=C(F)C=C4,=,0.03,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=CC=C1OCC2=C(C)C3=C(C=C2)C=CN3CC4=CC=CC=C4,=,0.01,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=CC=C1OCC2=C(C)C3=C(C=C2)C=CN3C4=CSC=C4,=,0.02,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=CC=C1OCC2=CC3=C(C=C2)C=CN3C4=CC=C(F)C=C4C,=,0.007,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=CC=C1OCC2=C(Cl)C3=C(C=C2)C=CN3CC4=CC=CC=C4,=,0.009,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=CC=C1OCC2=CC3=C(C=C2)C=CN3CC4CCCCC4,=,0.4,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=CC=C1OCC2=CC3=C(C=C2)N(C)C=C3CC4=CC=CC=C4,=,0.07,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=CC=C1OCC2=CC3=C(C=C2)C(Cl)=CN3C4=CC=C(F)C=C4C,=,0.04,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=CC=C1OCC2=CC3=C(C=C2F)C=CN3C4=CC=C(F)C=C4C,=,0.004,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,FC1=CC=C(N2C=CC(C=C3)=C2C=C3COC4=CC(OCC5CC(O[H])=O)=C5C=C4)C(C)=C1,=,0.02,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,CC(C1=C(C=C2)C=CN1CC3=CC=CC=C3)=C2COC4=CC=C([C@@H](C#CC)CC(O[H])=O)C=C4,=,0.02,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=CC3=C(C=C2)C=CN3C4=CC=C(F)C=C4C,=,0.02,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=C(C)C3=C(C=C2)C=CN3CC4=CC=C(S(C)(=O)=O)C=C4,=,0.03,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=C(C)C3=C(C=C2)C=CN3CC4=CC=C(OC)C=C4,=,0.01,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=C(C)C3=C(C=C2)C=CN3CC4=CC=C(C(F)(F)F)C=C4,=,0.07,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=C(C)C3=C(C=C2)C=CN3CC4=CC=CC(COC)=C4,=,0.04,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=C(C=CN3CC4=CC=CC=C4)C3=CC=C2,=,0.03,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=C(C=CN3C4=CC=C(F)C=C4C)C3=CC=C2,=,0.04,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=C(C)C(N(CC3=C(F)C=CC=C3F)C=C4)=C4C=C2,=,0.022,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=CC(N(CC3=CC=CC=C3)C(CCOC)=C4)=C4C=C2,=,0.04,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=C(C)C(N(CC3=CC=CC(CS(C)(=O)=O)=C3)C=C4)=C4C=C2,=,0.01,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=C(C)C(N(CC3=C(C)C=CC=C3)C=C4)=C4C=C2,=,0.06,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=C(C)C(N(CC3=C(F)C=CC=C3)C=C4)=C4C=C2,=,0.04,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=C(C)C(N(CC3=C(Cl)C=CC=C3)C=C4)=C4C=C2,=,0.09,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=C(C)C(N(CC3=C(C)C=CC=C3C)C=C4)=C4C=C2,=,0.2,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=C(Cl)C(N(CC3=CC=CC=C3)C=C4)=C4C=C2,=,0.06,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=CC(N(CC3=CC=CC=C3)C=C4)=C4C=C2F,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=C(C)C(N(CC3=CC=CC=C3F)C=C4)=C4C=C2,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=C(C)C(N(CC3=CC=CC(C(F)(F)F)=C3)C=C4)=C4C=C2,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=C(C)C(N(CC3=NC=C(C)N=C3)C=C4)=C4C=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=C(C)C(N(CC3=CC=C(CS(C)(=O)=O)C=C3)C=C4)=C4C=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=C(C)C(N(CC3=CC=C(Cl)N=C3)C=C4)=C4C=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=CC=CC3=NN(CC4=CC=CC=C4)C=C32,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=CC=CC3=C2C=NN3CC4=CC=CC=C4,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=C(F)C=C3C(N(CC4=CC=CC=C4)C=C3)=C2C,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=CC=C3C(N(CC4=CC=C(F)C=C4)C=C3)=C2C,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=CC=C3C(N(CC4=CC(F)=C(F)C=C4)C=C3)=C2C,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=CC=C3C(N(CC4=CC(F)=CC(F)=C4)C=C3)=C2C,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=CC=C3C(N(CC4=C(F)C=C(F)C=C4)C=C3)=C2C,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=C(F)C=C1OCC2=CC=CC3=C2C=CN3CC4=CC=CC=C4,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=C(F)C=C1OCC2=CC=C3C(N(CC4=CC=CC=C4)C=C3)=C2C,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=C2)=C(C)C3=C2C=CN3CC4=CSC=N4,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=C2)=C(C)C3=C2C=CN3CC4=CSC(C)=N4,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=CC3=NN(CC4=CC=CC=C4)C=C3C=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=C2)=CC3=C2C=NN3CC4=CC=CC=C4,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=C2)=C(C)C3=C2C=CN3CC4=NC=CN=C4,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=C2)=C(C)C3=C2C=CN3CC4=NC=NC=C4,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=C2)=C(C)C3=C2C(F)=CN3CC4=CC=CC=C4,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=C2)=C(C)C3=C2C=CN3CC4=CN(C)N=C4,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=C2)=C(C)C3=C2C=CN3CC4=NC=CC=N4,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CC(C1=NOCC1)C(C=C2)=CC=C2OCC(C=C3)=CC4=C3C=NN4CC5=CC=CC=C5,=,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=C2)=CC3=C2C=NN3CC4=CC=C(F)C=C4,=,0.01,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=CC3=NN(CC4=CC=C(F)C=C4)C=C3C=C2,=,0.07,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC(C=C2)=CC3=C2C=NN3CC4=NC=CC=N4,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=CC=CC3=NN(CC4=CC=C(F)C=C4)C=C32,=,0.03,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=CC(N(CC3=NC=C(C)N=C3)N=C4)=C4C=C2,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=CC(N(CC3=NC=NC=C3)N=C4)=C4C=C2,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=C3C(N(CC4=NC=C(C)N=C4)N=C3)=CC=C2,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=CC=CC3=NN(CC4=CN=C(C)C=N4)C=C32,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=CC(N(CC3=CN=CC=C3)N=C4)=C4C=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=C(C)C(N(CC3=CN=C(C)C=C3)C=C4)=C4C=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=CC(N(CC3=CN(C)N=C3)N=C4)=C4C=C2,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C1=NOC=C1)C(C=C2)=CC=C2OCC3=C(C)C(N(CC4=CC=CC=C4)C=C5)=C5C=C3,=,0.01,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C1=NOC=C1)C(C=C2)=CC=C2OCC3=C(C)C(N(CC4=CC=C(F)C=C4)C=C5)=C5C=C3,=,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C1=NOC=C1)C(C=C2)=CC=C2OCC3=CC(N(CC4=CC=CC=C4)N=C5)=C5C=C3,=,0.01,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C1=NOC=C1)C(C=C2)=CC=C2OCC3=CC(N(CC4=CC=C(F)C=C4)N=C5)=C5C=C3,=,0.01,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C1=NOC=C1)C(C=C2)=CC=C2OCC3=CC(N(CC(C)C)N=C4)=C4C=C3,=,0.01,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C1=NOC=C1)C(C=C2)=CC=C2OCC3=CC4=NN(CC(C)C)C=C4C=C3,=,0.4,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C1=NOC=C1)C(C=C2)=CC=C2OCC3=C(C)C(N(CC4=CN=CC=N4)C=C5)=C5C=C3,=,0.03,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=NC(N(CC3=CC=CC=C3)C=C4)=C4C=C2,=,0.01,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C1=NOC=C1)C(C=C2)=CC=C2OCC3=NC(N(CC4=CC=CC=C4)C=C5)=C5C=C3,=,0.03,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C1=NOC=C1)C(C=C2)=CC=C2OCC3=C(C)C(N(CC4=CN=C(C)C=N4)C=C5)=C5C=C3,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C(C=C1)=CC=C1OCC2=CC(N(CC3=CC=C(C)N=C3)N=C4)=C4C=C2,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C1=NOC=C1)C(C=C2)=CC=C2OCC3=C(C=NN4CC5=CC=CC=C5)C4=CC=C3,=,0.06,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C1=NOC=C1)C(C=C2)=CC=C2OCC3=NC4=C(C=CN4CC5=CC=C(F)C=C5)C=C3,=,0.1,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C1=NOC=C1)C(C=C2)=CC=C2OCC3=CC4=C(C=NN4C(C)C)C=C3,=,0.03,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C1=NOC=C1)C(C=C2)=CC=C2OCC3=CC4=C(C=NN4CC5CC5)C=C3,=,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C1=NOC=C1)C(C=C2)=CC=C2OCC3=NC4=C(C=CN4CC(C)C)C=C3,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C1=NOC=C1)C(C=C2)=CC=C2OCC3=CC4=NN(C(C)C)C=C4C=C3,=,1.3,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,CC(C)N1N=CC2=C1C=C(C=C2)COC3=CC(OCC4CC(O[H])=O)=C4C=C3,=,0.6,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C1=NOC=C1)C2=CC=C(OCC3=CC4=C(C=NN4C)C=C3)C=C2,=,0.09,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C1=NOC=C1)C2=CC=C(OCC3=CC4=C(C=NN4)C=C3)C=C2,=,0.4,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C1=NOC=C1)C2=CC=C(OCC3=CC4=C(C=NN4CC5CCCC5)C=C3)C=C2,=,0.01,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C1=NOC=C1)C2=CC=C(OCC3=NC4=C(C=CN4CC5=NC=CN=C5)C=C3)C=C2,=,0.8,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CC1C2=C(OC1)C=C(OCC3=CC4=C(C=NN4CC5=CC=CC=C5)C=C3)C=C2,=,0.4,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,FC1=C(CCC(O[H])=O)C=CC(OCC2=CC3=C(C=NN3CC4=CC=CC=C4)C=C2)=C1,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,FC1=C(CCC(O[H])=O)C=CC(OCC2=CC3=C(C=NN3CC4CCCC4)C=C2)=C1,=,0.2,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CC(CO1)C2=C1C=C(OCC3=CC4=C(C=NN4CC5CCCC5)C=C3)C=C2,=,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CC(CC1)C2=C1C=C(OCC3=CC4=C(C=NN4CC5=CC=CC=C5)C=C3)C=C2,=,0.4,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CC(CCC1)C2=C1C=C(OCC3=CC4=C(C=NN4CC5=CC=CC=C5)C=C3)C=C2,=,0.2,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C(N(CC3=CC=CC=C3)N=C4)C4=C2)C=C1,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC3=CN(CC4=CC=CC=C4)N=C3C=C2)C=C1,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CC(CO1)C2=C1C=C(OCC3=CC4=NN(CC5=CC=CC=C5)C=C4C=C3)C=C2,=,9.1,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,CC(C)CN1C2=C(C=N1)C=CC(COC3=CC=C([C@@H](C#CC)CC(O[H])=O)C=C3)=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,CC(C)CN1C2=C(C=C1)C=CC(COC3=CC=C([C@@H](C#CC)CC(O[H])=O)C=C3)=N2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C(N(C(C)C)N=C3)C3=C2)C=C1,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CC(C)C1=CC=C(OCC2=CC(N(CC3=CC=CC=C3)N=C4)=C4C=C2)C=C1,=,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CC1C2=C(CC1)C=C(OCC3=CC=C(N(CC4=CC=CC=C4)N=C5)C5=C3)C=C2,=,0.2,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CC1C2=C(CCC1)C=C(OCC3=CC=C(N(CC4=CC=CC=C4)N=C5)C5=C3)C=C2,=,0.06,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CC1C2=C(OCC1)C=C(OCC3=CC=C(N(CC4=CC=CC=C4)N=C5)C5=C3)C=C2,=,0.04,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CC(CO1)C2=C1C=C(OCC3=NC4=C(C=CN4CC5=CC=CC=C5)C=C3)C=C2,=,0.3,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,FC1=CC(C=NN2CC3=CC=CC=C3)=C2C=C1COC4=CC=C([C@@H](C#CC)CC(O[H])=O)C=C4,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,[H]OC(C[C@H](C#CC)C1=CC=C(OCC2=CC=C(N(CC3=CC=CC=C3)C=C4)C4=C2)C=C1)=O,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,[H]OC(C[C@H](C#CC)C1=CC=C(OCC2=CC=C(N(CC3=CC=CC=C3)N=N4)C4=C2)C=C1)=O,=,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,[H]OC(C[C@H](C#CC)C1=CC=C(OCC2=CC=C(N(CC3=CC=CC=C3)C=N4)C4=C2)C=C1)=O,=,0.02,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,[H]OC(C[C@H](C#CC)C1=CC=C(OCC2=CC(C)=C(N(CC3=CC=CC=C3)N=C4)C4=C2)C=C1)=O,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,[H]OC(C[C@H](C#CC)C1=CC=C(OCC2=CC3=CN(CC4=CC=CC=C4)N=C3C(C)=C2)C=C1)=O,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,CC1=C(N(CC2=CC=CC=C2)N=C3)C3=CC(COC4=CC5=C(C(CO5)CC(O[H])=O)C=C4)=C1,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,CC1=C(N(CC2=CC=CC=C2)N=C3)C3=CC(COC4=CC(OCC5)=C(C5CC(O[H])=O)C=C4)=C1,=,0.08,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,CC1=C(N(CC(C)C)N=C2)C2=CC(COC3=CC=C([C@@H](C#CC)CC(O[H])=O)C=C3)=C1,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,CC1=C(N(CC(C)C)N=C2)C2=CC(COC3=CC(OCCC4CC(O[H])=O)=C4C=C3)=C1,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,CC(C)CN1C2=CC=C(C=C2C=N1)COC3=CC=C([C@@H](C#CC)CC(O[H])=O)C=C3,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,CC(C)CN1C2=CC=C(C=C2C=N1)COC3=CC(OCC4)=C(C4CC(O[H])=O)C=C3,=,0.4,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C(N(CCC3=CC=CC=C3)N=C4)C4=C2)C=C1,=,0.004,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CC(CCO1)C2=C1C=C(OCC3=CC=C(N(CCC4=CC=CC=C4)N=C5)C5=C3)C=C2,=,0.2,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C(N(CCC(C)C)N=C3)C3=C2)C=C1,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CC(CCO1)C2=C1C=C(OCC3=CC=C(N(CCC(C)C)N=C4)C4=C3)C=C2,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C(N(CC3CCCCC3)N=C4)C4=C2)C=C1,=,0.01,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CC1C2=C(OCC1)C=C(OCC3=CC=C(N(CC4CCCCC4)N=C5)C5=C3)C=C2,=,0.3,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC3=CN(CC(C)C)N=C3C(C)=C2)C=C1,=,0.004,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C(N(CC3=NC=CC=C3)N=C4)C4=C2)C=C1,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CN=C(N(CC3=CC=CC=C3)C=C4)C4=C2)C=C1,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CN=C(N(CC(C)C)C=C3)C3=C2)C=C1,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CC1C2=C(OCC1)C=C(OCC3=C(C)C(N(CC4=CC=CC=C4)C=C5)=C5C=C3)C=C2,=,0.04,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CC1C2=C(OCC1)C=C(OCC3=CC4=CN(CC5=CC=CC=C5)N=C4C(C)=C3)C=C2,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C(N(CC3=CN=CC=C3)N=C4)C4=C2)C=C1,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC(N(CC(C)C)N=C3)=C3C=C2F)C=C1,=,0.003,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C(N(CC3CCCO3)N=C4)C4=C2)C=C1,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(OCC2=CC=C(N(CC3CCOC3)N=C4)C4=C2)C=C1,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CC(OC)C1=CC=C(OCC2=CC=C(N(CC3=CC=CC=C3)N=C4)C4=C2)C=C1,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,CC(CN1C2=NC=C(COC(C=C3)=CC=C3[C@@H](C#CC)CC(O[H])=O)C=C2C=N1)C,=,0.02,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC=C(N(CCOCC)N=C3)C3=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC=C(N(CC3=CC=CC=C3)N=C4)C4=C2,=,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CC(CC)C1=CC=C(C=C1)OCC2=CC=C(N(CC3=CC=CC=C3)N=C4)C4=C2,=,0.1,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC3=CN(CCOCC)N=C3C=C2,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC=C(N(CC3=CC=CC=C3)C(N4C)=O)C4=C2,=,0.005,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])CC(C#N)C1=CC=C(C=C1)OCC2=CC=C(N(CC3=CC=CC=C3)N=C4)C4=C2,=,0.02,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC=C(N(CC3CCCC3)N=C4)C4=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC=C(N(C3CCCC3)N=C4)C4=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC=C(N(CC3CC3)N=C4)C4=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(N(CC(C)C)NN3)=C3C=C2,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C1C(C1)C2=CC=C(C=C2)OCC3=CC(N(CC4=CC=CC=C4)N=C5)=C5C=C3,=,0.06,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(C)=C(N(C(C)C)N=C3)C3=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(C)=C(N(CC3CCCC3)N=C4)C4=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC=C(N(CC(C)C)N=C3C)C3=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(C)=C(N(C3CCCC3)N=C4)C4=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(N(C3CCCC3)N=C4)=C4C=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(N(CC3CCCC3)N=C4)=C4C=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC=C(N(CCOC)N=C3)C3=C2,<,0.5,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC=C(N(CCCOC)N=C3)C3=C2,=,0.04,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(N(CC3(C)COC3)N=C4)=C4C=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(N(CC(C)C)N=C3C)=C3C=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC3=NN(C(C)C)C(C)=C3C=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(N(C(C)C)N=C3)=C3C=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(C(CC(C)C)=NO3)=C3C=C2,=,0.006,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(N(CC(C)(C)C)N=C3)=C3C=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C(C)C=C(N(CC(C)C)N=C3)C3=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C(C=NN3CC(C)C)C3=CC=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(N(C(C)C)N=C3C)=C3C=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(C(CC(C)C)=NN3C)=C3C=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(N(CC(C)C)N=C3COC)=C3C=C2,=,0.005,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C3C(N(CC(C)C)N=C3F)=CC=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C3C(N(C(C)C)N=C3)=CC=C2,=,0.04,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(N(CC(C)C)N=C3COCC)=C3C=C2,=,0.01,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C3C(N(CC(C)C)N=C3Cl)=CC=C2,=,0.03,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(N(CC(C)C)N=C3COC(C)C)=C3C=C2,=,0.003,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C3C(N(C(C)C)N=C3F)=CC=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C3C(C(Br)=NN3C)=CC=C2,=,0.006,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C(C)C(N(CC(C)C)N=C3COC)=C3C=C2,=,0.005,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C3C(N(CCCC)N=C3)=CC=C2,=,0.005,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C3C(N(CCCC)N=C3F)=CC=C2,=,0.016,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C3C(N(CC4CC4)N=C3)=CC=C2,=,0.017,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C3C(N(CC4CC4)N=C3F)=CC=C2,=,0.009,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C3C(C(Cl)=NN3C)=CC=C2,=,0.01,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(N(C(C)C)N=C3CN4N=CC=C4)=C3C=C2,=,0.008,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C3C(C(F)=NN3C)=CC=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C3C(N(CC(C)C)C=C3)=NC=C2,=,0.009,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C3C(N(CCCC)N=C3C)=CC=C2,=,0.016,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C3C(C(CCCC)=NN3C)=CC=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C3C(C(CC(C)C)=NN3C)=CC=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C3C(N(CC(C)C)N=C3)=C(C)C=C2,=,0.005,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C3C(C(C(C)C)=NN3C)=CC=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C3C(C(CCC)=NN3C)=CC=C2,=,0.008,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C(C)C(N(CC(C)C)N=C3)=C3C=C2,=,0.004,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C(C)C(N(CC(C)C)N=C3C)=C3C=C2,=,0.002,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C3C(N(CC(C)C)N=C3F)=C(C)C=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C(C)C(N(CC)N=C3F)=C3C=C2,=,0.002,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C(C)C(N(CC(C)C)N=C3CN4CCOCC4)=C3C=C2,=,0.01,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C(Cl)C(N(CC(C)C)N=C3CN4CCOCC4)=C3C=C2,=,0.006,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C(C)C(N(CC(C)C)N=C3CN4CCCC4)=C3C=C2,=,0.02,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C(C)C(N(CC(C)C)N=C3CN4CCCCC4)=C3C=C2,=,0.014,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(N(CC(C)C)N=C3CN4CCOCC4)=C3C=C2,=,0.023,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C(C)C(N(C(C)C)N=C3)=C3C=C2,=,0.003,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C(C)C(N(CCC)N=C3)=C3C=C2,=,0.005,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C(C)C(N(CC(C)C)N=C3CF)=C3C=C2,=,0.005,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C3C(N(C(C)C)N=C3)=C(C)C=C2,=,0.011,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C3C(N(C(C)C)C=C3)=NC=C2,=,0.027,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C3C(N(CC(C)C)C=C3F)=NC=C2,=,0.013,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C(C)C(N(CC3=CC=CN=C3)N=C4)=C4C=C2,=,0.009,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C(C)C(N(CC(C)C)N=C3CN4CCCC(F)(F)C4)=C3C=C2,=,0.005,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C(C)C(N(CC(C)C)N=C3CN4N=CC=C4)=C3C=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C(C)C(N(CC(C)C)N=C3CN4C[C@@H](F)CC4)=C3C=C2,=,0.035,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=C(C)C(N(CC(C)C)N=C3CN4CC(F)(F)CC4)=C3C=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=NC(N(CC(C)C)C=C3CN4CC(F)(F)CC4)=C3C=C2,<,0.05,¦ÌM
,Preparation of heterocyclyl substituted (hetero)aryl carboxylic acids as GPR40 receptor agonists,WO2014073904,Patent,CHO-K1,Calcium flux asay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OCC2=NC(N(CC(C)C)C=C3CN4CCCC(F)(F)C4)=C3C=C2,=,0.012,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Design and Identification of a?GPR40?Full?Agonist?(SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety,10.1021/acs.jmedchem.0c00843,Article,CHO,Calcium flux asay,EC50,COC1=CC(N2CCC(CC2)COC3=CC=CC(C(CC(O[H])=O)C4CC4)=C3)=C(CCCC(C)(C)C)C=C1,=,0.011,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Design and Identification of a?GPR40?Full?Agonist?(SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety,10.1021/acs.jmedchem.0c00843,Article,CHO,Calcium flux asay,EC50,FC(C=CC(OC)=C1)=C1N2CCC(CC2)COC3=CC=CC(C(CC(O[H])=O)C4CC4)=C3,=,0.67,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Design and Identification of a?GPR40?Full?Agonist?(SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety,10.1021/acs.jmedchem.0c00843,Article,CHO,Calcium flux asay,EC50,CC(C=CC(OC)=C1)=C1N2CCC(CC2)COC3=CC=CC(C(CC(O[H])=O)C4CC4)=C3,=,0.27,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Design and Identification of a?GPR40?Full?Agonist?(SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety,10.1021/acs.jmedchem.0c00843,Article,CHO,Calcium flux asay,EC50,COC1=CC(N2CCC(CC2)COC3=CC=CC(C(CC(O[H])=O)C4CC4)=C3)=C(C(C)C)C=C1,=,0.12,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Design and Identification of a?GPR40?Full?Agonist?(SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety,10.1021/acs.jmedchem.0c00843,Article,CHO,Calcium flux asay,EC50,COC1=CC(N2CCC(CC2)COC3=CC=CC(C(CC(O[H])=O)C4CC4)=C3)=C(CCC(C)(C)C)C=C1,=,0.034,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Design and Identification of a?GPR40?Full?Agonist?(SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety,10.1021/acs.jmedchem.0c00843,Article,CHO,Calcium flux asay,EC50,COC1=CC(N2CCC(CC2)COC3=CC=CC(C(CC(O[H])=O)C4CC4)=C3)=C(CCC(C)(C)O[H])C=C1,=,0.97,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Design and Identification of a?GPR40?Full?Agonist?(SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety,10.1021/acs.jmedchem.0c00843,Article,CHO,Calcium flux asay,EC50,COC1=CC(N2CCC(CC2)COC3=CC=CC(C(CC(O[H])=O)C4CC4)=C3)=C(CN(C)CC(C)C)C=C1,=,1,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Design and Identification of a?GPR40?Full?Agonist?(SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety,10.1021/acs.jmedchem.0c00843,Article,CHO,Calcium flux asay,EC50,COC1=CC(N2CCC(CC2)COC3=CC=CC(C(CC(O[H])=O)C4CC4)=C3)=C(C(N(C)CC(C)(C)C)=O)C=C1,=,0.1,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Design and Identification of a?GPR40?Full?Agonist?(SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety,10.1021/acs.jmedchem.0c00843,Article,CHO,Calcium flux asay,EC50,COC1=CC(N2CCC(CC2)COC3=CC=CC(C(CC(O[H])=O)C4CC4)=C3)=C(C(N(C)C5=CC=CC=C5)=O)C=C1,=,0.14,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Design and Identification of a?GPR40?Full?Agonist?(SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety,10.1021/acs.jmedchem.0c00843,Article,CHO,Calcium flux asay,EC50,COC1=CC(N2CCC(CC2)COC3=CC=CC(C(CC(O[H])=O)C4CC4)=C3)=C(C(N(C)C5=NC=CC=C5)=O)C=C1,=,0.18,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Design and Identification of a?GPR40?Full?Agonist?(SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety,10.1021/acs.jmedchem.0c00843,Article,CHO,Calcium flux asay,EC50,O=C(N(CC(C)C)C1=NC=CC=C1)C(C=CC(OC)=C2)=C2N3CCC(COC4=CC=CC(C(C5CC5)CC(O[H])=O)=C4)CC3,=,0.029,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Design and Identification of a?GPR40?Full?Agonist?(SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety,10.1021/acs.jmedchem.0c00843,Article,CHO,Calcium flux asay,EC50,O=C(N(CC(C)(C)C)C1=NC=CC=C1)C(C=CC(OC)=C2)=C2N3CCC(COC4=CC=CC(C(C5CC5)CC(O[H])=O)=C4)CC3,=,0.026,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Design and Identification of a?GPR40?Full?Agonist?(SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety,10.1021/acs.jmedchem.0c00843,Article,CHO,Calcium flux asay,EC50,O=C(N(CC(C)(C)C#N)C1=NC=CC=C1)C(C=CC(OC)=C2)=C2N3CCC(COC4=CC=CC(C(C5CC5)CC(O[H])=O)=C4)CC3,=,0.16,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Design and Identification of a?GPR40?Full?Agonist?(SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety,10.1021/acs.jmedchem.0c00843,Article,CHO,Calcium flux asay,EC50,O=C(N(CC(C)(C)OC)C1=NC=CC=C1)C(C=CC(OC)=C2)=C2N3CCC(COC4=CC=CC(C(C5CC5)CC(O[H])=O)=C4)CC3,=,0.1,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Design and Identification of a?GPR40?Full?Agonist?(SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety,10.1021/acs.jmedchem.0c00843,Article,CHO,Calcium flux asay,EC50,O=C(N(CC(C)(C)C)C1=NC(C)=CC=C1)C(C=CC(OC)=C2)=C2N3CCC(COC4=CC=CC(C(C5CC5)CC(O[H])=O)=C4)CC3,=,0.017,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Design and Identification of a?GPR40?Full?Agonist?(SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety,10.1021/acs.jmedchem.0c00843,Article,CHO,Calcium flux asay,EC50,O=C(N(CC(C)(C)C)C1=NC(C)=CC=C1)C(C=CC(OC)=C2)=C2N3CCC(COC4=CC=CC(C(OC)CC(O[H])=O)=C4)CC3,=,0.062,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Design and Identification of a?GPR40?Full?Agonist?(SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety,10.1021/acs.jmedchem.0c00843,Article,CHO,Calcium flux asay,EC50,O=C(N(CC(C)(C)C)C1=NC(C)=CC=C1)C(C=CC(OC)=C2)=C2N3CCC(COC4=CC=CC(C(OCC)CC(O[H])=O)=C4)CC3,=,0.074,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Design and Identification of a?GPR40?Full?Agonist?(SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety,10.1021/acs.jmedchem.0c00843,Article,CHO,Calcium flux asay,EC50,O=C(N(CC(C)(C)C)C1=NC(C)=CC=C1)C(C=CC(OC)=C2)=C2N3CCC(COC4=CC=CC(C(COC)CC(O[H])=O)=C4)CC3,=,0.12,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Design and Identification of a?GPR40?Full?Agonist?(SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety,10.1021/acs.jmedchem.0c00843,Article,CHO,Calcium flux asay,EC50,O=C(N(CC(C)(C)C)C1=NC(C)=CC=C1)C(C=CC(OC)=C2)=C2N3CCC(COC4=CC=CC(C5(COC5)CC(O[H])=O)=C4)CC3,=,0.84,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Design and Identification of a?GPR40?Full?Agonist?(SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety,10.1021/acs.jmedchem.0c00843,Article,CHO,Calcium flux asay,EC50,O=C(N(CC(C)(C)C)C1=NC(C)=CC=C1)C(C=CC(OC)=C2)=C2N3CCC(COC4=NC=CC(C(C5CC5)CC(O[H])=O)=C4)CC3,=,0.017,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Design and Identification of a?GPR40?Full?Agonist?(SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety,10.1021/acs.jmedchem.0c00843,Article,CHO,Calcium flux asay,EC50,O=C(N(CC(C)(C)C)C1=NC(C)=CC=C1)C(C=CC(OC)=C2)=C2N3CCC(COC4=NC=CC([C@H](C5CC5)CC(O[H])=O)=C4)CC3,=,0.012,¦ÌM
JOURNAL OF MEDICINAL CHEMISTRY,Design and Identification of a?GPR40?Full?Agonist?(SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety,10.1021/acs.jmedchem.0c00843,Article,CHO,Calcium flux asay,EC50,O=C(N(CC(C)(C)C)C1=NC(C)=CC=C1)C(C=CC(OC)=C2)=C2N3CCC(COC4=NC=CC([C@@H](C5CC5)CC(O[H])=O)=C4)CC3,=,0.084,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold",10.1016/j.bmc.2016.04.065,Article,CHO,Calcium flux asay,EC50,O=C(CCC1=NN=C(C(N(C2=CC(C3=CC(C)=CC=C3)=CC=C2)[H])=O)S1)O[H],=,0.76,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold",10.1016/j.bmc.2016.04.065,Article,CHO,Calcium flux asay,EC50,O=C(CCC1=NN=C(C(N(C2=CC(C3=CC(Cl)=CC=C3)=CC=C2)[H])=O)S1)O[H],=,1.69,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold",10.1016/j.bmc.2016.04.065,Article,CHO,Calcium flux asay,EC50,O=C(CCC1=NN=C(C(N(C2=CC(C3=CC=C(F)C=C3)=CC=C2)[H])=O)S1)O[H],=,1.28,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold",10.1016/j.bmc.2016.04.065,Article,CHO,Calcium flux asay,EC50,O=C(CCC1=NN=C(C(N(C2=CC(C3=CC=CO3)=CC=C2)[H])=O)S1)O[H],=,1.64,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold",10.1016/j.bmc.2016.04.065,Article,CHO,Calcium flux asay,EC50,O=C(N(C1=CC=CC=C1)[H])C2=NN=C(S2)COC3=CC=C(CCC(O[H])=O)C=C3,=,1.06,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold",10.1016/j.bmc.2016.04.065,Article,CHO,Calcium flux asay,EC50,O=C(N(C1=CC=C(OC)C=C1)[H])C2=NN=C(S2)COC3=CC=C(CCC(O[H])=O)C=C3,>,10,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold",10.1016/j.bmc.2016.04.065,Article,CHO,Calcium flux asay,EC50,O=C(N(C1=C(F)C=CC=C1)[H])C2=NN=C(S2)COC3=CC=C(CCC(O[H])=O)C=C3,=,0.58,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold",10.1016/j.bmc.2016.04.065,Article,CHO,Calcium flux asay,EC50,O=C(N(C1=CC(C)=CC=C1)[H])C2=NN=C(S2)COC3=CC=C(CCC(O[H])=O)C=C3,=,1.77,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold",10.1016/j.bmc.2016.04.065,Article,CHO,Calcium flux asay,EC50,O=C(N(C1=CC=C(F)C=C1)[H])C2=NN=C(S2)COC3=CC=C(CCC(O[H])=O)C=C3,=,6.64,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold",10.1016/j.bmc.2016.04.065,Article,CHO,Calcium flux asay,EC50,O=C(N(C1=C(C)C=CC=C1)[H])C2=NN=C(S2)COC3=CC=C(CCC(O[H])=O)C=C3,=,1.52,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold",10.1016/j.bmc.2016.04.065,Article,CHO,Calcium flux asay,EC50,O=C(N(C1=CC=C(Cl)C=C1)[H])C2=NN=C(S2)COC3=CC=C(CCC(O[H])=O)C=C3,=,3.69,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold",10.1016/j.bmc.2016.04.065,Article,CHO,Calcium flux asay,EC50,O=C(N(C1=CC(F)=CC=C1)[H])C2=NN=C(S2)COC3=CC=C(CCC(O[H])=O)C=C3,=,1.19,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold",10.1016/j.bmc.2016.04.065,Article,CHO,Calcium flux asay,EC50,O=C(N(C1=CC(OC)=CC=C1)[H])C2=NN=C(S2)COC3=CC=C(CCC(O[H])=O)C=C3,=,4.68,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold",10.1016/j.bmc.2016.04.065,Article,CHO,Calcium flux asay,EC50,O=C(N(C1=CC=C(C)C=C1)[H])C2=NN=C(S2)COC3=CC=C(CCC(O[H])=O)C=C3,=,4.3,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,"Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold",10.1016/j.bmc.2016.04.065,Article,CHO,Calcium flux asay,EC50,O=C(N(C1=CC(Cl)=CC=C1)[H])C2=NN=C(S2)COC3=CC=C(CCC(O[H])=O)C=C3,=,10.62,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Discovery of Novel Pyrrole-Based Scaffold as Potent and Orally Bioavailable Free Fatty Acid Receptor 1 Agonists for the Treatment of Type 2 Diabetes,10.1016/j.bmc.2016.03.014,Article,CHO,Calcium flux asay,EC50,O=C(CC1C2=CC=C(OCC3=CC(N4C(C)=CC=C4C)=CC=C3)C=C2OC1)O[H],=,0.0469,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Discovery of Novel Pyrrole-Based Scaffold as Potent and Orally Bioavailable Free Fatty Acid Receptor 1 Agonists for the Treatment of Type 2 Diabetes,10.1016/j.bmc.2016.03.014,Article,CHO,Calcium flux asay,EC50,O=C(CC1C2=CC=C(OCC3=CC(N4C(C)=CC=C4C)=C(OC)C=C3)C=C2OC1)O[H],=,0.0347,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Discovery of Novel Pyrrole-Based Scaffold as Potent and Orally Bioavailable Free Fatty Acid Receptor 1 Agonists for the Treatment of Type 2 Diabetes,10.1016/j.bmc.2016.03.014,Article,CHO,Calcium flux asay,EC50,O=C(CC1C2=CC=C(OCC3=CC(N4C(C)=CC=C4C)=C(OCC)C=C3)C=C2OC1)O[H],=,0.0612,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,CC(C=CC=C1C)=C1C2=CC(COC(C=C3)=CC(F)=C3CCC(O[H])=O)=CC=C2,=,0.0142,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,CC(C=C(OCC)C=C1C)=C1C2=CC(COC(C=C3)=CC(F)=C3OCC(O[H])=O)=CC=C2,=,0.0693,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,CC(C=C(OCC)C=C1C)=C1C2=CC(CNC(C=C3)=CC(F)=C3OCC(O[H])=O)=CC=C2,=,0.0242,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,CC(C=C(OCC)C=C1C)=C1C2=CC(CNC(C=C3)=CC=C3OCC(O[H])=O)=CC=C2,=,0.1967,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,CC(C=C(OCCC)C=C1C)=C1C2=CC(CNC(C=C3)=CC(F)=C3OCC(O[H])=O)=CC=C2,=,0.0387,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,CC(C=C(OCCOC)C=C1C)=C1C2=CC(CNC(C=C3)=CC(F)=C3OCC(O[H])=O)=CC=C2,=,0.0516,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,CC(C=C(OCCCS(C)(=O)=O)C=C1C)=C1C2=CC(CNC(C=C3)=CC(F)=C3OCC(O[H])=O)=CC=C2,=,0.0598,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,[H]OC(COC1=C(F)C=C(NCC2=CC=CC(C3=CC=CC=C3)=C2)C=C1)=O,=,0.0585,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,[H]OC(COC1=C(F)C=C(NCC2=CC=C(Cl)C(C3=CC=CC=C3)=C2)C=C1)=O,=,0.0517,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,[H]OC(COC1=C(F)C=C(NCC2=CC=CC(C3=CC=CC=C3F)=C2)C=C1)=O,=,0.0365,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,[H]OC(COC1=C(F)C=C(NCC2=CC=CC(C3=CC=CC=C3Cl)=C2)C=C1)=O,=,0.0193,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,[H]OC(COC1=C(F)C=C(NCC2=CC=CC(C3=CC=CC=C3C)=C2)C=C1)=O,=,0.0048,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,[H]OC(COC1=C(F)C=C(NCC2=CC=CC(C3=CC=CC=C3C(F)(F)F)=C2)C=C1)=O,=,0.0157,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,[H]OC(COC1=C(F)C=C(NCC2=CC=CC(C3=CC=CC=C3C(C)C)=C2)C=C1)=O,=,0.0862,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,[H]OC(COC1=C(F)C=C(NCC2=CC=CC(C3=CC=CC=C3C#N)=C2)C=C1)=O,=,0.7286,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,[H]OC(COC1=C(F)C=C(NCC2=CC=CC(C3=CC=CC=C3OC)=C2)C=C1)=O,=,0.5362,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,[H]OC(COC1=C(F)C=C(NCC2=CC=CC(C3=CC=C(C)C=C3Cl)=C2)C=C1)=O,=,0.0225,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,[H]OC(COC1=C(F)C=C(NCC2=CC=CC(C3=CC=C(OCC)C=C3C)=C2)C=C1)=O,=,0.0116,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,[H]OC(COC1=C(F)C=C(NCC2=CC=CC(C3=CC=C(OCCC)C=C3C)=C2)C=C1)=O,=,0.0413,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,[H]OC(COC1=C(F)C=C(NCC2=CC=CC(C3=CC=C(O[H])C=C3C)=C2)C=C1)=O,=,0.0696,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,[H]OC(COC1=C(F)C=C(NCC2=CC=CC(C3=CC=C(OCCOC)C=C3C)=C2)C=C1)=O,=,0.0419,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,[H]OC(COC1=C(F)C=C(NCC2=CC=CC(C3=CC=C(OCCO[H])C=C3C)=C2)C=C1)=O,=,0.0361,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,[H]OC(COC1=C(F)C=C(NCC2=CC=CC(C3=CC=C(OCCCS(=O)=O)C=C3C)=C2)C=C1)=O,=,0.0456,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,[H]OC(COC1=C(F)C=C(NCC2=CC=CC(C3=C(C)ON=C3C)=C2)C=C1)=O,=,0.2253,¦ÌM
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold",10.1016/j.ejmech.2019.06.087,Article,CHO,Calcium flux asay,EC50,FC1=C(OCC(O[H])=O)C=CC(NCC2=CC=C(OC/C(C3=CC=CC=C3)=N\OC)C=C2)=C1,=,0.3975,¦ÌM
ARCHIV DER PHARMAZIE,Exploration of the nitrogen heterocyclic periphery around the core of the advanced FFA1 agonist fasiglifam (TAK©\875),10.1002/ardp.202000275,Article,CHO,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=CC=C1OCC(C=C2)=CC=C2CN3CC(C(COCC4=CC=CC=C4F)=NN5C)=C5CC3,=,0.65,¦ÌM
ARCHIV DER PHARMAZIE,Exploration of the nitrogen heterocyclic periphery around the core of the advanced FFA1 agonist fasiglifam (TAK©\875),10.1002/ardp.202000275,Article,CHO,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=CC=C1OCC(C=C2)=CC=C2CN3CC(C(COCC4=CC=CC(F)=C4)=NN5C)=C5CC3,=,0.6,¦ÌM
ARCHIV DER PHARMAZIE,Exploration of the nitrogen heterocyclic periphery around the core of the advanced FFA1 agonist fasiglifam (TAK©\875),10.1002/ardp.202000275,Article,CHO,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=CC=C1OCC(C=C2)=CC=C2CN3CC(C(COC4=CC=C(F)C=C4)=NN5C)=C5CC3,=,0.61,¦ÌM
ARCHIV DER PHARMAZIE,Exploration of the nitrogen heterocyclic periphery around the core of the advanced FFA1 agonist fasiglifam (TAK©\875),10.1002/ardp.202000275,Article,CHO,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=CC=C1OCC(C=C2)=CC=C2CN3CC(C(COC4=NC=CC(C)=C4)=NN5C)=C5CC3,=,0.43,¦ÌM
ARCHIV DER PHARMAZIE,Exploration of the nitrogen heterocyclic periphery around the core of the advanced FFA1 agonist fasiglifam (TAK©\875),10.1002/ardp.202000275,Article,CHO,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=CC=C1OCC(C=C2)=CC=C2CN3CC(C=C4)=C(N(CC5=CC=C(C(F)(F)F)C=C5)C4=O)CC3,=,1.74,¦ÌM
ARCHIV DER PHARMAZIE,Exploration of the nitrogen heterocyclic periphery around the core of the advanced FFA1 agonist fasiglifam (TAK©\875),10.1002/ardp.202000275,Article,CHO,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=CC=C1OCC(C=C2)=CC=C2CN3CC(C=C4)=C(N(CC)C4=O)CC3,=,0.69,¦ÌM
ARCHIV DER PHARMAZIE,Exploration of the nitrogen heterocyclic periphery around the core of the advanced FFA1 agonist fasiglifam (TAK©\875),10.1002/ardp.202000275,Article,CHO,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=CC=C1OCC(C=C2)=CC=C2CN3CC(C=C4)=C(N(CC5=CC=CC=C5)C4=O)CC3,=,2.97,¦ÌM
ARCHIV DER PHARMAZIE,Exploration of the nitrogen heterocyclic periphery around the core of the advanced FFA1 agonist fasiglifam (TAK©\875),10.1002/ardp.202000275,Article,CHO,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=CC=C1OCC(C=C2)=CC=C2CN3CC(C=C4)=C(N(CC5=CC=CC(F)=C5)C4=O)CC3,=,1.13,¦ÌM
ARCHIV DER PHARMAZIE,Exploration of the nitrogen heterocyclic periphery around the core of the advanced FFA1 agonist fasiglifam (TAK©\875),10.1002/ardp.202000275,Article,CHO,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=CC=C1OCC(C=C2)=CC=C2CN3CC4=C(N=C(OCC5=CC=C(C(F)(F)F)C=C5)C=C4)CC3,=,0.32,¦ÌM
ARCHIV DER PHARMAZIE,Exploration of the nitrogen heterocyclic periphery around the core of the advanced FFA1 agonist fasiglifam (TAK©\875),10.1002/ardp.202000275,Article,CHO,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=CC=C1OCC(C=C2)=CC=C2CN3CC4=C(N=C(OCC5=CC=C(Cl)C=C5)C=C4)CC3,=,0.33,¦ÌM
ARCHIV DER PHARMAZIE,Exploration of the nitrogen heterocyclic periphery around the core of the advanced FFA1 agonist fasiglifam (TAK©\875),10.1002/ardp.202000275,Article,CHO,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=CC=C1OCC(C=C2)=CC=C2CN3CC4=C(N=C(OCC5=CC=C(F)C=C5)C=C4)CC3,=,0.37,¦ÌM
ARCHIV DER PHARMAZIE,Exploration of the nitrogen heterocyclic periphery around the core of the advanced FFA1 agonist fasiglifam (TAK©\875),10.1002/ardp.202000275,Article,CHO,Calcium flux asay,EC50,O=C(O[H])CCC(C=C1)=CC=C1OCC(C=C2)=CC=C2CN3CC4=C(N=C(OCCOC)C=C4)CC3,=,0.15,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835,10.1016/j.bmc.2016.09.004,Article,CHO,Calcium flux asay,EC50,O=C(CCC1=CC=C(OCC2=CC=C(C=C2)CN3CCC(OCCC4OC)(C4)CC3)C=C1)O[H],>,20,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835,10.1016/j.bmc.2016.09.004,Article,CHO,Calcium flux asay,EC50,O=C(CCC1=CC=C(OCC2=CC=C(C=C2)CN3CCC(OCCC4OCC)(C4)CC3)C=C1)O[H],>,20,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835,10.1016/j.bmc.2016.09.004,Article,CHO,Calcium flux asay,EC50,O=C(CCC1=CC=C(OCC2=CC=C(C=C2)CN3CCC(OCCC4OCC5CC5)(C4)CC3)C=C1)O[H],>,20,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835,10.1016/j.bmc.2016.09.004,Article,CHO,Calcium flux asay,EC50,O=C(CCC1=CC=C(OCC2=CC=C(C=C2)CN3CCC(OCCC4OCC5=CC(F)=CC=C5)(C4)CC3)C=C1)O[H],=,1.3,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835,10.1016/j.bmc.2016.09.004,Article,CHO,Calcium flux asay,EC50,O=C(CCC1=CC=C(OCC2=CC=C(C=C2)CN3CCC(OCCC4OCC5=CC=C(C(F)(F)F)C=C5)(C4)CC3)C=C1)O[H],>,20,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835,10.1016/j.bmc.2016.09.004,Article,CHO,Calcium flux asay,EC50,O=C(CCC1=CC=C(OCC2=CC=C(C=C2)CN3CCC(OCCC4OCC5=CC=CC=C5)(C4)CC3)C=C1)O[H],=,1.16,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835,10.1016/j.bmc.2016.09.004,Article,CHO,Calcium flux asay,EC50,O=C(CCC1=CC=C(OCC2=CC=C(C=C2)CN3CCC(OCCC4OCC5=CC=C(F)C=C5)(C4)CC3)C=C1)O[H],=,2.01,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835,10.1016/j.bmc.2016.09.004,Article,CHO,Calcium flux asay,EC50,O=C(CCC1=CC=C(OCC2=CC=C(C=C2)CN3CCC4(OCCC(C)C4)CC3)C=C1)O[H],>,20,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835,10.1016/j.bmc.2016.09.004,Article,CHO,Calcium flux asay,EC50,O=C(CCC1=CC=C(OCC2=CC=C(C=C2)CN3CCC4(OCCC(CC5=CC=C(C(F)(F)F)C=C5)C4)CC3)C=C1)O[H],=,1.2,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835,10.1016/j.bmc.2016.09.004,Article,CHO,Calcium flux asay,EC50,O=C(CCC1=CC=C(OCC2=CC=C(C=C2)CN3CCC4(OCCC(CC5=CC=CC(F)=C5)C4)CC3)C=C1)O[H],>,20,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835,10.1016/j.bmc.2016.09.004,Article,CHO,Calcium flux asay,EC50,O=C(CCC1=CC=C(OCC2=CC=C(C=C2)CN3CCC4(OCCC(CC5=CC=C(F)C=C5)C4)CC3)C=C1)O[H],=,0.41,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835,10.1016/j.bmc.2016.09.004,Article,CHO,Calcium flux asay,EC50,O=C(CCC1=CC=C(OCC2=CC=C(C=C2)CN3CCC4(OCCC(CC5=CC=CC=C5)C4)CC3)C=C1)O[H],=,0.055,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835,10.1016/j.bmc.2016.09.004,Article,CHO,Calcium flux asay,EC50,O=C(CCC1=CC=C(OCC2=CC=C(C=C2)CN3CCC4(OCCC(CC5=CC=C(OC)C=C5)C4)CC3)C=C1)O[H],=,0.28,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835,10.1016/j.bmc.2016.09.004,Article,CHO,Calcium flux asay,EC50,O=C(CCC1=CC=C(OCC2=CC=C(C=C2)CN3CCC4(OCCC(CC5=CC=C(C)C=C5)C4)CC3)C=C1)O[H],=,0.077,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835,10.1016/j.bmc.2016.09.004,Article,CHO,Calcium flux asay,EC50,O=C(CCC1=CC=C(OCC2=CC=C(C=C2)CN3CCC4(OCCC(CC5=CC=CC=C5F)C4)CC3)C=C1)O[H],=,0.81,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835,10.1016/j.bmc.2016.09.004,Article,CHO,Calcium flux asay,EC50,O=C(CCC1=CC=C(OCC2=CC=C(C=C2)CN3CCC4(OCCC(CC5=NC(C6=CN=CC=C6)=NO5)C4)CC3)C=C1)O[H],>,20,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835,10.1016/j.bmc.2016.09.004,Article,CHO,Calcium flux asay,EC50,O=C(CCC1=CC=C(OCC2=CC=C(C=C2)CN3CCC4(OCCC(CC5=NC(C6CC6)=NO5)C4)CC3)C=C1)O[H],=,4.54,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835,10.1016/j.bmc.2016.09.004,Article,CHO,Calcium flux asay,EC50,O=C(CCC1=CC=C(OCC2=CC=C(C=C2)CN3CCC4(OCCC(CC5=NC(CCOC)=NO5)C4)CC3)C=C1)O[H],>,20,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY,Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835,10.1016/j.bmc.2016.09.004,Article,CHO,Calcium flux asay,EC50,O=C(CCC1=CC=C(OCC2=CC=C(C=C2)CN3CCC4(OCCCC4)CC3)C=C1)O[H],>,20,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine",10.1016/j.bmcl.2019.01.014,Article,Unknown,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OC[C@H]2COC3=CC=C(C=C3O2)C4=C(Cl)C=CC=C4,=,0.08,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine",10.1016/j.bmcl.2019.01.014,Article,Unknown,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OC[C@H]2COC3=CC=C(C=C3O2)C4=CC(Cl)=CC=C4,=,0.4,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine",10.1016/j.bmcl.2019.01.014,Article,Unknown,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OC[C@H]2COC3=CC=C(C=C3O2)C4=CC=CC=C4,=,0.16,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine",10.1016/j.bmcl.2019.01.014,Article,Unknown,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OC[C@H]2COC3=CC=C(C=C3O2)C4=CC=C(F)C=C4,=,0.12,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine",10.1016/j.bmcl.2019.01.014,Article,Unknown,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OC[C@H]2COC3=CC=C(C=C3O2)C4=CC=C(C)C=C4,=,0.24,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine",10.1016/j.bmcl.2019.01.014,Article,Unknown,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OC[C@H]2COC3=CC=C(C=C3O2)C4=CC=C(C#N)C=C4,=,0.15,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine",10.1016/j.bmcl.2019.01.014,Article,Unknown,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OC[C@H]2COC3=CC=C(C=C3O2)C4=CC=C(OC)C=C4,=,0.04,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine",10.1016/j.bmcl.2019.01.014,Article,Unknown,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OC[C@H]2COC3=CC=C(C=C3O2)C4=CC(OC)=CC=C4,=,6.5,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine",10.1016/j.bmcl.2019.01.014,Article,Unknown,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OC[C@H]2COC3=CC=C(C=C3O2)C4=CC=C(OC(F)(F)F)C=C4,=,0.29,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine",10.1016/j.bmcl.2019.01.014,Article,Unknown,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OC[C@H]2COC3=CC=C(C=C3O2)C4=CC=C(C(F)(F)F)C=C4,=,0.22,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine",10.1016/j.bmcl.2019.01.014,Article,Unknown,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OC[C@H]2COC3=CC=C(C=C3O2)C4=C(Cl)C=C(Cl)C=C4,=,0.07,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine",10.1016/j.bmcl.2019.01.014,Article,Unknown,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OC[C@H]2COC3=CC=C(C=C3O2)C4=CC(Cl)=C(Cl)C=C4,=,0.3,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine",10.1016/j.bmcl.2019.01.014,Article,Unknown,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OC[C@H]2COC3=CC=C(C=C3O2)C4=C(F)C=C(OC)C=C4,=,0.2,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine",10.1016/j.bmcl.2019.01.014,Article,Unknown,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OC[C@H]2COC3=CC=C(C=C3O2)C4=C(C)C=CC=C4C,=,0.12,¦ÌM
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,"Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine",10.1016/j.bmcl.2019.01.014,Article,Unknown,Calcium mobilization assay,EC50,O=C(O[H])C[C@H](C#CC)C1=CC=C(C=C1)OC[C@H]2COC3=CC=C(C=C3O2)C4=CC=CN=C4,=,0.22,¦ÌM
